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Abstract 
Tuberculous meningitis (TBM) is the most severe form of TB. Current diagnostics are 
insufficiently sensitive. Processes of excessive neuroinflammation are poorly understood. 
Detecting raised intracranial pressure is challenging. TBM-associated hyponatraemia is 
poorly understood. This thesis aims to improve diagnosis of TBM and its complications, and 
further understand TBM’s complex pathophysiology.  
Firstly, I present a prospective randomised evaluation of the diagnostic performance of 
GeneXpert MTB/RIF (Xpert) against GeneXpert MTB/RIF Ultra (Ultra) in 205 individuals 
with TBM. Diagnostic sensitivities of Ultra and Xpert against a clinical TBM reference 
standard were 47.2% (25/53, 95% confidence interval [CI] 34.4-60.3%) and 39.6% (21/53, 
95% CI 27.6-53.1%) respectively (p=0.56). 
Next, I present data from two randomised trials of adjunctive dexamethasone in clinical TBM 
(ACT HIV [NCT03092817] and LAST ACT [NCT0310078]). 668 adults with TBM 
underwent baseline S. stercoralis testing. Active S. stercoralis infection significantly 
associated with reduced median cerebrospinal fluid (CSF) interferon (IFN)-ɣ, interleukin 
(IL)-2, and tumour necrosis factor (TNF)-α concentrations (3.51 vs. 5.81pg/mL p=0.01; 5.05 
vs. 5.77pg/mL p=0.03; 2.17 vs. 3.58pg/mL p=0.02, respectively), and with reduced 
neurological complications by 3 months (3.8%[1/26] vs. 30.0%[33/110], respectively, 
p=0.01). In 107 adults with TBM, higher baseline optic nerve sheath diameter (ONSD) 
associated with more severe TBM and abnormal brain imaging (abnormal imaging 0.55cm vs. 
normal imaging 0.50cm, p=0.01). Baseline ONSD was higher in participants who died by 3 
months (0.56cm [15/72]) vs. participants who survived (0.52cm [57/72]), p=0.02. Finally, 208 
adults with TBM underwent longitudinal testing of plasma sodium, urinary sodium, serum 
osmolality, or urine osmolality. Baseline plasma sodium significantly associated with higher 
lumbar CSF opening pressure, and elevated CSF neutrophils. Plasma sodium was 
significantly lower at all time points after baseline in participants who died by 3 months. 
Ultra was not superior to Xpert for TBM diagnosis. However, given this study was powered 
to detect a 25% improvement in diagnostic sensitivity with Ultra it remains possible that Ultra 
was more sensitive than Xpert at a lower margin of superiority. S. stercoralis co-infection 
may modulate the intracerebral inflammatory response to M. tuberculosis. ONSD ultrasound 
may identify severity and predict death, in TBM. Persistent hyponatraemia associates with 
poor clinical outcomes.  
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Chapter 1 
Introduction 
1.1 Objectives of this thesis 
My thesis is titled ‘Improving diagnosis and understanding the pathophysiology of tuberculous 
meningitis’. Tuberculous meningitis (TBM) is the most severe form of TB, killing or severely 
disabling half of those it affects. Whilst promising progress has been made in this research field in 
recent years, the lack of high quality data to guide best practice is alarming. My objective is to 
improve diagnosis and better understand pathophysiology in TBM, focusing on important clinical 
questions which I will outline in the introduction, and on those participants with severe TBM in 
whom complications occur most frequently. I believe my thesis offers new insights into TBM, and 
describes new data that can both be used in clinical practice, and taken further forward with new 
research.  
My thesis will be separated into six chapters. Following an introduction to TBM focusing on the 
general themes to be explored in this thesis, I will include four data chapters; Ultra vs. Xpert 
(diagnosis), Strongyloides immunomodulation (pathogenesis and inflammation), ONSD ultrasound 
(diagnosis of severity), and hyponatraemia (pathogenesis), followed by a discussion and my 
conclusions. The individual chapter structure of my thesis is as follows: 
1.1.1 Chapter 1 
General introduction to TBM 
1.1.2 Chapter 2 
A prospective randomised evaluation of the diagnostic performance of standard 1st generation 
GeneXpert MTB/RIF against GeneXpert MTB/RIF Ultra in tuberculous meningitis 
Objectives 
1. Compare GeneXpert MTB/RIF Ultra with GeneXpert MTB/RIF for the diagnosis of TBM  
2. Evaluate the performance of GeneXpert MTB/RIF Ultra and GeneXpert MTB/RIF on anti-
tuberculosis chemotherapy  
1.1.3 Chapter 3 
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The influence of Strongyloides stercoralis co-infection on the presentation, pathogenesis, and 
outcome of tuberculous meningitis 
Objectives 
1. Identify the frequency of S. stercoralis co-infection in human immunodeficiency virus 
(HIV) co-infected and HIV uninfected adults with TBM 
2. Compare the performances of available diagnostic tests for S. stercoralis; stool microscopy, 
stool polymerase chain reaction (PCR), and serology 
3. Explore the relationship between S. stercoralis co-infection, TBM presentation and routine 
CSF parameters 
4. Explore the relationship between S. stercoralis co-infection and pre-treatment CSF cytokine 
concentrations in TBM 
5. Explore the relationship between S. stercoralis co-infection and clinical outcomes in TBM 
1.1.4 Chapter 4 
The role of optic nerve sheath ultrasound as a non-invasive tool for intracranial pressure (ICP) 
monitoring in adults with tuberculous meningitis 
Objectives 
1. Characterise optic nerve sheath diameter at baseline, by sex, final diagnosis, Medical 
Research Council (MRC) TBM grade, and HIV co-infection status, in adults with TBM 
2. Correlate ONSD with brain imaging consistent with raised ICP, or with abnormal brain 
imaging appearances 
3. Use receiver operating characteristic (ROC) curve analysis to select an ONSD cut-off value 
that predicts abnormal brain imaging, or death by 3 months, with clinically acceptable 
sensitivity and specificity 
4. Describe the association of non-quantitative optic nerve sheath appearances with brain 
imaging 
5. Describe the association between ONSD and plasma sodium 
6. Correlate ONSD with neurological complications by 3 months, and with death by 3 months 
7. Describe ONSD trends during the first 30 days of TBM treatment, stratified by HIV co-
infection, TBM severity grade, and clinical endpoints 
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1.1.5 Chapter 5 
A descriptive analysis of the pathophysiology of TBM-associated hyponatraemia by serial 
assessments of plasma and urinary sodium, serum and urinary osmolalities, fluid balance and 
intravascular volume 
Objectives 
1. Describe the phenotypic characteristics and laboratory parameters associated with 
hyponatraemia at TBM presentation 
2. Describe the association between baseline plasma sodium, serum osmolality, urinary 
sodium, urinary osmolality, and plasma cortisol, in TBM 
3. Describe the likely processes of hyponatraemia in TBM 
4. Describe the progression of sodium and volume parameters during the first 30 days of TBM 
treatment 
5. Describe the influence of baseline plasma sodium, serum osmolality, urinary sodium, 
urinary osmolality, and plasma cortisol, on clinical outcomes in TBM 
6. Describe the corrective sodium therapy used in hyponatraemia of TBM 
1.1.6 Chapter 6 
Discussion and conclusions 
1.2 Research contribution 
Below, in line with transparent research practices, I have detailed my contribution to each thesis 
chapter:     
Chapter 1: I planned and performed the literature review for this chapter, incorporating structuring 
advice from my PhD supervisors, and then wrote the introduction. 
Chapter 2: I assisted with case report form design and the setting up of study procedures. I reviewed 
and helped recruit participants on daily clinical ward rounds. I planned the analysis, performed all 
interim analyses, and wrote the analysis code using the computing language R. I performed data 
cleaning, reviewed for and collected missing data, and performed the final analysis. I wrote the 
manuscript and this chapter. 
Chapter 3: I reviewed and helped recruit participants on daily clinical ward rounds. I performed 
day-to-day management of the two large clinical trials through which these data were collected, 
ensuring compliance with study protocols and standard operating procedures. I regularly reviewed 
 
27 
 
study data and monitored the ongoing progress of the research. I arranged and coordinated S. 
stercoralis stool PCR testing in conjunction with Oxford University Clinical Research Unit 
(OUCRU) emerging infections group who performed this PCR testing. I performed CSF cytokine 
analysis in conjunction with a colleague from the TB research group with experience in these 
techniques. I reviewed for and collected, missing data, and cleaned data. I wrote the analysis code 
using the computing language R and performed the data analysis. I wrote the manuscript and this 
chapter. 
Chapter 4: I reviewed and helped recruit participants on daily clinical ward rounds. I performed 
day-to-day management of the two large clinical trials through which these data were collected, 
ensuring compliance with study protocols and standard operating procedures. I regularly reviewed 
study data and monitored the ongoing progress of the research. I developed skills in point-of-care 
optic nerve sheath ultrasound and underwent additional training overseas in this technique. I 
designed a pilot study to ensure accurate performance of ONSD measurement by 2 independent 
operators and performed >95% of ONSD ultrasounds. I designed data collection, re-designed the 
case report form, and sought successful ethics approval for the performing of this technique in 
healthy volunteers. I reviewed for and collected, missing data, and cleaned data. I wrote the analysis 
code using the computing language R and performed the data analysis. I wrote the manuscript and 
this chapter. 
Chapter 5: I reviewed and helped recruit participants on daily clinical ward rounds. I performed 
day-to-day management of the two large clinical trials through which these data were collected, 
ensuring compliance with study protocols and standard operating procedures. I regularly reviewed 
study data and monitored the ongoing progress of the research. I met with local laboratory 
collaborators in Ho Chi Minh City to set up testing for serum and urine osmolality (Cho Ray 
Hospital) and plasma cortisol (Medic Medical Center). I designed data collection, and re-designed 
the case report form. I regularly reviewed study data, and adherence to clinical trial protocols at the 
recruiting site. I reviewed for and collected, missing data, and cleaned data. I wrote the analysis 
code using the computing language R and performed the data analysis. I wrote the manuscript and 
this chapter. 
Chapter 6: I planned and wrote the discussion and conclusions 
1.3 An introduction to tuberculous meningitis 
1.3.1 Epidemiology 
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1.3.1.1 Global 
According to the most recent Global Tuberculosis (TB) report published by the World Health 
Organization (WHO), in 2019 an estimated 10 million individuals developed TB-illness, with an 
estimated 1.5 million TB deaths.[1] TB remains the leading cause of death from a single bacterial 
infection,[1] yet reducing incident cases and deaths has proven challenging. Given insufficient 
recent progress towards meeting the ambitious United Nations (UN) sustainable development goal 
(SDG) of ending the TB epidemic by 2030,[2] in September 2018 a UN high level meeting on TB 
was held, where political commitments to UN SDGs and to the WHO’s End TB strategy were 
confirmed, and new goals added.[1]  
Tuberculous meningitis is the most severe form of TB, leading to death in 30-50% of sufferers 
despite treatment.[3–6] The global incidence of TBM is uncertain. Limited data suggest TBM 
represents approximately 1% of all TB cases, leading to an estimated 100,000 global cases per year. 
In Germany, a study of 46,349 TB cases found TBM in 0.9%,[7] whereas a Brazilian study of 
427,548 TB cases found 57,217 extrapulmonary TB cases, with TBM accounting for 6% of these 
extrapulmonary cases.[8] TBM incidence is expected to vary by geographical location, all-form TB 
incidence, HIV co-infection rate, and population age structure.[9] Current estimates suggest TBM 
may in fact account for up to 2-5% of TB cases.[10] TBM can affect any group, but is especially 
common in young children and in those co-infected with HIV.[9] Prior bacillus Calmette-Guerin 
(BCG) vaccination appears to offer partial protection against childhood TBM and mortality, 
potentially through improved cellular immunity and prevention of Mycobacterium tuberculosis 
dissemination.[11–13] 
1.3.1.2 Vietnam 
The current TB incidence in Vietnam is 182 cases per 100,000 population, resulting in a calculated 
estimate of 174,000 TB cases in a country of 96 million individuals.[1] Applying 1% and 5% 
estimates of TBM incidence, an estimated 1740-8700 cases of TBM will occur in Vietnam each 
year. The proportion of these TBM cases presenting to health facilities in Vietnam is unknown, 
however those that do, and are correctly identified as TBM, are referred to tertiary referral sites. 
Additionally, many cases of undiagnosed brain disease are referred to tertiary referral sites where a 
diagnosis of TBM is then made. In Ho Chi Minh City, Vietnam, tertiary referral sites for TBM are 
the Hospital for Tropical Diseases (HTD) and Pham Ngoc Thach Hospital for Tuberculosis and 
Lung Disease, where approximately 100 adult cases of TBM, and 300 adult and 50 paediatric cases 
of TBM, respectively, are identified and treated each year.  
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1.3.2 Pathophysiology of TBM 
1.3.2.1 Infection and dissemination 
M. tuberculosis infection occurs when M. tuberculosis is inhaled by a human host, with subsequent 
infection of alveolar macrophages, formation of a primary complex, and dissemination to regional 
lymph nodes.[14] In individuals who develop TBM, bacteraemia follows; M. tuberculosis bacilli 
seed to the meninges or brain parenchyma forming small subpial or subependymal granulomas 
called ‘Rich foci’.[14] Rupture of these granulomas into the subarachnoid space remains the 
accepted theory of TBM pathogenesis, where two sequential foci (pulmonary then central) are 
required.[9,15] Upon rupture of the central granuloma, M. tuberculosis bacilli enter the central 
nervous system (CNS) and are taken up by microglial cells (in which they can also replicate), 
leading to release of microglial cytokines and chemokines.[9,16,17]  
The resulting inflammatory response to M. tuberculosis entering the CNS is variable, and likely 
dictated by both bacillary and host factors; but tissue damage and disease complications often 
result. Too little or too much inflammation are both considered detrimental to outcome.[18] The 
processes of M. tuberculosis induced host inflammation within the lung are well researched,[19] 
however, M. tuberculosis induced inflammation within the brain is not fully understood, but may 
involve activation of the microglial NLRP3 inflammasome, an immune complex of receptors and 
sensors that mediates innate immune responses and induces inflammation.[17,20]  
1.3.2.2 Intracerebral immune responses 
Both innate and acquired immune responses are part of the host response to TBM. A pro-
inflammatory immune response, largely regulated by CD4+ T cells, and predominated by tumour 
necrosis factor (TNF)-α, interferon (IFN)-ɣ, and interleukin (IL)-2 cytokine release, is typical of 
TBM. When this pro-inflammatory response is dysregulated and excessive, as often occurs, 
significant brain tissue damage can result.  
Neutrophils, long considered effector cells of the innate immune system,[21] appear to be an 
important factor in TBM-associated inflammation. In a study of HIV uninfected individuals over 14 
years old with TBM in Indonesia, higher CSF neutrophil counts were significantly associated with 
death.[22] In a study of TBM-associated immune reconstitution inflammatory syndrome (IRIS) 
after commencing anti-retroviral therapy (ART) in South Africa, more severe inflammation was 
associated with high baseline CSF neutrophil counts.[23] Neutrophils produce both pro- and anti-
inflammatory cytokines and chemokines,[24] including TNF-α and IFN-ɣ; therefore their role in 
TBM is likely complex. A variety of CSF pro-inflammatory cytokines are in fact elevated in TBM, 
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however these cytokine concentrations have shown little correlation with TBM severity or clinical 
outcome in most previous studies.[25–27] Host directed therapies such as corticosteroids and newer 
biological agents (e.g. infliximab), used to attempt to control host inflammation, have been used 
with limited and variable success.[5,28–30] The benefit of therapeutically reducing TNF-α 
concentrations in TBM remains uncertain.  
The presence of CSF lymphocytes, and the elevation of CSF IFN-γ and IL-2 (predominantly 
produced by T cells), provides evidence of an acquired immune response in TBM. In a prospective 
CSF flow cytometry study of 67 HIV uninfected individuals more than 14 years of age with definite 
or probable TBM in Indonesia, CSF analysis showed a predominance of αβ T cells (a T cell group 
inclusive of subsets displaying either the CD4+ or CD8+ receptor), alongside variable proportions 
of natural killer cells and neutrophils.[31] Cellular release of IFN-γ, upon clinical sample 
stimulation with mycobacterial antigens, forms the basis of IFN-γ release assay testing. This shows 
a clear acquired immune response to mycobacteria, and this testing has been described for CSF in 
TBM.[32]   
1.3.2.3 Factors influencing intracerebral inflammatory response 
1.3.2.3.1 Human immunodeficiency virus 
HIV co-infection increases mortality from TBM, compared with HIV uninfected individuals.[33] 
Amongst HIV co-infected individuals with TBM, lower peripheral CD4+ cell counts and lower CSF 
lymphocyte counts predict mortality at 9 months,[34,35] suggesting reduced immunological 
response to TBM is detrimental to outcome. In HIV co-infected TBM, M. tuberculosis 
identification by Xpert is higher than in HIV uninfected individuals[36,37] consistent with higher 
CSF M. tuberculosis bacillary loads in HIV co-infection. This indicates that increased bacterial 
replication is possible in HIV co-infection; however, patient factors (e.g. later presentation) or 
bacillary factors (e.g. increased virulence or drug resistance) must be considered as potential 
confounders. In a study of pre-treatment intracerebral inflammation in TBM from Vietnam, HIV 
co-infection was significantly associated with higher CSF neutrophil proportion and a globally 
increased production of CSF cytokines.[18] Taken together, this supports more M. tuberculosis 
bacilli and more intracerebral inflammation in HIV co-infected TBM, with both increased CSF 
neutrophils and an impaired T cell response contributing to worse outcomes.   
1.3.2.3.2 Host genetics 
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Host (i.e. human) genetic polymorphisms may influence susceptibility and response to infection 
with M. tuberculosis. In 2010 a zebrafish model demonstrated that the leukotriene A4 hydrolase 
(LTA4H) gene influenced the balance of pro and anti-inflammatory eicosanoids in response to M. 
tuberculosis infection.[38] LTA4H catalyses the final step in pro-inflammatory leukotriene B4 
(LTB4) synthesis,[38] with the effects of LTB4 balanced by anti-inflammatory lipoxin A4 (LXA4); 
the two together regulating an inflammatory response to M. tuberculosis without excessive tissue 
damage.[39] A single nucleotide polymorphism (SNP) (rs17525495) in the promoter region of the 
LTA4H gene alters the gene’s expression, and the critical LTB4:LXA4 balance; low (CC) and high 
(TT) inflammatory states result from LTA4H allele homozygosity whereas an intermediate (CT) 
inflammatory state results from allele heterozygosity.[38] Both TT and CC inflammatory states 
were associated with an increased risk of death in a retrospective adult TBM study.[40] In this 
retrospective study adjunctive dexamethasone improved survival in the high inflammatory TT 
group, with the effect of dexamethasone unclear in the CC and CT groups.[40] The influence of 
LTA4H genotype upon adjunctive corticosteroid therapy is now being evaluated in an ongoing 
randomised placebo-controlled LTA4H genotype stratified non-inferiority trial of HIV uninfected 
adults with TBM in Vietnam (NCT03100786).[41] If the benefit of adjunctive corticosteroids is 
limited to one (or more) LTA4H genotypes, this potentially paves the way for personalised 
corticosteroid therapy in TBM. 
Additionally, an SNP (rs17842268) in CD43, (a cell surface glycoprotein), has been associated with 
more severe presentation, and decreased survival, in TBM.[42] Why CD43 SNPs impact upon TBM 
this way is uncertain, however, CD43 does have a role in regulating proinflammatory cytokines,[42] 
suggesting immunomodulation as the mechanism. The CSF metabolome of TBM, with these 
downstream metabolomic markers influenced by host genotype, may reveal new genes important 
for survival in TBM. In a study of 33 HIV uninfected individuals with TBM, plus 22 control 
individuals, lower CSF tryptophan (one such metabolite) was associated with improved 
survival.[43] Tryptophan affects M. tuberculosis growth and CNS inflammation, and its production 
and/or release are under genetic influence. 
1.3.2.3.3 Bacillary genetics 
Broadly, M. tuberculosis complex (i.e. the group of closely related mycobacteria causing TB, 
including M. tuberculosis) can be separated into 8 phylogenetic lineages affecting humans.[44,45] 
The predominant lineage in Vietnam is the Beijing lineage (lineage 2); this lineage appears more 
transmissible between hosts, and has been increasing its proportion of all TB lineages in Vietnam 
over the past 10 years.[46] Genetic variation (insertions, deletions, rearrangement, or point 
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mutations) between M. tuberculosis strains allows for tracking of a particular strain, thereby 
improving the understanding of TB spread and pathogenicity.[47] A variety of bacillary mutations 
and virulence factors have been described for M. tuberculosis.[48,49]  
In an in-vitro study of M. tuberculosis isolates obtained from children in South Africa, M. 
tuberculosis growth patterns and host cytokine production (TNF and IL12p40) were different 
between M. tuberculosis lineages 2, 3, and 4.[50] It follows that different strains may evoke 
different CSF cytokine profiles in TBM; however limited data are available describing bacillary 
genetics and impact upon clinical TBM. In a retrospective lineage study of 222 Vietnamese 
individuals > 14 years of age with TBM, the Beijing lineage was significantly associated with HIV 
co-infection, and with multidrug resistance.[51] In an additional study from the same group 
comparing bacillary and host genetics of 187 adults with TBM vs. 237 non-disseminated pulmonary 
TB cases, infection with Euro-American (lineage 4) isolates resulted in lower mortality.[52] 
Additionally, a specific polymorphism in the host toll-like receptor (TLR)-2 gene was associated 
with TBM disease caused by the Beijing lineage. The Beijing lineage is considered an aggressive 
TB lineage in relation to its global spread and association with treatment failure. Yet, in a study of 
186 HIV co-infected adults with TBM in Vietnam, the Beijing lineage was associated with reduced 
mortality compared with the Indo-Oceanic lineage (lineage 1). Effects of bacillary genetics on 
intracerebral inflammation remain poorly understood, and the interaction of both host and bacterial 
factors is likely more important than bacillary lineage or specific bacillary mutations alone.    
1.3.2.3.4 Helminth co-infection 
The soil transmitted helminth Strongyloides stercoralis is a neglected tropical disease endemic to 
Vietnam. Helminths such as S. stercoralis induce downregulation of pro-inflammatory immunity, 
with predominance of eosinophils, and IgE antibody production. In TBM with S. stercoralis co-
infection pro-inflammatory immune responses of TBM may therefore be downregulated by 
helminth co-infection. In a pulmonary TB study, plasma IFN-ɣ, TNF-α, and IL-2 were reduced in 
TB S. stercoralis co-infection vs. TB alone.[53] Whether helminth co-infection detrimentally 
impairs immune response to TBM, or minimises harmful and excessive pro-inflammatory immune 
responses of TBM, will be described for the first time in this thesis (chapter 3). 
1.3.3 Clinical presentation of TBM 
TBM classically presents as a subacute meningitic illness,[15] with onset of headache, neck 
stiffness, confusion and fever over many days or weeks. This indolent presentation may delay 
presentation to hospital, and delayed treatment may reduce chances of a good clinical outcome.[15] 
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Early clinical presentation in children can be non-specific, with vomiting, malaise and failure to 
thrive.[15] More severe presentations of TBM include reduced consciousness and/or focal 
neurological signs, often as a result of raised ICP, with an urgent need for interventional 
neurocritical care.  
TBM severity is classified by the modified British MRC TBM severity grading, originally 
developed in 1948 and subsequently modified after the introduction of the Glasgow coma score 
(GCS).[9] The currently used MRC TBM severity grading is shown in table 1-1. Rates of mortality 
and severe neurological disability increase as TBM grade increases, and HIV co-infection increases 
mortality further.[9]  
Table 1-1: Modified MRC TBM severity grades 
TBM grade GCS and neurological signs 
Grade I GCS 15; no focal neurological signs 
Grade II GCS 11-14, or 15 with focal neurological signs 
Grade III GCS≤10 with or without focal neurological signs 
GCS=Glasgow coma score. MRC=Medical Research Council. TBM=tuberculous meningitis. 
 
The clinical presentation of TBM may be mistaken for one of many non-TB meningitides, which 
share symptoms, signs, and CSF parameter patterns with TBM. A history of symptoms of more than 
5 days usually excludes bacterial meningitis, supported by a high (but not excessively high) CSF 
white blood cell (WBC) count that typically is predominantly lymphocytic. Viral 
meningoencephalitides may share the lymphocytic CSF of TBM, and modestly raise CSF protein, 
but they rarely reduce CSF glucose (with notable exceptions such as mumps meningoencephalitis) 
or elevate CSF lactate. Listeria monocytogenes meningitis results in lymphocytic CSF and should 
be considered in immunosuppressed individuals, and in the elderly and infants. Cryptococcal 
meningitis, where CSF parameters may be similar to those in TBM, must be excluded, especially in 
those with HIV co-infection.  
1.3.4 Diagnosis of TBM 
1.3.4.1 Conventional diagnostics 
The diagnosis of TBM continues to present an enormous challenge to clinicians. Delayed diagnosis 
of TBM leads to worse outcomes, yet, conventional diagnostic tests are insufficiently sensitive to 
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consistently detect M. tuberculosis in CSF.[54] CSF in TBM is paucibacillary and M. tuberculosis 
bacilli are often present in numbers below the threshold of detection of current tests. Conventional 
confirmatory tests (identification of M. tuberculosis in CSF) include Ziehl-Neelsen (ZN) smear 
microscopy, M. tuberculosis nucleic acid amplification tests (NAAT), and mycobacterial culture. 
ZN smear microscopy is widely available but is often insensitive unless performed by experienced 
microscopists using large volumes of CSF that have been optimally processed. Mycobacterial 
culture allows drug susceptibility testing (DST) if positive, however bacterial growth usually takes 
at least 2 weeks and results cannot guide important initial anti-TB chemotherapy choice. Two 
mycobacterial culture methods, MGIT (mycobacteria growth indicator tube) and MODS 
(microscopic observation drug susceptibility), were shown to be diagnostically equivalent in a study 
of 156 individuals with suspected TBM in Vietnam.[55]  
Elevation of the host enzyme adenosine deaminase (ADA) in CSF may distinguish TBM from other 
CNS disease. In a recent meta-analysis[56] inclusive of 20 studies, pooled sensitivity and specificity 
of ADA for TBM diagnosis were 89% and 91% respectively, however variable reference standards 
and ADA cut-off values for TBM diagnosis, and heterogeneity of included studies, makes 
widespread clinical application of this testing challenging. Detection of the M. tuberculosis cell wall 
lipoarabinomannan (LAM) antigen in CSF or urine for the diagnosis of TBM is limited by studies 
showing poor test sensitivity vs. culture, clinical and NAAT standards in predominantly HIV co-
infected individuals in Zambia and Uganda.[57,58] 
1.3.4.2 Non-confirmatory tests 
Non-confirmatory diagnostic tests detect host response to M. tuberculosis, rather than M. 
tuberculosis itself. Discovery of metabolomics or proteomic signatures unique to TBM may pave 
the way for a new diagnostic test. The profiles of 425 metabolites have been characterised in 33 
HIV negative Indonesian adults with TBM,[43] and have been shown to differ between TBM and 
other brain infections in a CSF metabolomic study of 50 individuals with clinical TBM in 
China.[59] In a study of 47 South African children with suspected TBM, the median levels of 
16 host serum protein biomarkers were significantly elevated in those with definite or probable 
TBM, vs. in those not meeting this TBM diagnosis. An approach focusing on a 3-marker 
biosignature (adipsin, Aβ42, and IL-10) gave 83% and 75% diagnostic sensitivity and specificity 
respectively.[60] This is a developing field and more data are needed to understand metabolomic 
and proteomics signatures of TBM.    
1.3.4.3 GeneXpert MTB/RIF 
 
35 
 
Introduced into the diagnostic testing arsenal in 2010, Xpert changed the field of TB 
diagnostics.[61] Able to return a test result in less than two hours, Xpert is now widely used 
throughout the world.[62] According to the most up to date WHO data, the estimated percentage of 
TB cases with multidrug resistance or rifampicin resistance in Vietnam is 4.1% for new cases and 
25% for previously treated cases.[63] Neither ZN smear nor MGIT mycobacterial culture can 
identify rifampicin resistance at diagnosis. Xpert uses a hemi-nested real-time PCR assay to detect 
and amplify a M. tuberculosis specific sequence of the bacterial ribonucleic acid polymerase (rpoB) 
gene.[61] In >95% of cases rifampicin resistance is associated with mutations in the 81 base pair 
core region of this rpoB gene, with this area additionally flanked by M. tuberculosis specific DNA 
sequences; therefore identification of M. tuberculosis and detection of rifampicin resistance could 
be performed in a single test.[64]  
However, the paucibacillary nature of CSF in TBM results in a reduced diagnostic performance of 
Xpert for TBM, vs. sputum testing for pulmonary TB. In recent TBM studies,[37,54,65–67] 
sensitivity of Xpert ranged from 18-59%, compared with 26-67% for mycobacterial culture.[68] 
Variable test sensitivities may reflect differences in CSF sampling, processing, testing and 
differences in host and bacterial genetics, however inconsistent use of the uniform case 
definition[69] as a reference gold standard for diagnostic test performance analysis also contributes 
to this variation, and confounds test comparison. 
1.3.4.4 The emergence of GeneXpert MTB/RIF Ultra 
Xpert represents an ideal diagnostic test for TBM, if test sensitivity could be improved. The new 
Ultra cartridge aims to improve the sensitivity of TB diagnosis and enhance rifampicin resistance 
identification, through a larger reaction chamber, plus incorporation of two different multicopy 
amplification targets (IS6110 and IS1081).[54,70] These cartridge modifications are designed to 
lower the limit of detection of M. tuberculosis colony forming units (CFU); in vitro the lower limit 
of detection for M. tuberculosis decreased to 16 CFU/mL with Ultra, vs. approximately 100 
CFU/mL with Xpert.[68,71] Initial small studies[67,72] showed promise for an improved sensitivity 
of Ultra over Xpert for the diagnosis of TBM. Larger studies comparing Ultra and Xpert for the 
diagnosis of TBM were required and have now been performed (see chapter 2).     
1.3.5 Monitoring of TBM 
1.3.5.1 The detection and monitoring of raised intracranial pressure 
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Recognition and management of raised ICP in TBM is important to allow minimisation of 
intracerebral damage and maintenance of cerebral perfusion. The gold standard for measuring ICP 
is invasive intracranial monitoring; however, invasive devices and the neurosurgical expertise 
required to insert them are not available at many centres. Current non-invasive monitoring options 
are limited. Whilst raised ICP leads to blurring of the margins of the optic disc when viewed by 
fundoscopy (termed ‘papilloedema’), the development of papilloedema can lag behind elevation of 
ICP, and there are few data to support a positive correlation between lumbar CSF opening pressure 
and ICP. Measurement of CSF opening pressure may be performed at the time of lumbar puncture; 
lumbar puncture is minimally invasive, easy to learn, and equipment is widely available. However, 
no evidence yet supports opening pressure as a predictor of ICP or clinical outcome in individuals 
with TBM.  
Therefore, alternative non-invasive methods of ICP monitoring have been considered in TBM. 
Transcranial Doppler ultrasound uses a low frequency (≤2 MHz) transducer, placed on the scalp, to 
scan the basal arteries of the brain and measure cerebral blood flow (CBF) velocity.[73] 
Transcranial Doppler ultrasound may have a role in identifying raised ICP, however its ability to do 
this is not without limitations given a decrease in PaCO2 or an increase in arterial blood pressure 
may alter CBF independently of changes in ICP.[74]  
1.3.5.2 Optic nerve sheath ultrasound 
The optic nerve, a part of the central nervous system, is surrounded by a dural sheath that distends 
when ICP is elevated. This distension can be measured by ultrasound. ONSD ultrasound is a quick, 
reproducible, reliable, non-invasive and safe way to monitor ICP. An association between ONSD 
measured by ultrasound and ICP in non-infective brain pathology has now been demonstrated in 3 
meta-analyses.[75–77] Data supporting ONSD ultrasound in infective brain pathology are limited 
however. One small study has demonstrated successful use of ONSD ultrasound in TBM,[78] 
where a study group of 25 patients with suspected TBM (n=25, mean ONSD 5.81mm) was 
compared with a healthy control group (where no patients had papilloedema on fundoscopy, n=120) 
in whom the upper limit of normal for ONSD was 4.37mm.[78] More data are required to support 
ONSD ultrasound as a tool for detecting and monitoring raised ICP in TBM and as a tool to 
improve clinical outcomes through improved monitoring. This will be addressed in chapter 4 of this 
thesis. A distended optic nerve sheath in a Vietnamese adult with TBM is shown in figure 1-1.  
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Figure 1-1: Distended optic nerve sheath in tuberculous meningitis[79] 
 
An ultrasound image of the left optic nerve sheath in an adult with tuberculous meningitis. 
Refrence: Donovan J, et al. Lancet Neurol 2019. http://dx.doi.org/10.1016/S1474-4422(19)30154-1.  
 
1.3.5.3 Brain imaging 
Brain imaging allows identification of the causes (e.g. hydrocephalus, tuberculous masses, cerebral 
oedema) and consequences (brain shift and ischaemia) of raised ICP. Baseline brain imaging can 
alter immediate management if hydrocephalus is found, and follow-up brain imaging is 
recommended for patients with deteriorating symptoms.[9] Therefore brain imaging is a valuable 
monitoring tool in TBM. However, the best imaging modality, and exactly when to perform 
imaging, are not known. Brain computed tomography (CT) can identify dilated ventricles, mass 
effects, infarctions, and inflammatory exudates.[79] Brain magnetic resonance imaging (MRI) 
provides higher resolution of TBM brain pathology than CT, and has no radiation risks unlike CT, 
however, it is expensive, time consuming, and may require transfer of a critically ill patient to a 
hospital with MRI.[80,81] Retrospective data show that both CT and MRI have a role in detecting 
brain pathology associated with TBM.[82]  
1.3.6 Management of TBM 
1.3.6.1 Anti-TB chemotherapy 
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Despite reliance upon drugs that have been available for decades as first line anti-TB chemotherapy, 
optimum regimens, doses and routes for TBM treatment remain unknown. In severe TBM limited 
oral administration options, overlapping side effects and interactions with drugs used in critical 
illness, variable drug CNS penetration, and fewer patients for clinical trials, all contribute to 
inconsistent, sub-optimal and poorly researched anti-TB chemotherapy regimens. Rifampicin, 
isoniazid, pyrazinamide, and ethambutol are WHO-recommended first line agents for drug 
susceptible TB.[83,84] Yet international guidelines[84] are 10 years old, and do not specifically 
tackle TBM; rather TBM is grouped with other forms of extrapulmonary TB. In Vietnam, 
rifampicin (10mg/kg/24hrs; maximum 600mg), isoniazid (5mg/kg/24hrs; maximum 300mg), 
pyrazinamide (25mg/kg/24hrs; maximum 2g) and ethambutol (20mg/kg/24hrs; maximum 1.2g) are 
given as first line therapies for 2 months, with pyrazinamide then stopped, and rifampicin, isoniazid 
and ethambutol continued at the same doses to complete 12 months total anti-TB 
chemotherapy.[41,85] 
1.3.6.1.1 Pharmacokinetics 
Rifampicin is a critical drug in the treatment of TB, yet its pharmacokinetics, interactions and side 
effects present challenges for TBM treatment. Rifampicin distributes well throughout the body and 
freely enters body tissues, except the CNS, where CSF rifampicin levels frequently do not exceed, 
or only slightly exceed minimum inhibitory concentration (MIC).[15,86–88] Isoniazid is also a 
critical therapy, despite rising levels of mono-resistance to this drug worldwide. Metabolism of 
isoniazid includes acetylation by N-acetyltransferase (NAT)-2, with genetic polymorphism in the 
NAT-2 gene resulting in ‘fast’ or ‘slow’ acetylator phenotypes.[89] Fast acetylation may reduce 
blood isoniazid levels, thereby reducing efficacy of anti-TB chemotherapy; however, evidence is 
required to support higher isoniazid dosing in fast acetylators - this is currently the subject of a 
NAT2 stratified, randomised, parallel group trial in China (NCT03787940). Isoniazid, pyrazinamide 
and fluoroquinolones penetrate well into the CSF, as do ethionamide and cycloserine.[15,87] 
Ethambutol and aminoglycosides poorly penetrate the CSF in the absence of meningeal 
inflammation.[15,86–88] In addition to appropriate therapy choices, prompt treatment and 
avoidance of therapy interruptions are essential.  
1.3.6.1.2 Anti-TB chemotherapy clinical trials 
Given the poor CNS penetration of rifampicin, and its importance as a first line therapy, studies of 
high dose rifampicin dominate the current trial panorama in TBM.[90] Intravenous rifampicin 
600mg was associated with reduced mortality vs. rifampicin 450mg orally in an Indonesian 
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study,[6] but larger studies of intravenous therapy, potentially at higher doses, are required. A 
randomised trial comparing ‘intensified’ 15mg/kg rifampicin plus 20mg/kg levofloxacin (vs. 
standard treatment) in 817 Vietnamese adults with TBM did not lead to reduced mortality in the 
intensified arm,[91] suggesting either anti-TB chemotherapy could not be further optimised in this 
group, or higher doses or alternative drugs are required. A phase II open-label randomised trial of 
high dose rifampicin for TBM in adults (RiFT, ISRCTN42218549) is currently ongoing in Uganda, 
where a 35mg/kg oral rifampicin-containing regimen, with or without an initial two week 20mg/kg 
intravenous phase, is being compared with a standard oral 10mg/mg/kg rifampicin-containing 
regimen.[92] The ALTER, (Uganda, NCT04021121), SIMPLE, (Indonesia, NCT03537495) and 
LASER-TBM trials (South Africa, NCT03927313) will assess pharmacokinetics and safety of 
35mg/kg rifampicin in combination with linezolid, a second line drug with potential in TBM. A 
double-blinded parallel group randomised placebo-controlled phase III trial is due to start 
recruitment of 500 adults in January 2020, in Indonesia, South Africa and Uganda (HARVEST, 
ISRCTN15668391). HARVEST will compare anti-TB chemotherapy supplemented with an 
additional 1.2g rifampicin against fixed-dose combination anti-TB chemotherapy; with assessment 
of clinical outcomes and safety (including drug induced liver injury [DILI] - the most common 
drug-associated adverse event in TBM[93]).  
1.3.6.2 Drug resistance  
The choice of anti-TB chemotherapy regimens must consider the growing threat of drug resistance; 
TB resistant to first line anti-TB chemotherapy is becoming more common worldwide.[94] 
Prevalence of multidrug resistance (MDR) in TBM is approximately 4% in Europe[95] and 12% in 
China.[96] Mono-isoniazid resistance is more common (nine [6%] of 142 cases in the European 
study[95]) and is associated with worse outcomes, although its effect on treatment response is less 
than that of MDR, where mortality and morbidity are very high.[97–99] HIV co-infection may 
impact upon drug resistance and treatment options. In a prospective study of 180 adults with TBM 
in Vietnam, MDR TBM predicted death, but MDR was also independently associated with HIV co-
infection.[98] Whether patient behaviours associate MDR TBM with HIV co-infection, or whether 
M. tuberculosis is more likely to acquire resistance in the context of HIV co-infection, is unknown. 
In a trial of intensified anti-TB chemotherapy for TBM (15mg/kg rifampicin plus 20mg/kg 
levofloxacin, vs. standard anti-TB chemotherapy) intensified therapy reduced mortality in isoniazid 
resistant individuals, but only in those without HIV co-infection.[97] Additionally, isoniazid 
resistance is not straightforward. Resistance to isoniazid can be high level (usually due to mutations 
in the KatG gene), or low level (due to mutations in the promotor region of InhA).[100] Increased 
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dose isoniazid therapy may be beneficial in low level isoniazid resistance,[101] however evidence is 
required to support this in TBM. Certainly, early indication of MDR is vital, given this form of 
TBM is almost always fatal unless second line therapies are administered early.[97] Clinical trial 
data are needed to guide second line anti-TB chemotherapy in TBM, in addition to treatment data to 
support any use of newer anti-TB chemotherapies such as delamanid and bedaquiline.         
1.3.6.3 Adjunctive corticosteroids 
Adjunctive corticosteroids have been shown to reduce mortality from TBM, at least in the short 
term.[5,28,102] How they confer this clinical benefit is unclear however, although reduction in 
intracerebral inflammation seems the most plausible mechanism. Glucocorticoids bind to and 
activate the glucocorticoid receptor of macrophages and other cells, interfering with inflammatory 
mediator transcription and expression.[103] Additional indirect genomic effects (inhibition of pro-
inflammatory transcription factors e.g. activator protein-1), and non-genomic mechanisms, further 
mediate glucocorticoid anti-inflammatory effects.[104–107]  
Additionally, corticosteroids reduce brain oedema, primarily of vasogenic origin, with a limited 
effect on cytotoxic oedema due to haemorrhage or infarction.[108] Whilst corticosteroids are not 
beneficial in acute traumatic brain injury (TBI) where they may cause harm,[109,110] they are often 
used as a rescue therapy in cases of TBM-associated raised ICP, albeit with little evidence to 
support this use. Corticosteroids are also frequently used to treat neurological IRIS, a common 
complication of starting ART in TBM, however no controlled trials exist to support corticosteroid 
use in this condition. Corticosteroids may reduce the size of tuberculomas and control their 
symptoms however.[111] In a randomised paediatric study corticosteroid therapy reduced mortality, 
and enhanced the resolution of tuberculomas and basal exudate as seen by brain CT imaging.[112] 
In a study of Vietnamese adults, there were fewer episodes of MRI-proven hydrocephalus or 
cerebral infarction at day 60 in individuals receiving corticosteroids, compared with those receiving 
placebo, although these effects were not statistically significant.[113] 
Regardless of the mechanism of benefit, corticosteroid therapy in HIV uninfected individuals with 
TBM is now recommended, frequently in the form of dexamethasone which is both cheap and 
widely available. However the optimal corticosteroid preparation, dose, and route of administration, 
are unknown.[79] Whether beneficial therapeutic effects of corticosteroids extend to HIV co-
infected individuals is uncertain. In an HIV co-infected subgroup (n=98) from a randomised trial of 
adjunctive corticosteroids for TBM in Vietnamese adults, dexamethasone was associated with a 
non-significant trend towards improved survival.[5] A multicentre randomised controlled trial of 
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adjunctive corticosteroids for HIV co-infected adults with TBM is currently underway in Vietnam 
and Indonesia (NCT03092817).[85]  
1.3.7 TBM complications and critical illness 
1.3.7.1 Supportive care 
The management of TBM is complex, extending beyond drug therapies. Supportive care is hugely 
important; considerations must be given to head of bed elevation, fever control, ventilation 
strategies, and prevention of pressure damage, ventilator-associated pneumonia, and deep vein 
thrombosis prevention. Approaches and evidence gaps in the supportive care of individuals with 
TBM are shown in table 1-2.  
Table 1-2: Approaches and evidence gaps in the supportive care of individuals with 
tuberculous meningitis[79] 
Infection control and 
reducing potential in-
hospital  M. tuberculosis 
transmission 
 Respiratory isolation may be required in those with 
concomitant pulmonary TB.  
 Respiratory isolation in critical care is challenging when high 
patient visibility is required.  
 The effect of endotracheal intubation and a closed ventilation 
circuit on TB transmission is uncertain, given periodic breaks 
to this closed circuit to allow suction may induce coughing.  
Head-of-bed elevation to 
reduce ICP 
 Elevating the head end of a bed aids venous drainage and 
shifts CSF extracranially, but may also lower mean arterial 
pressure 
 The effect of head-of-bed elevation in TBM has not been 
studied. An optimal elevation is unknown. 
Maintaining normal 
glucose concentrations 
 Hyperglycaemia and hypoglycaemia  adversely affect the brain 
during critical illness, however optimal glucose control is not 
known.[114]  
Treating anaemia to 
ensure optimal tissue 
oxygenation 
 Haemoglobin is important for optimal oxygen delivery in 
patients at risk of ischaemia, and optimal transfusion 
thresholds have not been determined in TBM. 
Controlling  and reducing 
fever  
 It is not known if treating fever in TBM improves outcomes.  
 No trials describe therapeutic hypothermia in TBM. 
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Deep vein thrombosis 
prevention 
 The role of deep vein thrombosis prophylaxis in critically ill 
individuals with TBM, where corticosteroids and aspirin may 
add to gastrointestinal bleeding risk, has not been studied. 
 The effect of head-of-bed elevation or general patient 
positioning in TBM on deep vein thrombosis has not been 
studied. 
Protecting pressure areas   The effect of head-of-bed elevation or general patient 
positioning in TBM on pressure area damage has not been 
studied. 
Ventilator-associated 
pneumonia prevention 
 Mechanical ventilation is common in critical care of TBM 
(70% in a study by Cantier et al).[115] Almost one quarter of 
mechanically ventilated TBM patients developed ventilator-
associated pneumonia in a study by Misra et al.[116] 
 Ventilator-associated pneumonia prevention strategies 
uncertain in TBM 
Optimising nutrition  TB is a catabolic illness yet no nutritional guideline exists 
specifically for TBM.  
CSF=cerebrospinal fluid. ICP=intracranial; pressure. TB=tuberculosis. TBM=tuberculous 
meningitis. Reference: Donovan J, et al. Lancet Neurol 2019. http://dx.doi.org/10.1016/ S1474-
4422(19)30154-1. 
 
1.3.7.2 Polypharmacy 
Critical illness may be caused by, or exacerbated by, anti-TB chemotherapy or other drugs. 
Important side effects, and interactions of drugs used in the treatment of critically ill individuals 
with TBM are shown in table 1-3. DILI may manifest as vomiting, abdominal pain, jaundice, and 
elevated liver function tests. Any drug reactions affecting neurological status may interfere with 
patient monitoring and assessment of GCS. Isoniazid and fluoroquinolones,[91,117] both used in 
the treatment of TB, increase seizure risk. A study of patients with TBM or tuberculoma 
experiencing seizures found that co-administration of isoniazid and phenytoin resulted in 
significantly higher serum phenytoin levels in slow acetylators compared with fast acetylators.[118] 
Yet, acetylator status (NAT-2 genotype) is infrequently tested. Given the interaction of anti-TB 
chemotherapy and anti-convulsants, the cytochrome (CY) P450 inducing effects of rifampicin and 
multiple anti-convulsants, the CYP450 inhibiting effect of isoniazid, and the role of 
benzodiazepines as a CYP3A4 substrate with a narrow therapeutic window, anti-convulsants must 
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be used with caution in critically ill individuals with TBM. Sodium, potassium, and glucose 
abnormalities may result from TBM treatment strategies. 
Table 1-3: Drugs commonly used during management of tuberculous meningitis[79] 
Drug Therapeutic role 
in TBM 
Primary adverse 
drug effect/side-
effect 
Additional drugs 
affected 
Additional adverse/ 
side effects 
Rifampicin First line ATT - Inducer of 
cytochrome 3A4 
enzyme[119] 
 
- Reduction in 
serum levels of anti-
retroviral therapy 
including NNRTIs 
and PIs[119] 
- Benzodiazepines; 
substrates for 
cytochrome 
3A4[120] 
DILI, 
hypersensitivity 
including SJS, renal 
failure, adrenal 
insufficiency, 
haemolysis, 
cytopenia[119] 
 
Isoniazid First line ATT - Inhibitor of 
cytochrome 
3A4[121] 
 
- Phenytoin; higher 
serum phenytoin 
levels in slow 
acetylators[118] 
- Benzodiazepines; 
substrates for 
cytochrome 
3A4[120] 
DILI, neuropathy, 
seizures, 
psychiatric 
disorders, 
TEN, SJS, 
pancreatitis, 
haemolysis, 
cytopenia[121] 
Pyrazinamide First line ATT   DILI, 
hypersensitivity 
including urticarial 
Ethambutol First line ATT Ocular toxicity 
difficult to detect 
in comatose 
patient 
 
 Ocular toxicity, 
hypersensitivity 
including SJS, 
thrombocytopenia, 
leucopenia, renal 
failure[122] 
Quinolones (e.g. ATT (second - Lowers seizure  DILI, seizures, 
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levofloxacin, 
moxifloxacin, 
gatifloxacin) 
line agents) threshold, 
demonstrated in 
higher dose 
rifampicin plus 
levofloxacin arm 
of TBM trial[91] 
 
 
 
 
psychiatric 
disorders, QT 
prolongation,  
TEN, SJS, 
haemolysis, 
cytopenia, renal 
failure, 
tendinitis[123] 
Corticosteroids 
(e.g. 
dexamethasone) 
Adjunctive anti-
inflammatory 
drug 
Gastrointestinal 
bleeding risk 
higher in 
critically ill 
patients   
Aspirin; overlapping 
side effect profile 
Adrenal 
insufficiency on 
discontinuation, 
gastrointestinal 
bleeding, psychosis, 
infections 
Aspirin Anti-platelet / 
anti-thrombotic 
agent 
Gastrointestinal 
bleeding risk 
higher in 
critically ill 
patients   
Corticosteroids; 
overlapping side 
effect profile 
Gastrointestinal 
bleeding, 
hypersensitivity 
reactions 
Acetazolamide - Reduction of 
CSF 
production[124]  
 
 
May cause 
hyponatraemia 
in a condition 
where 
hyponatraemia is 
common and 
hazardous  
- Overlapping 
treatment effect 
profile with 
fludrocortisone 
- Increased 
metabolic acidosis 
and neurological 
effects with 
concomitant aspirin, 
interactions with 
anti-
convulsants[125]  
- Electrolyte 
imbalance, renal 
failure  
- Extensive side 
effects and drug 
interactions, 
covered 
elsewhere[126] 
ATT=anti-tuberculosis chemotherapy. ART=anti-retroviral therapy. CSF=cerebrospinal fluid. 
DILI=drug induced liver injury. NNRTIs=non-nucleoside reverse transcriptase inhibitors. 
PIs=protease inhibitors. SJS=Stevens-Johnson syndrome. TBM=tuberculous meningitis. TEN=toxic 
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epidermal necrolysis. Reference: Donovan J, et al. Lancet Neurol 2019. http://dx.doi.org/10.1016/ 
S1474-4422(19)30154-1. 
 
1.3.7.3 Neurological complications 
Numerous disease complications reduce consciousness, often through raised ICP which, as 
discussed, may be challenging to detect. Hydrocephalus, cerebral oedema, inflammatory 
complications such as paradoxical reactions and neurological IRIS, and cerebral infarction, all may 
contribute to raised ICP in varying degrees.[78] Whether targeted ICP-guided therapies upon 
detection of raised ICP improves outcomes in TBM is an area for future research. Identification of 
individuals who will benefit from neurosurgical management of raised ICP is difficult. Reduction 
and control of ICP, and maintenance of brain perfusion are critical in TBM, as illustrated in figure 
1-2. Below, the most common neurological complications of TBM are briefly discussed.  
Figure 1-2: Potential strategies for the management of intracranial pressure and maintenance 
of brain perfusion in critically ill individuals with tuberculous meningitis[79]  
 
Little evidence exists to guide these strategies in TBM; however, this figure illustrates potential 
approaches. Surgical interventions are labelled in red, disease processes are labelled in blue, and 
other interventions labelled in black. ETV=endoscopic third ventriculostomy. EVD=external 
ventricular drain. TBM=tuberculous meningitis. VP=ventriculoperitoneal. Reference: Donovan J, et 
al. Lancet Neurol 2019. http://dx.doi.org/10.1016/ S1474-4422(19)30154-1. 
 
1.3.7.3.1 Hydrocephalus 
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Hydrocephalus occurs when there is impairment of the passage of CSF from its point of production 
to its point of absorption (figure 1-3).[127] Hydrocephalus occurs in approximately 70% of TBM 
overall,[128] with higher rates reported in children; 80-86%,[129–133] than in series predominantly 
of adults; 43-48%.[134,135] Hydrocephalus is rare in early TBM, but almost always present once 
neck stiffness is present and loss of consciousness has occurred.[15] TBM-associated 
hydrocephalus is communicating in approximately 80% of cases, due to basal cistern 
block,[15,136,137] and medical therapy (acetazolamide plus furosemide) may be effective in these 
cases.[138] Obstruction of CSF flow at the brain aqueduct, or more commonly at the fourth 
ventricle foramina, results in non-communicating hydrocephalus.[15,139] Cerebral aqueduct 
obstruction occurs via constriction by exudate surrounding the upper brainstem, or an intraluminal 
tuberculoma, whereas the fourth ventricle outlet is obstructed by exudate.[128,139] Distinction 
between communicating and non-communicating hydrocephalus is vital, yet this is not reliably 
identified using conventional brain CT imaging or MRI.[140] Lumbar CSF drainage in non-
communicating hydrocephalus can widen the pressure differential across the two (or more) 
separated CSF compartments, resulting in cerebral tonsillar herniation.  
  
 
47 
 
Figure 1-3: Hydrocephalus in tuberculous meningitis 
 
CT imaging showing distended lateral ventricles of the brain (central black spaces) due to raised 
intraventricular pressure; this is hydrocephalus. CT=computed tomography. 
 
1.3.7.3.2 Cerebral infarction 
Cerebral infarcts are the main cause of irreversible brain damage in TBM,[141] occurring in 8-67% 
of patients.[141–147] The pathophysiology of cerebral infarction may depend upon the stage of 
TBM, with vasospasm more common than vasculitis in early disease.[141] In later disease vessel 
pathology likely occurs through a combination of infiltrative, proliferative and necrotising 
processes.[141,147] The role of thrombosis is unclear.[141] CT imaging in TBM has shown basal 
cistern exudate enveloping arteries, leading to arteritis, and endarteritis infiltration, particularly of 
small perforating arteries of the circle of Willis. Less frequently, occlusion of the middle cerebral 
artery or anterior cerebral artery cause major infarction.[148] Infarcts are frequently multiple.[144] 
Clinical presentation of cerebral infarction varies, however hemiplegia appears to be the most 
common presenting sign.[15,141] Long term neurological disability is common, prolonging hospital 
stay and time in bed, and increasing the risks of non-neurological complications such as ventilator 
associated pneumonia and pressure area damage. No adjunctive treatment has consistently reduced 
stroke or hemiplegia in TBM.[15]  
1.3.7.3.3 Tuberculomas 
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Tuberculomas may develop with or without TBM, and may develop or enlarge during appropriate 
anti-TB chemotherapy. If a tuberculous granuloma (Rich focus) does not rupture but instead 
continue to grow, a tuberculoma can result. Additionally tuberculomas may develop from resolving 
granulomatous inflammation weeks after commencing anti-TB chemotherapy, despite anti-TB 
chemotherapy being appropriate.[15] Studies of adults and children have reported an incidence of 
tuberculomas on imaging at 2-42%.[131,134,135] In a study of 43 adults with TBM randomised to 
dexamethasone or placebo in Vietnam, receiving dexamethasone did not affect the site or number of 
tuberculomas, nor the proportion of patients affected by a tuberculoma at day 60 or day 270 of 
treatment.[113] In an adult study, brain MRI revealed tuberculomas in 64% (14/22) patients at 
baseline, and 74% (20/27) patients at day 60,[113] whilst in a paediatric study brain MRI (average 
26 days post-admission) found tuberculomas in 59% (23/39) patients, compared with only 7% 
(3/44) patients using CT on admission in the same group.[149] Tuberculomas may exert mass effect 
upon brain tissue, or compression of the cerebral ventricles leading to a non-communicating 
hydrocephalus.  
1.3.7.3.4 Paradoxical reactions 
Paradoxical reactions manifest as worsening of an existing lesion or the appearance of new lesions, 
despite an initial response to treatment. Although most commonly considered an exuberant 
inflammatory response to dead or dying bacteria, their pathogenesis is poorly understood.[79,150] 
In a study of patients in India (mean age 30 years), 31% (44/141) patients developed a paradoxical 
reaction.[151] The timing of onset of paradoxical reactions is highly variable however onset is 
usually after 2-4 months of anti-TB chemotherapy.[152] In the context of TBM paradoxical 
reactions present as fever, headache, altered sensation or vision, or seizures, in addition to a 
worsening of CSF cell count or protein.[151] Tuberculomas are the most common paradoxical 
reaction in HIV uninfected TBM.[152] Basal cistern exudate may develop after commencement of 
anti-TB chemotherapy; this may be seen on follow up brain imaging, despite normal baseline 
imaging (figure 1-4).   
  
 
49 
 
Figure 1-4: Basal cistern exudate of tuberculous meningitis 
Panel A: 
 
 
Panel B: 
 
Panel A: Baseline MRI brain (transverse view) from a 22 year old male with tuberculous 
meningitis. Clinical presentation was with a 3-week history of fever, headache and neck stiffness, 
with no neurological deficit. Panel B: MRI brain (transverse view) taken after same patient 
readmitted with an acutely reduced level of consciousness and bilateral cranial nerve palsies, 3 
weeks after first imaging. Repeat imaging showed severe basal meningeal exudate secondary to 
tuberculous meningitis. MRI=magnetic resonance imaging 
 
1.3.7.3.5 Immune reconstitution inflammatory syndrome and anti-retroviral therapy 
Severe tuberculous exudate 
in the basal cistern 
enveloping the midbrain 
Midbrain 
 
Basal cistern free of 
tuberculous exudate 
Midbrain 
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In HIV co-infected individuals who have newly commenced ART, paradoxical reactions are usually 
attributed to IRIS. Imaging in TBM IRIS can reveal new or enlarging tuberculomas with or without 
meningitis, infarcts, hydrocephalus and radiculomyopathy, or less commonly optochiasmatic or 
spinal arachnoiditis.[151,153] A case series of neurological IRIS in South African patients with 
TBM suggested IRIS has considerable short term morbidity but reasonable long term 
outcomes.[153]  
The optimal timing for commencing ART in TBM, to allow immunological recovery without IRIS, 
is unknown. A study of 34 ART-naïve HIV co-infected patients with TBM found the occurrence of 
neurological IRIS (47% [16/34] patients) to be associated with higher CSF neutrophil counts and M. 
tuberculosis culture positivity at diagnosis. All patients received prednisolone 1.5mg/kg/day 
alongside anti-TB chemotherapy, and all patients commenced ART 2 weeks after starting anti-TB 
chemotherapy.[23] A randomised double-blind placebo-controlled trial compared immediate ART 
(within 7 days of starting anti-TB treatment) with deferred ART (2 months after starting anti-TB 
chemotherapy) in 253 Vietnamese adults with TBM;[154] in the immediate arm there was no 
reduction in mortality and this group experienced more grade 4 adverse events. In clinical practice 
in Vietnam, ART may be commenced 8 weeks after anti-TB chemotherapy, however, in individuals 
with normal baseline brain imaging and low CSF neutrophil counts, ART may be started earlier. 
1.3.7.3.6 Spinal disease 
Spinal disease is under recognised in TBM, yet contributes significantly to morbidity. Most 
commonly due to tuberculous arachnoiditis, spinal involvement is often only revealed paradoxically 
after commencing anti-TB chemotherapy, although high CSF protein may indicate a higher risk of 
development.[155] Neurological manifestations depend upon the affected level, however 
lumbosacral disease is most common.[155] It may be challenging to clinically recognise spinal 
disease in individuals with severe TBM disease in whom history is unavailable, and neurological 
examination is frequently unreliable. Reduced mobility resulting from spinal disease increases bed-
time and secondary complications of this such as damage to pressure areas. Urinary retention is 
often the first sign presenting to the clinician. Outcomes from spinal disease are usually poor.   
1.3.7.4 Hyponatraemia 
Hyponatraemia is a common electrolyte imbalance in individuals with TBM. Cerebral salt wasting 
(CSW) and the syndrome of inappropriate antidiuretic hormone secretion (SIADH) are considered 
the likely causes, however the pathogenesis of these conditions in TBM is not well understood. 
CSW may be mediated via hormonal mechanisms (likely via atrial natriuretic peptide [ANP], 
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released from atrial muscle after atrial stretch), or via direct effects on neural connections to the 
kidneys, where interruption of sympathetic stimulation leads to increased renal blood flow and 
naturesis.[156] Whilst ANP containing neurons exist in the brain, low brain ANP levels make it 
unlikely that production at this site is the mechanism of CSW.[156] ANP and brain natriuretic 
peptide (BNP) act in the brain to decrease salt appetite, water intake and corticotrophin release, and 
act in the kidney to decrease aldosterone and renin, resulting in renal sodium loss.[157] Conversely, 
SIADH occurs when anti-diuretic hormone is secreted independently of the body’s need to conserve 
water.[158]  
Distinguishing between CSW and SIADH is hugely challenging, given the need for extracellular 
fluid assessment. Determining the exact cause of hyponatraemia in TBM may indeed have limited 
clinical value; with the exception of avoiding fluid restriction in a high urinary volume, high urinary 
sodium, scenario. In this scenario haemodynamic instability rapidly results and intravenous fluid 
becomes mandatory. CSW and SIADH may in fact overlap or occur in sequence, confounding 
assessment further.  
Whether to correct hyponatraemia in the absence of hypovolaemia is uncertain, and no trials of 
sodium-containing fluids, sodium concentrations, or fluid durations, have been performed to date in 
TBM. A randomised controlled trial (RCT) compared intravenous and oral sodium supplementation 
with or without fludrocortisone (0.1-0.4 mg/day) in the treatment of 37 Indian adults with 
hyponatraemia (<135 mEq/L) caused by CSW associated with TBM.[159] Fludrocortisone 
(combined with intravenous and oral salt supplementation) was significantly associated with faster 
correction of plasma sodium than intravenous and oral salt supplementation alone (4 days vs. 15 
days), but did not influence mortality or disability at 6 months. Fludrocortisone was associated with 
severe hypokalaemia and hypertension in two patients with hyponatraemia necessitating its 
discontinuation.[79] In this thesis (chapter 5) I will perform a large longitudinal (first 30 days) 
descriptive analysis of hyponatraemia in TBM. 
1.3.8 Summary 
TBM carries an unacceptably high mortality and morbidity. To achieve progress in the field and 
improve patient outcomes, numerous challenges must be overcome and research gaps closed. True 
global incidence of TBM is uncertain, and the disease may be hard to recognise for the non-
specialist clinician. Current diagnostic tools for identifying M. tuberculosis in CSF are insufficiently 
sensitive, resulting in delayed treatments, which only worsens prognosis further. TBM treatment 
courses are lengthy with drug resistance a growing problem. Few clinical trial data are available to 
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guide best treatments. Numerous disease complications exist, and are challenging to detect, 
monitor, and manage.  
Yet the TBM research field is not remaining still. A recently formed TBM Research Consortium 
allows collaboration and discussion. Eleven TBM clinical trials have started or are due to start 
imminently, including two in paediatrics where data are especially sparse. More understanding is 
emerging regarding the complex TBM pathophysiology, and bacterial-host interaction. A growing 
ability to understand and quantify -omics data may lead to advances in diagnostics, advances in 
prognostic biomarkers, and may identify new therapeutic targets. Increasing global recognition of 
TBM, through development of specific TBM guidelines, involvement of TBM at international TB 
conferences, and more TBM-directed funding, is vital to raise the profile of TBM and continue the 
forward direction of research in this field.  
 
1.4 Publications related to this chapter 
Aspects of this introductory chapter appear in the following published review article:  
1. The neurocritical care of tuberculous meningitis 
Joseph Donovan, Anthony Figaji, Darma Imran, Nguyen Hoan Phu, Ursula Rohlwink, Guy E. 
Thwaites 
The Lancet Neurology 2019 Aug;18(8):771-783 
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Chapter 2 
A randomised comparison of GeneXpert MTB/RIF and GeneXpert 
MTB/RIF Ultra for the diagnosis of tuberculous meningitis    
2.1 Introduction 
2.1.1 Tuberculous meningitis: why do we need a new diagnostic test? 
TBM is the most severe form of TB, resulting in death or disability in approximately half of those it 
affects.[15] Delayed diagnosis and treatment are strongly linked to poor outcomes. Yet diagnosis of 
TBM is challenging and has remained so for many years. The indolent meningitic presentation of 
TBM mimics that caused by other pathogens; as such, a diagnosis of TBM may not be considered 
by the treating clinician. A consistent clinical history, CSF parameters, and chest X-ray (miliary or 
pulmonary TB) may increase the clinician’s suspicion of TBM; however, confirming a diagnosis of 
TBM rests upon the detection of acid-fast bacilli (AFB) in CSF. 
Unfortunately, the low number of M. tuberculosis bacilli in CSF makes their identification difficult. 
Current diagnostic tests lack sufficient accuracy to exclude TBM on the basis of a negative result. 
Current confirmatory diagnostic tests for TBM include smear microscopy (for example the ZN 
method of staining AFBs), mycobacterial culture, and molecular tests such as Xpert. Each of these 
three testing methods is currently performed at our research unit; OUCRU based at HTD in Ho Chi 
Minh City. Each of these three testing methods has limitations, which need consideration when 
these tests are used as a reference standard for new diagnostic tests. In this thesis chapter I will 
describe ZN smear microscopy and mycobacterial culture (confirmatory tests for the study 
described in this chapter), in addition to molecular assay testing (including Xpert). Additional 
diagnostic tests for TBM, confirmatory and non-confirmatory, are further discussed in chapter 1.  
2.1.2 Current confirmatory diagnosis tests 
2.1.2.1 Ziehl-Neelsen smear microscopy 
CSF ZN smear microscopy is the most basic test for TBM, requiring readily available laboratory 
equipment and an appropriate space to perform the test. A large volume of CSF (~10mls) [9] should 
first be centrifuged, enabling the concentration of AFBs into a pellet. Resuspended CSF pellet is 
pipetted onto a cleaned and labelled microscope slide. After drying, the sample is flooded with 
carbol-fuchsin, and then heated to drive the stain into the mycolic acid wall of M. tuberculosis, if it 
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is present. After decolourisation with acid-alcohol, a counterstain such as methylene blue is added. 
The slide is dried, and then read under a 100x lens using oil immersion.  
Whilst these are the general principles of CSF ZN smear microscopy, methods are variable between 
different centres, and diagnostic sensitivity globally is often poor.[65] Pre-centrifugation CSF 
volume, duration of microscopy, and microscopist experience are all important for improving M. 
tuberculosis identification.[65,160] Killed mycobacteria will also stain positive; a confounding 
factor for analysis of repeat clinical samples after initiation of anti-TB chemotherapy. Additionally, 
AFB include non-tuberculous mycobacteria, and non-mycobacterial bacteria such as Nocardia 
species; however, these are unlikely to be present in CSF, where AFBs invariably represent TBM. 
2.1.2.2 Mycobacterial culture 
Culture of M. tuberculosis from CSF offers proof of the organism and fully confirms TBM. Given 
M. tuberculosis grows faster in liquid media than solid media,[161] liquid mycobacterial culture 
methods such as MGIT and MODS are favoured in TBM (vs. solid culture). In MGIT culture (for 
example the BACTEC MGIT 960 system), mycobacteria are cultured in media together with 
mycobacterial growth supplements and antibiotics; M. tuberculosis growth is identified via 
detection of fluorescence from an oxygen sensitive compound in the tube.[162] With MODS, the 
characteristic cord formation of M. tuberculosis is viewed in liquid culture by regular 
microscopy.[161] MGIT and MODS were shown to be equivalent for the diagnosis of TBM in a 
study of 156 individuals in Vietnam.[55] Although cheaper than MGIT, MODS is time consuming, 
and may increase risk of exposure to aerosolised mycobacteria; however, this risk is uncertain with 
TBM where CSF has lower bacillary load than sputum.   
Mycobacterial culture sensitivity rarely exceeds 60%, and is often lower.[37,65,67] When M. 
tuberculosis does grow in culture media, DST can be performed, and anti-TB chemotherapy can be 
modified if resistance is found. Mycobacterial culture from CSF often takes many weeks and 
therefore cannot guide initial treatment. Like smear microscopy, optimisation of sample (large 
volume, centrifugation) is critical to increase the chances of M. tuberculosis growth and a positive 
result. 
2.1.2.3 GeneXpert MTB/RIF 
According to the most up to date WHO data, the estimated percentage of TB cases with MDR or 
rifampicin resistance in Vietnam is 4.1% for new cases and 25% for previously treated cases.[63] 
Given neither ZN smear microscopy nor mycobacterial culture can identify rifampicin resistance at 
diagnosis, development of a new diagnostic test was essential. Xpert offered a breakthrough in TB 
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diagnostics; a rapid high sensitivity NAAT with additional rifampicin susceptibility testing. Xpert 
uses a hemi-nested real-time PCR assay to detect and amplify a M. tuberculosis specific sequence 
of the bacterial rpoB gene.[61] In >95% of cases rifampicin resistance is associated with mutations 
in the 81 base pair core region of the rpoB gene, with this area additionally flanked by M. 
tuberculosis specific DNA sequences; therefore identification of M. tuberculosis and detection of 
rifampicin resistance can be performed in a single test.[64] Xpert results are available in less than 
two hours,[61] and testing systems allow multiple samples to be tested (each within its own 
cartridge) simultaneously.   
Xpert is now widely distributed throughout the world; over 7500 Xpert systems have been deployed 
globally, including over 3500 installed in 110 high burden developing countries.[62] As with smear 
microscopy and mycobacterial culture, patient factors, clinical sampling, and sample processing can 
all influence Xpert sensitivity; HIV co-infection,[33] large CSF volume, CSF centrifugation, and 
the addition of a vortexing step after addition of sample reagents,[37] all increase the chances of a 
positive test result.  
2.1.3 Evidence supporting GeneXpert MTB/RIF for tuberculosis testing 
2.1.3.1 Pulmonary tuberculosis 
Xpert can be used to identify M. tuberculosis in a variety of clinical samples. A Cochrane review of 
the performance of Xpert for the detection of M. tuberculosis in sputum found Xpert to have high 
sensitivity and specificity for diagnosing pulmonary TB (pooled sensitivity 89%, pooled specificity 
99%).[163] In individuals with pulmonary TB and HIV co-infection pooled sensitivity reduced to 
79%, consistent with a reduced sputum bacillary load in HIV co-infection.  
2.1.3.2 Tuberculous meningitis 
The diagnostic performance of Xpert for M. tuberculosis identification in CSF unfortunately does 
not match the same high performance of Xpert with sputum samples, likely due to the 
paucibacillary nature of CSF in TBM. A South African study of 204 individuals (87% HIV co-
infected) with suspected TBM found Xpert to be 67% sensitive at detecting M. tuberculosis in CSF 
(pooled centrifuged and uncentrifuged samples) vs. a liquid culture or Amplicor PCR positive 
reference standard.[164] When the diagnostic sensitivity of Xpert for the detection of M. 
tuberculosis in the same CSF samples was compared to a liquid culture or Amplicor PCR positive 
reference standard, plus the meeting of criteria for probable or definite TBM (defined by the 
uniform case definition for TBM[69]), Xpert sensitivity reduced to just 36% for TBM diagnosis. 
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These differing sensitivities, 67% vs. 36%, neatly demonstrates the issue of reference standard use 
when comparing diagnostic tests for TBM, a disease for which there is no gold standard for test 
comparison. 
A study of Vietnamese adults with TBM showed Xpert sensitivity to be 59.3% (108/182; 95% CI 
51.8-66.5%) compared to a clinical diagnosis of TBM (definite, probable, and possible), with test 
specificity 99.5% (95% CI 97.2-100%).[37] The addition of a vortexing step to the Xpert procedure 
(after addition of sample reagent to resuspended CSF, in order to facilitate cell breakdown and 
release of intracellular M. tuberculosis DNA) part way through data collection in this study, 
improved Xpert sensitivity for TBM diagnosis; without vortexing: 50.0% (13/26 [95% CI 29.9-
70.1%]) vs. with vortexing: 60.9% (95/156 [95% CI 52.8-68.6%]).This study [37] also 
demonstrated the impact of CSF volume and HIV co-infection on Xpert sensitivity. Xpert 
sensitivity was assessed by CSF volume tested, and by HIV co-infection status. Using the same 
reference standard of definite probable and possible TBM, sensitivities of Xpert by CSF volume 
tested were; 51.7% (95% CI 32.5-70.6%) for low-volume (≤2ml) samples, 61.5% (95% CI 44.2-
73.0%) for medium-volume (2.1-5.0ml) samples, and 59.2% (95% CI 44.2-73.0%) for high-volume 
(>5ml) samples.[37] In participants with HIV co-infection, Xpert sensitivity was 78.8% (95% CI 
77.6-79.7%), and in HIV-uninfected participants sensitivity was 47.9% (95% CI 47.0-48.7%).  
Bahr et al described the performance of Xpert for the identification of M. tuberculosis in CSF 
samples of patients with meningitis in whom cryptococcal meningitis had been excluded.[165] 
Xpert was compared against microbiologically proven TBM using CSF that was non-centrifuged 
(Xpert sensitivity 28%) and centrifuged with subsequent resuspension (Xpert sensitivity 72%).[165] 
In this study, when Xpert testing of centrifuged CSF was compared with definite or probable TBM 
(using the uniform case definition[69]), sensitivity of Xpert for M. tuberculosis detection was 65%, 
with a specificity of 100%.[165] Sensitivity reduced to just 20% when Xpert was compared with 
definite, probable and possible TBM.[165]  
2.1.3.2.1 Meta-analyses 
A meta-analysis (13 studies, 839 samples) of Xpert performance for TBM diagnosis compared vs. 
mycobacterial culture as a reference standard found a pooled sensitivity of Xpert of 80.5% (95% CI 
59.0-92.2%), and a pooled specificity of 97.8% (95% CI 95.2-99.0%).[166] In this study, when 
Xpert was compared against clinical reference standards (inclusive of presenting signs, symptoms, 
biochemical and microbiological tests; defined by the individual studies) the pooled sensitivity of 
Xpert for TBM diagnosis was 62.8% (95% CI 47.7-75.8%), and the pooled specificity was 98.8% 
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(95% CI 95.7-100%) (5 studies, 711 samples). A WHO meta-analysis of studies published between 
2007 and 2012 inclusive, found 16 studies (709 samples) where CSF tested by Xpert was compared 
against CSF culture as a reference standard.[167] In this analysis pooled sensitivity was 79.5% 
(95% CI 62.0-90.2%) and the pooled specificity was 98.6% (95% CI 95.8-99.6%).[167]  
2.1.4 Alternative molecular tests to Xpert platforms 
Whilst Xpert tests are the dominant molecular assays worldwide for TB and TBM diagnosis, 
alternative diagnostics are in development and testing. Loop-mediated isothermal amplification 
(LAMP) is a unique isothermal (constant temperature) test-tube based loop DNA amplification 
technique, which has been applied to M. tuberculosis (TB-LAMP; Eiken Chemical Company Ltd, 
Tokyo, Japan), and is now recommended by the WHO as an alternative to sputum smear 
microscopy for pulmonary TB diagnosis.[168] LAMP utilises specially designed primers to attach 
to target DNA, resulting in the production of loop-DNA structures which can continue to amplify 
under constant temperature.[169] The isothermal approach reduces cost, the test is quick (< 1 hour), 
and the colour reaction within the test tube can be read by the naked eye. Critically, LAMP cannot 
identify rifampicin resistance. In a 2018 meta-analysis of LAMP performance for extrapulmonary 
TB diagnosis, pooled LAMP sensitivity and specificity were 76% and 99%, respectively, for the 
identification of M. tuberculosis in CSF (4 studies, variable composite reference standards).[170]  
The new molecular assays Truenat MTB and Truenat MTB Plus (Truenat) (Molbio Diagnostics, 
Goa, India) are semi-automated chip-based PCR tests that use 2 individual devices (1: sample 
preparation and DNA extraction, 2: PCR) to identify M. tuberculosis and then optionally proceed to 
identification of rifampicin resistance if required.[171] Preliminary data suggest Truenat tests have 
comparable diagnostic accuracy with Xpert tests when testing sputum of suspected pulmonary 
TB.[172] There are no published studies describing Truenat for the diagnosis of TBM.   
2.1.5 Reference standards for TBM diagnostics 
2.1.5.1 Inconsistent use of reference standards 
Whilst meta-analyses show impressive sensitivity for M. tuberculosis identification in CSF by 
molecular methods, against a standard of mycobacterial culture,[166,167], diagnostic sensitivity 
falls when a reference standard more representative of true TBM cases is used. A reference standard 
of positive mycobacterial culture does not reflect all cases of TBM, many of which are culture 
negative. 
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Inconsistency in reference standard use for TBM diagnostic tests leads to confusion regarding test 
sensitivity, and limits comparison between studies. Diagnostic test comparison against a reference 
standard that includes only ZN smear or mycobacterial culture positive individuals likely selects a 
reference standard containing higher bacillary loads, resulting in a misleading conclusion of higher 
test sensitivity, as the test under investigation (e.g. Xpert) now has a greater chance of identifying  
M. tuberculosis bacilli. An ideal reference standard should identify and include all patients with 
TBM. 
2.1.5.2 The uniform case definition for tuberculous meningitis 
The uniform case definition for TBM[69] offers a system for the standardisation of TBM research. 
This case definition incorporates clinical data, CSF parameters, brain imaging, evidence of 
extraneural TB, and positive diagnostic tests, to categorise suspected TBM cases into 1 of 4 
diagnostic groups; definite, probable, possible, and not-TBM. However, in the absence of a ‘gold 
standard’ diagnostic test, this uniform case definition has now become a new ‘gold standard’ for 
TBM diagnostic test comparison; despite this not being its purpose.  
2.1.5.3 Possible TBM 
Within the uniform case definition, what constitutes a ‘diagnosis of TBM’ for the purpose of a 
reference standard may differ; this was not defined by the authors as this practice was not intended. 
Given the intention of a reference standard should be to select all cases of a disease (i.e. TBM), and 
no cases without the disease, common approaches have been to combine ‘definite and probable 
TBM’,[67] or to combine ‘definite, probable and possible TBM’,[37,65] and label these groups as 
having a diagnosis of TBM.  
The inclusion of individuals with ‘possible TBM’ in a TBM reference standard ensures all ‘true’ 
cases of TBM are likely to be included in the standard; however, some diseases other than TBM are 
also likely to be included. This is a particular issue in HIV co-infected TBM, where HIV-associated 
clinical data and CSF parameters may build up the numerical diagnostic score to a value close to 
triggering a diagnosis of at least possible TBM. Inclusion of possible TBM in a reference standard 
may artificially lower sensitivity of the index test (i.e. the test being evaluated); any non-TBM cases 
will test negative by the index test, and this will reduce its sensitivity. Yet exclusion of possible 
TBM from a reference standard may artificially elevate test sensitivity, given the possible TBM 
group likely includes some TBM cases, possibly those with lower bacillary load. A definite plus 
probable TBM reference standard may select a reference population with higher bacillary load, 
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therefore creating more chance of index test positivity. The true sensitivity may lie in between the 
sensitivity values from each of these two reference standards. As such, presentation of index test 
data against multiple standards is commonplace.  
2.1.5.4 Inclusion of the index test in a reference standard 
Another consideration with TBM reference standards is whether the index test (e.g. Xpert) should 
be included in the reference standard. This confusion may arise from the presence in the uniform 
case definition of CSF NAAT (e.g. Xpert) as a criterion for definite TBM (when positive). The 
greatest impact of including the index test in a reference standard is that specificity cannot be 
accurately assessed; any false positive result would not be detected when the index test forms part 
of the reference standard, as the result would instead be labelled a true positive. This is particularly 
a risk if the index test is more sensitive than any other aspect of the reference standard, i.e. the index 
test (within the reference standard) is the only positive component of that reference standard. When 
assessing molecular tests in CSF, false positive M. tuberculosis results are likely exceptional; the 
CSF is highly unlikely to contain DNA of M. tuberculosis that is not relevant to the clinical 
presentation. However, to ensure accurate sensitivity data, an index test should be excluded from a 
reference standard against which it is being compared.   
2.1.6 GeneXpert MTB/RIF Ultra 
2.1.6.1 A new generation of Xpert 
In recent years a new generation of Xpert has become commercially available for M. tuberculosis 
detection; Ultra. Ultra aims to improve the sensitivity of TB diagnosis and enhance rifampicin 
resistance identification, using the same cartridge based nested PCR amplification as Xpert. A 
larger reaction chamber, plus incorporation of two different multicopy amplification targets (IS6110 
and IS1081), intend to improve test sensitivity through a reduced limit of detection of bacterial 
colony forming units.[70] Adaptation of molecular probes and testing approach are designed to 
differentiate between silent mutations (those not conferring resistance), and mutations conferring 
resistance.[71] Whereas Xpert has a limit of detection of 130 CFU/mL, Ultra’s limit of detection is 
approximately 10 CFU/mL.[62] Given this lower limit of M. tuberculosis detection, a new semi-
quantification category (trace) has been added to Ultra. This trace category, the lowest possible 
positive detection category, adds to existing categories of ‘high’ (rarely seen in TBM), ‘medium’, 
‘low’ and ‘very low’ M. tuberculosis detection.  
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2.1.6.2 GeneXpert MTB/RIF Ultra for pulmonary tuberculosis 
Ultra has already shown its diagnostic superiority in pulmonary TB. In a prospective multicentre 
study of adults with pulmonary TB (n=1520), comparing Ultra vs. Xpert testing of sputum samples, 
Ultra demonstrated a 4.9% increase in sensitivity over Xpert (sensitivities; 87.8 vs. 82.9%, 
respectively), with an associated 3.2% decrease in specificity (specificities; 94.8 vs. 98%, 
respectively).[70] Additionally, in this study Ultra had a higher diagnostic sensitivity than Xpert; 63 
vs. 46% in smear negative, culture positive sputum samples (n=135); and 90 vs. 77% in culture 
positive sputum samples from HIV co-infected individuals (n=115).[173] However, no 
improvement in sensitivity was seen amongst a subgroup of HIV-uninfected individuals (test 
sensitivities 91 vs. 90%, Ultra and Xpert respectively), and Ultra specificity was lower than Xpert. 
2.1.6.3 GeneXpert MTB/RIF Ultra for the diagnosis of tuberculous meningitis 
In 2018 a study comparing Ultra and Xpert for the diagnosis of TBM was published,[67] 
subsequently followed by three studies evaluating the role of Ultra in the diagnosis of 
extrapulmonary TB,[72,174,175] inclusive of varying numbers of CSF samples. In the 2018 TBM 
study, frozen CSF was stored from patients screened for a trial of the treatment of HIV co-infected 
cryptococcal meningitis.[67] In 23 HIV co-infected individuals subsequently diagnosed with 
definite or probable TBM, pre-centrifuged cryopreserved CSF was thawed and then tested with 
Ultra and Xpert. Ultra and Xpert sensitivities were 69.6% (16/23) and 43.5% (10/23) respectively, 
compared with a reference standard of definite or probable TBM. Of 21 cases positive by Ultra, 
Ultra was the only positive mycobacterial test in 8 cases, suggesting Ultra may detect cases of TBM 
below the threshold of detection of other confirmatory mycobacterial tests. An additional, highly 
impressive, diagnostic sensitivity of 95% was reported when Ultra (the index test) was included in 
the reference standard; all 8 cases where Ultra was the only positive test were thus given a final 
diagnosis of ‘definite TBM’ on the basis of Ultra alone. This inclusion of Ultra in the reference 
standard assumes these 8 cases were not false positive diagnoses. Of these 8 cases positive only by 
Ultra, 4 died, 1 was lost to follow up, and a further 2 died on treatment. Certainty of TBM was 
lacking in these 8 cases, and the possibility of false positives cannot be rejected entirely. 
Subsequent to this study the WHO recommended Ultra replace Xpert in all settings.[167] 
In the three additional studies comparing Ultra and Xpert testing of extrapulmonary samples, 43, 4 
(retrospectively tested), and 16 (prospectively tested) CSF samples of suspected TBM cases were 
included. The study containing the largest group (n=43) used at least 3mls of uncentrifuged CSF for 
testing.[72] Sensitivities of Ultra and Xpert were 44.2% (19/43) vs. 18.6% (8/43) respectively, 
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p=0.01. Whilst the reported sensitivity of Ultra was higher when testing bacteriologically confirmed 
TBM; 86.4% (19/22) vs. 36.4% (8/22) respectively, p=0.001, cases positive only by NAAT were 
included in the reference standard. Of the 43 cases, all were smear negative and only 3 were culture 
positive.  
A larger evidence base is required to support Ultra for the diagnosis of TBM, and assess superiority 
of Ultra over Xpert. No randomised comparison of Ultra and Xpert had been performed at the time 
of conducting the study that will now be described.  
2.2 Methods 
2.2.1 Study design 
This study was a prospective randomised diagnostic study comparing the diagnostic performances 
of Ultra and Xpert for the diagnosis of TBM. Enrolled participants were randomised (1:1) to receive 
baseline CSF testing by either Ultra or Xpert (figure 2-1).  
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Figure 2-1: Study flow 
 
 
 
 
 
 
 
 
 
  
 
 
  
 
 
 
  
 
 
CSF=cerebrospinal fluid. MGIT=mycobacterial growth indicator tube. TBM=tuberculous 
meningitis. Ultra=GeneXpert MTB/RIF Ultra. Xpert=GeneXpert MTB/RIF. ZN=Ziehl-Neelsen 
staining.  
 
In addition, repeat Ultra or Xpert testing was performed on routine follow up CSF sampled at 3-4 
weeks, using the allocation test (Ultra or Xpert) following the initial randomisation. The rationale 
for a randomised study design, rather than using both tests for each CSF sample, was as follows: 
TBM is associated with very low numbers of M. tuberculosis bacteria in CSF, and the performance 
of tests that detect M. tuberculosis are dependent on the CSF volume tested. Using large CSF 
Randomise to Ultra or Xpert  
Xpert  Day 0 Ultra  
If still undergoing TBM treatment at 3-4 weeks 
Maintain previous randomisation 
Xpert  3-4 weeks Ultra  
ZN 
MGIT 
If CSF clear or mildly cloudy, >5 days of symptoms and/or low CSF 
glucose and/or raised CSF lactate 
 
Routine CSF tests performed 
 
Study consent obtained 
 
Lumbar puncture is indicated 
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volumes (≥6mls), and randomising to one of Ultra or Xpert, provides estimates of the diagnostic 
performances of these two tests matching clinical practice. Halving the CSF sample (and the M. 
tuberculosis bacteria) to perform both Ultra and Xpert reduces the sensitivity of both tests. 
Randomisation was performed using a randomisation list generated by a program written in R 
(version 3.4). 
2.2.2 Study participants 
Study participants were enrolled into a prospective study of brain infection in Vietnamese adults, 
with this comparison of Ultra and Xpert forming part of that study. Participants were ≥16 years old, 
with suspected TBM based on clinical and CSF findings (clear or mildly cloudy CSF, in addition to 
one of >5 days of symptoms, low CSF glucose, or raised CSF lactate), based at HTD, Ho Chi Minh 
City, Vietnam. Patients were excluded from enrollment if a lumbar puncture was contraindicated or 
if informed consent was not given by the patient (or by a relative if the patient did not have 
capacity). Ethical approvals for this study were obtained from the Oxford Tropical Research Ethics 
Committee (OxTREC) (16-17), and the ethical committee of HTD (27/ HDDD). This study was 
funded by the Wellcome Trust (grant numbers 204904/Z/16/Z and 106680/B/14/Z) and the 
Foundation for Innovative New Diagnostics (FIND) who supplied test cartridges and logistics.  
2.2.3 Cerebrospinal fluid 
2.2.3.1 Processing 
At least 6mls of CSF (if available) was sampled by lumbar puncture and used for dedicated 
mycobacterial tests. No lower limit of CSF volume was set for study entry however, and if <6mls 
was available ZN smear, NAAT (Ultra or Xpert), and MGIT were still performed. All CSF volumes 
were recorded. Approximately 2-3mls of CSF was sent for bacterial and fungal stain, microscopy 
and culture, and viral PCR. CSF for mycobacterial testing was centrifuged at 3,000g (4000rpm in a 
large centrifuge or 6500rpm in an Eppendorf centrifuge) for 15 minutes. All supernatant except 
500µL was removed, and the deposit was resuspended in the remaining 500µL. 100µL resuspended 
deposit was used for ZN smear, 200µL for mycobacterial culture (MGIT), and 200µL for either 
Ultra or Xpert.  
2.2.3.2 Testing 
CSF ZN smear, Xpert and MGIT culture were performed as previously described.[37] Briefly, CSF 
ZN smears were prepared by placing two drops of CSF deposit placed on a cleaned slide, and 
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performing hot ZN staining according to local procedures.[37] Slides were examined until positive 
(single AFB identified) or for up to 30 minutes.  
For Xpert 2mls of reagent was added to a 200µl sample in a sterile container. After 5 minutes the 
sample was shaken gently. This sample was inserted into an entry port in the bottom of the Xpert 
cartridge. The cartridge was inserted into the Xpert machine and the test was started. For MGIT 
testing, CSF deposit was added to a MGIT tube containing MGIT supplement (antibiotics and 
growth supplements) and incubated in a BACTEC MGIT960 system (Becton, Dickinson, New 
Jersey, USA) until automatically identified as positive or for 56 days. Positive MGIT cultures were 
tested for susceptibility to rifampin, isoniazid, streptomycin, and ethambutol using a BACTEC 
MGIT SIRE kit (Becton, Dickinson, New Jersey, USA). 
Ultra testing procedure was identical to that of Xpert, with the exception of a different test cartridge. 
Both Ultra and Xpert were conducted with laboratory technicians blinded to the patient’s clinical 
characteristics.  
2.2.4 Data collection 
2.2.4.1 Clinical data 
Clinical data was collected to establish a ‘final diagnosis’ for each participant using the uniform 
case definition for TBM.[69] Demographic data (age, sex), GCS, MRC TBM grade, presenting 
symptoms and signs, and relevant past medical history were recorded at baseline. CSF parameters, 
including white cell count, white cell differential, protein, glucose (paired with serum glucose), and 
lactate were recorded. Results of baseline chest X-ray and brain imaging were recorded. HIV testing 
was not mandatory for this study; testing was performed when clinically indicated. In practice most 
participants with suspected TBM undergo HIV testing. Participants reported as HIV negative had a 
negative test for HIV. Participants reported as HIV positive had either a confirmatory test for HIV, 
or an already established diagnosis of HIV.  
2.2.4.2 Assigning TBM diagnosis  
Final TBM diagnoses were assigned following the uniform case definition for TBM clinical 
research (appendix A).[69] Patients with probable and possible diagnoses were reassigned to not 
TBM if the treating clinician did not consider the final diagnosis to be TBM and the patient 
recovered without anti-TB chemotherapy. Final reference standard TBM diagnoses were assigned 
without the Ultra or Xpert result contributing to the final diagnosis (i.e. reference standards did not 
include the index test). 
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2.2.5 Evaluating test performance 
Test diagnostic performances (sensitivity, specificity, positive predictive value, and negative 
predictive value) of Ultra, Xpert, ZN smear and MGIT, were compared against a clinical reference 
standard (the uniform case definition for TBM),[69] and against a mycobacterial culture reference 
standard. Definite, probable and possible TBM, definite and probable TBM, and definite TBM 
alone, were all used as clinical reference standards against which to compare diagnostic tests.  
In addition, the diagnostic performances of Ultra and Xpert were evaluated by HIV co-infection 
status, given higher Xpert sensitivity has been reported in HIV co-infected TBM.[37] Test 
performances after 3-4 weeks anti-TB chemotherapy were also evaluated on routine follow up CSF 
samples against the uniform case definition for TBM. Diagnostic performances of rifampicin 
resistance prediction were assessed against a reference standard of phenotypic DST (for MGIT-
positive cases). Semi-quantification of CSF bacterial load was compared between Ultra and Xpert 
positive cases, using high, medium, low, very low and trace categories. Additionally, an assessment 
of Ultra and Xpert performance was performed with tested CSF volume divided into 3 groups; 
>5mls, >2mls and ≤5mls, and ≤2mls.  
2.2.6 Statistical analysis 
2.2.6.1 Sample size calculation 
The previously described Ultra study[67] by Bahr et al suggested Ultra was 25% more sensitive 
than Xpert for the diagnosis of TBM. Assuming a sensitivity of Xpert of 60%,[37] using a sample 
size calculation for binary outcomes, a significance level of 5%, and 80% power, a calculated 49 
patients with TBM were required in each of the testing arms to be able to detect a 25% difference in 
sensitivity if it existed. In addition to ~100 participants with TBM, 100 non-TBM brain infection 
‘controls’ were tested to generate specificity data. The specificity of Ultra for M. tuberculosis 
detection in CSF is unknown, however a study of Ultra testing for M. tuberculosis in sputum 
samples of patients with pulmonary TB demonstrated a 3.2% decrease in specificity with Ultra 
compared to Xpert (Ultra 94.8%, Xpert 98%).[173]  
2.2.6.2 Recruitment 
Approximately 100 cases of TBM present to HTD each year. Based upon Xpert testing practice (i.e. 
those referred for testing) during a previous study at HTD[37] it was expected that in approximately 
50% of cases where CSF Xpert testing was requested by a treating clinician, the patient would be 
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confirmed as having definite, probable or possible TBM. This enables recruitment to both TBM and 
control testing groups. 
2.2.6.3 Statistical tests 
Test performance (sensitivity, specificity, positive and negative predictive values) with associated 
Wilson CIs were calculated for Ultra and Xpert and compared with those for ZN smear and MGIT. 
Study tests were compared using the Chi-squared test. Statistical analysis was performed using the 
programming language R (version 3.5.1). 
2.3 Results 
2.3.1 Study population 
From October 2017 to February 2019, 205 participants were consecutively enrolled into this study 
and randomised to CSF testing by Ultra (n=103) or Xpert (n=102) (figure 2-2). 204/205 participants 
were assigned a final diagnosis; 82 (40.2%) definite TBM, 6 (2.9%) probable TBM, 20 (9.8%) 
possible TBM, and 96 (47.1%) not TBM. Repeat testing was performed after 3-4 weeks of anti-TB 
chemotherapy in participants with a diagnosis of TBM in whom repeat CSF was available for 
testing. 
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Figure 2-2: Study enrolment 
 
Study enrolment by randomisation arm, with final diagnosis shown for both initial and follow up 
testing. TBM=tuberculous meningitis; Ultra=GeneXpert MTB/RIF Ultra; Xpert=GeneXpert 
MTB/RIF; ZN=Ziehl-Neelsen 
 
2.3.2 Baseline characteristics 
Baseline characteristics of enrolled participants stratified by randomisation arm are shown in table 
2-1. Median age was 42 years (Ultra: 42 years; Xpert: 44 years), and 62.9% of participants were 
male (Ultra: 60.2%; Xpert: 65.7%). Baseline variables in the Ultra and Xpert arms were well 
matched. Median CSF volumes of 5.8mls CSF (interquartile range [IQR] 5.0-6.0mls) and 5.5mls 
CSF (IQR 5.0-6.0mls) were used for mycobacterial testing in each of the arms. Median days to 
MGIT positivity in the Ultra and Xpert arms were 13 (IQR 10-17) and 15 (IQR 13-20), 
respectively, p=0.09. Disease severity (MRC TBM grade 3 in 25.5% [14/55] vs. 28.3% [15/53]), 
HIV status (HIV positivity in 16.5% [17/103] vs. 14.1% [14/99]), and CSF parameters (CSF WCC 
Patients enrolled
N = 205
Ultra
N = 103
TBM diagnosis
definite: 44
probable: 1
possible: 10
not TBM: 48
Repeat testing after 4 
weeks of anti-TB drugs
definite: 23
probable: 1
possible: 3
Xpert
N = 102
TBM diagnosis
definite: 38
probable: 5
possible: 10
not TBM: 48
missing data: 1
Repeat testing after 4 
weeks of anti-TB drugs
definite: 16
probable: 3
possible: 3
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310 per mm3[172-597] vs. 334 per mm3[120-484], CSF:blood glucose ratio 0.35 [0.22-0.46] vs. 
0.35 [0.25-0.43]) also appeared well matched between the two arms.  
Table 2-1: Baseline characteristics of enrolled participants 
 Total 
no 
All patients Total 
no 
Ultra Total 
no 
Xpert 
Age (years) 
(Median[IQR]) 
205 42  
(31-57) 
103 42  
(31-57) 
102 44  
(33-58) 
Sex (male) (No [%]) 205 129  
(62.9%) 
103 62  
(60.2%) 
102 67  
(65.7%) 
Final diagnosis (No 
[%]) 
Definite TBM 
Probable TBM 
Possible TBM 
Not TBM 
204  
 
82 (40.2%) 
6 (2.9%) 
20 (9.8%) 
96 (47.1%) 
103  
 
44 (42.7%) 
1 (1.0%) 
10 (9.7%) 
48 (46.6%) 
101  
 
38 (37.6%) 
5 (5.0%) 
10 (9.9%) 
48 (47.5%) 
TBM MRC Grade * 
(No [%]) 
1 
2 
3 
108  
 
32 (29.6%) 
47 (43.5%) 
29 (26.9%) 
55  
 
19 (34.5%) 
22 (40.0%) 
14 (25.5%) 
53  
 
13 (24.5%) 
25 (47.2%) 
15 (28.3%) 
HIV status (No [%])  
Positive 
Negative 
Unknown 
202  
 
31 (15.3%) 
96 (47.5%) 
77 (38.1%) 
103 
 
 
 
17 (16.5%) 
48 (46.6%) 
38 (36.9%) 
99  
 
14 (14.1%) 
48 (48.5%) 
37 (37.4%) 
CSF characteristics 
* (Median[IQR]) 
CSF WCC (per 
mm3) 
CSF lymphocyte 
(%) 
CSF protein  
(g/L) 
 
 
108 
 
107 
 
108 
 
 
 
332  
(142-529) 
74  
(41-87) 
1.90  
(1.14-2.85) 
 
 
55 
 
55 
 
55 
 
 
 
310  
(172-597) 
76  
(38-88) 
1.87  
(1.12-2.79) 
 
 
53 
 
52 
 
53 
 
 
 
334  
(120-484) 
74  
(41-86) 
1.96  
(1.31-2.92) 
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CSF:blood glucose 
ratio 
108 0.35  
(0.25-0.3) 
55 0.35  
(0.22-0.46) 
53 0.35  
(0.25-0.43) 
CSF volume for 
mycobacterial tests 
(mls) 
(Median[IQR]) 
201 5.8  
 
 
(5.0-6.0) 
100 5.8  
 
 
(5.0-6.0) 
101 5.5  
 
 
(5.0-6.0) 
* MRC TBM grade and CSF characteristics shown only for 108 patients with definite, probable or 
possible TBM. CSF=cerebrospinal fluid; HIV=human immunodeficiency virus; IQR=interquartile 
range; MRC=Medical Research Council; MGIT=mycobacteria growth indicator tube; 
TBM=tuberculous meningitis; Ultra=GeneXpert MTB/RIF Ultra; WCC=white cell count; 
Xpert=GeneXpert MTB/RIF 
 
2.3.3 Diagnostic performance 
The diagnostic performances of Ultra, Xpert, ZN smear and MGIT against a reference standard of 
definite, probable and possible TBM, and against a reference standard of definite and probable 
TBM, are shown in table 2-2. The diagnostic sensitivities of Ultra and Xpert against a reference 
standard of definite, probable and possible TBM were 47.2% (25/53, 95% CI 34.4-60.3%) and 
39.6% (21/53, 95% CI 27.6-53.1%) respectively (p=0.56). Specificities of Ultra and Xpert were 
each 100% (44/44, 95% CI 92.0-100% and 48/48, 95% CI 92.6-100%, respectively). Against the 
same definite, probable and possible TBM reference standard sensitivities of ZN smear and MGIT 
were 71.3% (77/108, 95% CI 62.5-79.0%) and 47.9% (45/94, 95% CI 38.1-57.9%) respectively. 
Against a MGIT reference standard, sensitivities of Ultra and Xpert were 90.9% (20/22, 95% CI 
72.2-97.5%) and 81.8% (18/22, 95% CI 61.6-92.7) and specificities were 93.9% (62/66, 95% CI 
85.4-97.6%) and 96.9% (63/65, 95% CI 89.5-99.2%) respectively. The diagnostic sensitivities of 
Ultra and Xpert against a reference standard of definite plus probable TBM were 58.1% (25/43, 
95% CI 43.3-71.6%) and 48.8% (21/43, 95% CI 34.6-63.2%) respectively. The diagnostic 
sensitivities of Ultra and Xpert against a reference standard of definite TBM alone were 59.5% 
(25/42, 95% CI 44.5-73.0%) and 55.3% (21/38, 95% CI 39.7-69.9%), p=0.87.  
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Table 2-2: Diagnostic performances against a clinical reference standard  
* Of 55 cases of definite probable or possible TBM tested by Ultra, 2 returned an error result. 
Therefore only 53 cases are included in the sensitivity calculation. CI=confidence interval; 
MGIT=mycobacteria growth indicator tube; NAAT=nucleic acid amplification test; NPV=negative 
predictive value; PPV=positive predictive value; Ultra=GeneXpert MTB/RIF Ultra; 
Xpert=GeneXpert MTB/RIF; ZN=Ziehl-Neelsen 
 
 Ultra Xpert ZN smear MGIT culture 
Reference standard: definite, probable and possible TBM 
Positive 
tests 
25/53* 21/53 77/108 45/94 
Sensitivity 
(95% CI) 
47.2%  
(34.4-60.3%) 
39.6%  
(27.6-53.1%) 
71.3% 
(62.5-79.0%) 
47.9% 
(38.0-57.9%) 
Specificity 
(95% CI) 
100%  
(92.0-100%) 
100%  
(92.6-100%) 
100% 
(96.1-100%) 
100% 
(95.6-100%) 
PPV  
(95% CI) 
100%  
(86.7-100%) 
100%  
(84.5-100%) 
100% 
(95.2-100%) 
100% 
(92.1-100%) 
NPV 
(95% CI) 
61.1%  
(49.6-71.5%) 
60.0%  
(49.0-70.0%) 
72.2% 
(67.2-82.1%) 
63.2% 
(54.7-70.9%) 
Reference standard: definite and probable TBM 
Positive tests 25/43 21/43 77/88 45/75 
Sensitivity 
(95% CI) 
58.1% 
(43.3-71.6%) 
48.8% 
(34.6-63.2%) 
87.5% 
(79.0-92.9%) 
60.0% 
(48.7-70.3%) 
Specificity 
(95% CI) 
100% 
(93.4-100%) 
100% 
(93.8-100%) 
100% 
(96.8-100%) 
100% 
(96.4-100%) 
PPV  
(95% CI) 
100% 
(86.7-100%) 
100% 
(84.5-100%) 
100% 
(95.2-100%) 
100% 
(92.1-100%) 
NPV  
(95% CI) 
75.0% 
(63.9-83.6%) 
72.5% 
(61.9-81.1%) 
91.3% 
(85.0-95.1%) 
77.4% 
(69.6-83.7%) 
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Figure 2-3 shows positive mycobacterial tests in individuals with at least one confirmatory test for 
TBM. In this Venn diagram the overlap of positive CSF Ultra, Xpert, smear and culture are shown, 
and cases identified where only one confirmatory mycobacterial test was positive. In addition to 
positives and negatives, six error results were returned in the Ultra arm, and none in the Xpert 
group. Eight MGIT samples showed contaminated growth. 
Figure 2-3: Positive mycobacterial tests in individuals with at least one confirmatory test for 
tuberculous meningitis 
 
168 positive mycobacterial tests (25 positive Ultra, 21 positive Xpert, 77 positive ZN smear, 45 
positive MGIT) from 82 patients with a diagnosis of definite TBM. MGIT=mycobacteria growth 
indicator tube; Ultra: GeneXpert Ultra MTB/RIF; Xpert: GeneXpert MTB/RIF; ZN: Ziehl-Neelsen 
 
2.3.4 Diagnostic performance in HIV co-infection 
HIV testing was performed in 127/205 (62.0%) participants, and in 100/108 (92.6%) participants 
with TBM. HIV co-infection was diagnosed in 31 cases (17/65 Ultra and 14/62 Xpert tested 
participants). A comparison of diagnostic performances in HIV co-infected and HIV-uninfected 
participants against a reference standard of definite, probable and possible TBM is shown in table 2-
3. The diagnostic sensitivities of Ultra and Xpert in HIV-uninfected participants against this 
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reference standard were 38.9% (14/36, 95% CI 24.8-55.1%) and 22.9% (8/35, 95% CI 12.1-35.0%) 
respectively (p=0.23). The specificities of Ultra and Xpert in HIV-uninfected participants were 
100% (0/9, 95% CI 70.1-100% and 0/13, 95% CI 77.2-100%, respectively).  
The diagnostic performances of Ultra and Xpert were additionally compared against a reference 
standard of definite plus probable TBM in HIV co-infected participants, for direct comparison 
against test performance data published by Bahr et al.[67] Diagnostic sensitivities of Ultra and 
Xpert against this reference standard were 81.8% (9/11, 95% CI 52.3-94.9%) and 83.3% (10/13, 
95% CI 55.2-95.3%) respectively (p=1.0). Specificities of Ultra and Xpert were both 100% (0/6, 
95% CI 61.0-100% and 0/1, 95% CI 34.2-100%, respectively). The diagnostic sensitivities of Ultra 
and Xpert were higher in HIV co-infected cases than in HIV uninfected cases; 64.3%, 9/14, 95% CI 
38.8-83.7% vs. 38.9%, 14/36, 95% CI 24.8-55.1% for Ultra, and 76.9%, 10/13, 95% CI 49.7-91.8% 
vs. 22.9%, 8/35, 95% CI 12.1-39.0% for Xpert, respectively, against a reference standard of definite 
probable and possible TBM.  
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Table 2-3: Diagnostic performance of Ultra and Xpert against a clinical reference standard, 
by HIV co-infection status  
 Ultra Xpert 
 HIV negative HIV positive HIV negative HIV positive 
Reference standard: definite, probable and possible TBM 
Positive tests 14/36  9/14 8/35 10/13 
Sensitivity (95% CI) 38.9% 
(24.8-55.1%) 
64.3% 
(38.8-83.7%) 
22.9% 
(12.1-39.0%) 
76.9% 
(49.7-91.8%) 
Specificity (95% CI) 100% 
(70.1-100%) 
100% 
(43.9-100%) 
100% 
(77.2-100%) 
100% 
(20.7-100%) 
PPV (95% CI) 100% 
(78.5-100%) 
100% 
(70.1-100%) 
100% 
(67.6-100%) 
100% 
(72.2-100%) 
NPV (95% CI) 29.0% 
(16.1-46.6%) 
37.5% 
(13.7-69.4%) 
32.5% 
(20.1-48.0%) 
25.0% 
(4.6-69.9%) 
Reference standard: definite and probable TBM  
Positive tests 14/29 9/11 8/27 10/12 
Sensitivity (95% CI) 48.3% 
(31.4-65.6%) 
81.8% 
(52.3-94.9%) 
29.6% 
(15.9-48.5%) 
83.3% 
(55.2-95.3%) 
Specificity (95% CI) 100% 
(80.6-100%) 
100% 
(61.0-100%) 
100% 
(84.5-100%) 
100% 
(34.2-100%) 
PPV (95% CI) 100% 
(78.5-100%) 
100% 
(70.1-100%) 
100% 
(67.6-100%) 
100% 
(72.2-100%) 
NPV (95% CI) 51.6% 
(24.8-68.0%) 
75.0% 
(40.9-92.9%) 
52.5% 
(37.5-67.1%) 
50.0% 
(15.0-85.0%) 
CI: confidence interval; NAAT: nucleic acid amplification test; NPV: negative predictive value; 
PPV: positive predictive value; TBM: tuberculous meningitis; Ultra: GeneXpert MTB/RIF Ultra; 
Xpert: GeneXpert MTB/RIF 
 
2.3.5 Identification of rifampicin resistance 
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Rifampicin resistance was detected in 17.4% (8/46) cases where NAAT was positive; 5/25 (20.0%) 
Ultra, 3/21 (14.3%) Xpert. An additional 5 cases ‘trace’ positive by Ultra returned a result of 
‘indeterminate resistance’, the resistance result given for this semi-quantification category. 
Rifampicin resistance testing was negative in 71.7% (33/46) cases where NAAT was positive. Of 
45 positive MGIT cultures, 8 showed rifampicin resistance by phenotypic DST, all of which were 
detected by Xpert or Ultra (5 Ultra, 3 Xpert). 
2.3.6 Semi-quantification of CSF bacterial numbers by Ultra and Xpert 
Xpert can categorise specimen bacterial numbers into high, medium, low or very low. Ultra has an 
additional ‘trace’ category. High bacterial numbers are rare in TBM and were not seen in this study. 
Semi-quantification categories obtained from the CSF are shown in figure 2-4. Of those cases 
positive by Ultra, 15/25 (60.0%) cases were categorised as containing very low or trace numbers of 
bacteria, compared with 8/21 (38.1%) samples with very low bacterial numbers detected by Xpert. 
Figure 2-4: Semi-quantification of positive Ultra and Xpert results 
 
Semi-quantification results for positive Ultra (dark shading, n=25) and Xpert (light shading, n=21). 
The filled shaded areas represent all positive tests in that semi-quantification category. The 
patterned (vertical lined) area in each bar represents the number of those cases also positive by ZN 
smear (A), MGIT (B), or that have (C) or do not have (D) HIV co-infection. Semi-quantification 
results for Ultra were: medium 5/25 (20.0%); low 5/25 (20.0%); very low 10/25 (40.0%); trace 5/25 
(20.0%). Semi-quantification results for Xpert were: medium 3/21 (14.3%); low 10/21 (47.6%); 
very low 8/21 (38.1%). Ultra=GeneXpert MTB/RIF Ultra; Xpert=GeneXpert MTB/RIF. Dr Vinh 
Dao Nguyen assisted with the design of this figure. 
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2.3.7 Diagnostic performance after the start of anti-TB chemotherapy 
Routine follow up CSF was sampled and tested in 49 participants treated for TBM (27 Ultra, 22 
Xpert). A median of 5.5mls CSF was tested in each of the Ultra and Xpert arms. In these 49 
participants, 48.1% (13/27) of the Ultra arm had a positive test and 36.4% (8/22) of the Xpert arm at 
presentation. After a mean of 27 (Ultra) and 28 (Xpert) days of anti-TB chemotherapy, 22.2% 
(6/27) of the Ultra arm had a positive test versus 9.1% (2/22) of the Xpert arm (figure 2-5).  
Figure 2-5: A comparison of the diagnostic sensitivities of Ultra and Xpert between baseline 
and testing after 3-4 weeks anti-tuberculosis chemotherapy 
 
Data shown for patients undergoing both baseline and follow up CSF sampling (n=49; Ultra 27, 
Xpert 22). Ultra and Xpert sensitivities shown against a reference standard of definite, probable or 
possible TBM. All cases with a positive NAAT at follow up testing (n=8), were positive at baseline 
testing. NAAT=nucleic acid amplification test; Ultra=GeneXpert MTB/RIF Ultra; 
Xpert=GeneXpert MTB/RIF 
 
2.3.8 CSF parameters in individuals undergoing repeat diagnostic testing 
CSF parameters are shown for 44/49 patients who underwent repeat diagnostic testing (25/27 Ultra, 
19/22 Xpert), for whom non-mycobacterial CSF parameters were available at both time points 
(table 2-4). At repeat testing, CSF parameters were generally worse (elevated WCC, protein and 
lactate) in those individuals who re-tested as positive in both Ultra and Xpert groups, compared 
with those who re-tested as negative. 
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Compared with baseline testing, CSF parameters of individuals positive by Ultra were generally 
improved (reduced WCC and lactate, and increased CSF:blood glucose ratio). Compared with 
baseline testing, CSF parameters of individuals positive by Xpert were generally worse (elevated 
WCC, protein and lactate). Whilst the number of cases positive at repeat testing is small, these 
results may support a proposed role for Ultra in the detection of cases with lower bacillary load 
(where repeat CSF parameters for cases positive at repeat testing by Ultra are generally improved 
compared with repeat CSF parameters for cases positive at repeat testing by Xpert).    
Table 2-4: CSF parameters in individuals undergoing repeat diagnostic testing 
 Ultra 
 
Xpert 
Median values Baseline 
 
 
 
N=25 
Repeat 
 
Baseline 
 
 
 
N=19 
Repeat 
  
Positive 
tests 
N=6 
Negative 
tests 
N=19 
Positive 
tests 
N=2 
Negative 
tests 
N=17 
CSF WCC per 
mm3) 
(95% CI) 
340 
 
(207-623) 
136 
 
(63-241) 
70 
 
(42-126) 
144 
 
(104-422) 
314 
 
(240-389) 
73 
 
(35-262) 
Lymphocyte 
(%) 
(95% CI) 
82 
 
(28-88) 
60 
 
(45-73) 
87 
 
(84-89) 
80 
 
(67-87) 
64 
 
(64-65) 
87 
 
(67-89) 
Protein (g/L) 
(95% CI) 
1.66 
(1.11-2.75) 
1.93 
(1.30-2.38) 
0.81 
(0.44-1.52) 
2.12 
(1.64-2.88) 
6.03 
(5.12-6.93) 
1.61 
(0.60-2.41) 
CSF/blood 
glucose ratio 
(95% CI) 
0.31 
 
(0.20-0.40) 
0.37 
 
(0.32-0.78) 
0.52 
 
(0.45-0.62) 
0.34 
 
(0.25-0.39) 
0.47 
 
(0.40-0.51) 
0.43 
 
(0.40-0.51) 
Lactate 
(mmol/L) 
(95% CI) 
4.31 
 
(3.40-7.60) 
4.12 
 
(3.35-4.67) 
2.87 
 
(2.54-3.40) 
3.89 
 
(3.27-5.50) 
5.13 
 
(4.62-5.63) 
3.54 
 
(3.20-5.19) 
CI=confidence interval; CSF=cerebrospinal fluid; Ultra=GeneXpert MTB/RIF Ultra; WCC=white 
cell count; Xpert=GeneXpert MTB/RIF 
 
Analysing only those participants testing positive by Ultra or Xpert at presentation, 38.5% (5/13) in 
the Ultra arm were still positive after 4 weeks treatment, compared with 25.0% (2/8) in the Xpert 
arm. The influence of drug resistance on a 4-week positive Ultra or Xpert is shown in table 2-5. Of 
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those participants with a positive baseline CSF NAAT and positive baseline CSF MGIT (with 
DST), and a positive follow-up NAAT, 4/5 (80.0%) had an M. tuberculosis isolate resistant to at 
least one first line anti-TB drug. Of those with a positive baseline CSF NAAT and positive baseline 
CSF MGIT (with DST), and a negative follow-up NAAT, 5/11 (45.6%) had an M. tuberculosis 
isolate resistant to at least one first line anti-TB drug. Anti-TB chemotherapy data were not 
analysed for this study, therefore adjustment of anti-TB chemotherapy regimens upon discovering 
drug resistance could not be confirmed, confounding analysis of the effect of drug resistance upon 
repeat NAAT testing.   
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Table 2-5: Association between TBM drug susceptibility testing and follow up NAAT testing 
NAAT Baseline 
CSF 
NAAT 
result 
Baseline 
CSF MGIT 
result 
MGIT drug 
susceptibility 
testing 
Follow up 
CSF 
NAAT 
result 
Follow up CSF 
MGIT result 
Ultra Positive Positive RHZES Positive Positive 
Ultra Positive Positive HZS Positive Negative 
Ultra Positive Positive S Positive Not performed 
Ultra Positive Negative Not performed Positive Negative 
Ultra Positive Negative Not performed Positive Negative 
Xpert Positive Positive HS Positive Negative 
Xpert Positive Positive Fully sensitive Positive Negative 
Ultra Positive Positive RHS Negative Negative 
Ultra Positive Positive RHS Negative Negative 
Ultra Positive Positive S Negative Negative 
Ultra Positive Positive Fully sensitive Negative Not performed 
Ultra Positive Positive Fully sensitive Negative Negative 
Ultra Positive Positive Fully sensitive Negative Negative 
Ultra Positive Positive Fully sensitive Negative Negative 
Ultra Positive Positive Fully sensitive Negative Negative 
Xpert Positive Positive HZS Negative Negative 
Xpert Positive Positive Z Negative Contaminated 
Xpert Positive Positive Fully sensitive Negative Negative 
Xpert Positive Negative Not performed Negative Negative 
Xpert Positive Negative Not performed Negative Negative 
Xpert Positive Positive Not performed Negative Negative 
Follow up NAAT testing is shown for samples where baseline NAAT was positive (n=21). Drug 
susceptibility testing of M. tuberculosis isolated from CSF is compared with follow up testing 
results. With MGIT drug susceptibility testing the listed anti-TB chemotherapy agents are those for 
which there is resistance in each case. CSF=cerebrospinal fluid; E=ethambutol; H=isoniazid; 
MGIT=mycobacterial growth indicator tube; NAAT=nucleic acid amplification test; R=rifampicin; 
S=streptomycin; TBM=tuberculous meningitis; Ultra=GeneXpert MTB/RIF Ultra; 
Xpert=GeneXpert MTB/RIF; Z=pyrazinamide 
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2.3.9 Diagnostic performance by CSF volume tested 
CSF volume used for mycobacterial testing was divided into 3 categories; >5mls, 2-5mls and 
≤2mls, consistent with CSF volume intervals in a previous study.[37] Diagnostic sensitives of Ultra 
and Xpert against a reference standard of definite probable and possible TBM were 46.5% (20/43, 
95% CI 32.5-61.1%) vs. 36.4% (16/44, 95% CI 23.8-51.1%) for CSF volumes > 5mls, and 40.0% 
(6/15, 95% CI 19.8-64.3%) vs. 38.5% (5/13, 95% CI 17.7-64.5%) for CSF volumes of 2-5mls.  
Only three patients with TBM (two definite, one possible) underwent testing of CSF volumes ≤2mls 
(Ultra; 1/2 positive, Xpert 1/1 positive).  
2.4 Discussion 
TBM diagnosis continues to challenge clinicians. Currently available diagnostic tests are 
insufficiently sensitive for M. tuberculosis detection in the paucibacillary CSF of TBM. Xpert 
offers rapid results and detection of rifampicin resistance; both vitally important to guiding early 
and appropriate anti-TB chemotherapy. However, Xpert has limitations in the diagnosis of 
TBM.[176] An improved cartridge offering increased diagnostic sensitivity would be hugely 
welcome.    
In this study Ultra was not superior to Xpert for the detection of M. tuberculosis in CSF of 
individuals with TBM, using either clinical or culture reference standards. There was, however, a 
suggestion that Ultra was able to detect more patients with TBM with very low, or trace, numbers 
of bacteria in their CSF and that Ultra may be more sensitive than Xpert once anti-TB treatment has 
started. Modifications to the Ultra cartridge include a larger reaction chamber (allowing more 
sample for PCR), and the addition of two multicopy genes; both of which aim to improve test 
sensitivity. These modifications may be insufficient to improve the diagnostic sensitivity of M. 
tuberculosis detection in CSF, and M. tuberculosis DNA load may remain below the lower limit of 
detection of the test in many cases. CSF processing at our site involves large volume CSF sampling 
(to increase the M. tuberculosis load), centrifugation (to concentrate the M. tuberculosis in the 
pellet), followed by the resuspension of 200µL of pellet prior to testing. A larger reaction chamber 
may not further enhance this process.  
Ultra showed improved diagnostic sensitivity over Xpert in HIV-uninfected individuals, against all 
variations of the clinical TBM reference standard (definite probable and possible, definite and 
probable, or definite alone), and against mycobacterial culture. However, these did not reach 
statistical significance. In HIV uninfected TBM CSF bacillary load is lower than in HIV co-infected 
disease.[36] Ultra has already shown promise in the diagnosis of smear negative culture positive, 
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and HIV co-infected, sputum samples of individuals with pulmonary TB;[173] both situations when 
the bacillary load is lower. 
The diagnostic sensitivity of Ultra was higher for HIV co-infected samples than for HIV uninfected 
samples, against the composite reference standard or against culture; a pattern also seen with Xpert, 
ZN smear and culture, and described previously with Xpert.[37] This is likely attributed to a higher 
bacillary load in HIV co-infected individuals.[36]  
In a previous study of 23 HIV co-infected individuals with definite or probable TBM, Ultra showed 
diagnostic superiority over Xpert (69.6 vs. 43.5% respectively) against a reference standard of 
definite plus probable TBM.[67] When analysing an HIV co-infected sub-group, against an 
identical reference standard of definite plus probable TBM, this study reported sensitivities of 81.8 
and 83.3% for Ultra and Xpert respectively. These results may be explained by the methodological 
differences between this study and that by Bahr et al.[67] This study prospectively tested fresh CSF 
with a freezing and re-thawing process. The effect of freezing CSF on diagnostic sensitivity is 
unknown. In addition to this, the randomised design of this study ensured CSF pellet was not split 
between too many tests, instead reflecting testing procedure as it is carried out in current practice. 
Performing two NAATs on the same CSF sample reduces the bacillary load per sample and reduces 
sensitivity of all testing methods.   
The specificity of Ultra in this study was 100% (as was that of Xpert) when a uniform case 
definition for TBM was used as a reference standard. NAAT specificity only fell in this study when 
MGIT was used as a reference standard. In a previous study where Ultra was used to test sputum in 
suspected pulmonary TB, Ultra showed reduced specificity vs. Xpert; however mycobacterial 
culture was the reference standard used in that study.[173] A fall in NAAT specificity may be 
expected when a reference standard of mycobacterial culture is used; culture will only detect viable 
bacteria, whilst NAAT may detect DNA of dead bacteria which cannot be cultured, leading to false 
positive NAAT results against a mycobacterial culture reference standard.[177] This study adds 
important specificity data for Ultra testing of CSF for M. tuberculosis. In previously published data 
describing M. tuberculosis detection in CSF with Ultra, of 21 samples positive by Ultra, 8 cases (3 
probable TBM, 3 possible TBM, 2 not TBM) were positive by Ultra alone with no additional 
confirmatory mycobacterial tests testing positive.[67] In this study there were 25 positive Ultra 
tests, from 55 patients with definite probable or possible TBM who were tested by Ultra. Of these, 
all 25 (100%) had a positive ZN smear, and 20 (80.0%) had a positive MGIT. No positive Ultra 
results were recorded in TBM cases with a probable or possible diagnosis of TBM, nor in any cases 
where another non-TBM diagnosis was confirmed. In the setting of this study Ultra did not 
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diagnose additional cases of TBM missed by other confirmatory mycobacterial testing methods. 
This is likely due to the high sensitivity of ZN smear microscopy at our site, where sensitivity of 
ZN smear is superior to that of Xpert and MGIT. 
The strengths of this study are that it is large, prospective and randomised, and includes information 
on the performance of both tests after the start of anti-TB treatment. Laboratory technicians were 
blinded to the suspected diagnosis on baseline testing, and testing was performed immediately after 
randomisation. CSF was sampled, processed and tested the same way for both Ultra and Xpert. 
Median volumes of 5.8mls and of 5.5mls were used for mycobacterial testing in the Ultra and Xpert 
arms, respectively. A limitation of the study is that specificity data comes mostly from HIV-
uninfected individuals. HIV testing was not mandatory for all patients. Individuals with TBM were 
routinely tested for HIV following standard ward procedures; however additional non-TBM cases 
were tested for HIV at the discretion of the treating clinician. Of 96 patients in the ‘not TBM’ 
category, from whom specificity data are generated, only 4/96 (4.2%) had HIV co-infection. 
Therefore, additional data are required to confirm a high specificity of Ultra in HIV co-infection. 
An additional limitation is that whilst this study was powered to detect a 25% improvement in 
diagnostic sensitivity with Ultra, it cannot be concluded that Ultra is not superior to Xpert at a lower 
margin of superiority, given this study was not powered to detect a smaller superiority margin. 
Likewise, this study was not powered to detect superiority specifically in an HIV-uninfected 
subgroup.  
This study showed that Ultra was not superior to Xpert for the diagnosis of TBM. However, given 
this study was powered to detect a 25% improvement in diagnostic sensitivity with Ultra it remains 
possible that Ultra was more sensitive than Xpert at a lower margin of superiority. Xpert and Ultra 
remain vital parts of the diagnostic arsenal of mycobacterial tests. They offer rapid results with 
rifampicin resistance predication, yet unfortunately cannot exclude TBM when negative. A rapid 
high sensitivity diagnostic test for TBM unfortunately remains elusive. 
2.5 Publications related to this chapter 
Data contained within this chapter were published in the following journal article: 
1. A randomised comparison of GeneXpert Ultra MTB/RIF and GeneXpert MTB/RIF for the 
diagnosis of tuberculous meningitis 
Joseph Donovan, Do Dang Anh Thu, Nguyen Hoan Phu, Vu Thi Mong Dung, Tran Phu Quang, Ho 
Dang Trung Nghia, Pham Kieu Nguyet Oanh, Tran Bao Nhu, Nguyen Van Vinh Chau, Vu Thi 
Ngoc Ha, Vu Thi Ty Hang, Dong Huu Khanh Trinh, Ronald B. Geskus, Le Van Tan, Nguyen Thuy 
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Thuong Thuong, Guy E. Thwaites 
The Lancet Infectious Diseases. Jan 2020; 20: 308–17  
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Chapter 3 
The influence of Strongyloides stercoralis co-infection on the presentation, 
pathogenesis and outcome of tuberculous meningitis 
3.1 Introduction 
3.1.1 Background and epidemiology of strongyloidiasis 
The soil transmitted helminth S. stercoralis is the cause of Strongyloidiasis, a neglected chronic 
parasitic disease of humans. Found throughout tropical and subtropical regions of the world, 
including Vietnam, S. stercoralis infects an estimated 30-100 million individuals worldwide.[178] 
S. stercoralis larvae are found in faecally polluted moist soil,[179] and barefoot activities such as 
rice cultivation, cleaning of irrigation ditches, and contact with stagnant water represent risks for 
acquiring infection.[180] The vast majority of Strongyloides species do not affect humans.[181] 
Human strongyloidiasis is almost entirely caused by infection with S. stercoralis, with additional S. 
fuelleborni cases in Africa and Papua New Guinea.[181]  
Strongyloidiasis was first described in French troops stationed in Vietnam during the late 19th 
century.[182] Subsequent studies described S. stercoralis infection in prisoners of war in Southeast 
Asia during the Second World War,[183] and in war personnel who had returned to home countries 
after previously being stationed in Vietnam.[184]  
3.1.2 Epidemiology of strongyloidiasis in Vietnam 
Limited data describe the current prevalence of S. stercoralis infection in Vietnam. In 2016 Schar et 
al[179] identified 79 published studies of S. stercoralis infection in Southeast Asia, inclusive of 
only one study originating from Vietnam. This Vietnamese study of children in a southern 
mountainous ethnic minority commune identified no cases of Strongyloidiasis by stool microscopy 
testing.[185] Subsequently, a large retrospective serological study in southern Vietnam performed 
42,920 Strongyloides enzyme linked immunosorbent assay (ELISA) tests.[186] S. stercoralis 
antibodies were detected in 7.4% samples, with male sex (prevalence 8.6% in males vs. 6.6% in 
females, p<0.0001) and increased age (prevalence 11.2% in >60 years of age vs. 7.1% in <60 years 
of age, p<0.0001) both risk factors for S. stercoralis seropositivity. Selection bias was a major 
limitation of this study, given its inclusion only of samples from unwell patients or those who chose 
to submit a sample for testing.  
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A subsequent serological study assessed S. stercoralis positivity in 1340 adults (age range 40-70 
years) and 270 children (age range 13-15 years), in four regions of Vietnam.[187] In the adult 
population seropositivity in Ho Chi Minh City was 18.2% (61/335), with higher seropositivity 
reported in other country regions.[187] Seropositivity was significantly higher amongst males 
(33.3%, 223/670) than females (24.9%, 167/670), p=0.001.[187] The authors used a commercially 
available ELISA kit (S. ratti, Bordier Affinity Products SA, Crissier, Switzerland) to determine IgG 
antibodies against S. stercoralis (test performance for S. stercoralis: 88% sensitivity overall, 77% 
specificity with sera of patients with other helminthic diseases).[188] Both of these studies reported 
results of serological testing; it is unlikely seropositivity represents active infection in all cases. 
3.1.3 Pathogenesis and life cycle of S. stercoralis 
S. stercoralis has a unique and complex life cycle, which can be ‘free living’ (outside of the human 
body after passage of rhabditiform larvae in the stool), and ‘parasitic’ (after penetration of human 
skin by infective filariform larvae).[189] Outside the body male and female worms reproduce 
sexually and produce larvae.[190] When filariform larvae penetrate human skin they migrate to the 
lungs, reaching the small intestine after being coughed up and swallowed, or directly via connective 
tissue penetration.[189] In the small intestine larvae develop into adult female worms which 
reproduce asexually.[190] Female worms, threaded in the small intestine epithelium, produce eggs 
which hatch into non-infective rhabditiform larvae and exit the body in human stool, or transform 
into infective filariform larvae which may achieve ‘autoinfection’ by penetrating intestinal 
epithelium or perianal skin of the host.[189,190] 
3.1.4 Clinical disease of Strongyloidiasis 
Infection with S. stercoralis is often asymptomatic. Mild clinical disease may manifest as 
abdominal symptoms (pain and diarrhoea), cough (as the worm transits the lungs), or as a rash 
which can be either migratory and urticarial (termed ‘larva currens’), or stationary in the form of 
urticarial crops.[181]  
It is the effect of host immunosuppression on S. stercoralis that can lead to acute, severe and 
sometimes fatal manifestations of Strongyloidiasis. Altered host immune status may produce an 
increased parasite burden, larval dissemination, the ‘hyperinfection’ syndrome, and/or death.[191] 
In hyperinfection, blood eosinophil counts are often suppressed.[192] Hyperinfection-precipitating 
host immunosuppression may be secondary to drugs (particularly corticosteroids), disease states 
(e.g. haematological malignancy or organ transplantation), or immunosuppressive infections (e.g. 
human T-lymphotropic virus-1 [HTLV-1]).[191] Although HIV-1 co-infection may produce 
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advanced immunosuppression, the frequency of life threatening disseminated strongyloidiasis in 
this patient group is unexpectedly low, suggesting the immune processes suppressed in acquired 
immunodeficiency syndrome (AIDS) are less important for defense against S. stercoralis.[181] 
Widespread corticosteroid use makes these drugs the most likely inducer of hyperinfection to be 
encountered by clinicians. Why corticosteroids represent such a strong risk factor for S. stercoralis 
hyperinfection is uncertain; although the drug may directly induce hyperinfection by acting on a 
receptor found on the L3 larvae of S. stercoralis.[193]  
3.1.5 Diagnosis of Strongyloidiasis 
Diagnosing strongyloidiasis requires either identification of S. stercoralis larvae or DNA in clinical 
samples (stool, upper gastrointestinal tract, pulmonary), or measurement of an immunological 
response. Diagnosis may be challenging, and current tests have limitations. 
3.1.5.1 S. stercoralis serology 
S. stercoralis ELISA usually detects serum IgG against an extract of infective larvae.[194] 
Serological testing may represent a cost effective way to screen large populations for S. stercoralis 
infection; diagnostic sensitivity is usually high. Specificity is uncertain however; a positive result 
may represent cross-reactivity with non-S. stercoralis parasites, or serological persistence despite 
treatment and clearance.[195] Serological tests including an IgM component may have improved 
active strongyloidiasis detection, however supporting evidence is lacking currently. An analysis 
comparing five distinct serological tests for the detection of S. stercoralis found serology sensitivity 
to be 75.4-93.9% against a reference standard of S. stercoralis larvae detected in stool, and 
specificity 92.2-100% in individuals with no stool larvae and no exposure.[196] Four of the five 
serological tests showed varying degrees of cross reactivity in the presence of other parasitic 
disease.  
3.1.5.1.1 S. stercoralis seroconversion after treatment 
Whether serological responses revert to negative after successful S. stercoralis treatment is 
uncertain. Titers of antibodies against S. stercoralis may reduce after anti-helminthic therapy, 
however a serological cut-off for parasitological cure needs to be defined.[197] In a study of S. 
stercoralis seroconversion at least 3 months after receiving anti-helminthic therapy including at 
least one dose of ivermectin, 35 (83%) of 42 cases seroconverted from positive to negative, and 6 
(14%) of 42 cases seroconverted from positive to equivocal.[198] Non-ivermectin based anti-
helminthic therapies were less effective at achieving seroconversion.[198] In a further study of 40 
individuals who had received at least two doses of ivermectin therapy, optical density (OD) was 
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used to measure reductions in antibody titers against S. stercoralis.[199] A fall in OD was noted in 
38 (95%) of 40 individuals, and 26 (65%) of 40 individuals had reductions in OD consistent with 
cure. 
3.1.5.2 S. stercoralis serology in HIV-infected individuals 
The value of S. stercoralis serological tests in HIV co-infected individuals is unclear. Depletion of 
CD4+ T cells in advanced HIV disease leads to loss of humoral immunity which may reduce 
detectable antibody, and HIV-induced B cell hyperactivity may also create false positive serological 
results.[200] S. stercoralis ELISA sensitivities in HIV co-infection do not appear to match those 
seen in non-immunosuppressed individuals.[201] In a study of HIV co-infected immigrants to Italy, 
15 (11%) of 138 individuals tested positive for S. stercoralis, however 4 cases positive by stool 
microscopy or stool culture had a negative serological test.[202] 
3.1.5.3 S. stercoralis stool microscopy 
Multiple diagnostic methods exist for S. stercoralis larvae detection in stool. Routine wet 
preparation stool microscopy has low sensitivity; larval shedding in stool is intermittent resulting in 
false negative cases. A stool concentration method increases the identification of ova, cysts and 
larvae, especially when parasite numbers are low.[203] The stool concentration method and 
alternative stool diagnostic methods to wet preparation microscopy are described in the appendix (B 
and C), respectively. A single stool examination may detect larvae in only 15-24% of positive cases, 
using direct faecal smear or formalin-ether concentration methods.[204]  
3.1.5.4 S. stercoralis stool PCR 
Stool PCR tests offer a potentially more sensitive approach to S. stercoralis identification. The stool 
excretion and distribution of parasite DNA is less variable than for parasite eggs,[205] however 
whilst PCR testing is more sensitive than stool microscopy, stool PCR remains insufficiently 
sensitive for S. stercoralis identification. A meta-analysis of 14 studies compared S. stercoralis 
stool PCR testing to conventional stool diagnostic methods and/or serology as a reference 
standard.[195] Stool PCR had high specificity, yet lacked sufficient diagnostic sensitivity (56.5% 
[95% CI 39.2-72.4%]) against a reference standard of stool larval detection and serology.[195]  
3.1.6 Anti-helminthic therapy 
3.1.6.1 Uncomplicated S. stercoralis infection 
 
87 
 
The optimal treatment of uncomplicated strongyloidiasis is ivermectin. Trial data have shown 
superiority of ivermectin over albendazole,[206–210] an improved side effect profile of ivermectin 
compared to thiabendazole,[180,211–213] and unlikely benefit of double dose ivermectin compared 
to single dose ivermectin.[214,215] Trial data assessing ivermectin, albendazole and thiabendazole 
for strongyloidiasis, and issues surrounding confirmation of cure, are described in appendix D.   
3.1.6.2 Hyperinfection syndrome 
Best therapy for Strongyloides hyperinfection is uncertain, and based on the life cycle of S. 
stercoralis rather than trial data. Anti-helminthic therapies may be ineffective on larvae that have 
not fully matured.[216] United States Center for Disease Control and Prevention (CDC) guidelines 
advise ivermectin 200µg/kg orally daily, with continuation of treatment until stool microscopy is 
negative for 2 weeks.[217] The action of ivermectin on extraintestinal parasites is unclear. In 
practice, daily ivermectin for a minimum of 2 weeks is commonplace,[191] however this duration 
may be too short to ensure all larval stages have matured to a therapy-susceptible stage. 
Immunosuppression is suspended if possible. Prophylaxis against S. stercoralis is discussed in 
appendix E. S. stercoralis co-infection in the context of necessary corticosteroid therapy lacks an 
evidence base to guide treatment. 
3.1.7 Immunopathology of tuberculous meningitis 
3.1.7.1 Pathogenesis of TBM 
The current model of TBM disease follows a two-step process, with first a pulmonary focus, and 
then after M. tuberculosis dissemination through the blood stream, a CNS focus, which is the point 
of M. tuberculosis entry into the CSF.[9,15] Much of the damage caused in TBM is due to a 
dysregulated and excessive inflammatory response to M. tuberculosis.[9] The pathogenesis of TBM 
is described further in the introductory chapter (chapter 1) of this thesis.  
3.1.7.2 Cerebrospinal fluid cytokine concentrations in tuberculous meningitis 
Cytokines are messengers secreted by almost all cells, that act to control and alter their own 
behaviour or that of other cells, with a key role in modulating inflammation via a complex network 
of interactions.[218,219] In TBM pro-inflammatory cytokines are acutely elevated. In a study in 
India, CSF cytokine concentrations in 16 individuals with clinical TBM were compared with 
cytokine concentrations of 10 controls. Concentrations of TNF-α, IL-1β, IL-6, IL-8, IL-10 were 
elevated in TBM, and declined during treatment, yet levels were not related to severity, brain MRI 
abnormalities nor clinical outcome.[25] In a separate study of 15 individuals with TBM (age range 
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12-58 years) CSF TNF-α, IL-10, and IFN-γ concentrations were persistently elevated, with 
elevation not related to stage or outcome.[26] In a paediatric study of TBM, CSF TNF-α, IL-1β, and 
IFN-γ concentrations were elevated in acute TBM, however these concentrations did not correlate 
with disease severity, nor were they influenced by corticosteroid administration.[27] 
In Vietnamese adults (age >14 years) recruited to a randomised double-blind placebo-controlled 
trial of dexamethasone for the treatment of TBM,[5] CSF cytokine concentrations (TNF, IL-1β, IL-
6, IL-8,  IL-10, IL-12p70) were measured at multiple time points, and compared between patients 
receiving dexamethasone and placebo.[220] Dexamethasone did not significantly alter the levels of 
these CSF cytokines. CSF concentrations of IL-6, IL-8, and IL-10 fell slowly after commencement 
of anti-TB chemotherapy, and TNF fell rapidly, all irrespectively of dexamethasone. IL-1β, IL-
12p70 were rarely detected in pre-treatment CSF samples (7/61 and 6/61 CSF samples, 
respectively). In a follow up study of patients from the same trial, low CSF IFN-γ was associated 
with death in adults (>14 years) with TBM and HIV co-infection.[221] 
In a further study in Vietnamese adults with TBM, CSF concentrations of TNF-α, IFN-ɣ, IL-1β, IL-
2, IL4, IL-5, IL-6, IL-10, IL-12p70, IL-13 were measured.[18] In HIV uninfected adults with TBM 
concentrations of pro-inflammatory IL-1β, IL-2, and IL-6 (but not TNF-α) were significantly 
associated with LTA4H genotype; low concentrations in CC genotype, intermediate concentrations 
in CT genotype, and high concentrations in TT genotype). LTA4H genotype did not affect CSF 
cytokine concentrations in HIV co-infected patients, in whom there was a global increase in pro-
inflammatory cytokine concentrations.  
3.1.8 S. stercoralis and immunomodulation 
3.1.8.1 Pro-inflammatory vs. anti-inflammatory immunity 
Two major types of effector T cell exist in humans; T helper and T cytotoxic, which display either 
CD4 or CD8 molecules respectively on their cell surface.[219] Effector Th1 and Th2 are distinct 
subpopulations of T lymphocytes expressing the CD4 receptor, and are differentiated by the 
cytokines they secrete.[219] A classical Th1 response is characterised by secretion of IFN-ɣ and IL-
2, and activation of IL-12 secretion from macrophages, whereas a Th2 response is characterised by 
secretion of IL-4, IL-5, IL-6, IL-9, IL-10, IL-13 and IL-21.[219,222] Although some overlap exists 
in the variety of cytokines secreted by Th1 and Th2 cells, Th1 cells secrete IFN-ɣ but not IL-4, and 
Th2 cells secrete IL-4 but not IFN-ɣ.[223] A pattern of ‘type 1 immunity’ is largely regulated by 
Th1 cells, with a pro-inflammatory effect leading to, amongst other processes, phagocytosis and 
intracellular killing of microbes.[223] ‘Type 2 immunity’ involves stimulation of antibody by Th2 
 
89 
 
cells, an antibody class switch to IgE, IL-5 driven production and activation of eosinophils, and 
mast cell stimulation and degranulation.[223]  
In humans, helminths, such as S. stercoralis, characteristically induce a host type 2 immune 
response, with activation of cells of the innate and adaptive immune systems, and marked elevation 
of IL-4, IL-5 and IL-13.[224] Nematode infection induces antigen-specific IgE production, which 
coats the nematode. Eosinophils bind to the antibody and release large cytotoxic granules onto the 
surface of the nematode to kill it.[219] Eosinophils have an additional role as an antigen presenting 
cell in defense against S. stercoralis, activating T cells via major histocompatibility complex class 
II.[225] 
Interplay between Th1 and Th2 pathways are complex. The ‘hygiene hypothesis’ suggests exposure 
to bacterial and viral infections in early life may influence future immune responses to allergens, as 
impairment of the development of type 1 immunity results in imbalance in immunity and excessive 
type 2 immune responses to allergens.[226,227] Similarly, a lack of helminth exposure during 
childhood and throughout life may result in a dysregulated immune system and an increased risk of 
atopic and autoimmune disease.[222] Th1 and Th2 responses appear cross-inhibitory, with an 
increase in either Th1 or Th2 cells coupled with a reduction in the other.[228,229] Helminth co-
infection, and the Th2 immune response this produces may either beneficially reduce pathology, or 
impair essential lifesaving immune responses.[226] 
The ability of Th2 cells to downregulate Th1 processes raises questions regarding host immune 
function in the context of bacterial infection and helminth co-infection.[224] Helminth co-infection 
appears to modulate the host immune response in the context of M. tuberculosis infection, with 
impairment of IFN-ɣ response and suppression of type 1 immune responses, resulting in more 
severe TB disease.[224]  
3.1.8.2 S. stercoralis co-infection and tuberculosis 
In a study of 40 individuals with pulmonary TB, helminth co-infection was diagnosed in 11 (28%) 
of 40 individuals (in 8/11 cases the helminth was S. stercoralis).[230] A non-significant trend was 
found towards more severe disease in helminth co-infected individual with pulmonary TB vs. the 
TB-only control group. Interestingly, there were significantly lower blood IFN-ɣ levels in helminth 
co-infected individuals vs. the TB-only control group, both at presentation and at completion of 24 
weeks of anti-TB chemotherapy.[230] This study suggests suppression of Th1 responses required 
for effective TB control in helminth co-infection.[230] A larger study of plasma inflammatory 
cytokines in individuals with pulmonary TB (n=88, 42/88 co-infected with S. stercoralis) and latent 
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TB (n=88, 44/88 co-infected with S. stercoralis) found significantly lower levels of TNF-α, IFN-ɣ 
and IL-2, (key cytokines involved in type 1 immunity and the immune response to TB), in 
pulmonary TB patients co-infected with S. stercoralis compared to in the TB control group.[53] In 
addition plasma concentrations of type 2 and regulatory cytokines (IL-4, IL-5, IL-10 and IL-13) 
were significantly elevated in individuals with latent TB and S. stercoralis (n=44) vs. individuals 
with only latent TB (n=44). Interestingly a significant difference in these cytokine concentrations 
was not seen in active TB with and without S. stercoralis infection.    
3.1.9 Research objectives 
Whether such an immunomodulatory role is seen with S. stercoralis co-infection in TBM is 
unknown. Given mortality and morbidity of TBM are often through an excessive host inflammatory 
response, suppression of Th1 responses in TBM have potential to be neuroprotective.  
Here I will describe the frequency of S. stercoralis co-infection in TBM. I will investigate the 
influence of S. stercoralis on TBM clinical presentation, on the intracerebral inflammatory response 
to M. tuberculosis through routine CSF parameters and CSF cytokine analysis, and on outcomes of 
TBM. 
3.2 Methods 
3.2.1 Study participants 
Participants were enrolled from two on-going randomised placebo-controlled phase III trials of 
adjunctive corticosteroid therapy for HIV co-infected and uninfected adults with TBM (ACT HIV; 
clinicaltrials.gov NCT03092817[85] or LAST ACT; clinicaltrials.gov NCT03100786[41]). 
Participants in this study of S. stercoralis co-infection in TBM are Vietnamese adults (≥ 18 years of 
age), with or without HIV co-infection, with a clinical diagnosis of TBM (symptoms and CSF 
abnormalities consistent with TBM, and anti-TB chemotherapy planned or started by the attending 
clinician). Potential participants were excluded if an additional brain infection to TBM was 
suspected, more than 6 consecutive days of anti-TB chemotherapy were received, more than 3 days 
(ACT HIV, and LAST ACT until September 2018) or more than 6 days (LAST ACT after 
September 2018) of corticosteroid were received, dexamethasone was mandatory or 
contraindicated, or the patient had already entered the ACT HIV or LAST ACT trial. Eligible 
participants were enrolled into ACT HIV or LAST ACT between June 2017 and December 2019, 
inclusive, at HTD or Pham Ngoc Thach Hospital for Tuberculosis and Lung Disease (both in Ho 
Chi Minh City, Vietnam).  
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All enrolled participants (or a family member if the patient was incapacitated) gave written 
informed consent to participate in this study. Ethical approvals for ACT HIV and LAST ACT were 
obtained from OxTREC (36-16 and 52-16, respectively), the ethical committees of HTD (14/ 
HDDD and 37/ HDDD, respectively) and Pham Ngoc Thach Hospital for Tuberculosis and Lung 
Disease (1033/ HDDD-PNT and 460/ HDDD-PNT, respectively), and from the Vietnam Ministry of 
Health (108/CN-BDGDD and 151/CN-BDGDD, respectively). ACT HIV and LAST ACT are 
funded by an Investigator Award to Professor Guy Thwaites (Wellcome Trust, UK: 
110179/Z/15/Z).  
3.2.2 Clinical data 
Demographic data (age, gender), baseline MRC TBM severity grade[9] and HIV co-infection status 
were recorded. Death and neurological complications by 3 months were recorded. Neurological 
complications were defined as any of a fall in GCS of ≥ 2 points for ≥ 48 hours, a focal neurological 
sign, seizure, cerebellar signs, coma, or cerebral herniation.   
3.2.3 S. stercoralis testing 
3.2.3.1 Schedule 
All enrolled participants were tested for S. stercoralis. S. stercoralis serology (NovaTec 
Immunodiagnostica GmbH, Dietzenbach, Germany) was performed in all participants at baseline 
(defined as day of signing informed consent). Stool microscopy was performed in each participant 
at baseline, and again at day 21-30 prior to discharge if the participant was discharged home (to 
ensure eradication of larvae). Stool S. stercoralis PCR testing was performed in a sub-group of 
participants (those with S. stercoralis infection diagnosed by serology or stool microscopy 
[allowing comparison of diagnostic tests], and in consecutively enrolled participants negative for S. 
stercoralis until approximately 200 samples had been identified for stool S. stercoralis PCR 
testing). A limit was placed on PCR testing due to test cost. An eosinophil count (full blood count) 
was tested at baseline. 
3.2.3.2 Serology 
S. stercoralis serology (an immunoenzymatic determination of IgG and IgM antibodies against S. 
stercoralis) was performed following manufacturer instructions. As per manufacturer (NovaTec 
Immunodiagnostica GMBH) details; microtiter strip wells are pre-coated with recombinant S. 
stercoralis antigens to bind corresponding antibodies of the specimen, unbound sample material is 
removed by washing the wells, and bound S. stercoralis specific antibodies are detected by the 
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additional of horseradish peroxidase labeled anti-human IgG and IgM conjugate. The subsequently 
formed immune complex is visualized by adding tetramethylbenzidine substrate which gives a blue 
reaction. The intensity is proportional to the amount of S. stercoralis-specific antibodies in the 
specimen. The addition of sulphuric acid stops the reaction. Absorbance at 450nm is read using an 
ELISA microwell plate reader. Serology results were reported as follows; positive: >11 units, 
indicating antibodies against the pathogen are present; equivocal: 9-11 units, indicating antibodies 
against the pathogen could not be detected clearly, recommend repeat in 2-4 weeks (a repeat 
equivocal test means a negative result); negative: <9 units, indicating the sample contains no 
antibodies against the pathogen and the test is negative. Product specifications report 87.9% 
sensitivity and 95.8% specificity for this test. 
3.2.3.3 Stool PCR 
Routine wet preparation microscopy was used to identify S. stercoralis larvae. Stool concentration 
methods were not used. Stool Strongyloides stercoralis PCR was performed using an in-house 
(OUCRU, Ho Chi Minh City, Vietnam) stool PCR developed from the materials and methods of 
Verweij et al[205] (a real time PCR assay targeting the 18S ribosomal RNA gene sequence of S. 
stercoralis). Subsequently tested against 212 stool samples from Ghana and compared against the 
Baermann stool method and two stool microscopies for the detection of L1 or L3 S. stercoralis 
larvae, this stool PCR [205] showed 61% sensitivity (33/54 cases positive) for S. stercoralis 
detection. Stool PCR was positive in 12 (7.6%) of 158 samples negative by conventional tests, and 
excellent stool PCR specificity was demonstrated when the stool PCR was tested against stool 
‘controls’. 
3.2.4 Cerebrospinal fluid testing 
3.2.4.1 Tuberculosis 
At least 6mls of lumbar CSF was sampled (if available) at baseline in all participants. All CSF 
volumes were recorded. CSF processing and testing followed previously described procedures.[37] 
CSF supernatant was removed and stored at -800C for future CSF cytokine testing.   
3.2.4.2 Cytokines 
Cytokines were selected for CSF concentration analysis based on previous CSF cytokine studies in 
TBM as previously described, cytokines predicted to be affected by S. stercoralis co-infection,[53] 
and availability of testing kits (RnD Systems, Inc, Minnesota, USA); CSF TNF-α, IFN-γ, IL-1β, IL-
2, IL-4, IL-5, IL-6, IL10, IL-12p70 and IL-13 were measured (table 3-1).  
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Table 3-1: CSF cytokines, site of production, and role in immunity 
Cytokine Produced by Role 
TNF-α  Macrophages Immune activation and induction of an inflammatory 
response. Pro-inflammatory.[231] 
IFN-ɣ T cells and NK cells Activates macrophage and neutrophil intracellular killing, 
stimulates NK function, increases MHC class II expression 
on APCs. Antiviral actions. Pro-inflammatory.[231] 
IL-1β 
(IL-1 family) 
Macrophages, B 
cells, dendritic cells 
Role in innate immunity and inflammation. Pro-
inflammatory.[231,232] 
IL-2 Mostly T cells Activates CD4+ T cells, CD8+ T cells, and NK cells, 
supporting their growth and function. Involvement in 
adaptive immunity. Mostly pro-inflammatory.[233] 
IL-4 CD4+ T cells B and T lymphocyte proliferation, enhancement of MHC II 
expression, involvement in IgE and IgG responses. Anti-
inflammatory. 
IL-5 CD4+ T cells Promotes growth of B cells and eosinophils, stimulates IgA 
and IgM production. Anti-inflammatory. 
IL-6 CD4+ T cells, 
macrophages, 
fibroblasts 
Promotes B cell growth and IgG production, induces acute 
phase responses. Pro-inflammatory.[231] 
IL-10 CD4+ T cells, 
activated monocytes 
Inhibits the production of IFN-α, IL-1, IL-6, TNF-α, and 
stops antigen presentation. Anti-inflammatory. 
IL-12p70 
(p35/p40 
subunits of 
IL-12) 
T cells Induces IFN-gamma production and supports T cell 
responses. Mostly pro-inflammatory.[234] 
IL-13 Activated T cells Stimulates B cells. Anti-inflammatory. 
Table based on data from Parkin and Cohen[219] (with original reference for table Kumar and 
Clark, Clinical Medicine, 4th edition) and Turner et al.[218] Additional data referenced in the table. 
APC=antigen presenting cell. CD=cluster of differentiation. IL=interleukin. MHC=major 
histocompatibility complex. NK=natural killer.   
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CSF cytokine testing was performed by magnetic microbead immunoassay (RnD Systems, Inc, 
Minnesota, USA) following manufacturer instructions.[235] Briefly, magnetic microparticles 
coated with cytokine-specific antibodies were combined with CSF samples in a 96-well plate. 
Addition of Streptavidin-phycoerythrin after washing phases allows light emitting diodes (LEDs) to 
quantify the cytokine bound to the microparticle, whereas another LED identifies the microparticle 
region (and thus identifies the cytokine). CSF samples underwent cytokine concentration 
measurement across 2 plates, alongside 6 sequentially diluted standards on each plate. Cytokine 
concentrations were measured using a Luminex 200 (Luminex, Texas, USA). Data analysis set up 
of the Luminex 200 stated use of a 50µL CSF sample, however in practice 180µL of CSF was used. 
Therefore, final results were divided by 3.6 (180/50). Cytokine concentrations were measured using 
a Luminex 200 (Luminex, Texas, USA). The Luminex 200 xPONENT version 3.1.971.0 was used 
for analysis.  
3.2.4.2.1 Derivation of undetected cytokine concentrations 
Where CSF cytokine concentrations were undetected, either the lowest limit of extrapolation 
divided by 2, or the lowest limit of detection divided by two, was used, whichever was lowest. CSF 
cytokine testing was performed across two 96-well plates, and value extrapolation was plate-
specific. Rarely, where cytokine concentrations were too high for quantification, the upper limit of 
detection multiplied by 2 was used; samples and testing kits were unavailable for sample dilution 
and repeat testing. Log2 calculations of CSF cytokine concentration were performed.  
3.2.5 Treatment 
3.2.5.1 Anti-tuberculous chemotherapy 
All participants received anti-TB chemotherapy following Vietnamese national guidelines. 
Rifampicin (10mg/kg/24 hours; maximum dose 600mg), isoniazid (5mg/kg/24 hours; maximum 
300mg), pyrazinamide (25mg/kg/24 hours; maximum 2g), and ethambutol (20mg/kg/24 hours; 
maximum 1.2g), were given as outlined in the published study protocols.[41,85] Total anti-TB 
chemotherapy duration is 12 months, with pyrazinamide discontinued after 2 months. In cases of 
drug resistance, or where adverse events necessitate treatment discontinuation, local and national 
advice will be followed. Drug regimens are further described in appendix F. 
3.2.5.2 Study drug for ACT HIV and LAST ACT 
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Additionally, all participants were randomised to dexamethasone or placebo (termed ‘study drug’), 
a double blinded allocation following 1:1 randomisation (except LTA4H TT-genotype HIV 
uninfected participants from LAST ACT [~7% total participants] who all received open-label 
dexamethasone). Study drug was administered over 8 weeks (TBM grade 2 or 3) or 6 weeks (TBM 
grade 1), following a tapering course, with weekly reductions (table 3-2). The ACT HIV and LAST 
ACT trials are ongoing and treatment allocations remain blinded.  
Table 3-2: Study drug doses in ACT and LAST ACT after randomisation[41,85] 
 MRC Grade I 
Daily dexamethasone 
dose/route 
MRC Grades II and III 
Daily dexamethasone 
dose/route 
Week 1 0.3 mg/kg/24 hrs IV 0.4 mg/kg/24 hrs IV 
Week 2 0.2 mg/kg/24 hrs IV 0.3 mg/kg/24 hrs IV 
Week 3 0.1 mg/kg/24 hrs IV 0.2 mg/kg/24 hrs IV 
Week 4 3mg/24 hrs oral 0.1 mg/kg/24 hrs IV 
Week 5 2mg/24 hrs oral 4 mg/24 hrs oral 
Week 6 1 mg/24 hrs oral 3 mg/24 hrs oral 
Week 7 Stop 2 mg/24 hrs oral 
Week 8  1 mg/24 hrs oral 
IV=intravenous. MRC=Medical Research Council  
 
3.2.5.3 S. stercoralis 
Treatment of S. stercoralis follows Vietnamese local and national guidelines. Uncomplicated S. 
stercoralis infection is treated with ivermectin 200µg/kg daily for 1-2 days. All stool positive cases 
receive S. stercoralis eradication therapy. Participants only positive by serology are treated on a 
case-by-case basis, with clinical state, risks for dissemination, and magnitude of serological titer, 
considered. Complicated S. stercoralis infection is treated with ivermectin for at least 2 weeks, and 
repeat negative stool samples are then sought.  
3.2.6 Statistical analysis 
3.2.6.1 Sample size 
The prevalence of S. stercoralis co-infection in Vietnamese adults with TBM is not known. A 
prevalence from 7.4-18.2% may be expected using serological estimates from non-TBM 
cohorts.[186,187] In the study by George et al,[53] plasma cytokines were measured in 42 S. 
stercoralis co-infected individuals with pulmonary TB, and significant differences in plasma 
cytokine concentrations were found vs. a non-S. stercoralis group. However, given 
immunomodulation in TBM by S. stercoralis is uncertain, a sample size calculation was not 
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possible and this study was exploratory. CSF cytokine concentration analysis was based upon 
sample availability.  
3.2.6.2 Analysis populations 
Primary analysis populations were selected based on clinical categories of S. stercoralis infection. 
A S. stercoralis ‘uninfected’ group was selected based upon participants having been tested by all 
of S. stercoralis serology, stool microscopy, and stool PCR, and all being negative. This approach 
gave the highest certainty of a S. stercoralis uninfected status. A ‘past infection’ group was selected 
based upon participants having positive S. stercoralis serology with no positive stool result (but at 
least one of stool microscopy or stool PCR performed). An ‘active infection’ group was selected 
based upon a positive S. stercoralis stool microscopy or stool PCR result, regardless of other testing 
performed.  
In addition, secondary analyses were performed on three additional sub-populations; participants 
who had serology performed, participants who had both serology and stool microscopy performed 
(divided into groups A-C), and participants who had all of serology, stool microscopy and stool 
PCR performed (divided into groups 1-4) (figure 3-1). These secondary analyses compared baseline 
TBM severity, CSF inflammatory parameters, and clinical endpoints (neurological complications by 
3 months, and death by 3 months) between those with and without positive S. stercoralis tests, for 
each sub-population. CSF cytokine analysis was performed only for primary analysis populations.  
3.2.6.3 Statistical tests 
Comparison between proportions was assessed by the chi squared test. Non-normally distributed 
variables, including CSF cytokine concentrations, were compared using the Wilcoxon rank sum 
test. Given variable CSF concentrations between cytokines, ratios of cytokine changes were 
compared and tabulated. A multivariate analysis (with odds ratios and 95% CIs) was performed to 
evaluate whether age, MRC TBM grade, HIV co-infection and active S. stercoralis infection 
predicted neurological complications by 3 months. Data were analysed using R (version 3.6). 
3.2.6.4 Statistical analysis plan 
A statistical analysis plan written in advance of data analysis outlined the following: 
1. Evaluate the number of positive S. stercoralis serological, stool microscopy, and stool PCR 
tests, and compare by age, sex, and HIV co-infection 
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2. Compare HIV co-infection rate, TBM final diagnosis, MRC TBM grade, and baseline 
blood eosinophil count between participants uninfected for S. stercoralis, and participants 
with active or past S. stercoralis co-infection 
3. Compare CSF TNF-α, IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL10, IL-12p70 and IL-13 
between participants with and without S. stercoralis co-infection 
4. Compare neurological complications by 3 months, and death by 3 months, between 
participants uninfected for S. stercoralis, and participants with active or past S. stercoralis 
co-infection 
Subsequent to the initial data analysis, given the immunomodulation suggested by clinical 
presentation, CSF cytokine, and clinical endpoint data, routine CSF parameters (WBC, neutrophil 
count, neutrophil percentage, and protein), CSF/blood glucose ratio, and Xpert positivity were also 
compared between participants with and without S. stercoralis co-infection to further evaluate the 
effect of S. stercoralis on CSF inflammation.  
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Figure 3-1: Populations stratified by S. stercoralis tests performed 
 
N = number of participants
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3.3 Results 
3.3.1 The study population 
From June 2017 to December 2019 inclusive, 668 participants with clinical TBM underwent 
baseline testing for S. stercoralis co-infection, by one or more of serology, stool microscopy, and 
stool PCR. The median age of the study population was 39 (IQR 31-50) years. 67.5% (451/668) 
participants were male. MRC TBM severity grades[9,236] amongst the study population were, 
Grade 1: 45.1% (n=301), Grade 2: 43.3% (n=289), Grade 3: 11.7% (n=78). 43.4% (n=290) study 
participants were diagnosed with definite TBM, 38.3% (n=256) with probable TBM, and 16.0% 
(n=107) with possible TBM. 44.6% (298/668) participants were HIV co-infected.  
3.3.2 S. stercoralis testing 
Overall, 9.4% (63/668) participants tested positive for S. stercoralis by at least one of serology 
(n=53), stool microscopy (n=11), or stool PCR (n=17). All three diagnostic tests were performed in 
141/668 (21.1%) participants, with a positive result for all three tests in only one participant (figure 
3-2). 
Figure 3-2: Venn diagram of positive S. stercoralis tests  
 
Positive tests: 53 serology, 11 stool microscopy, 17 stool PCR. 81 positive S. stercoralis tests 
represented in 63 patients testing positive for S. stercoralis by serology, stool microscopy, stool 
PCR or combinations of these tests. PCR=polymerase chain reaction 
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A positive S. stercoralis diagnosis was made by stool microscopy alone in 3 participants and by 
stool PCR alone in 6 participants. The total numbers of S. stercoralis tests performed are shown in 
figure 3-1. The median age of participants who tested positive for S. stercoralis by any method was 
49 (IQR 37-59) years vs. 40 (IQR 32-51) years in participants who tested negative for S. stercoralis 
by serology, stool microscopy, and stool PCR. 55/63 (87.3%) of S. stercoralis positive participants 
were male vs. 75/110 (68.2%) of S. stercoralis negative participants. HIV co-infection was present 
in 16/63 (25.4%) S. stercoralis positive participants vs. in 37/110 (33.6%) S. stercoralis negative 
participants. 
3.3.3 Influence of S. stercoralis infection on TBM presentation and routine CSF parameters 
A comparison of baseline TBM severity and routine CSF parameters between primary analysis 
populations is shown in table 3-3.  
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Table 3-3: A comparison of baseline TBM severity and CSF inflammatory parameters for 
cytokine testing groups  
 S. stercoralis testing 
Uninfected Past infection Active infection 
  P value  P value 
Patients (No.) 110 30  26  
HIV status  
(No. [%])  
- Positive 
- Negative 
 
 
37 (33.6%) 
73 (66.4%) 
 
 
4 (13.3%) 
26 (86.7%) 
 
 
0.05 
 
 
9 (34.6%) 
17 (65.4%) 
 
 
1.0 
Final diagnosis 
- Definite 
- Probable 
- Possible 
 
58 (52.7%) 
38 (34.5%) 
13 (11.8%) 
 
9 (30.0%) 
14 (46.7%) 
6 (20.0%) 
 
Ref 
0.11 
0.13 
 
5 (19.2%) 
16 (61.5%) 
5 (19.2%) 
 
Ref 
0.01 
0.06 
MRC TBM Grade 
(No. [%]) 
- 1 
- 2 
- 3 
 
 
44 (40.0%) 
45 (40.9%) 
21 (19.1%) 
 
 
16 (53.3%) 
12 (40.0%) 
2 (6.7%) 
 
 
Ref 
0.62 
0.14 
 
 
13 (50.0%) 
12 (46.2%) 
1 (3.8%) 
 
 
Ref 
1.0 
0.11 
Baseline eosinophil 
count (109/L) 
(Median[IQR]) 
0 
 
(0-0.1) 
0.2 
 
(0.1-0.2) 
<0.001 0.1 
 
(0-0.4) 
0.02 
CSF WBC 
(cells/mm3) 
(Median[IQR]) 
123 
 
(29-297) 
74 
 
(9-254) 
0.20 70 
 
(7-168) 
0.13 
CSF neutrophil count 
(cells/mm3) 
(Median[IQR]) 
14 
 
(1-83) 
6 
 
(0-36) 
0.25 3 
 
(0-25) 
0.04 
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CSF neutrophil 
percentage  
(Median[IQR]) 
10 
 
(5-27) 
11 
 
(0-15) 
0.20 5 
 
(0-14) 
0.04 
CSF/blood glucose 
ratio  
(Median[IQR]) 
0.38 
 
(0.26-0.52) 
0.43 
 
(0.33-0.52) 
0.34 0.45 
 
(0.31-0.59) 
0.16 
CSF protein (g/L) 
(Median[IQR]) 
1.45 
(0.95-2.18) 
1.39 
(1.13-1.94) 
0.69 0.94 
(0.60-1.84) 
0.08 
Xpert (No. [%]) 
- Positive 
- Negative 
 
31 (28.2%) 
68 (61.8%) 
 
6 (20.0%) 
21 (70.0%) 
 
0.50 
 
1 (3.8%) 
24 (92.3%) 
 
0.03 
P values are shown for group comparison with S. stercoralis uninfected group in each case. The chi 
squared test was used to compare categorical data. Ref: with final diagnosis, P values represent 
comparison of each of probable and possible TBM, with definite TBM. With MRC TBM Grade P 
values represent comparison of each of Grade 2 and Grade 3 TBM, with Grade 1 TBM. With final 
diagnosis, n=1 (past infection group) participant scored < 6 points for the TBM diagnostic 
score.[69] This case was considered to be TBM by the treating clinician and was treated as such. 
The Wilcoxon rank sum test was used to compare continuous data. Uninfected = all 3 testing 
methods used, and all negative (correlates with group ‘1’ in figure 3-1). Past infection = positive S. 
stercoralis serology with no positive stool testing (but at least one of stool microscopy of stool PCR 
performed). Active infection = Positive stool microscopy or stool PCR for S. stercoralis, regardless 
of other testing performed. Baseline eosinophil counts, CSF WBC, and CSF neutrophil percentage 
are non-normally distributed and are shown as median (IQR). ‘Ref’ refers to the final diagnosis or 
grade against which comparison was made. CSF=cerebrospinal fluid. HIV=human 
immunodeficiency virus. IQR=interquartile range. MRC=Modified Research Council. 
TBM=tuberculous meningitis. WBC=white blood cell. Xpert=GeneXpert MTB/RIF 
 
Baseline eosinophils were significantly elevated in active S. stercoralis infection compared with S. 
stercoralis uninfected participants; 0.1 x109/L (0-0.4) vs. 0 x109/L (0-0.1) respectively, p=0.02. 
Median CSF neutrophil count and neutrophil percentage were reduced in active S. stercoralis 
infection compared with uninfected participants; 3 cells/mm3 (0-25) vs. 14 cells/mm3 (1-83) 
respectively, p=0.04, and 5% (0-14) vs. 10% (5-27) respectively, p=0.04. Additionally, trends 
towards reduced grade 3 disease (3.8% [1/26] vs. 19.1% [21/110]), reduced total CSF WCC 
cells/mm3 (70 [7-168] vs. 123 cells/mm3 [29-297]), reduced CSF protein (0.94g/L [0.60-1.84] vs. 
1.45g/L [0.95-2.18]), and elevated CSF/blood glucose ratio (0.45 [0.31-0.59] vs. 0.38 [0.26-0.52]), 
were seen with active S. stercoralis infection vs. uninfected participants, respectively. In active S. 
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stercoralis infection there was a reduced proportion of definite TBM; 19.2% (5/26) vs. 52.7% 
(58/110) (p=0.01 vs. probable TBM), and reduced Xpert positivity; 3.8% (1/26) vs. 28.2% (31/110) 
(p=0.03), compared with uninfected participants.   
Baseline TBM severity and CSF inflammatory parameter analyses performed in sub-populations of 
participants who had serology performed, or both serology and stool microscopy performed, are 
shown in tables 3-4 and 3-5.  
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Table 3-4: A comparison of baseline TBM severity and CSF inflammatory parameters in 
participants who had S. stercoralis serology performed 
 S. stercoralis testing 
Negative S. stercoralis 
serology 
Positive S. stercoralis 
serology 
P value 
Patients (No.) 606 53  
HIV status (No. [%])  
- Positive 
- Negative 
 
280 (46.2%) 
326 (53.8%) 
 
11 (20.8%) 
42 (79.2%) 
 
0.001 
Final diagnosis 
- Definite 
- Probable 
- Possible 
 
272 (41.2%) 
223 (39.4%) 
97 (17.3%) 
 
16 (30.2%) 
26 (49.1%) 
10 (18.9%) 
 
Ref 
0.05 
0.26 
MRC TBM Grade (No. [%]) 
- 1 
- 2 
- 3 
 
267 (44.1%) 
266 (43.9%) 
73 (12.0%) 
 
28 (52.8%) 
20 (37.7%) 
5 (9.4%) 
 
Ref 
0.35 
0.53 
Baseline eosinophil count 
(109/L) 
(Median[IQR]) 
0  
 
(0-0.1) 
0.1  
 
(0-0.3) 
0.002 
CSF WBC (cells/mm3) 
(Median[IQR]) 
75  
(6-243) 
70  
(7-257) 
0.90 
CSF neutrophil count 
(cells/mm3) 
(Median[IQR]) 
6 
 
(0-46) 
4 
 
(0-49) 
0.86 
CSF neutrophil percentage  
(Median[IQR]) 
8  
(0-22) 
10  
(0-15) 
0.95 
CSF/blood glucose ratio  0.39 0.39  0.51 
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(Median[IQR]) (0.26-0.50) (0.29-0.51) 
CSF protein (g/L) 
(Median[IQR]) 
1.38 
(0.73-2.19) 
1.46 
(0.91-2.24) 
0.36 
Xpert (No. [%]) 
- Positive 
- Negative  
 
161 (26.6%) 
410 (67.7%) 
 
10 (18.9%) 
41 (77.4%) 
 
0.25 
‘Negative S. stercoralis serology group corresponds with ‘serology NEGATIVE’ group in figure 3-
1. ‘Positive S. stercoralis serology group corresponds with ‘serology POSITIVE’ group in figure 3-
1. With final diagnosis, n=2 (negative S. stercoralis serology) and n=1 (positive S. stercoralis 
serology) participants scored < 6 points for the TBM diagnostic score.[69]. These were considered 
to be TBM by the treating clinician and were treated as such. With final diagnosis, P values 
represent comparison of each of probable and possible TBM, with definite TBM. With MRC TBM 
Grade P values represent comparison of each of Grade 2 and Grade 3 TBM, with Grade 1 TBM. 
The chi squared test was used to compare categorical data. The Wilcoxon rank sum test was used to 
compare continuous data. Baseline eosinophil counts, CSF WBC, and CSF neutrophil percentage 
are non-normally distributed and are shown as median (IQR). CSF=cerebrospinal fluid. 
HIV=human immunodeficiency virus. IQR=interquartile range. MRC=Modified Research Council. 
TBM=tuberculous meningitis. WBC=white blood cell. Xpert=GeneXpert MTB/RIF. ‘Ref’ refers to 
the final diagnosis or grade against which comparison was made.  
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Table 3-5: A comparison of baseline TBM severity and CSF inflammatory parameters in 
participants who had S. stercoralis serology and stool microscopy performed 
 S. stercoralis testing 
Group A Group B Group C 
Negative by 
serology and 
stool 
microscopy 
Positive by 
serology and 
negative by stool 
microscopy 
P value Positive by 
both serology 
and by stool 
microscopy 
P value 
Patients (No.) 475 37  7  
HIV status (No 
(%))  
- Positive 
- Negative 
 
 
199 (41.9%) 
278 (58.5%) 
 
 
7 (18.9%)  
30 (81.1%) 
 
 
0.01 
 
 
1 (14.3%)  
6 (85.7%) 
 
 
0.29 
Final diagnosis 
- Definite 
- Probable 
- Possible 
 
208 (43.8%) 
172 (36.2%) 
83 (17.5%) 
 
9 (24.3%)  
19 (51.4%) 
8 (21.6%)  
 
Ref 
0.03 
0.18 
 
2 (28.6%)  
3 (42.9%) 
2 (28.6%) 
 
Ref 
0.84 
0.70 
MRC TBM Grade 
(No (%)) 
- 1 
- 2 
- 3 
 
 
220 (46.3%) 
202 (42.5%) 
53 (11.2%) 
 
 
21 (56.8%)  
15 (40.5%) 
1 (2.7%) 
 
 
Ref 
0.59 
0.15 
 
 
5 (71.4%)  
2 (28.6%) 
0 (0%) 
 
 
Ref 
0.53 
0.60 
Baseline eosinophil 
count (109/L) 
(Median[IQR]) 
0.1 
  
 
(0-0.2) 
0.2  
 
 
(0.1-0.3)  
0.002 0.1  
 
 
(0-0.6)  
0.30 
CSF WBC 
(cells/mm3) 
(Median[IQR]) 
72  
 
(8-253) 
70  
 
(6-243)  
0.55 72  
 
(49-285)  
0.56 
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CSF neutrophil 
count (cells/mm3) 
(Median[IQR]) 
5 
 
(0-46) 
4 
 
(0-35) 
0.81 3 
 
(2-43) 
0.89 
CSF neutrophil 
percentage  
(Median[IQR]) 
5  
 
(0-20) 
5  
 
(0-15)  
0.85 8  
 
(3-13)  
0.79 
CSF/blood glucose 
ratio  
(Median[IQR]) 
0.39  
 
(0.26-0.50) 
0.46  
 
(0.35-0.53)  
0.06 0.34  
 
(0.26-0.46)  
0.81 
CSF protein (g/L) 
(Median[IQR]) 
1.35  
(0.75-2.17) 
1.29  
(0.75-1.71)  
0.36 1.49  
(0.94-1.87)  
0.78 
Xpert 
- Positive 
- Negative 
 
125 (26.3%) 
323 (68.0%) 
 
6 (16.2%)  
29 (78.4%) 
 
0.24 
 
1 (14.3%)  
6 (85.7%) 
 
0.71 
Groups A, B and C correspond with testing groups A, B and C in figure 3-1. With final diagnosis, 
n=1 (negative for S. stercoralis by serology and stool microscopy) and n=1 (positive for S. 
stercoralis by serology and negative by stool microscopy) participants scored < 6 points for the 
TBM diagnostic score.[69]. These were considered to be TBM by the treating clinician and were 
treated as such. With final diagnosis, P values represent comparison of each of probable and 
possible TBM, with definite TBM. With MRC TBM Grade P values represent comparison of each 
of Grade 2 and Grade 3 TBM, with Grade 1 TBM. P values are shown for comparison with negative 
group in each case. The chi squared test was used to compare categorical data. The Wilcoxon rank 
sum test was used to compare continuous data. Baseline eosinophil counts, CSF WBC, and CSF 
neutrophil percentage are non-normally distributed and are shown as median (IQR). 
CSF=cerebrospinal fluid. HIV=human immunodeficiency virus. IQR=interquartile range. 
MRC=Modified Research Council. TBM=tuberculous meningitis. WBC=white blood cells. 
Xpert=GeneXpert MTB/RIF. ‘Ref’ refers to the final diagnosis or grade against which comparison 
was made.  
 
In participants who had S. stercoralis serology performed, a significantly reduced proportion of 
HIV co-infection was found in the positive S. stercoralis serology group compared with the 
negative S. stercoralis serology group (20.8% [11/53] vs. 46.2% [280/606], respectively, p=0.001) 
(table 3-4). In participants tested by both S. stercoralis serology and stool microscopy, a reduction 
in definite TBM (vs. probable TBM) was seen in participants with positive S. stercoralis serology 
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and negative stool microscopy vs. in participants testing negative by both S. stercoralis serology 
and stool microscopy (24.3% [9/37] vs. 41.2% [208/475], p=0.03) (table 3-5).  
3.3.4 Baseline CSF cytokine concentrations in Strongyloides stercoralis co-infection 
I hypothesised that in those with active S. stercoralis infection CSF concentrations of the pro-
inflammatory cytokines IFN-ɣ, IL-2, and TNF-α would be reduced, and CSF concentrations of the 
regulatory cytokines IL-4, IL-5, IL-10, and IL-13 would be increased, compared with S. stercoralis 
uninfected participants. These cytokines, in addition to IL-1β, IL-6 and IL-12p70 (as exploratory 
analyses) were measured in CSF, and compared between primary analysis populations. CSF 
cytokine testing flow is shown in figure 3-3.  
Figure 3-3: CSF cytokine testing flow diagram 
 
14 samples were excluded from testing when no stored CSF sample was available. 5 samples 
were not tested as S. stercoralis tests returned as positive after cytokine testing had been  
arranged and set up. 2A computer error during the analysis led to loss of one sample result.  
Uninfected = all 3 testing methods used, and all negative. Past infection = positive S. stercoralis  
serology with no positive stool testing (but at least one of stool microscopy of stool PCR  
performed). Active infection = Positive stool microscopy or stool PCR for S. stercoralis,  
regardless of other testing performed. Other=not meeting criteria for the uninfected, past  
infection, or active infection, groups. N=number of participants undergoing testing 
 
The numbers of each cytokine detected in CSF, by testing plate, are shown in table 3-6. 
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Table 3-6: CSF cytokine detection shown by plate and in total, for 10 tested cytokines 
 
Cytokine 
Plate 1 (N=87) Plate 2 (N=76) Total (N=163) 
Detected Undetected Detected Undetected Detected Undetected 
TNF-α 87 0 71 5 158 5 
IFN-ɣ 87 0 75 1 162 1 
IL-1β 43 44 32 44 75 88 
IL-2 64 23 66 10 130 33 
IL-4 64 23 76 0 140 23 
IL-5 24 63 25 51 49 114 
IL-6 87 0 76 0 163 0 
IL-10 79 8 68 8 147 16 
IL-12p70 32 55 15 61 47 116 
IL-13 87 0 39 37 126 37 
 
For IL-6 there were 71 samples with results reported as > 1180 pg/mL. IL-6 was the only cytokine 
to return values greater than an upper threshold. CSF=cerebrospinal fluid. IL=interleukin. N 
represents the number of CSF samples tested on each plate. 
 
Log2 CSF concentrations of IFN-ɣ, IL-2, and TNF-α are shown in figure 3-4.  
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Figure 3-4: Log2 CSF IFN-ɣ, IL-2 and TNF-α concentrations in participants uninfected with S. stercoralis, with past S. stercoralis 
infection, or with active S. stercoralis infection  
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For each individual boxplot, the central horizontal bar represents the median value. The box 
contains data between 3rd quartile (upper end of box) and 1st quartile (lower end of box). Vertical 
lines above and below each box extend to the most extreme data point that is within 1.5x the 
vertical height of the box. Dots represent individual data points. Uninfected = all 3 testing methods 
used, and all negative. Past infection = positive S. stercoralis serology with no positive stool testing 
(but at least one of stool microscopy of stool PCR performed). Active infection = Positive stool 
microscopy or stool PCR for S. stercoralis, regardless of other testing performed. Cytokine 
concentrations are shown in pg/mL. Statistical comparison of cytokine concentrations was 
performed by the Wilcoxon rank sum test. CSF=cerebrospinal fluid 
 
Log2 CSF concentrations of pro-inflammatory cytokines were significantly reduced in participants 
with active S. stercoralis infection (n=25), vs. in uninfected participants (n=105); IFN-ɣ: 3.51 vs. 
5.81, p=0.01; IL-2: 5.05 vs. 5.77, p=0.03; TNF-α: 2.17 vs. 3.58, p=0.02; IL-6: 3.61 vs. 9.36, p=0.01. 
Additionally log2 CSF concentrations of IFN-ɣ, TNF-α, IL-2, but not IL-6, were significantly 
reduced in participants with past S. stercoralis infection (n=17) vs. in uninfected participants; IFN-
ɣ: 3.77 vs. 5.81, p=0.02; IL-2: 4.82 vs. 5.77, p=0.03; TNF-α: 2.19 vs. 3.58, p=0.02; IL-6: 5.76 vs. 
9.36, p=0.10.  Log2 CSF concentrations of IL-10, and IL-13, and IL-4 are shown in figure 3-5.  
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Figure 3-5: Log2 CSF IL-10, IL-13, and IL-4 concentrations in participants uninfected with S. stercoralis, with past S. stercoralis 
infection, or with active S. stercoralis infection  
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For each individual boxplot, the central horizontal bar represents the median value. The box 
contains data between 3rd quartile (upper end of box) and 1st quartile (lower end of box). Vertical 
lines above and below each box extend to the most extreme data point that is within 1.5x the 
vertical height of the box. Dots represent individual data points. Uninfected = all 3 testing methods 
used, and all negative. Past infection = positive S. stercoralis serology with no positive stool testing 
(but at least one of stool microscopy of stool PCR performed). Active infection = Positive stool 
microscopy or stool PCR for S. stercoralis, regardless of other testing performed. Cytokine 
concentrations are shown in pg/mL. Statistical comparison of cytokine concentrations was 
performed by the Wilcoxon rank sum test. CSF=cerebrospinal fluid 
 
 
Contrary to our hypothesis, log2 CSF concentrations of IL-10 and IL-4 were significantly reduced 
in active S. stercoralis infection vs. in S. stercoralis uninfected participants; IL-10: 2.71 vs. 3.59, 
p=0.004; IL-4: 2.05 vs. 3.15, p=0.01. In participants with past S. stercoralis infection log2 CSF 
concentrations of IL-13 were reduced (2.71 vs. 4.58, p=0.03), and log2 CSF concentrations of IL-5 
were increased (-1.44 vs. -1.44, p=0.02), vs. in uninfected participants.  
Log2 CSF concentrations of IL-12p70, IL-1β, and IL-5, for S. stercoralis uninfected, past infection 
and active infection groups, are shown in figure 3-6. Seventy percent of participants had 
undetectable IL-5 in their CSF samples, hence heavily skewed median values based on 
interpretation of these undetected values. CSF IL-5 concentrations were significantly higher 
participants with past S. stercoralis infection, vs. S. stercoralis uninfected participants, despite 
identical median values in these groups. Ratio of CSF cytokine change, and statistical comparison 
between groups, are shown in table 3-7. The ratios of change of each of TNF-α, IFN-ɣ, and IL-2, 
were of similar magnitude when comparing uninfected participants to those with past infection, and 
uninfected participants to those with active infection.  
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Figure 3-6: Log2 CSF IL-12p70, IL-1β, and IL-5 concentrations in participants uninfected with S. stercoralis, with past S. stercoralis 
infection, or with active S. stercoralis infection  
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For each individual boxplot, the central horizontal bar represents the median value. The box 
contains data between 3rd quartile (upper end of box) and 1st quartile (lower end of box). 
Vertical lines above and below each box extend to the most extreme data point that is within 
1.5x the vertical height of the box. Dots represent individual data points. Uninfected = all 3 
testing methods used, and all negative. Past infection = positive S. stercoralis serology with no 
positive stool testing (but at least one of stool microscopy of stool PCR performed). Active 
infection = Positive stool microscopy or stool PCR for S. stercoralis, regardless of other testing 
performed. Cytokine concentrations are shown in pg/mL. Statistical comparison of cytokine 
concentrations was performed by the Wilcoxon rank sum test. CSF=cerebrospinal fluid 
 
Table 3-7: Median log2 CSF cytokine concentrations by testing group  
Log2 
Cytokine 
S. stercoralis testing Ratio of reduction 
Uninfected Past 
infection 
Active 
infection 
Uninfected/ Past 
infection 
(Ratio [Wilcoxon]) 
Uninfected/ Active 
infection 
(Ratio [Wilcoxon]) 
TNF-α 3.58 2.19 2.17 1.63 (p=0.02) 1.65 (p=0.02) 
IFN-ɣ 5.81 3.77 3.51 1.54 (p=0.02) 1.66 (p=0.01) 
IL-1β 1.08 1.08 1.08 1.00 (p=0.26) 1.00 (p=0.05) 
IL-2 5.77 4.82 5.05 1.20 (p=0.03) 1.14 (p=0.03) 
IL-4 3.15 2.31 2.05 1.36 (p=0.12) 1.54 (p=0.01) 
IL-5 -1.44 -1.44 -5.38 1.00 (p=0.02) 0.27 (p=0.55) 
IL-6 9.36 5.76 3.61 1.63 (p=0.10) 2.59 (p=0.01) 
IL-10 3.59 3.32 2.71 1.08 (p=0.17) 1.32 (p=0.004) 
IL-12p70 2.12 2.12 0.17 1.00 (p=0.92) 12.5 (p=0.21) 
IL-13 4.58 2.71 4.28 1.69 (p=0.03) 1.07 (p=0.30) 
P values are shown for comparison with negative group in each case. The Wilcoxon rank sum 
test was used to compare cytokine data. Cytokine concentrations are shown in pg/mL. 
 
IL-12p70 and IL-6 concentrations experienced the greatest ratio of reduction (12.5x and 2.6x, 
respectively) in active S. stercoralis infection compared with uninfected participants.   
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3.3.5 S. stercoralis co-infection and outcome from TBM 
A comparison of neurological complications by 3 months, and death by 3 months, between 
primary analysis populations, is shown in table 3-8.  
Table 3-8: A comparison of neurological complications and death by 3 months for 
cytokine testing groups 
 S. stercoralis testing 
Uninfected Past infection Active infection 
  P value  P value 
Patients (No.) 110 30  26  
Neurological 
complications by 3 
months 
- Yes (%) 
- No (%) 
 
 
33 (28.2 %) 
77 (71.8%) 
 
 
5 (13.3%) 
25 (86.7%) 
 
 
0.22 
 
 
1 (3.8%) 
25 (96.2%) 
 
 
0.01 
Death by 3 months 
- Yes (%) 
- No (%) 
 
31 (28.2%) 
79 (71.8%) 
 
5 (13.3%) 
25 (86.7%) 
 
0.30 
 
4 (15.4%) 
22 (84.6%) 
 
0.27 
P values are shown for group comparison with S. stercoralis uninfected group in each case. The 
chi squared test was used to compare categorical data. Uninfected = all 3 testing methods used, 
and all negative. Past infection = positive S. stercoralis serology with no positive stool testing 
(but at least one of stool microscopy of stool PCR performed). Active infection = positive stool 
microscopy or stool PCR for S. stercoralis, regardless of other testing performed.  
 
Neurological complications by 3 months were significantly reduced in participants with active 
S. stercoralis infection (3.8% [1/26]), vs. uninfected participants (28.2% [33/110]) (p=0.01). 
Neurological complications are listed in Table 3-9.  
  
 
117 
 
Table 3-9: Neurological complications in S. stercoralis uninfected, past infection, and 
active infection groups 
 S. stercoralis testing 
Uninfected 
(N=110) 
Past infection 
(N=30) 
Active infection 
(N=26) 
Neurological events  
(No. [%]) 
33 
(30.0%) 
5  
(16.7%) 
1  
(3.8%) 
Fall in GCS ≥ 2 points for 
≥ 48 hours 
(No. [%]) 
26 
 
(23.6%) 
4 
 
(13.3%) 
0 
 
(3.8%) 
Focal neurological sign 
(No. [%]) 
5 
(4.5%) 
0 
(0%) 
0 
(0%) 
Seizure 
(No. [%]) 
2 
(1.8%) 
0 
(0%) 
0 
(0%) 
Paraplegia/paraparesis 
(No. [%]) 
0 
(0%) 
1 
(3.3%) 
0 
(0%) 
N=number of participants. GCS=Glasgow coma score 
 
A fall in GCS ≥ 2 points for ≥ 48 hours was the most common neurological complication 
recorded, accounting for 80% (4/5) neurological complications in past S. stercoralis infection, 
and 78.8% (26/33) neurological complications in S. stercoralis uninfected participants. In a 
multivariate logistic regression active S. stercoralis infection was significantly and 
independently associated with reduced neurological events by 3 months (p=0.01) (table 3-10). 
Death by 3 months was not significantly reduced between active S. stercoralis infection and 
uninfected groups; 15.4% (4/26) vs. 28.2% (31/110), respectively, p=0.27.  
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Table 3-10: Multivariate analysis of factors predicting neurological complications by 3 
months  
Variable Odds Ratio 95% CI P value 
Age (years) 0.99 0.95-1.02 0.38 
MRC TBM Grade 2 9.72 3.06-38.7 <0.001 
MRC TBM Grade 3 11.2 3.05-49.1 <0.001 
HIV co-infection 2.38 0.84-7.03 0.10 
Active S. stercoralis co-infection  0.09 0.00-0.54 0.01 
Odds ratios with CIs are shown for the prediction of neurological complications with each 
variable. Age represents an increase in 1 year. MRC TBM Grade 2 and 3 represents 
comparisons with MRC TBM Grade 1 in each case. HIV co-infection represents comparison 
with HIV uninfected participants. Active S. stercoralis co-infection represents comparison with 
S. stercoralis uninfected participants. Q=quartile. CI=confidence interval. HIV=human 
immunodeficiency virus. MRC=Medical Research Council. TBM=tuberculous meningitis. 
 
Additional sub-population comparisons of clinical endpoints in participants with and without 
positive S. stercoralis testing are shown in tables 3-11 and 3-12.  
Table 3-11: A comparison of neurological complications and death by 3 months in 
participants who had S. stercoralis serology performed 
 Negative S. 
stercoralis 
serology 
Positive S. 
stercoralis 
serology 
P value 
Patients (No.) 606 53  
Neurological complications 
by 3 months 
- Yes (%) 
- No (%) 
 
 
143 (23.6%) 
463 (76.4%) 
 
 
8 (15.1%) 
45 (84.9%) 
 
 
0.21 
Death by 3 months 
- Yes (%) 
- No (%) 
 
156 (25.7%) 
450 (74.3%) 
 
8 (15.1%) 
45 (84.9%) 
 
0.12 
P values are shown for group comparison with the chi squared test used to compare data.  
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Table 3-12: A comparison of neurological complications and death by 3 months in 
participants who had S. stercoralis serology and stool microscopy performed 
 S. stercoralis testing 
Group A Group B Group C 
Negative by 
serology and 
stool 
microscopy 
Positive by 
serology and 
negative by 
stool 
microscopy 
P value Positive by 
both 
serology and 
by stool 
microscopy 
P value 
Patients (No.) 475 37  7  
Neurological 
complications 
by 3 months 
- Yes (%) 
- No (%) 
 
 
106 (22.3%) 
369 (77.7%) 
 
 
4 (8.1%)  
33 (91.9%) 
 
 
0.15 
 
 
0 
7 
 
 
0.34 
Death by 3 
months 
- Yes (%) 
- No (%) 
 
 
111 (23.4%) 
364 (76.6%) 
 
 
4 (10.8%)  
33 (89.2%) 
 
 
0.12 
 
 
0 
7 
 
 
0.31 
P values are shown for comparison with negative group in each case. The chi squared test was 
used to compare data. 
 
In participants who had serology performed (n=659), a reduction in death by 3 months was 
suggested; (15.1% [8/53] vs. 25.7% [156/606] respectively, p=0.12), however these data did not 
reach statistical significance. When participants who had both S. stercoralis serology and stool 
microscopy performed were compared, neither neurological events by 3 months, nor death by 3 
months, were significantly different between participants with positive S. stercoralis serology 
and positive stool microscopy, positive S. stercoralis serology but negative stool microscopy, 
and participants negative for S. stercoralis. 
3.4 Discussion 
TBM is the most severe form of TB and causes death or disability in up to 50% of cases. S. 
stercoralis is a neglected tropical infection with a large global disease and latent carriage 
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burden. The ability of helminths to modulate the host immune system is well recognised, 
however immunomodulation of the severe and dysregulated inflammatory response of TBM has 
not previously been described. In this study of 668 Vietnamese adults with TBM, active S. 
stercoralis infection was associated with a reduced severity of presenting TBM disease, a CSF 
inflammatory parameter and cytokine profile suggestive of reduced intracerebral inflammation, 
and reduced neurological complications by 3 months. 
In this study 9.2% individuals tested positive for S. stercoralis by at least one of serology, stool 
microscopy, or stool PCR. The true S. stercoralis co-infection rate is likely higher, given not all 
668 participants received all 3 tests. In particular, in HIV co-infected individuals, S. stercoralis 
serology (the most frequently performed test in this study) may be falsely negative. This high 
proportion of S. stercoralis co-infection is especially concerning given the widespread use of 
corticosteroid-containing traditional medicines, and the resulting risk of hyperinfection.  
The CSF profile of TBM is characterised by elevated total WCC and protein, and reduced 
glucose (<50% serum glucose), with elevated pro-inflammatory CSF cytokine 
concentrations.[25,26,221] A predominantly neutrophilic CSF (contrary to the ‘typical’ 
lymphocytic predominance of TBM) may indicate more intracerebral inflammation, and a 
higher risk of developing neuroinflammatory complications. In this study active S. stercoralis 
infection was associated with significant reductions in the absolute CSF neutrophil count and 
the neutrophil proportion, vs. S. stercoralis uninfected participants. Additionally, active S. 
stercoralis infection was associated with non-significant reductions in CSF total WCC, CSF 
protein, and an increase in CSF/blood glucose ratio, vs. S. stercoralis uninfected participants. 
An association between TBM severity and S. stercoralis co-infection was also observed. Grade 
3 TBM represents the more severe form of TBM. Active S. stercoralis infection was associated 
with a non-significant reduction in grade 3 TBM, compared with grade 3 TBM in S. stercoralis 
uninfected participants. 
An analysis of log2 CSF cytokine concentrations supported a conclusion of reduced 
intracerebral inflammation in active S. stercoralis infection. The pro-inflammatory cytokines 
IFN-γ, IL-2, IL-6, and TNF-α.were all significantly reduced with active S. stercoralis infection 
in a pre-treatment CSF analysis.  
Interestingly, S. stercoralis co-infection was also associated with changes in classical Th2 CSF 
cytokine responses. CSF IL-4 and IL-10 concentrations were significantly reduced in 
participants with active S. stercoralis co-infection vs. in participants uninfected with S. 
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stercoralis. CSF IL-5 and IL-13 concentrations, however, were not reduced between these S. 
stercoralis groups.  
Interplay between Th1 and Th2 pathways are clearly complex, and division of immune 
responses and cytokines profiles into Th1 and Th2 categories an oversimplification. Suppression 
of IL-4 and IL-10 does not fit with the hypothesis of reduced ‘pro-inflammatory’ cytokines in 
the context of active S. stercoralis. Further work is required to understand the mechanisms of S. 
stercoralis immunomodulation. Previous data in TBM have in fact shown IL-10 to be elevated 
in TBM, decreasing after anti-TB chemotherapy.[25,26] The mechanism of cytokine reduction 
in S. stercoralis co-infected TBM be may mediated through reduced CSF neutrophils; 
neutrophils highly express IL-4 and IL-10 in M. tuberculosis infection.[24] 
S. stercoralis co-infection in TBM was associated with a significant reduction in neurological 
complications by 3 months, consistent with presenting severity and CSF parameter data 
indicating reduced intracerebral inflammation. Reduced neurological complications could not be 
explained by age, or HIV co-infection. Active S. stercoralis co-infection in TBM appears to 
modulate pro-inflammatory CSF cytokine concentrations, with this immunomodulation 
conferring neuroprotection. This is a striking finding, although not unexpected. Helminths are 
known to downregulate classical Th1 immune responses, and in TBM where often a fine line 
exists between appropriate and excessive inflammation; resulting improved clinical endpoints 
are feasible. Therapies in severe TBM often attempt to suppress such an excessive host immune 
response. Corticosteroids are the most widely used adjunctive anti-inflammatory agent, although 
their benefit may only be short lived, and may not occur in all patient groups. Infliximab and 
thalidomide, both able to reduce TNF-α, have been proposed as future immunomodulating 
therapies, yet trial data in TBM is lacking. Our findings raise the question of whether helminth 
associated immunomodulation can be used to identify novel therapeutic targets for adjunctive 
therapies in TBM.  
How should these results be translated to patient care? It is unknown how treating and 
eradicating S. stercoralis affects subsequent immune responses to TBM. An immune signature 
may be left which may lead to persistent immunomodulation, or immunomodulatory effects 
may quickly subside. Duration of S. stercoralis infection, worm burden, and anti-helminthic 
treatments may all impact upon immunomodulation and need further study. It is interesting to 
consider why S. stercoralis has such an effect on CNS diseases and CSF cytokines, given S. 
stercoralis is not routinely a CNS pathogen. S. stercoralis does indeed migrate through the body 
 
122 
 
to the intestine, but this route should not involve the CNS. Only rarely in immunodeficient 
states does S. stercoralis penetrate the blood brain barrier, or the blood-CSF barrier.[237–239]  
There are limitations with this study. Our study population may not demographically reflect a 
typical Vietnamese population; predominance towards males and younger adults may select for 
a higher risk group for S. stercoralis. This, plus the variable numbers of tests performed in 
participants, makes it difficult to understand the prevalence of S. stercoralis in southern 
Vietnam. The S. stercoralis diagnostic tests used in this study are sub-optimal; the sensitivity of 
stool microscopy for S. stercoralis detection is <30% [240] due to intermittent larval shedding 
in the stool. Stool PCR is more sensitive (~65%)[195], yet S. stercoralis DNA is also shed in the 
stool non-uniformly. S. stercoralis serological tests are affected by reduced sensitivity in 
advanced immunosuppression[201,202] and by persistence of serological positivity despite 
successful parasite eradication.[195] In a sub-group of participants undergoing S. stercoralis 
serology testing, serology was less likely to be positive in HIV co-infection, a possible result of 
false negative S. stercoralis serology in this group. IL-6 concentrations in the active S. 
stercoralis group were higher than the reference range in many cases; sample and kit 
availability did not allow for repeat testing with CSF sample dilution. Longer term impacts on 
neurological complications or death could not be assessed in this study; study follow up was 
limited to 3 months. Additionally, the study drug allocation (dexamethasone or placebo) of trial 
participants is not known. However, this will not influence baseline phenotype, or pre-treatment 
CSF analyses; all of which represent data or sampling prior to study drug administration. Given 
the randomised study drug allocation (1:1), dexamethasone and placebo are expected to be 
evenly distributed within each individual analysis population. Finally, given participants 
positive for S. stercoralis by serology alone are treated on a case-by-case basis, there may be 
inconsistency of S. stercoralis eradication therapy between participants. 
The strengths of this study are that it is large and prospective. Patients included in this study 
were enrolled into one of two randomised double blinded placebo-controlled trials, with careful 
clinical characterisation of TBM and S. stercoralis co-infection, treatment protocols, standard 
operating procedures, and standardised testing and data collection procedures. Analysis of CSF 
allows observation of disease and immunomodulation at the site of a disease rather than reliance 
on blood inflammatory changes to assess intracerebral inflammation.  
In conclusion, this study showed that S. stercoralis co-infection was associated with reduced 
disease severity, CSF inflammation, and neurological complications by 3 months. S. stercoralis 
may cause immunomodulation of host immune responses of TBM, conferring neuroprotection. 
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Further understanding of this immunomodulatory process may aid the development of novel 
host directed therapies to manage excessive and damaging inflammation of TBM.  
3.5 Publications related to this chapter 
The methods described within this study are published in the research protocols below: 
1. Adjunctive dexamethasone for the treatment of HIV-uninfected adults with tuberculous 
meningitis stratified by Leukotriene A4 hydrolase genotype (LAST ACT): Study protocol for a 
randomised double blind placebo controlled non-inferiority trial 
Joseph Donovan, Nguyen Hoan Phu, Le Thi Phuong Thao, Nguyen Huu Lan, Nguyen Thi 
Hoang Mai, Nguyen Thi Mai Trang, Nguyen Thi Thu Hiep, Tran Bao Nhu, Bui Thi Bich Hanh, 
Vu Thi Phuong Mai, Nguyen Duc Bang, Do Chau Giang, Dang Thi Minh Ha, Jeremy Day, 
Nguyen TT Thuong, Nguyen Nang Vien,  Ronald B. Geskus, Tran Tinh Hien, Evelyne 
Kestelyn, Marcel Wolbers, Nguyen Van Vinh Chau, Guy E. Thwaites 
Wellcome Open Research 2018 Mar 20;3:32 
2. Adjunctive dexamethasone for the treatment of HIV-infected adults with tuberculous 
meningitis (ACT HIV): Study protocol for a randomised controlled trial 
Joseph Donovan, Nguyen Hoan Phu, Nguyen Thi Hoang Mai, Le Tien Dung, Darma Imran, 
Erlina Burhan, Lam Hong Bao Ngoc, Nguyen Duc Bang, Do Chau Giang, Dang Thi Minh Ha, 
Jeremy Day, Le Thi Phuong Thao, Nguyen TT Thuong, Nguyen Nang Vien, Ronald B. Geskus, 
Marcel Wolbers, Raph L. Hamers, Reinout van Crevel, Mugi Nursaya, Kartika Maharani, Tran 
Tinh Hien, Kevin Baird, Nguyen Huu Lan, Evelyne Kestelyn, Nguyen Van Vinh Chau, Guy E. 
Thwaites 
Wellcome Open Research 2018 018 Jun 20;3:31 
 
The data contained within this chapter are under review in the following submission: 
3. The influence of Strongyloides stercoralis co-infection on the presentation, pathogenesis and 
outcome of tuberculous meningitis 
Joseph Donovan, Trinh Thi Bich Tram, Nguyen Hoan Phu, Nguyen Thi Thu Hiep, Vu Thi Thu 
Van, Dang Thi Hong Mui, Nguyen Thi Han Ny, Ho Dang Trung Nghia, Nguyen Ho Hong 
Hanh, Le Van Tan, Nguyen Thuy Thuong Thuong, Guy E. Thwaites 
Under review at the Journal of Infectious Diseases on the date of PhD submission  
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Chapter 4 
What is the role of optic nerve sheath ultrasound as a non-invasive tool 
for intracranial pressure monitoring in adults with tuberculous 
meningitis? 
4.1 Introduction 
4.1.1 Tuberculous meningitis and raised intracranial pressure 
Death results in up to 50% of those with TBM disease,[3–6] largely due to severe neurological 
complications which are hard to predict and difficult to manage. Hydrocephalus, tuberculomas 
and other paradoxical neuroinflammation, IRIS and cerebral infarction all contribute to the 
devastating morbidity and poor outcomes of TBM. Neurological complications of TBM often 
converge on the same endpoint of raised ICP, which, after compensatory mechanisms are 
exhausted, quickly leads to coma and death. The true incidence of raised ICP in TBM is not 
known.[79] 
4.1.2 Homeostatic processes and brain compartments 
Homeostatic processes seek to control ICP and maintain it within a normal range in the face of 
neurological insults. Maintenance of normal ICP occurs largely through adjustments in 
intracranial volumes within brain compartments. Intracranial volume changes are thought to 
follow the principles of the Monroe Kellie doctrine, which states that volume within the skull is 
constant and changes in one compartment (brain, CSF or blood) result in compensatory changes 
in one or both of the other compartments.[241,242] Hydrocephalus of TBM increases the 
volume of the CSF compartment, whereas inflammatory masses elevate pressure within the 
brain compartment. Cerebral blood and/or cerebrospinal fluid may exit the skull to attempt to 
compensate for increased volume elsewhere within the brain. Cerebral blood flow is maintained 
by the process of autoregulation.[243]  
In the average adult, the average intracranial volume is approximately 1600-1700mls, with CSF 
and blood making up approximately 100-150mls each, and the remaining volume comprising of 
brain tissue.[244] Normal ICP in adults in less than 15mmHg, with sustained values above this 
considered pathological.[243] Normal ICP is lower in children than in adults, with variation by 
age.[245]  
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4.1.3 Hydrocephalus and cerebrospinal fluid flow 
In hydrocephalus there is blockage of CSF flow from its origin in the choroid plexus 
(cerebroventricular system) to its absorption in the arachnoid granulations (outside the cerebral 
ventricles). In non-communicating hydrocephalus CSF becomes trapped within the cerebral 
ventricular system, in the central portion of the brain. In TBM approximately 20% of 
hydrocephalus is considered non-communicating, due to fourth ventricular outlet or aqueduct 
obstruction.[15,139] The remaining ‘communicating’ cases are largely due to distal block of 
CSF flow by tuberculous exudate within the basal cisterns of the brain, rather than blockage 
within or between the central cerebral ventricles.  
This distinction between non-communicating and communicating forms of hydrocephalus is 
important, but often difficult to make. Performing a lumbar puncture in non-communicating 
hydrocephalus may create a greater pressure differential between the ‘trapped’ high pressure 
intraventricular CSF compartment (where CSF is being continually produced) and the extra-
ventricular CSF in the lumbar region (where CSF and its pressure can now be removed), 
resulting in life threatening cerebellar tonsil coning through the foramen magnum. Even in 
communicating forms of hydrocephalus, pressure is unlikely to communicate equally to all CSF 
regions due to the thick exudative nature of CSF in early TBM.  
4.1.4 Monitoring intracranial pressure in tuberculous meningitis 
Early recognition and management of raised ICP is vital in order to minimise intracerebral 
damage and maintain cerebral perfusion; late recognition may prove too late to have a 
meaningful effect on clinical outcome. Table 4-1 lists methods for detecting raised ICP in TBM, 
with further discussion below. 
Table 4-1: Methods for detecting raised intracranial pressure in tuberculous meningitis 
[79]  
Non-invasive Invasive 
Clinical assessment including GCS Lumbar CSF opening pressure 
Fundoscopy Intraventricular catheters  
ONSD ultrasound Intraparenchymal pressure transducers 
Transcranial Doppler ultrasound Subarachnoid bolts 
Brain imaging (CT or MRI) Epidural transducers 
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CSF=cerebrospinal fluid. CT=computed tomography. GCS=Glasgow coma score. 
MRI=magnetic resonance imaging. ONSD=optic nerve sheath diameter.   
 
4.1.4.1 Invasive monitoring 
4.1.4.1.1 Invasive device insertion 
The gold standard technique for ICP monitoring in brain injury is invasive intracranial 
monitoring. These invasive techniques require temporary placement of a probe or catheter 
within the brain tissue or CSF spaces of the brain, and therefore require specialised 
neurosurgical input at neurosurgical centres. Potential invasive devices include intraventricular 
catheters, intraparenchymal pressure transducers, subarachnoid bolts or epidural 
transducers,[79] however these devices are expensive and not available at many 
centres.[79,246]  
4.1.4.1.2 Lumbar cerebrospinal fluid opening pressure 
Lumbar puncture is a minimally invasive procedure used to sample CSF. CSF opening pressure 
can be measured, and this pressure is often used as a surrogate marker of ICP. At lumbar 
puncture, a transparent single-use manometer is connected to a needle sheath after placement of 
the sheath in the lumbar subarachnoid space. CSF flows into the manometer, and the height of 
the CSF column within the manometer is noted; with larger pressures leading to greater height 
(normal pressure ~6-20cm in manometer). Alternatively, CSF drops per unit time can be 
counted as a proxy measurement of lumbar CSF pressure. The subarachnoid space represents 
one continuous pressure compartment, in which pressure should in theory be evenly distributed 
throughout the brain and spine; however individual pathologies may interfere with CSF flow, 
creating separate compartments under differing pressures. 
In a study of 12 children (mean age 8.5 years) with lumbar and invasive pressure measurements 
in the United States, a poor correlation was found between lumbar opening pressure and 
invasive intracranial bolt pressure, with a suggestion that lumbar puncture measurements 
overestimated pressure.[247] In a study from Sweden, lumbar CSF opening pressure was shown 
to correlate with ICP measurement via intraparenchymal catheter tip in 10 adults, however 
crucially all participants had normal pressure hydrocephalus with a communicating CSF 
system.[248] Few data currently support a positive correlation between lumbar CSF opening 
pressure and ICP.  
4.1.4.2 Non-invasive monitoring 
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4.1.4.2.1 Clinical assessment 
The effects of raised ICP may be visible through patient symptoms (headache, vomiting) and 
signs (cranial nerve palsies, reduced GCS, and coma). However, these clinical signs may occur 
late, and an earlier warning system for raised ICP is warranted. 
4.1.4.2.2 Fundoscopy 
A fundoscope uses light and magnification to view the fundus of the eye and detect changes in 
the head of the optic nerve (the optic disc). Papilloedema, where the edges of optic nerve head 
are blurred (normal margins are sharply delineated), may indicate raised ICP. However, similar 
blurred edge appearances may appear with inflammation of the optic nerve head without raised 
ICP (termed ‘papillitis’). The success of detecting papilloedema by fundoscopy is highly 
dependent on operator clinical skill, plus the prior dilation of the pupil by topical medication, 
widening the hole through which the fundus is viewed thereby improving the view. Importantly 
the development of papilloedema can lag behind elevation of ICP;[249] therefore fundoscopy is 
of limited value as a monitoring tool in the acute setting. 
4.1.5 Optic nerve sheath ultrasound 
Current non-invasive methods for detecting raised ICP are insufficient. Yet given the particular 
burden of TB in resource poor settings,[94] affordable, non-invasive and widely available ICP 
monitoring has the potential to improve TBM patient monitoring globally.  
The optic nerve, forming part of the CNS, is surrounded by a dural sheath that is distensible in 
its retrobulbar segment when ICP is elevated. Whilst papilloedema may develop over hours to 
days, changes in ONSD due to raised ICP can take only seconds.[250] ‘Real-time’ changes in 
ONSD have been demonstrated in studies performing ONSD ultrasound 30 minutes after 
therapeutic lumbar puncture,[251] and only 5 minutes after lumbar puncture.[249] Under 
ultrasound imaging the optic nerve appears hypoechogenic, closely surrounded by echogenic pia 
mater, hypoechogenic subarachnoid space, and then hyperechogenic dura mater and periorbital 
fat.[252] ONSD is measured as the distance inside the dura mater (i.e. the distance from the 
inside border of the dura mater on one side of the optic nerve, to the inside border of the dura 
mater on the other side of the optic nerve).[252] Optic nerve sheath imaging, with correlation 
with surrounding anatomy, is shown in figure 4-1. 
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Figure 4-1: Distended optic nerve sheath consistent with raised ONSD 
Panel A:          Panel B: 
   
Panel C: 
 
0.74cm 
0.3cm 
Ultrasound 
CSF spaces 
Vitreous body of eye Ultrasound images of the right eye are 
shown with, (panel A) and without, (panel 
B) descriptive labels. The borders of the 
optic nerve sheath are marked with a 
dotted line in panel A. In panel C a 
diagram is shown illustrating the 
appearances seen under ultrasound, 
showing how these appearances relate to 
patient position, CSF spaces (yellow) and 
optic nerve (blue). ONSD measured 0.3cm 
from the posterior border of the globe of 
the eye was 0.74cm. CSF=cerebrospinal 
fluid. ONSD=optic nerve sheath diameter. 
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4.1.6 Strengths and limitations of ONSD ultrasound 
ONSD ultrasound is a safe method of ICP monitoring. Medical ultrasound uses high frequency 
sound waves to produce an image of an area of the body. Sound waves travel from the ultrasound 
probe, encountering body tissues which reflect them back to the probe to differing degrees, where 
they are then converted into an image. Ultrasound scanning modes commonly list mechanical and 
thermal indices. The mechanical index indicates the relative potential for ultrasound to induce non-
thermal adverse events including cavitation, whereas the thermal index indicates the relative 
potential for tissue temperature rise.[253] British medical ultrasound guidelines advise on safety for 
ultrasound use in different tissue types.[253] For ultrasound of the eye, a thermal index > 1.0 is not 
recommended, and a mechanical index > 0.7 may induce cavitation if contrast agents are used (due 
to destruction of shells of micro-bubbles found in contrast agents).[253] Contrast agents are not 
used in ONSD ultrasound.  
ONSD ultrasound is quick to perform; typically scans can be performed in five minutes. ONSD 
ultrasound has acceptably low intra-operative and inter-operative variability. A study of 67 healthy 
individuals who underwent ONSD ultrasound by 3 independent operators showed an average 
(median) intra-operative variability of +/- 0.1mm, with 5th-95th centile values of +/- 0-0.4mm. 
After 17 ONSD ultrasound scans were performed the median difference between 2 observers 
scanning the same patient was no more than 0.3mm (3 comparisons were performed; operator 1 to 
operator 2, operator 1 to operator 3, operator 2 to operator 3). Median inter-operative variation was 
+/-0.2-0.3mm, with 5th-95th centile values of +/- 0-0.7mm.  
The first described use of ONSD ultrasound was in the 1980s to differentiate optic nerve 
lesions.[254,255] B scan ultrasound is now commonly used for ONSD ultrasound. A scan 
ultrasound may be more accurate for measurements yet this is technically more difficult to 
perform.[254] Using B scan ultrasound, confounding features may give similar appearances to those 
associated with raised ICP, such as solid ONS thickening (due to Graves orbitopathy, ONS 
meningiomas or leukaemic infiltration of the optic nerve) or swelling of the pial and arachnoid 
sheaths (due to engorged vessels in severe orbital congestion).[255] These conditions are rare 
however.[256] Ultrasound artefacts may distort or change the image that appears, for example 
artefact from the multi-layered collagen fibers (lamina cribrosa) through which the optic nerve 
passes.[255]  
4.1.6.1 Standardisation 
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Little standardisation exists in the field of ONSD ultrasound. No practice guidelines exist, and no 
clinical training courses specifically focus on this technique. Methods for repeating scans and 
averaging values differ by study. Elevation of the head of patient bed may affect ICP and should be 
considered. Where to place measuring calipers has not been defined. Many ultrasound machines 
have ophthalmic pre-set modes which pre-define mechanical and thermal indices, but not all. In the 
absence of an ophthalmic mode, ‘best’ indices are uncertain. These uncertainties add to the 
challenges of performing this technique.  
4.1.7 Evidence supporting ONSD ultrasound for ICP monitoring 
4.1.7.1 Individual studies 
ONSD has been well correlated with invasively measured ICP in individuals with brain injury of a 
non-infective aetiology. Individual studies of note are discussed further in appendix G. Together 
these studies show that ONSD correlates well with gold standard ICP monitoring and that an 
optimal cutoff value for detecting raised ICP is uncertain.  
4.1.7.2 Meta-analyses 
Three meta-analyses have positively correlated ONSD and invasively measured ICP,[75–77] 
although studies of Europeans with non-infective pathology have predominated to date. The initial 
two meta-analyses, performed in 2011 and 2018, included six studies with TBI or intracranial 
haemorrhage (231 patients)[75] and seven studies (320 patients),[76] respectively. The third and 
largest systematic review and meta-analysis, performed in 2019, identified an optimal ONSD cut-
off of 5mm for the identification of raised ICP in adults and children (71 studies, 4551 patients), 
however limitations included small study sizes, and no evaluation of clinical outcomes.[77] An 
individual patient data systematic review is currently underway, in order to identify a definitive cut-
off value of ONSD that correlates with an ICP above 20mmHg;[257] results are as yet unpublished.  
Additionally, a systematic review and meta-analysis specifically comparing ONSD with CT brain-
detected raised ICP (rather than invasively measured ICP) showed ONSD to be a high sensitivity 
tool for ruling out raised ICP in a low-risk group, and highly specific for ruling in raised ICP in a 
high risk group.[258] Individual studies comparing ONSD with brain imaging suggestive of raised 
ICP, and the development of brain imaging scoring systems that indicate raised ICP, are described 
in the appendix (G and H).     
4.1.8 Defining a ‘normal’ optic nerve sheath diameter 
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Defining an optimal cut-off of ONSD to indicate pathology requires an understanding of normal 
ONSD values. ONSD values in healthy individuals vary by ethnicity.[259] Mean ONSD 
measurements in healthy patients have been documented as follows; 4.4mm (Turkey),[260] 4.2mm 
(Korea),[261] 4.4mm (Bangladesh),[262] 4.17-4.1mm (Nigeria),[263] 2.5-4.1mm (United 
Kingdom),[264] 5.4mm (Germany),[265] 3.6mm (Greece)[266] and 3.68mm (Canada).[267] ONSD 
does not appear to vary with age, gender, or body mass index,[265,268] with waistline, head 
circumference, blood pressure or pathological subtype,[268] or side of eye measured.[263] Whilst 
there appears to be no correlation between ONSD and age in an adult population, a difference in 
ONSD has been shown between infants and older children (where older age was associated with 
increasing ONSD).[269] Once a normal range is set for a population, a ROC curve analysis can be 
performed to set a ‘best’ cut-off value with sensitivity and specificity for predicting raised ICP.  
4.1.9 Evidence supporting ONSD ultrasound for ICP monitoring in brain infection 
ONSD ultrasound for ICP monitoring has infrequently been described in individuals with brain 
infection. In a study of 57 HIV co-infected, ART-naive patients with suspected meningitis 
(predominantly cryptococcal) undergoing ONSD ultrasound in Uganda, median ONSD (average 
across both eyes) was 5.5mm (IQR 5.0-6.0mm) before performing lumbar puncture, and 5.5 mm 
(IQR 4.9–5.9 mm) after performing lumbar puncture.[270] There was a moderate positive 
correlation (Spearman correlation coefficient, ρ=0.44; p<0.001) between ICP (lumbar CSF opening 
pressure by manometer) and ONSD.[270] Based on ROC curve analysis, an average ONSD taken 
across both eyes of ≥5 mm had a 85% sensitivity and 59% specificity for predicting raised ICP> 
20mmHg.[270]  
One small study has described ONSD ultrasound in TBM.[78,271] In this study 25 Indian adults 
with suspected TBM based on consistent brain MRI appearances (n=25, mean ONSD 5.81mm) 
were compared with a control group where individuals lacked MRI appearances of TBM or 
papilloedema on fundoscopy (n=120, upper limit of normal for ONSD 4.37mm).[78] Larger studies 
are required to further investigate the role of ONSD ultrasound in TBM. 
4.1.10 Research questions 
ONSD ultrasound has potential value in the detection and monitoring of raised ICP in TBM. 
Therefore, I set out to establish whether ONSD measured by ultrasound at baseline, correlated with 
sex, final diagnosis, MRC TBM severity grade, HIV status, plasma sodium, and clinical endpoints 
by 3 months. Additionally, I sought to correlate ONSD with brain imaging, construct ROC curves 
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allowing ‘best’ ONSD cut-offs predicting abnormal brain imaging and death, and investigate how 
ONSD changes during the first 30 days of anti-TB chemotherapy. 
4.2 Methods 
4.2.1 Study participants 
The study was nested within the ACT HIV (clinicaltrials.gov NCT03092817)[85] and LAST ACT 
(clinicaltrials.gov NCT03100786)[41] clinical trials. Participants in this study were Vietnamese 
adults (≥ 18 years of age) based only at HTD, Ho Chi Minh City, Vietnam. Inclusion and exclusion 
criteria, anti-TB chemotherapy, double blinded study drug, ethical approval, and funding, for ACT 
HIV and LAST ACT, are described earlier in this thesis (chapter 3). 
4.2.2 Clinical data 
Baseline age, sex, final TBM diagnosis, TBM disease severity (MRC TBM grade) and HIV status 
were recorded. Participants were followed up for 3 months after enrolment, at which point 
neurological complications and survival were recorded. Neurological complications were defined as 
a fall in GCS of ≥ 2 points for ≥ 48 hours, a focal neurological sign, seizure, cerebellar signs, coma, 
or cerebral herniation.   
4.2.3 Brain imaging 
Baseline brain MRI or CT imaging was performed in enrolled individuals whenever it was safe and 
appropriate to do so, and independently reported by an independent UK-based neuroradiologist 
using a standard template (table 4-2).  
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Table 4-2: MRI and CT brain reporting template 
Study identification number  Enter no. ______ 
Quality OK?  Yes / No 
MRI?  Yes / No 
CT?  Yes / No 
Normal?  Yes / No 
Evidence of bleeding?  Yes / No 
 
Meningeal enhancement?   Yes / No 
If yes Basal Yes / No 
 Sylvian Yes / No 
 Convexity Yes / No 
 Posterior fossa Yes / No 
 Ependymal Yes / No 
 
Hydrocephalus?  Yes / No 
If yes Communicating Yes / No 
 
Infarcts?   Yes / No 
If yes Total number Enter no. _____ 
 No. diffusion restricted Enter no. _____ 
 No. cortical Enter no. _____ 
 No. callosal Enter no. _____ 
 No. lacunar Enter no. _____ 
 
Tuberculomas?  Yes / No 
If yes Total no. Enter no. _____ 
 No. parenchymal Enter no. _____ 
 No. ependymal Enter no. _____ 
 No. meningeal Enter no. _____ 
 
Local sulcal effacement?  Yes / No 
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Hemispheric sulcal effacement?  Yes / No 
Basal cistern effacement?  Yes / No 
Consistent with elevated ICP?  Yes / No 
Additional notes?  
CT=computed tomography. ICP=intracranial pressure. ID=identification. MRI=magnetic resonance 
imaging.  
 
Hydrocephalus, number and location of cerebral infarctions and tuberculomas, meningeal 
enhancement, and raised ICP features were recorded. For brain MRI, T1, T1 contrast, T1 contrast 
fluid attenuated inversion recovery (FLAIR) and T2 weighted sequences were performed. Brain 
imaging was classified as abnormal if it contained one or more of the following: hydrocephalus, 
cerebral infarction(s), tuberculoma(s), meningeal enhancement and/or features of raised ICP. 
Regarding allocation of ‘raised ICP’, a yes/no allocation was recorded for each case, based on the 
global impression of the reporting neuroradiologist, including the presence or absence of sulcal 
effacement, severity of hydrocephalus, presence of transependymal oedema and any cerebral 
herniation.  
4.2.4 Optic nerve sheath ultrasound 
4.2.4.1 Schedule 
ONSD ultrasound was performed on days 0, 3, 7, 14, 21 and day 30 (± 1 day) after patient 
randomisation into ACT HIV or LAST ACT, whenever possible. Day 0 was the day of the taking 
the first dose of study drug in ACT HIV or LAST ACT, usually also the day of study drug 
randomisation. Day 30 ultrasound was only performed in participants who remained in hospital at 
this time point.  
4.2.4.2 Timing with brain MRI 
ONSD was correlated with brain imaging. MRI facilities were not available at HTD, and participant 
transport to off-site MRI facilities often took several hours. For participants too unwell for transfer 
CT brain was performed instead in most cases. A ‘day 0’ ONSD ultrasound was always performed 
on day 0 ± 1 day. ONSD was correlated with brain imaging that was performed not more than 72 
hours before or after that ONSD measurement. This 72 hour time window was practical for 
critically ill patients, and factored in an off-site MRI scanner, relative visiting times, and 
maintenance of head of bed elevation during enteral nutrition periods (during which head of bed 
elevation is often > 300 and unsuitable for this ONSD ultrasound).  
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4.2.5 Standard procedure 
ONSD ultrasound was performed by two clinicians with training in critical care ultrasound, and 
experience of this scanning technique. Ultrasound was performed using a Sonosite M-Turbo 
(Fujifilm Sonosite Ltd, Washington, US) or a Lumify (Philips, Amsterdam, Netherlands) ultrasound 
machine using the following standard procedure: 
1. Ensure informed consent obtained for performing ONSD ultrasound in 26TB or 27TB 
studies. Avoid scanning if visible or known history of ocular trauma. 
2. Correctly position patient as able; head-of-bed elevation should be no more than 300 
(where 00 is a fully flat bed). Record patient angle. 
3. If patient is unconscious, gently turn head to forward facing position. If patient is 
conscious, ask patient to face forwards, look forwards, and keep eyes closed during scan.  
4. Use cleaned L25x 6-13MHz linear probe of M-turbo, or multi-purpose probe of Lumify. 
Select an appropriate scanning mode (ophthalmic preset). Enter patient identification (ID) 
in machine; ‘ONSD’ plus 26TB/27TB study ID plus day (‘D’) of performing study e.g. 
ONSD2042D7. Use the ‘text’ function to apply an ‘R’ or ‘L’ to the image screen, thus 
labelling the image as ‘right eye’ or ‘left eye’ respectively. Reduce depth by pressing depth 
button two times. Do not adjust gain or area of focus.  
5. Stand in the most appropriate place for scanning (usually behind the patient head if space 
available) and position the screen so that it can be seen by the operator.  
 6. Apply a small volume of ultrasound gel to the ultrasound probe. 
7. Place probe gently over temporal portion of the upper eyelid, angling nasally and 
inferiorly. Ensure pressure is not applied to the eye, and position globe of the eye in the 
centre of the screen.  
8. Identify optic nerve sheath, and then identify where optic nerve is viewed at widest. Scan 
in both transverse and vertical planes if required. Use ‘freeze’ button to select and select 
best view.  
9. Perform an assessment of image quality using the following criteria: a) ONS seen to 
within 1mm of globe of eye, b) 6mm of continuous optic nerve seen, c) Absence of 
movement artefact. If image quality is considered satisfactory then proceed to qualitative 
assessment of raised ICP.  
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10. Perform a qualitative assessment of ICP using the following criteria: a) Retrobulbar 
bulge of optic nerve seen, b) CSF spaces taper proximally and disappear, c) Papilloedema 
seen. Assess for the presence or absence of raised ICP, as suggested by a ‘yes’ score for a, b 
or c. Proceed to quantitative assessment of ONSD. 
11. Measure a 0.3cm distance from most posterior border of the globe of the eye using the 
caliper measuring function of ultrasound machine. At 3mm from the most posterior part of 
the globe, measure the diameter of the ONS. This is the distance from echogenic dura mater 
to echogenic dura mater. Perform 2 measurements for each eye. Record all data on the 
ONSD case report form. Record image on ultrasound machine and store for later review if 
required. 
4.2.5.1 Recording of ONSD measurements 
Previous recording and averaging methods have been described for ONSD (appendix I). For this 
study ONSD was measured for the right eye twice, and for the left eye twice. An overall average of 
all four measurements (two right eye and two left eye) was calculated and used for analysis.   
4.2.5.2 Non-numerical assessment of ONSD 
Each ONSD image was reviewed for quality, before proceeding to the recording of further data. 
Meeting the following criteria was necessary for measurement: ONS seen to within 1mm of globe 
of eye, b) 6mm of continuous optic nerve seen, c) absence of movement artefact. In addition, given 
the unavoidable risk of introducing errors in ONSD measurements, as outlined in the limitations of 
this scanning technique, addition non-numeric data were collected. Three questions, asked for each 
eye at each time of scanning, assessed for appearances considered consistent with raised ICP, 
independent of ONSD size. These questions, chosen based on experience, and expert opinion, were 
as follows: retrobulbar bulge of optic nerve seen, CSF spaces taper proximally and disappear, 
papilloedema seen? The presence of any of these three signs was taken to indicate raised ICP. 
4.2.6 Pilot data and inter-observer variability 
Pilot data was initially collected, with participants and procedures as above, to demonstrate that 
both ONSD ultrasound operators obtained the same ONSD values from the same patient-eyes, 
within an acceptable margin of error (i.e. acceptable inter-operative variability). Data from 
Ballantyne et al,[264] where median average inter-operative variability reduced to 0.3mm with 
serial scanning, was used to define an acceptable inter-operative variability. A study power 
calculation[272] was performed for this pilot data; using a significance level of 0.05, a power to 
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detect the effect size of 0.9, standard deviation (SD) of 0.42 (using TBM ONSD data[78]), and a 
difference in means of 0.3, a sample size of 23 was calculated. This indicated that if the true 
difference in the means of matched pairs was 0.3, 23 pairs of ONSD values were required to be able 
to reject the null hypothesis if it was false. These data showed the inter-operator variability to be 
acceptable low. 
4.2.7 Statistical analysis 
4.2.7.1 Allocating test ‘days’ 
ONSD and sodium values were assigned to days (0, 3, 7, 14, 21, 28) if they were performed on that 
day, ± 1 day. Day 0 tests are also referred to as ‘baseline’. 
4.2.7.2 Sample size 
Using a 5% significance level, 90% power to detect effect size, and an expected difference in means 
of 1.3mm with SD 1.1mm, I calculated 15 patients were required per group (abnormal brain 
imaging vs. normal brain imaging) to reject the null hypothesis if it were false. This sample size 
calculation was based on data from a non-TBM study,[273] given the limited TBM data for this 
purpose. This study,[273] which compared ‘brain pathology with raised ICP confirmed by CT’ 
(mean 5.4mm, SD 1.1mm) to ‘brain pathology without raised ICP confirmed by CT’ (mean 4.1mm, 
SD 0.5mm), contained more conservative data (wider SD and smaller difference in means) than 
many other studies. ONSD changes between brain pathology groups are uncertain within lower or 
higher TBM severity grades, or between HIV co-infection and HIV uninfected. Therefore, 
comparisons within these subgroups were exploratory. 
4.2.7.3 Statistical analysis plan 
A statistical analysis plan written in advance of data analysis outlined the following: 
1. Evaluate median baseline ONSD, by sex, final TBM diagnosis, MRC TBM grade, and HIV 
co-infection status 
2. Investigate whether there is a positive correlation between ONSD and brain imaging 
consistent with raised ICP, or with abnormal brain imaging appearances 
3. Establish whether a ROC curve can be constructed to select an ONSD cut-off value 
predictive of raised ICP in TBM 
4. Describe the association between ONSD and plasma sodium measurement, stratified by 
HIV co-infection, and clinical endpoints 
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5. Establish whether non-quantitative ONSD appearances (ultrasound operator impression of 
abnormal optic nerve sheath changes) correlates with brain imaging consistent with raised 
ICP 
6. Correlate ONSD with neurological complications by 3 months, and with death by 3 months 
7. Describe ONSD trends during the first 30 days of TBM treatment, stratified by HIV co-
infection, TBM severity grade, and clinical endpoints 
After data collection, due to the few cases reported as showing ‘raised ICP’ by imaging 
(classification of imaging as showing raised ICP is challenging as this has limitations), I 
investigated whether there was a positive correlation between ONSD (or non-quantitative ONSD 
appearances), with abnormal brain imaging appearances. In addition, I constructed ROC curves to 
identify ONSD cut-off values predictive of abnormal brain imaging, or of death by 3 months. 
Given correlation between baseline ONSD and disease severity, I also analysed the correlation 
between baseline ONSD and baseline CSF parameters indicating inflammation or severe disease. 
Disease severity and CSF parameters were also shown for the abnormal brain imaging, and normal 
brain groups, for whom an association with ONSD had been seen. This allowed me to further 
explore the relationship between elevated ONSD and neuroinflammation.  
4.2.7.4 Statistical tests 
Comparison between proportional data was assessed by the chi squared test. Non-normally 
distributed data were compared using the Wilcoxon rank sum test. Correlation between continuous 
variables was performed using Spearman’s rank correlation co-efficient. Data were analysed using 
R (version 3.6). 
4.3 Results 
4.3.1 Study population 
From June 2017 to December 2019 inclusive, 107 Vietnamese adults with TBM had 267 ONSD 
ultrasound scans performed at day 0 (n=72), day 3 (n=48), day 7 (n=45), day 14 (n=44), day 21 
(n=42) and day 30 (n=16). Four images were recorded at each of these 267 scanning time points. 
Median age of the study population was 37 (IQR 29-45) years. 68.2% (73/107) participants were 
male and 31.8% (34/107) were female. Final diagnoses of the study population were as follows; 
75.7% (81/107) definite TBM, 12.1% (13/107) probable TBM, and 12.1% (13/107) possible TBM. 
Modified MRC TBM severity grades were; Grade 1: n=33, Grade 2: n=58, Grade 3: n=16. 32.7% 
(35/107) participants had HIV co-infection. ONSD measurements ranged from 0.38-0.74cm. 
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4.3.2 Baseline ONSD associations 
Baseline ONSD was performed in 67.3% (72/107) participants. Median baseline ONSD is shown 
by sex, final diagnosis, MRC TBM grade, and HIV co-infection status in table 4-3.  
Table 4-3: Median baseline ONSD by sub-categories 
 Total No. 
(N=72) 
Median ONSD (cm)  
(IQR) 
P value  
 
All patients 72 0.53 (0.49-0.57)  
Sex  
- Male (No [%]) 
- Female (No [%]) 
 
47 (65.3%) 
25 (34.7%) 
 
0.52 (0.49-0.57) 
0.54 (0.48-0.57) 
 
0.89 
Final diagnosis (No [%]) 
- Definite TBM 
- Probable TBM 
- Possible TBM 
 
53 (73.6%) 
7 (9.7%) 
12 (16.7%) 
 
0.54 (0.49-0.57) 
0.52 (0.50-0.55) 
0.51 (0.49-0.55) 
 
0.25* 
 
MRC TBM Grade (No [%]) 
- 1 
- 2 
- 3 
 
23 (31.9%) 
39 (54.2%) 
10 (13.9%) 
 
0.50 (0.48-0.54) 
0.55 (0.49-0.57) 
0.56 (0.52-0.58) 
 
0.01 # 
 
HIV status (No [%])  
- Positive 
- Negative 
 
20 (27.8%) 
52 (72.2%) 
 
0.56 (0.49-0.58) 
0.52 (0.49-0.55) 
 
0.17 
* Definite TBM compared with non-definite. # Grade 1 compared with grades 2 & 3. The Wilcoxon 
rank sum test was used to compare ONSD values. Total No. reflects the total number of 
observations available for the corresponding variable. Medical Research Council grades are as 
follows: Grade 1 indicates a GCS of 15 with no neurological signs, grade 2 a GCS of 11 to 14 (or 
15 with focal neurological signs), and grade 3 a GCS of 10 or less. HIV=human immunodeficiency 
virus. IQR=interquartile range. MRC= Medical Research Council. ONSD=optic nerve sheath 
diameter. TBM=tuberculous meningitis.  
 
Baseline ONSD significantly increased with more severe disease (grade 1: 0.50cm, grade 2: 
0.55cm, grade 3: 0.56cm), p=0.01. HIV co-infection was not significantly associated with increased 
ONSD at baseline (table 4-3). No significant correlation was seen between baseline ONSD and 
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baseline disease temperature, lumbar CSF opening pressure, CSF white blood cells, CSF lactate, 
CSF protein, or CSF/blood glucose ratio (table 4-4). 
Table 4-4: Correlation of baseline ONSD with baseline disease severity and CSF 
inflammatory parameters 
Parameter  Total 
No. 
Correlation 
co-efficient 
P value 
Highest temperature (0C) 71 0.08 0.49 
Plasma sodium (mmol/L) 65 -0.09 0.48 
Lumbar CSF opening pressure (cmH20) 49 0.09 0.56 
CSF WBC (cells/mm3) 72 0.08 0.52 
CSF neutrophils (%) 71 0.23 0.05 
CSF neutrophil count (cells/mm3) 71 0.15 0.22 
CSF/blood glucose ratio  71 -0.05 0.65 
CSF protein (g/L) 72 0.11 0.38 
CSF lactate (mmol/L) 72 0.12 0.31 
Co-efficient and significance (p value) are shown using Spearman’s rank correlation co-efficient. 
Highest temperature represents the highest temperature on the day of baseline assessment. 
CSF=cerebrospinal fluid. ONSD=optic nerve sheath diameter. WBC=white blood cells.   
 
4.3.3 The association between ONSD and brain imaging 
I set out to investigate whether increased ONSD correlated with brain imaging consistent with 
raised ICP, or with abnormal brain imaging appearances. There were 63 participants for whom 
ONSD and brain imaging were performed within 72 hours of each other at the start of treatment. In 
9.5% (6/63) participants brain imaging suggested raised ICP, and in 90.4% (57/63) participants 
brain imaging did not suggest raised ICP. Median ONSD for the raised ICP and non-raised ICP 
groups were 0.55cm and 0.52cm respectively, p=0.59 (figure 4-2).  
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Figure 4-2: ONSD in participants with brain imaging not suggestive of raised ICP vs. in 
participants with brain imaging suggestive of raised ICP 
 
ICP=intracranial pressure 
 
In this same group of 63 participants, 61.9% (39/63) participants had brain imaging with abnormal 
appearances consistent with TBM, and 38.1% (24/63) participants had normal brain imaging. 
Median ONSD for the abnormal imaging and normal imaging groups were 0.55cm and 0.50cm 
respectively (p=0.01) (figure 4-3).  
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Figure 4-3: Box plot of ONSD values in those with normal brain imaging vs. in those with 
abnormal brain imaging 
 
ONSD=optic nerve sheath diameter  
 
Median ONSD values by brain pathology groups were as follows; hydrocephalus: 0.55cm (n=10), 
tuberculoma(s): 0.52cm (n=13), cerebral infarction(s): 0.55cm (n=18), meningeal enhancement: 
0.52cm (n=29). To further investigate the difference in ONSD between normal and abnormal brain 
imaging groups, TBM severity and CSF inflammatory parameters were compared between these 
two groups (table 4-5).  
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Table 4-5: Disease severity and CSF inflammatory parameters for normal and abnormal 
brain imaging groups 
 Total 
No. 
Normal brain 
imaging 
(N=24) 
Total 
No. 
Abnormal brain 
imaging 
(N=39) 
P value 
 
Age  
(Median[IQR]) 
24 41 
(28-50) 
39 34 
(29-40) 
0.08 
Sex  
- Male (No [%]) 
- Female (No [%]) 
24 
 
 
 
16 (66.7%) 
8 (33.3%) 
39 
 
 
 
25 (64.1%) 
14 (35.9%) 
1.0 
MRC TBM Grade (No [%]) 
- 1 
- 2 
- 3 
24  
12 (50%) 
11 (45.8%) 
1 (4.2%) 
39  
10 (25.6%) 
25 (64.1%) 
4 (10.3%) 
0.09* 
HIV status (No [%])  
- Positive 
- Negative 
24  
6 (25%) 
18 (75%) 
39  
9 (23.1%) 
30 (76.9%) 
1.0 
Highest temperature (0C) 
(Median[IQR]) 
24 38.7 
(38.0-39.5) 
39 39.0 
(38.7-39.5) 
0.31 
Lumbar CSF opening 
pressure (cmH20) 
(Median[IQR]) 
15 18 
 
(15-24) 
26 20 
 
(17-29) 
0.54 
CSF WBC (cells/mm3) 
(Median[IQR]) 
24 283 
(137-501) 
39 304 
(200-538) 
0.32 
CSF neutrophil % 
(Median[IQR]) 
23 13  
(11-30) 
39 48 
(20-73) 
0.002 
CSF neutrophil count 
(cells/mm3) 
23 43  
 
39 142 
 
0.01 
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(Median[IQR]) (19-120) (39-229) 
CSF/blood glucose ratio 
(Median[IQR]) 
24 0.39 
(0.24-0.44) 
39 0.27 
(0.23-0.36) 
0.02 
CSF lactate (mmol/L) 
(Median[IQR]) 
24 4.0 
(3.0-5.7) 
39 5.8 
(4.7-7.7) 
0.001 
* Grade 1 compared with grades 2 & 3. The Wilcoxon rank sum test and chi squared test were used 
to compare averages of continuous and categorical data, respectively. Highest temperature, lumbar 
CSF opening pressure, CSF WBC, CSF neutrophil percentage, CSF/blood glucose ratio and CSF 
lactate are non-normally distributed and are shown as median (IQR). Highest temperature 
represents the highest temperature on the day of baseline assessment. CSF=cerebrospinal fluid. 
HIV=human immunodeficiency virus. IQR=interquartile range. MRC=Medical Research Council. 
TBM=tuberculous meningitis. WBC=white blood cells. 
 
In the abnormal brain imaging group, there were significantly elevated neutrophil percentage, 
absolute CSF neutrophils, and CSF lactate, and significantly reduced CSF/blood glucose ratio, 
consistent with increased disease severity in this group.  
I then set out to establish whether a ROC curve could be constructed to select an ONSD cut-off 
value predictive of abnormal brain imaging in TBM, with clinically acceptable sensitivity and 
specificity values. A ROC table was compiled using 63 pairs of ONSD and brain imaging data 
(figure 4-4). Clinically acceptable values (i.e. sufficiently sensitive and specific for clinical utility) 
could not be found for the prediction of abnormal brain imaging. 
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Figure 4-4: ROC curves for the prediction of abnormal brain imaging in TBM 
 
 
ROC=receiver operating characteristic. TBM=tuberculous meningitis 
 
4.3.4 The association of non-quantitative optic nerve sheath diameter with brain imaging 
Optic nerve sheath appearances suggestive of elevated ICP (independent of ONSD) were compared 
with brain imaging. The presence of any of the following features indicated raised ICP; a 
retrobulbar bulge of optic nerve seen, CSF spaces tapering proximally and disappearing, 
papilloedema seen. An ultrasound operator impression of raised ICP (as above) vs. no raised ICP, 
did not correlate with abnormal brain imaging (vs. normal brain imaging) (p=0.96).   
4.3.5 The association of optic nerve sheath diameter with plasma sodium 
155 paired ONSD and plasma sodium measurements were analysed, taken from 82 individual 
participants. No significant correlation was seen between ONSD and paired sodium measurements 
(correlation co-efficient -0.13 [95% CI -0.28-0.03], p=0.10). Paired data points (performed on the 
same ‘day’) are shown below in figure 4-5, figure 4-6 (colour stratified by HIV co-infection), and 
figures 4-7 and 4-8 (stratified by clinical endpoints).  
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Figure 4-5: The association of optic nerve sheath diameter and plasma sodium in TBM 
 
 
Each dot represents a pair of ONSD and plasma sodium measurements (performed on the same 
‘day’). Line of best fit shown with surrounding 95% confidence interval in shading. ONSD=optic 
nerve sheath diameter. TBM=tuberculous meningitis.  
 
Figure 4-6: The association of optic nerve sheath diameter and plasma sodium in TBM, 
stratified by HIV co-infection status 
 
Each dot represents a pair of ONSD and plasma sodium measurements (performed on the same 
‘day’). HIV=Human immunodeficiency virus. Neg=negative. ONSD=optic nerve sheath diameter. 
Pos=positive. TBM=tuberculous meningitis 
  
 
147 
 
Figure 4-7: The association of optic nerve sheath diameter and plasma sodium in TBM, 
stratified by death by 3 months 
 
Each dot represents a pair of ONSD and plasma sodium measurements (performed on the same 
‘day’). Line of best fit shown with surrounding 95% confidence interval in shading. ONSD=optic 
nerve sheath diameter. TBM=tuberculous meningitis.  
 
Figure 4-8: The association of optic nerve sheath diameter and plasma sodium in TBM, 
stratified by neurological complications by 3 months 
 
Each dot represents a pair of ONSD and plasma sodium measurements (performed on the same 
‘day’). Line of best fit shown with surrounding 95% confidence interval in shading. ONSD=optic 
nerve sheath diameter. TBM=tuberculous meningitis.  
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4.3.6 Response to treatment, and outcomes by 3 months 
Baseline ONSD was significantly higher in participants who died (0.56cm [15/72]) vs. in 
participants who survived (0.52cm [57/72]), p=0.02 (table 4-6).  
Table 4-6: Median baseline ONSD by clinical endpoints 
 Total No. 
(N=72) 
Median ONSD (cm) 
(IQR) 
P value  
 
Neurological complication by 3 
months (No. [%]) 
- Yes 
- No 
 
 
12 (16.7%) 
60 (83.3%) 
 
 
0.53 (0.51-0.57) 
0.53 (0.49-0.56) 
 
 
0.61 
Death by 3 months (No. [%]) 
- Yes 
- No 
 
15 (20.8%) 
57 (79.2%) 
 
0.56 (0.53-0.59) 
0.52 (0.48-0.56) 
 
0.02 
P values represent comparison for ONSD values by the Wilcoxon rank sum test. Total No reflects 
the total number of observations available for the corresponding variable. Medical Research 
Council grades are as follows: Grade 1 indicates a GCS of 15 with no neurological signs, grade 2 a 
GCS of 11 to 14 (or 15 with focal neurological signs), and grade 3 a GCS of 10 or less. 
ONSD=optic nerve sheath diameter. 
 
At least one ONSD value was recorded for 107 individual participants (figure 4-9).  
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Figure 4-9: Optic nerve sheath diameter by day of measurement 
 
For each individual boxplot, the central horizontal bar represents the median value. The box  
contains data between 3rd quartile (upper end of box) and 1st quartile (lower end of box).  
Vertical lines above and below each box extend to the most extreme data point that is within 
1.5x the vertical height of the box. Dots represent individual data points outside of these limits.  
ONSD=optic nerve sheath diameter. 
 
Median ONSD was higher in participants who died by 3 months, vs. in participants who survived 
by 3 months, at all follow up time points (days 3, 7, 14, 21 and 28) (figure 4-10), and significantly 
so at baseline, day 3 and day 21 (figure 4-11).   
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Figure 4-10: ONSD over 30 days of anti-TB chemotherapy, stratified by death by 3 months  
 
 
 
For each individual boxplot, the central horizontal bar represents the median value. The box contains data between 3rd quartile (upper  
end of box) and 1st quartile (lower end of box). Vertical lines above and below each box extend to the most extreme data point that is  
within 1.5x the vertical height of the box. Dots represent individual data points outside of these limits. P values represent statistical  
comparison of ONSD values performed by the Wilcoxon rank sum test. ONSD=optic nerve sheath diameter. TB=tuberculosis. 
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There was no significant difference in baseline ONSD between participants who experienced 
neurological complications by 3 months, vs. participants who did not (0.53cm vs. 0.53cm, 
respectively, p=0.61). Follow up data suggested a trend of higher ONSD in participants 
experiencing neurological events by 3 months vs. participants without neurological events (figure 4-
11).  
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Figure 4-11: ONSD over 30 days of anti-TB chemotherapy, stratified by neurological complications by 3 months 
 
 
 
For each individual boxplot, the central horizontal bar represents the median value. The box contains data between 3rd quartile (upper  
end of box) and 1st quartile (lower end of box). Vertical lines above and below each box extend to the most extreme data point that is 
within 1.5x the vertical height of the box. Dots represent individual data points outside of these limits. P values represent statistical  
comparison of ONSD values performed by the Wilcoxon rank sum test. ONSD=optic nerve sheath diameter. TB=tuberculosis. 
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A ROC curve was constructed to investigate whether ONSD could predict death by 3 months 
(figure 4-12) with acceptable sensitivity and specificity. A baseline ONSD of 0.53cm or above 
predicted death by 3 months with 73% sensitivity and 54% specificity. 
Figure 4-12: ROC curve plotting true positive rate (sensitivity) and false positive rate (1-
specificity) for ONSD as a predictor of death by 3 months 
 
 
ONSD=optic nerve sheath diameter. ROC=receiver operating characteristic 
 
Higher ONSD values were observed in those with more severe disease (figure 4-13). In participants 
with grade 1 TBM, ONSD increases but then returns to baseline, consistent with ongoing recovery 
from TBM. In grade 2 and grade 3 TBM, ONSD continues to trend higher by 30 days, consistent 
with more severe disease in these groups.  
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Figure 4-13: ONSD values over 30 days of anti-TB chemotherapy, stratified by TBM severity grade and death by 3 months 
 
 
 
Individual data points represent individual ONSD values at a specified day of measurement. Data are shown stratified by grade 1, 2 and 3, 
where grade refers to MRC TBM severity grade. Blue dots represent ONSD values in patients who were alive by 3 months, whereas red dots 
represent ONSD values in patients who died by 3 months. The mean ONSD value across time points, for each grade, is represented by a 
green line with associated 95% CI. CI=confidence interval. MRC=Medical Research Council. ONSD=optic nerve sheath diameter. 
TBM=tuberculous meningitis.  
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ONSD stratified by HIV over the first 30 days of anti-TB chemotherapy is shown in figures 4-14 
and 4-15. ONSD was generally higher in HIV co-infection (non-significantly so) during early 
treatment, falling to a similar value (in those who survive), before rising again towards the end of 
the first month.  
Figure 4-14: Boxplot over time of ONSD for all patients stratified by HIV 
 
 
For each individual boxplot, the central horizontal bar represents the median value. The  
box contains data between 3rd quartile (upper end of box) and 1st quartile (lower end of  
box). Vertical lines above and below each box extend to the most extreme data point that  
is within 1.5x the vertical height of the box. Dots represent individual data points outside of  
these limits. HIV=human immunodeficiency virus. ONSD=optic nerve sheath diameter.  
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Figure 4-15: Scatterplot over time of ONSD for all patients stratified by HIV 
 
 
Individual data points represent individual ONSD values at a specified day of measurement. Data 
are shown stratified by grade 1, 2 and 3, where grade refers to MRC TBM severity grade. The 
central bar represents the mean ONSD value (with 95% CI) across time points. CI=confidence 
interval. HIV=human immunodeficiency virus. ONSD=optic nerve sheath diameter.  
 
4.4 Discussion 
A high rate of neurological disability and death result from TBM, often secondary to neurological 
complications that act to raise ICP. Once compensatory mechanisms have been overwhelmed, 
neurological decline and coma result; after this critical point patient outcomes are especially poor. 
More evidence guiding the best detection and management of raised ICP in TBM is required. Rapid 
identification of raised ICP may allow earlier intervention, with potentially improved clinical 
outcomes. Therefore, point of care tools such as ONSD ultrasound may aid raised ICP detection in 
TBM, and guide management.  
In this study ONSD was significantly higher in more severe presenting disease, in participants with 
abnormal brain imaging compared with participants with normal brain imaging, and in participants 
who then died by 3 months. Neurocomplications of TBM, such as hydrocephalus, tuberculomas, 
and paradoxical neuroinflammatory reactions, may elevate ICP. The number of participants for 
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whom changes consistent with raised ICP were noted on baseline brain imaging was small; and 
likely why ONSD did not significantly correlate with brain imaging suggestive of raised ICP. In this 
study median ONSD was significantly higher in participants with brain imaging consistent with 
neurocomplications of TBM, compared with in participants with brain imaging reported as normal. 
When CSF parameters were compared between these abnormal and normal brain imaging groups, 
significantly increased median CSF neutrophil percentage and lactate, and a significantly reduced 
CSF/glucose ratio, were seen in the abnormal brain imaging group vs. the normal brain imaging 
group. This worse CSF profile in the abnormal brain imaging represents more inflammation, and 
more severe disease. It appears likely that the higher ONSD values in the abnormal brain imaging 
group are capturing this more severe disease, with these changes manifest in changes in optic nerve 
size.  
Additionally, baseline ONSD was significantly higher in participants who died by 3 months 
compared with participants who survived. This suggests that ONSD is elevated in participants with 
brain pathology that produces worse clinical outcomes. This correlation between ONSD and severe 
TBM disease leading to poor outcomes illustrates the potential value of ONSD in the management 
of TBM. Previous data have correlated ONSD and other proxy markers of raised ICP;[78] however 
our study is the first to associate higher ONSD with worse outcomes in TBM. In clinical practice, 
ONSD ultrasound therefore has the potential to enable earlier identification of neuroinflammatory 
complications that may progress to death, allowing prompt investigation and management. Using 
ROC curve analysis, we identified a ‘best’ ONSD cut-off value of 0.53cm to separate participants 
who died by 3 months from those who survived by 3 months.  
Hyponatraemia is commonly found with TBM, although the reasons are poorly understood. Low 
plasma sodium predicts death in HIV co-infection.[35] Sodium-association and 30-day trend data 
cannot link ONSD values and plasma sodium. Low plasma sodium contributes to cerebral oedema, 
as the reduced oncotic pressure leads to fluid leak into the brain, resulting in raised ICP; sodium in 
TBM is discussed further elsewhere in this PhD.  
We postulate that the future of ONSD ultrasound may be in the identification of patients at risk of 
neurological complications or death, and the initiation of earlier 3D brain imaging that would 
otherwise have not been performed. However, further work is required to build on this preliminary 
data and show that ONSD ultrasound can be a practically useful technique in TBM. Critically, data 
must show that ONSD measurements guide patient management strategies that reduce mortality and 
morbidity from TBM. Optimal management of neurocritical illness in TBM is uncertain, yet some 
strategies have accepted benefits, even if their use does not improve outcomes in all individuals. 
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Surgical relief of hydrocephalus through ventriculoperitoneal shunting or endoscopic third 
ventriculostomy may be lifesaving. Neuroinflammatory changes may respond to corticosteroids or 
other host directed adjunctive anti-inflammatory therapy. One approach therefore would be to use a 
high ONSD value as a trigger to perform 3D brain imaging. Brain imaging can be expected to 
identify the likely cause of elevated ONSD in TBM, and best management can proceed from there. 
Evidence that ONSD reduces after administration of ICP-reducing adjunctive therapies that 
improve outcome would be valuable. Further research questions include what ONSD cut-off should 
initiate 3D brain imaging, should an ONSD cut-off vary by population or resource availability, and 
how frequently should ONSD ultrasound be performed in order to identify high risk patients at a 
stage where changes in management improve clinical outcomes?  
This study has limitations. It was not possible to perform ONSD ultrasound at every time point for 
each participant, due to constraints on operator, participants and resources. Most scans were 
performed by a single operator. Whilst this allowed for consistency in scanning technique and 
reduced inter-operator variability, it also meant measurement could not be reviewed by a second 
operator. ONSD ultrasound itself has limitations; lacking standardisation of technique and value 
interpretation. Additionally, ONSD appearances apparently consistent with raised ICP may in fact 
reflect non-raised ICP pathology. Solid thickening of the optic nerve sheath (for example occurring 
secondary to ophthalmopathy of Graves’ disease or an optic nerve sheath meningioma), or severe 
orbital congestion (for example occurring secondary to an arteriovenous fistula), may produce 
confounding appearances.[255] However, these findings are rare.  
A further limitation is that ONSD was compared with brain imaging performed within 72 hours. 
Changes in ICP may have occurred in between ONSD ultrasound and brain imaging, reducing 
correlation between these two scanning modalities. The number of participants for whom 
radiological changes consistent with raised ICP were noted on baseline brain imaging was small, 
and likely why ONSD did not significantly correlate with brain imaging labelled as ‘raised ICP’.  
Finally, it is not known if participants received corticosteroids. Participants in this study were 
enrolled into one of two randomised double blinded placebo-controlled trials of adjunctive 
corticosteroid therapy in TBM, and the dexamethasone/placebo allocation remains unknown. 
Baseline data including baseline ONSD ultrasound and 3D brain imaging, prior to dexamethasone 
or placebo administration, were unaffected by this. Neurological complications and death by 3 
months are affected by dexamethasone; an improving individual patient ONSD trend may reflect 
dexamethasone use if ICP was raised due to a dexamethasone-responsive cause such as 
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neuroinflammation. However, this blinded allocation should not affect the ability of ONSD to 
monitor and chart this trend.  
A strength of this study is that study data was collected as part of two clinical trials with study 
protocols, standard operating procedures, and careful conduct of research. This is the largest study 
to date of ONSD ultrasound in TBM, combining longitudinal ONSD data in individual participants 
with clinical endpoints. Brain imaging was independently reported by an experienced 
neuroradiologist, and correlated with CSF parameters, which reflect measurements of inflammation 
at the site of disease, rather than correlation with blood parameters.  
In conclusion this study demonstrated that higher ONSD values correlated with an increase disease 
severity, brain imaging abnormalities consistent with TBM, and an increased risk of death by 3 
months, and that higher median ONSD correlated with abnormal brain imaging. ONSD ultrasound 
has potential for use as a bedside tool for ICP monitoring in TBM. Further research is required to 
understand how to harness its potential, and implementation strategies are required to translate this 
evidence into improved patient care.   
4.5 Publications related to this chapter 
The methods described within this study are published in the research protocols below: 
1. Adjunctive dexamethasone for the treatment of HIV-uninfected adults with tuberculous 
meningitis stratified by Leukotriene A4 hydrolase genotype (LAST ACT): Study protocol for a 
randomised double blind placebo controlled non-inferiority trial 
Joseph Donovan, Nguyen Hoan Phu, Le Thi Phuong Thao, Nguyen Huu Lan, Nguyen Thi Hoang 
Mai, Nguyen Thi Mai Trang, Nguyen Thi Thu Hiep, Tran Bao Nhu, Bui Thi Bich Hanh, Vu Thi 
Phuong Mai, Nguyen Duc Bang, Do Chau Giang, Dang Thi Minh Ha, Jeremy Day, Nguyen TT 
Thuong, Nguyen Nang Vien,  Ronald B. Geskus, Tran Tinh Hien, Evelyne Kestelyn, Marcel 
Wolbers, Nguyen Van Vinh Chau, Guy E. Thwaites 
Wellcome Open Research 2018 Mar 20;3:32 
2. Adjunctive dexamethasone for the treatment of HIV-infected adults with tuberculous meningitis 
(ACT HIV): Study protocol for a randomised controlled trial 
Joseph Donovan, Nguyen Hoan Phu, Nguyen Thi Hoang Mai, Le Tien Dung, Darma Imran, Erlina 
Burhan, Lam Hong Bao Ngoc, Nguyen Duc Bang, Do Chau Giang, Dang Thi Minh Ha, Jeremy 
Day, Le Thi Phuong Thao, Nguyen TT Thuong, Nguyen Nang Vien, Ronald B. Geskus, Marcel 
Wolbers, Raph L. Hamers, Reinout van Crevel, Mugi Nursaya, Kartika Maharani, Tran Tinh Hien, 
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Kevin Baird, Nguyen Huu Lan, Evelyne Kestelyn, Nguyen Van Vinh Chau, Guy E. Thwaites 
Wellcome Open Research 2018 018 Jun 20;3:31 
 
The data contained within this chapter are under review in the following submission: 
3. Optic nerve sheath ultrasound for the detection and monitoring of raised intracranial pressure in 
tuberculous meningitis 
Joseph Donovan, Pham Kieu Nguyet Oanh, Nicholas Dobbs, Nguyen Hoan Phu, Ho Dang Trung 
Nghia, David Summers, Nguyen Thuy Thuong Thuong, Guy E. Thwaites  
on behalf of the Vietnam ICU Translational Applications Laboratory (VITAL) investigators 
Under review at the Clinical Infectious Diseases on the date of PhD submission 
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Chapter 5 
TBM associated hyponatraemia: an observational study of cause, 
treatment and outcome 
5.1 Introduction 
5.1.1 The control of blood sodium 
Sodium, the main extracellular fluid cation in humans, is important for maintaining irritability and 
conduction of nerve and muscle tissues, acid-base balance,[274] and fluid homeostasis. Normal 
homeostatic mechanisms usually ensure tight control of blood sodium; the Na+ K+ ATPase plasma 
membrane pump moves Na+ extracellularly in exchange for K+ moving intracellularly,[275] whilst 
the renin-angiotensin-aldosterone system controls sodium’s renal reabsorption and excretion. A fall 
in blood sodium leads to renal water excretion, whereas a rise in blood sodium leads to water 
conservation through increasing thirst, and the action of vasopressin in the renal tubules.[274,276] 
Despite these homeostatic mechanisms, disease and drug therapies may elevate or reduce blood 
sodium, with a variety of clinical manifestations depending on the amount and rate of change.  
5.1.2 Clinical hyponatraemia 
Hyponatraemia, defined as a blood sodium concentration of < 135mmol/L, is the most common 
electrolyte disorder in medical practice.[277] European clinical practice guidelines define 
hyponatraemia as mild (130-135 mmol/L), moderate (125-129 mmol/L) or profound 
(<125mmol/L).[277] When blood sodium falls in conjunction with reduced serum osmolality, as is 
usually the case, an osmotic gradient is created across cells in the brain. Water freely diffuses down 
this gradient and into cells, increasing cellular size[278] and resulting in oedema. The brain adapts 
to this oedema by reducing the number of intracellular osmotically active particles, a process which 
takes 24-48 hours.[277] However in acute hyponatraemia, where blood sodium falls over 48 hours 
or less, the brain is unable to compensate at the necessary rate, manifesting clinically as nausea, 
vomiting, headache, and confusion, followed by seizures, coma, and death.[277–279]  
Chronic hyponatraemia presents differently to the acute form; typical presentation is of fatigue, 
disorientation, cognitive and gait deficits, and falls.[277–279] Caution is required when 
administering sodium in chronic hyponatraemia. Too rapid a correction of chronic hyponatraemia 
may precipitate central pontine myelinolysis, also termed the ‘osmotic demyelination syndrome’, a 
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neurological syndrome strongly associated with correction of sodium by greater than 12 mmol/L 
per day.[280] 
5.1.3 Aetiology of hyponatraemia 
Identifying the cause of hyponatraemia allows administration of correct treatment. However, 
defining the cause depends upon the measurement of multiple parameters, exclusion of confounding 
pathologies, and accurate interpretation of these data. Diagnostic flow charts, such as that in the 
European clinical practice guidelines,[277] rule in or out causes based upon key values such as 
urinary sodium and clinical assessment of fluid balance. In addition, diagnosis is supported by 
magnitude of blood sodium reduction, serum and urinary osmolalities, exclusion of endocrine 
pathologies (hypocortisolaemia and hypothyroidism), plus consideration of sodium-affecting 
treatments such as hypertonic saline or diuretics.  
5.1.4 Hyponatraemia in tuberculous meningitis 
Hyponatraemia is a common feature of TBM; in fact hyponatraemia may occur more frequently in 
TBM than in brain infection of different aetiology.[116] In a recent study of hyponatraemia in 
TBM, hyponatraemia (defined as blood sodium < 135mEq/l, twice, 24 hours apart) was identified in 
34 (45%) of 76 patients.[281] Severe TBM is often associated with raised ICP due to hydrocephalus 
and neuro-inflammatory complications such as tuberculomas and IRIS. Brain oedema secondary to 
hyponatraemia may exacerbate raised ICP of TBM. In a study of patients with TBM in Vietnam, 
hyponatraemia was a predictor of mortality in HIV co-infected patients.[35]  
Few studies have studied TBM-associated hyponatraemia. In clinical practice CSW, and SIADH are 
considered the most likely causes of hyponatraemia in TBM; yet few data support this.  
5.1.5 Syndrome of inappropriate antidiuretic hormone secretion 
SIADH results from an increase in body water coupled with an inability to adequately dilute urine 
and create a compensatory diuresis.[282] Plasma volume expansion results in a compensatory 
natriuresis to preserve volume, yet this exacerbates hyponatraemia.[282] Excessive body water 
accumulation may occur through inappropriate regulation of thirst, excessive oral intake by the 
patient independent of thirst (polydipsia), through iatrogenic administration of intravenous fluid, or 
anti-diuretic hormone (ADH) (also termed ‘vasopressin’) release from the hypothalamus by 
mechanisms which remain unclear.[282]  
Given not all individuals with SIADH have elevated circulating levels of vasopressin, SIADH is 
also often referred to as the syndrome of inappropriate diuresis (SIAD).[283] A landmark study by 
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Zerbe et al in 1980 found and described four patterns of vasopressin release in SIADH; erratic, reset 
osmostat, vasopressin leak, and hypovasopressinemic antidiuresis, patterns that did not appear 
specific for individual diseases processes.[284] SIADH can now be classified as one of four types; 
A, B, C and D, each with a different mechanism; these are further described in table 5-1.  
Table 5-1: Types of SIADH 
Type of 
SIADH 
Frequency of 
occurrence 
Features 
A The most 
common type; 
occurring in 
30-70% cases 
Excessive and random secretion of vasopressin, with high and fixed 
urine osmolality, most typically seen in lung and nasopharyngeal 
cancers.[282,284]  
High vasopressin levels appear unresponsive to water intake which 
makes severe hyponatraemia a particular risk. 
Vasopressin secretion continues independent of fluid intake.[285]  
B Occurs in 20-
40% cases 
Vasopressin secretion at a lower osmolality than normal; termed 
‘vasopressin leak’.  
Urine osmolality is often fixed but at a lower level than type A, and 
protection from severe hyponatraemia occurs when further lowering of 
serum osmolality suppresses vasopressin.[282,284] 
C A rare cause Failure to suppress vasopressin at low serum osmolality, possibly due 
to dysfunction of inhibitory neurons in the hypothalamus.  
During the correction of hyponatraemia vasopressin levels begin to rise 
inappropriately before blood sodium is corrected. This osmoregulatory 
defect is usually termed ‘reset osmostat’.[282,284] 
D A very rare 
cause 
Gain-of-function mutation at the V2 receptor where vasopressin acts, 
leads to anti-diuresis despite undetectable vasopressin and normal 
osmoregulation of vasopressin.[282,284,285]   
SIADH can be classified as one of four types; A, B, C and D, each with a different mechanism. The 
terms antidiuretic hormone and vasopressin can be used interchangeably. SIADH=syndrome of 
inappropriate antidiuretic hormone secretion.  
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5.1.5.1 Diagnosis of SIADH 
SIADH is suspected when blood sodium and serum osmolality are low, and urine osmolality is 
inappropriately high. There is continued renal excretion of sodium, an absence of clinical volume 
depletion, and normal renal and adrenal function, as described by Bartter and Schwartz in 
1967.[286] In clinical practice guidelines for hyponatraemia[277,287] SIADH diagnostic criteria 
closely resemble those used in 1967 (table 5-2).  
Table 5-2: Diagnostic criteria for SIADH 
Essential criteria 
 
Supplemental criteria 
 
Effective serum osmolality <275 mOsm/kg Serum uric acid <0.24 mmol/l (<4 mg/dl) 
Urine osmolality >100 mOsm/kg at some 
level of decreased effective osmolality 
Serum urea <3.6 mmol/L (<21.6 mg/dl) 
Clinical euvolaemia Failure to correct hyponatraemia after 0.9% saline 
infusion 
Urine sodium concentration >30 mmol/L 
with normal dietary salt and water intake 
Fractional sodium excretion >0.5% 
 
Absence of adrenal, thyroid, pituitary or 
renal insufficiency 
Fractional urea excretion >55% 
No recent use of diuretic agents Fractional uric acid excretion >12% 
 Correction of hyponatraemia through fluid 
restriction 
SIADH=syndrome of inappropriate antidiuretic hormone secretion 
 
5.1.6 Cerebral salt wasting 
CSW, defined as renal sodium loss with accompanying reduced extracellular fluid volume during 
intracranial disease[156] is poorly understood. First described in 1950 by Peters et al,[288] in three 
individuals with intracranial pathology, its very existence has been doubted.[289] The trigger to 
excrete large amounts of urinary sodium, a typical feature of CSW, is uncertain.[290]  
5.1.6.1 Natriuretic peptides 
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Natriuretic peptides, particularly ANP and BNP, may be involved in pathogenesis, and roles for C-
type natriuretic peptide (CNP) and dendroaspis natriuretic peptide (DNP) have also been 
suggested.[290] ANP and BNP are predominantly produced by the atrial and ventricular walls of 
the heart respectively, with additional lower level production in the brain.[291]  
Whether a TBM brain insult results in increased natriuretic peptide production, or increased 
secretion either by the brain or the heart, is not known. Both ANP and BNP have natriuretic and 
aldosterone-inhibiting properties.[291] Both act in the brain to decrease salt appetite, water intake 
and corticotrophin release. The ANP receptor is predominantly located adjacent to the third 
ventricle of the brain, in an area not separated from the blood by the blood–brain barrier, and ANP 
binding at this site affects salt appetite and water drinking.[157] Low brain ANP levels make it 
unlikely that ANP actions at this site lead to CSW, although actions in the CNS may influence 
cardiac secretion of ANP.[156] BNP receptors are found in the hypothalamus, where BNP binding 
inhibits vasopressin secretion.[157] Conditions such a congestive heart failure, where BNP is 
elevated, are not strongly associated with hyponatraemia.[290] 
Receptors for both ANP and BNP are also present in the kidneys.[157] Both ANP and BNP act in 
the kidney to decrease aldosterone and renin, resulting in renal sodium loss.[157] The actual 
mechanism of CSW may involve both hormonal mechanisms (ANP released from atrial muscle 
after atrial stretch with downregulation of the renin-angiotensin axis), or direct effects on neural 
connections to the kidneys, where interruption of sympathetic stimulation leads to increased renal 
blood flow and naturesis.[156,290]  
5.1.6.2 Diagnosis of CSW 
CSW is characterised by hyponatraemia, hypovolaemia and inappropriately high urinary sodium 
and urine output. Differentiating CSW from SIADH is challenging given the key parameter to 
distinguish it from SIADH; extracellular fluid status, is a highly challenging assessment 
criterion.[290] No strict diagnostic criteria exist for CSW, and this is often a diagnosis of exclusion. 
Hypovolaemia may require aggressive fluid replacement and infusion of vasopressor agents such as 
noradrenaline. Brain ischaemia is a risk of hypovolaemia induced brain hypoperfusion, whereas 
overcorrection of fluid balance may result in cerebral oedema.  
5.1.6.3 Assessment of extracellular fluid 
Assessing a patient’s extracellular volume is difficult.[292] Assessment depends on clinical history 
and clinical assessment, and clinical assessment alone may be inaccurate. In clinical practice, 
intravascular volume is frequently used as a proxy for extracellular fluid, despite it making up only 
 
166 
 
a small proportion of the extracellular fluid compartment (the majority is interstitial fluid). Gold 
standard measurement of intravascular volume is by radioisotopic volume measurement; 
unfortunately this is costly, time-consuming and not practical in most settings.[293] 
5.1.6.4 Assessment of intravascular volume 
5.1.6.4.1 Clinical signs of dehydration 
Conventional clinical signs for identifying dehydration or reduced intravascular volume are limited. 
A study of 58 hyponatraemic patients (blood sodium < 130mmol/L) compared clinical assessment 
of extracellular fluid against ‘hypovolaemia’ and ‘euvolaemia’ diagnoses as measured by response 
to intravenous saline therapy.[294] Patients predicted to be ‘saline responders’ met at least 2 of the 
following 6 criteria for hypovolaemia; 1) a history or clinical setting consistent with extracellular 
fluid loss, 2) decreased skin turgor, axillary moisture, dry mucous membranes, or thirst, 3) greater 
than 0.5kg weight loss, 4) ≥ 10% decrease in orthostatic blood pressure, 5) ≥ 10% increase in 
orthostatic pulse rate, 6) Urea:Cr ratio > 20.[294] However, a saline response was only seen in 7 
(24%) of 29 patients predicted by this hypovolaemia assessment. Of the 29 patients predicted to not 
be saline responsive, 21 (72%) of 29 patients were indeed saline non responsive.[294] In a study of 
32 patients in whom history suggested hypovolaemia, capillary refill time was measured before and 
after 450ml blood transfusions.[295] Using age and sex specific upper limits of normal for capillary 
refill time, the sensitivity of capillary refill times for the detection of hypovolaemia in patients with 
abnormal orthostatic signs or with hypovolaemia were 26% (95% CI 7-50%) and 46% (18-75%). 
Capillary refill time alone was not sufficient for the detection of hypovolaemia. A systematic 
review of physical examination signs correlating with hypovolaemia found dry axillae and moist 
mucous membranes to be useful, but capillary refill time and poor skin turgor to have no proven 
diagnostic value.[296] A combination of signs was important to guide diagnosis of hypovolaemia 
whilst no individual clinical sign was particularly useful on its own.[296]  
5.1.6.4.2 Clinical tools 
Standing from a lying position causes ~10-15% blood to pool in lower extremities or the splanchnic 
system. Termed postural hypotension, this fall in blood pressure upon standing may occur 
secondary to dehydration (also in the elderly, due to drugs, or in those with autonomic 
dysfunction).[297] An already-reduced intravascular volume may experience a greater blood 
pressure reduction upon blood displacement to lower extremities. Central venous pressure (CVP) 
assessment may guide fluid resuscitation; however, interpreting CVP values requires understanding 
 
167 
 
of strengths and limitations of this technique.[298] However, none of these techniques consistently 
predicts intravascular volume and fluid requirements.   
5.1.6.4.3 Use of inferior cava ultrasound as a clinical tool for fluid assessment 
Given the difficulty in assessing intravascular fluid, as an aid to SIADH and CSW differentiation, 
point-of-care ultrasound of the inferior vena cava (IVC) may be beneficial. The IVC is a thin walled 
compliant vein, and its diameter varies with respiration. Using Doppler ultrasound IVC diameter 
can be measured at different phases of the respiratory cycle. In a spontaneously breathing patient, 
negative pressure within the thorax during inspiration causes blood to exit the IVC and enter the 
heart. The degree of IVC collapse during respiration, measured by the IVC collapsibility index, 
guides volume status and fluid management. In patients with a greater magnitude of hypovolaemia 
a greater degree of IVC collapse is expected. In a mechanically ventilated patients, the positive 
intrathoracic pressure associated with inspiration leads to an increased volume of IVC blood as 
blood is partially prevented from entering the heart. Therefore, in mechanically ventilated patients 
the maximal IVC diameter occurs during inspiration; a reverse of the measurements in 
spontaneously breathing patients. However, the difference in IVC diameter between inspiration and 
expiration can be measured regardless of when in the respiratory cycle the maximal diameter 
occurs. Evidence supporting IVC diameter measurement in fluid assessment is described in 
appendix J.  
5.1.6.4.4 Use of inferior vena cava ultrasound as a clinical tool for fluid assessment 
In 2016 the United States Critical Care Society published an assessment of published evidence 
regarding IVC ultrasound for fluid assessment, alongside guidance.[299] Guidance recommended 
using IVC ultrasound in mechanically ventilated patients to assess likely fluid responsiveness, and 
advised a cutoff value of a 15% change in IVC diameter between inspiration and expiration to select 
those responsive from those non-responsive to fluid.[299] The Society was unable to make a 
recommendation regarding measurement of IVC in spontaneously breathing patients, although 
stated it could not be concluded that IVC ultrasound for assessment of fluid responsiveness was 
without merit in this group.[299]  
In an American College of Emergency Physicians (ACEP) review of IVC ultrasound, a thorough 
scanning procedure was outlined.[300] Calculation of the caval index was as follows: [(IVC 
expiratory diameter - IVC inspiratory diameter), divided by IVC expiratory diameter × 100]. A 
caval index (written as a percentage) close to 100% indicates almost complete venous collapse (and 
therefore marked volume depletion), whilst an index close to 0% suggests little collapse and 
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potential fluid overload.[300] ACEP recommendations advise that, in spontaneously ventilated 
patients with volume depletion, IVC variation will be greater than 50%, fluid overload is associated 
with a fixed and distended IVC, and an IVC diameter > 2.5cm, or fixed and distended, is thought to 
correlate with a CVP of at least 15mmHg.[300] It is important to note that responsiveness to fluid 
does not equate to reduced volume, although it is a helpful guide.  
5.1.7 Distinguishing CSW from SIADH 
Both CSW and SIADH present with low serum osmolality, high urinary osmolality and high 
urinary sodium.[301] Diagnostic algorithms for hyponatraemia include an assessment of 
extracellular fluid [277] (or in practice intravascular fluid), Intravascular fluid assessments are 
difficult to make, and clinical prediction of fluid status in individuals with hyponatraemia has 
limited sensitivity and specificity.[291]  
Laboratory values may aid assessment of fluid status and guide differentiation between CSW and 
SIADH. Laboratory values favouring CSW are elevated haematocrit, elevated urea creatinine ratio 
and elevated serum protein, all of which suggest dehydration.[156] Serum uric acid may be low in 
SIADH, but low or normal in CSW,[156,290] whereas urinary uric acid excretion will be high in 
both conditions, normalising after correction of blood sodium in SIADH only.[301] In addition, 
serum osmolality is expected to be low in both CSW and SIADH, although it may be lower in 
SIADH.[156] Urinary volume should be significantly greater in CSW than in SIADH.[302] 
Measurement of serum ANP and ADH does not appear beneficial in distinguishing between CSW 
and SIADH, due to difficulty in distinguishing cause from effect.[156] ADH may rise (to varying 
magnitudes) and cause SIADH, or rise as a response to compensate for the hypovolaemia of CSW 
to preserve volume (despite vasopressin secretion further exacerbating hyponatraemia). The 
pathophysiologies of CSW and SIADH may in fact be intertwined, both involving natriuretic 
peptide release. In CSW ADH secretion preserves circulating volume. This pattern of vasopressin 
secretion, where vasopressin cannot be completely suppressed in the presence of hypo-osmolality 
(due to a requirement to maintain volume) is similar to SIADH type B, and Moritz suggests that 
cases of CSW may have been included in the group originally labelled as type B SIADH.[303] 
Response to salt and volume replacement may aid distinction between CSW and SIADH. 
Hyponatraemia and hypovolaemia can be corrected with hypertonic saline, and assuming 
replacement can keep up with losses in the face of a continued natriuresis driven by pathology, 
euvolaemia may be restored, and sodium deficits may be corrected. Stern et al suggest that to 
confirm CSW based upon response to treatment, salt administration must not only correct sodium 
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(as it would do this for both CSW and SIADH) but also promote a water diuresis as the 
hypovolaemic stimulus for vasopressin secretion is lost.[304]  
In the only comparable study of sodium in TBM, Misra et al defined hyponatraemia as sodium < 
135 mmol/L on two occasions 24 hours apart (with sodium testing alternate days until day 14, or 
until discharge if that were sooner).[281] Serum and urine osmolalities, and urinary sodium, were 
measured; however no longitudinal osmolality data were described. CSW was associated with low 
GCS and cerebral infarction, compared with non-CSW hyponatraemic patients. The authors 
distinguished CSW from SIADH using clinical and laboratory findings of dehydration, negative 
fluid balance and CVP (table 5-3).[281]  
Table 5-3: Criteria to distinguish CSW from SIADH 
Criteria used by Misra et al [281] 
CSW was considered in the presence of at least 
2 out of 4 following features in a patient with 
hyponatraemia 
SIADH was considered in the presence of at 
least 2 out of 4 following features in a patient 
with hyponatraemia 
Clinical findings of hypovolemia such as 
hypotension, dry mucous membranes, 
tachycardia or postural hypotension 
No signs of hypovolemia such as hypotension, 
dry mucous membrane, tachycardia or postural 
hypotension 
Laboratory evidence of dehydration such as 
elevated hematocrit, hemoglobin, serum 
albumin or blood urea nitrogen 
No laboratory evidence of dehydration such as 
elevated hematocrit, haemoglobin, serum 
albumin or blood urea nitrogen 
Negative fluid balance as determined by intake 
output chart and/or weight loss 
Normal or positive fluid balance with absence of 
weight loss 
CVP < 6 cm of water CVP > 6 cm of water 
CSW=cerebral salt wasting. CVP=central venous pressure. SIADH=syndrome of inappropriate 
antidiuretic hormone secretion. 
 
Causes of hyponatraemia were given as CSW (n=17), SIADH (n=3), drug induced (n=6), recurrent 
vomiting (n=4), nutritional (n=2) and adrenal insufficiency (hypopituitarism and Addison’s disease, 
n=2).[281] No cases were linked to hypothyroidism. It was not clear how non-CSW non-SIADH 
diagnoses were reached; although the authors state that a history of vomiting, diarrhoea, and uses of 
carbamazepine, mannitol and glycerine were recorded. 
5.1.7.1 Measurable differences between CSW and SIADH 
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When all literature is taken together, parameters suggesting CSW rather than SIADH are as follows: 
hypovolaemia (low extracellular volume, low plasma volume, low CVP, hypotension, signs and 
symptoms of dehydration),[156,277,290,301] laboratory values consistent with dehydration 
(elevated haematocrit,[156,290] elevated urea/creatinine ratio,[156,290,301] elevated serum 
protein,[156] higher urea,[277] higher serum potassium,[301] high uric acid excretion after sodium 
correction,[301] higher urinary sodium,[277,290] higher urinary volume,[277,290] and response to 
salt and fluid replacement).[156] Administration of furosemide and 0.9% saline worsen 
hyponatraemia in SIADH,[290] however these tests carry substantial risk.  
5.1.7.2 Natriuretic peptides and ADH 
In one prospective study of 24 patients with TBM and hydrocephalus a significant correlation was 
found between elevated plasma ANP and lower plasma sodium levels, although CSF ANP was 
undetected in all cases.[305] The authors hypothesised that patients with TBM may have 
hypothalamic ischaemia (via endarteritis affecting hypothalamic and basal ganglia perforating 
vessels), resulting in sympathetic discharge and atrial ANP release.[305] Whilst this study 
associates hyponatraemia and ANP, it does not distinguish between CSW and SIADH where both 
may involve ANP release.  
In a further study of 67 patients with TBM in India, most of whom had hyponatraemia, serum ANP 
and BNP levels were significantly elevated at the time of hyponatraemia compared with hospital 
admission, although these natriuretic peptides were unable to distinguish CSW from SIADH.[306] 
In 1980 Smith and Godwin-Austen described three cases of TBM and hypersecretion of 
vasopressin, where in cases 1 and 2 plasma vasopressin levels were high for serum osmolality, in 
cases 1 and 2 there was biochemical response to fluid restriction, and in cases 2 and 3 there was 
little damage to the hypothalamus on post mortem which the authors hypothesised made 
vasopressin release through direct hypothalamic-vasopressin axis damage unlikely.[307]  
In a study of 20 children with TBM in South Africa, Cotton et al demonstrated that in those children 
with laboratory values consistent with SIADH, vasopressin levels were significantly higher.[308] A 
range of plasma vasopressin levels were seen in SIADH and the authors ascribed this to patients 
with both ‘excessive random secretion’ and ‘vasopressin leak’ mechanisms of SIADH. A further 
study linking laboratory diagnosis of SIADH to raised ICP did not correlate with plasma or CSF 
ADH levels.[309]  
Neuroendocrine hormone imbalance is common in TBM, although whether this is part of the 
pathogenesis of hypovolaemia in TBM is unknown. In a study of 115 patients with TBM in India 
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who underwent thorough blood pituitary hormone testing 62 (54%) had at least one hormone 
abnormality, and neuroimaging demonstrated hypothalamic-pituitary region abnormalities in 33 
(29%), with most of these basal exudates.[310] Ten percent of patients were considered to have 
posterior pituitary damage, with a diagnosis of SIADH following the authors’ definition. Serum 
ADH was not measured. 
5.1.8 Research objectives 
In a prospective descriptive analysis of the pathophysiology of TBM-associated hyponatraemia I 
describe the characteristics associated with hyponatraemia at presentation, and the association 
between plasma sodium, serum osmolality, urinary sodium and urinary osmolality. I discuss the 
cause(s) of hyponatraemia in TBM, and describe the progression of sodium and fluid parameters 
during the first 30 days of TBM treatment 
5.2 Methods 
5.2.1 Methods of patient recruitment from ACT HIV and LAST ACT trials 
The study was nested within the ACT HIV (clinicaltrials.gov NCT03092817)[85] and LAST ACT 
(clinicaltrials.gov NCT03100786)[41] clinical trials. Participants in this study were Vietnamese 
adults (≥ 18 years of age) based only at HTD, Ho Chi Minh City, Vietnam. Inclusion and exclusion 
criteria, anti-TB chemotherapy, double blinded study drug allocation, ethical approval, and funding, 
for ACT HIV and LAST ACT, are described earlier in this thesis (chapter 3). 
5.2.2 Clinical data 
Baseline age, sex, TBM disease severity (MRC TBM grade) and HIV status were recorded. 
Participants were followed up for 3 months after enrolment, at which point neurological 
complications and survival were recorded. Neurological complications were defined as a fall in 
GCS of ≥ 2 points for ≥ 48 hours, a focal neurological sign, seizure, cerebellar signs, coma, or 
cerebral herniation.   
5.2.3 Sodium parameters 
5.2.3.1 Schedule 
Study participants underwent measurement of plasma sodium, urinary sodium, serum osmolality, 
urinary osmolality, 24-hour fluid balance, and intravascular volume assessment at days 0, 3, 7, 14, 
and/or day 21 (+/- 1 day), in addition to day 28 (+/- 1 day) for laboratory tests and urinary output 
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measurement, and at day 30 (+/- 1 day) for IVC ultrasound. Measurements were timed from 
randomisation into ACT HIV or LAST ACT. Day 30 assessment was performed only if the patient 
remained in hospital at this time point. Plasma cortisol was measured at day 0 to exclude 
hypocortisolaemia.  
5.2.3.2 Plasma and urine sodium 
Plasma and urinary sodium were measured by a Cobas 6000 c501 chemistry analyser (Roche 
Diagnostics, Basel, Switzerland), available at the HTD laboratory. Spot urine sodium (rather than 
24-hour collection) was used. Given plasma and urinary sodium may be influenced by diuretics, and 
administration of intravenous fluid containing sodium, the administration of hypertonic (3%) saline, 
0.9% saline, mannitol, and/or furosemide in the preceding 24 hour period before a sodium 
measurement was also recorded.    
5.2.3.3 Serum osmolality 
Serum osmolality was measured by an Osmomat 3000 freezing point osmometer (Gonotec GmbH, 
Berlin, Germany). Serum was frozen at -800C before transfer to Cho Ray Hospital, Ho Chi Minh 
City, for testing. Frozen serum samples were removed from the laboratory freezer at HTD and 
transported in a cool box (with ice) to Cho Ray Hospital, where they were tested on the same day. 
The short transfer period (approximately 10 minutes by road) was sufficient to defrost the sample, 
which is ready for analysis at arrival. Calculation of serum osmolality has reduced accuracy if other 
osmotically active substances (examples include alcohol, ketones, and mannitol) are present. Due to 
the chance of encountering such osmotically active substances in TBM, serum osmolality 
measurement (rather than calculation) was used. 
5.2.3.4 Urine osmolality 
Few data exist regarding storage of urine samples and subsequent measurement of osmolality. In 
this study urine samples were centrifuged following methods described by Sureda-Vives et al,[311] 
and transported to Cho Ray Hospital as per serum samples; in a cool box with ice, allowing 
defrosting on route. Sureda-Vives et al took fresh urine samples from 10 individuals, centrifuged 
them at 1000 rpm for 5 min at 4°C, and aliquoted them afterwards into 1-mL sterile tubes.[311] 
Frozen aliquots (-21°C) were then thawed in a 37°C water bath before being assayed and mixed. 
Frozen urine samples did not show any significant change in osmolality for up to 14 days.[311] In 
this study urinary osmolality was measured by an Osmomat 3000 freezing point osmometer 
(Gonotec GmbH, Berlin, Germany). 
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5.2.3.5 Limitations of serum and urine osmolality 
5.2.3.5.1 Extreme values 
In a retrospective cohort study of 16,598 critical care patients from an online data base in the United 
States,  extreme osmolality (defined as > 340mmol/L) was associated with mortality.[312] Serum 
osmolality > 400mmol/L is expected to be rapidly fatal. For the exclusion of erroneous high serum 
osmolality results a cut-off of > 450mmol/L was used, where values above this threshold were 
excluded. Using a cut-off of > 450mmol/L, 4 serum osmolality values; 468, 476, 594, and 700 
mmol/L, were identified and excluded from analysis. 
Serum osmolality represents 2 times the sum of blood sodium and potassium, plus urea and glucose. 
Blood sodium must therefore be at least as low as half the serum osmolality. For the exclusion of 
erroneous low serum osmolality results a cut-off of < 180mmol/L was used, where values below 
this threshold were excluded. Serum osmolality < 180mmol/L would suggest plasma sodium < 
80mmol/L) which would be incompatible with life. Using a cut-off of < 180mmol/L, one serum 
osmolality value was identified; 132mmol/L and excluded from analysis. 
5.2.3.5.2 Prolonged sample storage 
Lengthy storage periods, beyond the known time thresholds of sample stability, may affect 
osmolality results. However, using the methods for serum and urine osmolality processing and 
storage described above, samples have known stability for at least 56 days (serum) and at least 14 
days (urine) (appendix K). In this study, for two periods of time (each ~ 2-3 months) in this study, 
the sole method of osmolality testing became unavailable due to necessary machine repairs. During 
these time periods samples were stored past the evidence-based time limits and tested as soon as 
this testing became available again. Dates of sampling and testing were recorded. This affected only 
a small group of serum osmolality samples (5 samples for 3 participants). This affected 123 urine 
osmolality samples in 41 participants; however, most were tested within 3-4 weeks of sampling. 
Results from these 123 urine osmolality tests did not indicate prolonged storage led to abnormal 
results. No data suggest urine osmolality results are affected when samples are stored beyond these 
time limits following the processing steps used in this study, and these results were included in the 
final analysis.  
5.2.3.6 The effect of dexamethasone on plasma sodium 
The effect on the renal axis of high dose corticosteroid therapy must be considered. The side effects 
of dexamethasone include sodium retention, fluid retention, and potassium loss,[313] as expected 
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for a corticosteroid. Aldosterone and cortisol both act with equal affinity on the mineralocorticoid 
receptor in the distal nephron of the kidney, however the receptor is protected from the action of 
cortisol by 11β-hydroxysteroid dehydrogenase which converts cortisol to inactive cortisone.[314] In 
the context of 11β-OHSD deficiency, dexamethasone suppresses cortisol production and acts on the 
type II glucocorticoid receptor,[315] but there is also an action of cortisol on the mineralocorticoid 
receptor leading to, amongst other things, sodium retention.[316] Sodium transport effects are 
mediated through both the mineralocorticoid and glucocorticoid receptors, and dexamethasone, 
which binds preferentially to the glucocorticoid receptor, may still influence sodium transport this 
way.[317] An effect of dexamethasone on plasma sodium is expected to be small, however this 
effect cannot be known for certain until the treatment allocation is unblinded at the end of the trial.  
5.2.4 Plasma cortisol 
Hypocortisolaemia may result in hyponatraemia; therefore, a single plasma cortisol test at baseline 
was performed to exclude this cortisol deficient state. Day 0 serum samples were frozen at -200C 
before transport in batches to Medic Medical Center, Ho Chi Minh City. Plasma cortisol was 
measured by a Cobas E602 chemistry analyser (Roche Diagnostics, Basel, Switzerland).   
5.2.5 Fluid balance 
Fluid balance was recorded over a 24-hour period, with measurements of fluid input and output, and 
a record of the date of start of the 24-hour period. Following standard ward procedures 24-hour 
collection begins at 6am.  
5.2.5.1 Intravascular fluid assessment 
5.2.5.1.1 IVC ultrasound 
Intravascular volume was assessed by Doppler ultrasound of the IVC. IVC ultrasound was 
performed when participant, ultrasound operator, and ultrasound machine were available; as such it 
was not expected that IVC ultrasound would be available at all time points. IVC ultrasound was 
performed by one of two clinicians with training in critical care ultrasound, using an M-Turbo 
(Fujifilm Sonosite Ltd, Washington, United States) or Lumify (Philips, Amsterdam, Netherlands) 
ultrasound machine. The procedure for performing IVC ultrasound is as follows: 
1) Ensure informed consent for performing IVC ultrasound.  
Avoid scanning if abdominal trauma makes ultrasound probe position inaccessible.  
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2) Correctly position patient; patient should be lying on their back. Head-of-bed elevation 
should be no more than 300 (where 00 is a fully flat bed). 
3) Use a clean linear probe (low frequency, e.g. 5-2 MHz). Select ‘abdominal’ scanning mode. 
Enter patient ID in machine; ‘IVC’ plus study ID plus day (D) of performing study e.g. 
IVC2015D14. 
4) Select an appropriate scanning mode. 
5) Stand in the most appropriate place for scanning (usually on patient’s right side, level with 
waist) and position the screen so that it can be seen by operator.  
6) Apply sufficient ultrasound gel to the ultrasound probe.  
7) To obtain a sub-xiphoid view of the IVC place probe on the patient's abdomen just below 
the xiphoid bone with the marker facing to the head of the patient.  
8) Adjust the probe position until the IVC can be visualised in the longitudinal plane as it 
enters the right atrium. 
9) Keep IVC image on screen for period of 2-3 regular breaths. 
10) Perform an assessment of image quality using the following criteria; a) IVC is be visualised 
in the longitudinal plane as it enters the right atrium, b) Presence of movement artefact. If 
image quality is considered satisfactory then proceed to quantitative assessment of IVC.  
11) Measure IVC diameter at maximum and minimum diameter (to allow index calculation) at 
a point 2cm from IVC entry into the right atrium. 
12) Record all data on the IVC case report form.  
The caval index is calculated by: IVC expiratory diameter - IVC inspiratory diameter, divided by 
IVC expiratory diameter × 100.[300] Data collection additionally requires the recording of 
mechanical or spontaneous ventilation, and whether the patient is synchronised with their 
mechanical ventilation. IVC diameter measurements by ultrasound were used allocate participants 
to fluid categories; 1) Expanded: IVC diameter > 2.5cm, or IVC fixed and distended[300]; 2) 
Reduced: >15% respiratory variation in IVC diameter (mechanical ventilation[299]) or >50% 
respiratory variation in IVC diameter (spontaneous ventilation[300]). Normal: assessment of IVC 
does not meet criteria for ‘expanded’ or ‘reduced’. IVC maximum and IVC minimum were each 
recorded twice, and two caval index values were calculated. An average caval index value was then 
calculated for each patient. 
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5.2.5.2 Clinical assessment 
Fluid responsiveness may not always be consistent with extravascular volume status. Therefore, a 
clinical assessment of extracellular fluid status was also performed, for the purpose of 
distinguishing hypovolaemia from euvolaemia. Signs of hypovolaemia were recorded as follows: 
capillary refill time > 2 seconds, decreased skin turgor, dry mucous membranes, tachycardia (heart 
rate >100 bpm), sunken eyes. These assessment parameters were adapted from UK National 
Institute for Health and Care Excellence (NICE) guidelines[318] for fluid assessment, with 
selection of those parameters that select between reduced volume and euvolaemia. Merits and 
limitations of clinical signs, including in combination, for the identification of dehydration or 
hypovolaemia, are described in the introduction to this chapter.  
In additional to IVC size and clinical assessment, laboratory parameters (elevated baseline 
haemoglobin, haematocrit, and urea), 24-hour fluid balance, and urinary output, were used in the 
assignment of causality of hyponatraemia, as part of an algorithm (table 5-4) described further 
below.  
5.2.6 Assigning cause of hyponatraemia 
Causation of hyponatraemia was initially assessed using a flowchart adapted from the European 
Journal of Endocrinology (EJE) 2014 hyponatraemia guidelines,[277] (figure 5-1) with participants 
with suspected CSW or SIADH then separated using this study’s criteria (table 5-4). 
  
 
177 
 
Figure 5-1: Diagnostic flowchart for hyponatraemia 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Flow chart adapted from European Journal of Endocrinology Clinical Practice Guidelines on 
Diagnosis and Treatment of Hyponatraemia.[277] CSW=cerebral salt wasting. SIADH=syndrome 
of inappropriate antidiuretic hormone secretion.  
 
Figure 5-1 lists diuretics, renal disease, adrenal insufficiency or vomiting/diarrhoea, as non-CSW 
non-SIADH causes of hyponatraemia. Diuretic use was defined by furosemide (20mg or 40mg 
dosing) in the 24 hours preceding plasma sodium measurement, followed by new hyponatraemia 
(where ‘hyponatraemia’ was defined as plasma sodium reducing by ≥5mmol/L). Renal disease was 
Plasma sodium < 135mmol/L on one occasion 
YES 
Urine osmolality > 100 mOsm/Kg ≤ 100 mOsm/Kg 
Consider other 
causes 
Urine sodium concentration 
> 30 mmol/L ≤ 30 mmol/L 
Consider other causes 
based on fluid status 
 Assess fluid status for 
CSW or SIADH 
Cause identified? 
Diuretics, renal 
disease, adrenal 
insufficiency or 
vomiting/diarrhoea? 
YES 
NO 
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defined by creatinine > 110 μmol/L (males) or creatinine > 90 μmol/L (females) in the 24 hours 
preceding plasma sodium measurement. Adrenal insufficiency was defined by a morning plasma 
cortisol of < 6 mcg/dL. Vomiting and/or diarrhoea was defined as the recording as an adverse event 
of one these in the 24-hour period prior to plasma sodium measurement. Whist vomiting and 
diarrhea may occur unreported as an adverse event (low grade, or present since before 
commencement of study drug); episodes severe enough to alter electrolyte balance were likely to 
have been recorded. Hypothyroidism is a rare cause of hyponatraemia without a strong evidence 
base, and clinically significant hyponatraemia may only occur in severe hypothyroidism.[319] 
Thyroid function tests were not measured in this study.  
5.2.6.1 Assigning CSW or SIADH 
Assigning causality of hyponatraemia is problematic, requiring wide ranging data and often-
challenging extracellular fluid assessment. In this study, assigning diagnoses of CSW and SIADH 
required essential information; plasma sodium < 135 mmol/l, urine sodium > 30 mmol/l, urine 
osmolality > 100 mOsm/kg, and no additional cause identified, plus the presence or absence of 2 of 
5 criteria indicating hypovolaemia (CSW) or euvolaemia (SIADH). Using published literature and 
existing diagnostic criteria,[156,277,281,290,301] parameters that distinguish CSW from SIADH, 
and that were measurable and recordable within the hyponatraemia study of ACT HIV and LAST 
ACT, were identified. These parameters were used to define five criteria assessing hypovolaemia; 
clinical, laboratory, fluid balance, ultrasound, and urinary output, thereby differentiating CSW from 
SIADH. The presence of a result for each criterion scored 1 point for either CSW or SIADH (table 
5-4, and below). Criteria were then totaled for each of CSW and SIADH. If more than 2 points were 
totaled for both CSW and SIADH, then the diagnosis with the highest score was assigned. In the 
event of neither CSW nor SIADH receiving 2 or more points, or equal totals for both CSW and 
SIADH, a diagnosis of ‘Uncertain’ was assigned. Hyponatraemia causality using these methods was 
assigned only at baseline. Further novel methods to define CSW and SIADH, using polyuria alone, 
hypovolaemia by ultrasound alone, and urinary sodium alone, were used to assign hyponatraemia 
causality at all time points (as described further below). Criteria used to distinguish CSW from 
SIADH in this study, alongside criteria used in a recent study of hyponatraemia in TBM,[281] are 
shown below in table 5-4. 
  
 
179 
 
Table 5-4: Comparison of criteria for distinguishing CSW from SIADH in this study vs. Misra 
data[281] 
This study Misra et al [281] 
CSW was considered in the presence of at least 
2 out of 5 following features in a patient with 
hyponatraemia 
CSW was considered in the presence of at least 
2 out of 4 following features in a patient with 
hyponatraemia 
Clinical: Clinical findings of hypovolaemia: 
tachycardia, dry mucus membranes, delayed 
capillary refill time, sunken eyes, OR decreased 
skin turgor = 1 point 
Clinical findings of hypovolemia such as 
hypotension, dry mucous membranes, 
tachycardia or postural hypotension 
Laboratory: Elevated blood haemoglobin, 
haematocrit, OR urea * = 1 point 
Laboratory evidence of dehydration such as 
elevated hematocrit, hemoglobin, serum 
albumin or blood urea nitrogen 
Fluid balance: Negative fluid balance as 
determined by input output chart (24-hour fluid 
balance lower than +500mls) = 1 point 
Negative fluid balance as determined by intake 
output chart and/or weight loss 
Ultrasound: IVC variability (defined by >50% 
change in spontaneous ventilation, or > 18% 
change in mechanical ventilation), or IVC flat 
and under filled = 1 point 
CVP < 6 cm of water 
Urinary output: Polyuria (defined as urine 
output ≥ 30mls/Kg in 24 hours)[320] = 1 point 
 
 
SIADH was considered in the presence of at 
least 2 out of 5 following features in a patient 
with hyponatraemia 
SIADH was considered in the presence of at 
least 2 out of 4 following features in a patient 
with hyponatraemia 
Clinical: No clinical findings of hypovolaemia: 
tachycardia, dry mucus membranes, delayed 
capillary refill time, sunken eyes, decreased skin 
turgor = 1 point 
No signs of hypovolemia such as hypotension, 
dry mucous membrane, tachycardia or postural 
hypotension 
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Laboratory: No elevated haematocrit, 
haemoglobin, or urea * = 1 point 
No laboratory evidence of dehydration such as 
elevated hematocrit, haemoglobin, serum 
albumin or blood urea nitrogen 
Fluid balance: Normal or positive fluid balance 
as determined by input output chart (24-hour 
fluid balance ≥ 500mls) = 1 point 
Normal or positive fluid balance with absence of 
weight loss 
Ultrasound: Absence of IVC variability (defined 
as absence of >50% change in spontaneous 
ventilation, or absence of > 18% change in 
mechanical ventilation), or absence of flat and 
under filled IVC = 1 point 
CVP > 6 cm of water 
Urinary output: Absence of polyuria (defined as 
urine output < 30mls/Kg in 24 hours)[320] = 1 
point 
 
This study’s criteria are assigned after participants reach the point of assessing fluid status for either 
CSW or SIADH using the flowchart in figure 5-1. * Laboratory parameters were defined as 
‘elevated’ if they were greater than the normal range, or defined as ‘not elevated’ if none were 
greater than the normal range. Upper limits of normal; haemoglobin: 16mg/dL, haematocrit: 46, 
urea: 7.5 mmol/l. CSW=cerebral salt wasting. CVP=central venous pressure. IVC=inferior vena 
cava. SIADH=syndrome of inappropriate antidiuretic hormone secretion  
 
5.2.6.1.1 Clinical criterion 
The presence or absence of tachycardia, dry mucous membranes, delayed capillary refill time, 
sunken eyes, and decreased skin turgor were recorded for participants. If any one of these clinical 
features were present, then ‘yes’ was recorded for the hypovolaemia ‘clinical’ criterion. If none 
were present, then ‘yes’ was recorded for euvolaemic ‘clinical’ criterion (assuming no oedema 
suggestive of fluid overload). 
5.2.6.1.2 Laboratory criterion 
The blood values of haemoglobin, haematocrit, and urea were recorded at baseline. If any one of 
these parameters were elevated above the normal range (upper limits of normal; haemoglobin: 
16mg/dL, haematocrit: 46, urea: 7.5 mmol/l, with identical ranges used for both males and females) 
then ‘yes’ was recorded for the hypovolaemic ‘laboratory’ criterion. If none of these laboratory 
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parameters were elevated above the normal range then ‘yes’ was recorded for the euvolaemic 
‘laboratory’ criterion.  
5.2.6.1.3 Fluid balance criterion 
Measurements of fluid input and output in a 24-hour period were recorded, and the fluid balance 
calculated. If fluid balance was negative, factoring in insensible losses (i.e. a value lower than 
+500mls in 24 hours), then ‘yes’ was recorded for the hypovolaemia ‘fluid balance’ criterion. If 
fluid balance was positive, factoring in insensible losses (i.e. greater than or equal to 500mls in 24 
hours), ‘yes’ was recorded for the euvolaemic ‘fluid balance’ criterion. 
5.2.6.1.4 Ultrasound criterion 
Regarding the ‘ultrasound’ volume criterion, IVC appearances were viewed, and IVC variability 
calculated if measurements were available. If IVC appearances and IVC variability were suggestive 
of hypovolaemia (IVC variability >50% in spontaneously ventilating patients, or > 18% in 
mechanically ventilating patients, or if IVC variability could not be measured but IVC was flat and 
appeared under-filled), ‘yes’ was recorded for the hypovolaemic ‘ultrasound’ criterion. If IVC 
appearances and IVC variability were not suggestive of hypovolaemia (IVC variability was not 
>50% in spontaneously ventilating patients, nor > 18% in mechanically ventilating patients, or if 
IVC variability could not be calculated and IVC was not flat and did not appear under-filled), ‘yes’ 
was recorded for the euvolaemic ‘ultrasound’ criterion (unless ultrasound appearances suggested 
expanded IVC with <5% variation).  
5.2.6.1.5 Urinary output criterion, and urinary sodium 
Data suggest urinary output is higher in CSW compared with in SIADH,[277,290,321] however no 
evidence-based cut-off exists to distinguish between the two conditions. I therefore used an 
accepted definition of polyuria;  urine output >30mls/Kg in 24 hours,[320] in these cases recording 
‘yes’ for the hypovolaemic polyuria criterion. ‘Higher’ urinary sodium (for identification of CSW) 
does not have an accepted cut-off value and therefore was not used for the first hyponatraemia 
causality allocation. 
5.2.6.2 Alternative methods to define CSW and SIADH 
A hypovolaemic high urinary volume state is typical of the clinical syndrome recognised as CSW. 
Therefore, as additional novel analyses, CSW and SIADH were defined based on a polyuric urinary 
output alone (second novel analysis), by hypovolaemia assessed by IVC ultrasound alone (third 
novel analysis), and by the degree of urinary sodium (fourth novel analysis). Polyuria, and 
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hypovolaemia assessed by IVC ultrasound, were each defined as above. Urinary sodium ≥ 
100mmol/L was used to assign CSW (which is associated with greater urinary sodium loss), and 
urinary sodium <100mmol/L was used to allocate SIADH (hypovolaemia). 
As previously described, polyuria was selected by the presence of 24-hour urinary output > 
30mls/kg/day. Hypovolaemia by IVC ultrasound was defined by ‘ultrasound criteria’ listed above.  
5.2.7 Assessing sodium-influencing treatments 
Many drugs promote hyponatraemia; however, most are infrequently used in TBM at this study site. 
Use of sodium-containing fluids (hypertonic [3%] saline, ‘normal’ [0.9%] saline, Ringer’s lactate), 
and hyponatraemia promoting drugs (e.g. furosemide) confound identification of causality of 
hyponatraemia. Hypertonic 3% saline has particularly widespread use in hyponatraemic individuals 
with TBM and focal neurological deficits or coma. Hypertonic 3% saline use will affect the trends 
of sodium and associated parameters. An electronic data search for details of hypertonic saline 3%, 
saline 0.9%, and furosemide 40mg, including fluid volume, and time and date of administration, 
was performed for study participants. 
5.2.8 Statistical analysis 
5.2.8.1 Sample size 
This study was descriptive and exploratory, with no sample size calculation. As many participants 
as possible were recruited during the available time-window, which closed on 31st December 2019.  
5.2.8.2 Statistical analysis plan 
A statistical analysis plan written in advance of data analysis outlined the following: 
- Evaluate median baseline plasma sodium, by HIV co-infection status and clinical characteristics 
including MRC TBM grade  
- Establish whether there is any correlation between baseline plasma sodium, serum osmolality, 
urinary sodium, urinary osmolality, and plasma cortisol, in TBM 
- Describe the progression of sodium and associated parameters during the first 30 days of TBM 
treatment 
- Describe the influence of baseline plasma sodium, serum osmolality, urinary sodium, urinary 
osmolality, and plasma cortisol, on clinical outcomes in TBM 
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Subsequent to data collection, the number of baseline parameters assessed for correlation with 
baseline plasma sodium was expanded and defined, to include: days of symptoms, cranial nerve 
palsy, seizures, highest temperature (0C), lumbar CSF opening pressure (cmH20), and baseline CSF 
parameters. 
Additionally, at the end of data collection a decision was made to search for sodium-containing 
fluid treatment details, to allow description of use of these therapies.  
5.2.8.3 Statistical tests 
The Shapiro-Wilk test for normality was applied to data. Measured parameters (for example plasma 
sodium) were both normally distributed, and non-normally distributed, when assessed at individual 
time points (e.g. day 21). Therefore, data was treated as non-parametric data in this analysis; data 
are shown using medians (with IQR). Non-normally distributed data were compared by the 
Wilcoxon rank sum test. Correlation between continuous variables was performed using 
Spearman’s correlation. Data were analysed using R (version 3.6). 
5.3 Results 
5.3.1 The study population 
From June 2017 to December 2019 inclusive, 208 participants with TBM underwent sodium 
parameter testing, undergoing at least one test for plasma sodium, urinary sodium, serum 
osmolality, or urine osmolality, at 1 or more of 6 time points (days 0, 3, 7, 14, 21, and 28). The 
median age of the study population was 37 (IQR 29-46) years. 71.9% (153/208) participants were 
male. MRC TBM severity grades[9,236] amongst the study population were, Grade 1: 38.5% 
(n=80), Grade 2: 47.6% (n=99), Grade 3: 13.9% (n=29). 71.6% (n=149) study participants were 
diagnosed with definite TBM, 9.6% (n=20) with probable TBM, and 14.4% (n=30) with possible 
TBM. 42.8% (89/208) participants were HIV co-infected.  
In total, during the first 30 days of anti-TB chemotherapy for these 208 participants the following 
measurements were performed: 734 plasma sodium, 407 urinary sodium, 743 serum osmolality, 728 
urinary osmolality, 208 plasma cortisol, 769 fluid balance, 764 urine output, and 226 IVC 
ultrasound, measurements.  
5.3.2 Baseline plasma sodium 
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Baseline plasma sodium (day 0 +/- 1 day) was available for 91.3% (190/208) participants. Median 
baseline plasma sodium with IQR is shown for all participants, and stratified by HIV co-infection 
and by MRC TBM grade, in table 5-5.   
Table 5-5: Baseline plasma sodium 
 No. participants Plasma sodium (mmol/L) P value 
All participants 
(Median[IQR]) 
190 126 (122-131)  
HIV co-infection  
(Median[IQR]) 
- Co-infected 
- Uninfected 
 
 
80 
110 
 
 
125 (121-130) 
126 (122-131) 
 
 
0.18 
MRC TBM severity grade 
(Median[IQR]) 
- 1 
- 2 
- 3 
 
 
70 
91 
29 
 
 
128 (124-132) 
125 (121-128) 
126 (121-132) 
 
 
0.002 # 
# Grade 1 compared with grades 2 & 3 combined. Median plasma sodium value is shown with IQR. 
P value represents Wilcoxon rank sum test; given plasma sodium values were non-normally 
distributed. HIV=human immunodeficiency virus. IQR=interquartile range. MRC=Medical 
Research Council. TBM=tuberculous meningitis. 
 
5.3.3 Severity of baseline hyponatraemia 
176/190 (92.6%) participants for whom baseline plasma sodium was available were hyponatraemic 
(defined as Na<135mmol/L) at baseline. In 134/190 (70.5%) participants baseline plasma sodium 
was <130mmol/L, and in 75/190 (39.5%) participants baseline plasma sodium was <125mmol/L. 
Participants were separated into either mild (Na≥130, Na<135, mmol/L), moderate (Na <130, 
Na≥125, mmol/L) or profound (Na<125mmol/L) severity categories for hyponatraemia.[277] 
Severity of hyponatraemia, stratified by HIV co-infection status and MRC TBM severity grade, is 
described in table 5-6.   
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Table 5-6: Mild, moderate, and profound severity of hyponatraemia in participants with TBM 
 No. Mild 
hyponatraemia 
(Na≥130, Na<135) 
 
N (%) 
Moderate 
hyponatraemia 
(Na <130, Na≥125) 
N (%) 
Profound 
hyponatraemia 
(Na<125mmol/L) 
 
N (%) 
All participants 176 42 (23.9%) 59 (33.5%) 75 (42.6%) 
HIV 
Co-infected 
Uninfected 
 
73 
103 
 
16 (21.9%) 
26 (25.2%) 
 
20 (27.4%) 
39 (37.9%) 
 
37 (50.7%) 
38 (36.9%) 
MRC TBM  
severity grade 
1 
2 
3 
 
 
66 
88 
22 
 
 
25 (37.9%) 
13 (14.8%) 
4 (18.2%) 
 
 
23 (34.8%) 
31 (35.2%) 
5 (22.7%) 
 
 
18 (27.3%) 
44 (50.0%) 
13 (59.1%) 
Plasma sodium concentrations reported in mmol//L. HIV=human immunodeficiency virus. 
MRC=Medical Research Council. TBM=tuberculous meningitis. 
 
5.3.4 Comparison of baseline parameters by status and severity of hyponatraemia 
Data describing plasma osmolality, urinary sodium, urinary osmolality, and urine output, by 
severity of hyponatraemia at baseline, alongside participants without hyponatraemia at baseline, are 
shown in table 5-7. Trends of reducing serum osmolality, increasing urinary sodium, and increasing 
urinary osmolality occurred as hyponatraemia severity progressed from mild to profound. 
Additionally, plasma cortisol levels increased with increasing severity of hyponatraemia.   
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Table 5-7: Baseline parameters by status and severity of hyponatraemia 
 N All 
participants 
N Non-
hyponatraemic 
(Na≥135mmol/L) 
N Mild 
hyponatraemia 
(Na≥130, 
Na<135) 
N Moderate 
hyponatraemia 
(Na <130, 
Na≥125) 
N Profound 
hyponatraemia 
(Na<125mmol/L) 
Urinary sodium 
(mmol/L) 
(Median[IQR])  
135 89 
(52-119) 
10 84 
(38-105) 
29 80 
(42-110) 
47 86 
(56-112) 
49 111 
(58-133) 
Serum 
osmolality 
(mOsm/Kg) 
(Median[IQR])  
146 271  
(262-281) 
11 289 
(285-297) 
34 279 
(276-287) 
47 268 
(262-274) 
54 264 
(253-270) 
Urinary 
osmolality 
(mOsm/Kg) 
(Median[IQR])  
142 490 
(378-630) 
10 438 
(397-551) 
31 386 
(299-596) 
48 493 
(400-622) 
53 546 
(414-654) 
24-hour urinary 
output (mls) 
(Median[IQR])  
151 2400 
(2100-
2800) 
9 2600 
(2300-3500) 
32 2500 
(2100-2750) 
48 2400 
(2100-2600) 
62 2300 
(2000-2800) 
Hypovolaemic 
IVC 
(N[%]) 
57 16/57 
(28.1%) 
3 1/3 
(33.3%) 
15 1/15 
(6.7%) 
16 6/16 
(37.5%) 
23 8/23 
(34.8%) 
 
187 
 
Plasma cortisol 
(mcg/dL) 
(Median[IQR])  
190 19.8 
(15.1-25.0) 
14 18.8 
(16.8-20.9) 
42 18.5 
(10.1-23.1) 
59 19.3 
(13.5-25.2) 
75 22.2 
(16.9-27.0) 
Haemoglobin 
(g/dL)  
(Median[IQR])  
189 12.6 
(11.0-13.8) 
14 12.5 
(10.3-14.2) 
42 13.1 
(11.2-14.0) 
58 12.7 
(11.4-13.6) 
75 12.1 
(10.7-13.6) 
Urea (mmol/L) 
(Median[IQR])  
164 4.3 
(3.2-5.6) 
12 5.6 
(4.2-10.9) 
35 4.5 
(3.2-5.2) 
51 5.0 
(3.4-5.9) 
66 4.0 
(3.0-5.0) 
All participants with available plasma sodium at baseline are represented. Data are non-normally distributed, as such they are summarised by 
median and IQR. Haemoglobin and urea were measured from blood. IQR=interquartile range. IVC=inferior vena cava. N=number of 
participants. Na=sodium. 
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5.3.5 Baseline plasma sodium correlations 
Correlation of baseline plasma sodium with clinical and CSF parameters is shown in table 5-8. 
Lower plasma sodium correlated significantly with higher lumbar CSF opening pressure, higher 
absolute CSF neutrophils and CSF neutrophil %, and with lower CSF/blood glucose ratio. A trend 
towards higher CSF lactate was seen with lower plasma sodium.   
Table 5-8: Correlation of baseline plasma sodium with clinical and CSF parameters 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Correlation is show for plasma sodium at baseline (day 0) with each listed variable in the table. Co-
efficient and significance (p value) are shown using Spearman’s rank correlation co-efficient. 
*Comparison for binary variables (cranial nerve palsies and seizures) was performed by Wilcoxon 
rank sum test given plasma sodium values were non-normally distributed, therefore no correlation 
co-efficient is shown. Data for baseline cranial nerve palsy (n=198) reflects total of cranial nerve 
palsy (n=39) and no cranial nerve palsy (n=159). Data for baseline seizures (n=200) reflects total of 
seizures (n=8) and no seizures (n=192). CSF=cerebrospinal fluid. NA=not applicable. WBC=white 
blood cells.   
 
Parameter  Total 
No. 
Correlation co-
efficient 
P value 
Days of symptoms 135 -0.02 0.76 
Cranial nerve palsy 198 NA * 0.11 
Seizures 200 NA * 0.12 
Glasgow coma score 187 0.11 0.14 
Highest temperature (0C) 187 -0.11 0.14 
Lumbar CSF opening pressure (cmH20) 111 -0.22 0.02 
CSF WBC (cells/mm3) 183 -0.12 0.12 
CSF neutrophil % 181 -0.21 0.01 
Absolute CSF neutrophil count (cells/mm3) 181 -0.19 0.01 
CSF/blood glucose ratio  183 0.19 0.01 
CSF protein (g/L) 184 -0.04 0.57 
CSF lactate (mmol/L) 184 -0.13 0.08 
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A significant negative association was seen for baseline plasma sodium and each of CSF neutrophil 
differential (p=0.01) (figure 5-2), lumbar CSF opening pressure (p=0.02) (figure 5-3), and absolute 
CSF neutrophils. A significant positive association was seen for baseline plasma sodium and 
CSF/blood glucose ratio (figure 5-4).  
Figure 5-2: The correlation of plasma sodium and CSF neutrophil differential 
  
Individual points represent individual participants with both plasma sodium and CSF neutrophil 
measurements. A central blue line of best fit is surrounding by grey shading defined the 95% 
confidence interval. CSF=cerebrospinal fluid 
 
Figure 5-3: The correlation of plasma sodium and lumbar CSF opening pressure 
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Individual points represent individual participants with both plasma sodium and CSF neutrophil 
measurements. A central blue line of best fit is surrounding by grey shading defined the 95% 
confidence interval. CSF=cerebrospinal fluid 
 
Figure 5-4: The correlation of plasma sodium and CSF/blood glucose ratio 
 
Individual points represent individual participants with both plasma sodium and paired CSF/blood 
glucose measurements. A central blue line of best fit is surrounding by grey shading defined the 
95% confidence interval. CSF=cerebrospinal fluid 
 
To fully describe the clinical picture of hyponatraemia in TBM, an analysis of the associations of 
plasma sodium with other relevant parameters was performed. Correlation of baseline plasma 
sodium with baseline serum and fluid parameters is shown in table 5-9.    
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Table 5-9: Correlation of baseline plasma sodium with other baseline sodium and fluid 
parameters 
Parameter  Total No. Correlation co-efficient P value 
Urinary sodium (mmol/L) 135 -0.20 0.02 
Serum osmolality (mmol/L) 146 0.62  <0.001 
Urinary osmolality (mmol/L) 142 -0.18 0.04 
24-hour fluid balance 151 -0.04 0.59 
24-hour fluid output 151 0.06 0.50 
Baseline cortisol 190 -0.23 0.001 
Correlation is shown for plasma sodium at baseline (day 0) with each listed variable in the table. 
Co-efficient and significance (p value) are shown using Spearman’s rank correlation co-efficient. 
CSF=cerebrospinal fluid. WBC=white blood cells.   
 
5.3.5.1 Baseline plasma sodium and urinary sodium 
A significant correlation was seen between baseline plasma sodium and baseline urinary sodium 
(n=135, p=0.02) in all participants. No significant correlation was seen within HIV co-infection 
subgroups (HIV co-infection: n=47, correlation co-efficient -0.17, p=0.26; HIV uninfected: n=88, 
correlation co-efficient -0.19, p=0.08), nor with MRC TBM severity grade subgroup 1 or 3 (Grade 
1: n=52, correlation co-efficient -0.01, p=0.95; Grade 3: n=18, correlation co-efficient -0.32, 
p=0.20). In participants with MRC TBM severity grade 2, a significant correlation between baseline 
plasma sodium and urinary sodium was seen (Grade 2: n=65, correlation co-efficient -0.26, p=0.03). 
Correlation of baseline plasma sodium and urinary sodium, for all participants, is shown in figure 5-
5. In an analysis of correlation between baseline plasma sodium and baseline urinary sodium 
stratified by severity of hyponatraemia (mild, moderate, or profound - as defined in table 5-7), no 
significant correlations were seen; mild hyponatraemia: n=29, correlation co-efficient -0.02, p=0.90; 
moderate hyponatraemia: n=47, correlation co-efficient -0.09, p=0.54; profound hyponatraemia: 
n=49, correlation co-efficient 0.08, p=0.58.  
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Figure 5-5: Correlation of baseline plasma sodium and urinary sodium 
  
Individual points represent individual participants with both plasma sodium and urinary sodium 
measurements. A central blue line of best fit is surrounded by grey shading defining the 95% 
confidence interval.  
 
5.3.5.2 Baseline plasma sodium and baseline serum osmolality 
A positive correlation was seen between baseline plasma sodium and baseline serum osmolality 
(correlation co-efficient 0.6, p<0.001). A further analysis of the association between baseline 
plasma sodium and baseline serum osmolality showed that significant positive correlation between 
these parameters is retained in participants with HIV co-infection (n=47, correlation co-efficient 
0.66, p<0.001) and in HIV uninfected participants (n=99, correlation co-efficient 0.59, p<0.001). 
Additionally, significant correlation is retained between baseline plasma sodium and baseline serum 
osmolality in participants with TBM grade 2 (n=69, correlation co-efficient 0.53, p<0.001), and in 
participants with TBM grade 3 (n=20, correlation co-efficient 0.90, p<0.001), but not in participants 
with TBM grade 1 (n=57, correlation co-efficient 0.56, p=0.86). Correlation of plasma sodium and 
serum osmolality is shown for all participants in figure 5-6. In an analysis of correlation between 
baseline plasma sodium and baseline serum osmolality stratified by severity of hyponatraemia 
(mild, moderate, or profound), significant correlations were seen with mild hyponatraemia: n=34, 
correlation co-efficient 0.41, p=0.02; and with moderate hyponatraemia: n=47, correlation co-
efficient 0.32, p=0.02. A trend towards significance was seen with profound hyponatraemia: n=54, 
correlation co-efficient 0.24, p=0.07.  
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Figure 5-6: Correlation of baseline plasma sodium and serum osmolality 
  
Individual points represent individual participants with both plasma sodium and serum osmolality 
measurements. A central blue line of best fit is surrounded by grey shading defining the 95% 
confidence interval. CSF=cerebrospinal fluid 
 
5.3.5.3 Plasma sodium and urinary osmolality 
A significant correlation between plasma sodium and urinary osmolality was seen for all 
participants (correlation co-efficient -0.18, p=0.04) (figure 5-7). 
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Figure 5-7: Correlation of baseline plasma sodium and urinary osmolality 
 
 
Individual points represent individual participants with both plasma sodium and urine osmolality 
measurements. A central blue line of best fit is surrounded by grey shading defining the 95% 
confidence interval. 
 
A significant correlation between plasma sodium and urinary osmolality was seen in HIV 
uninfected participants (n=98, correlation co-efficient -0.20, p=0.05), but not in HIV co-infected 
participants (n=44, correlation co-efficient -0.10, p=0.53). No significance between plasma sodium 
and urinary osmolality was seen stratified by MRC TBM grade (grade 1: n=56, correlation co-
efficient -0.12, p=0.39; grade 2: n=66, correlation co-efficient -0.14, p=0.26; grade 3: n=20, 
correlation co-efficient -0.18, p=0.45). 
5.3.5.4 Baseline plasma sodium and baseline plasma cortisol 
Plasma sodium was significantly and inversely associated with plasma cortisol at baseline 
(correlation co-efficient -0.23, p=0.001), suggesting a stress response (elevated plasma cortisol) 
with more severe disease (lower plasma sodium) (figure 5-8). Median baseline cortisol was higher 
in participants with profound hyponatraemia (median 22.2mcg/dL, IQR 16.9-27.0) vs. participants 
with mild or moderate hyponatraemia (median 18.9mcg/dL, IQR 13.1-23.7) (p=0.01).  
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Figure 5-8: Correlation of baseline plasma sodium and plasma cortisol 
 
Individual points represent individual participants with both plasma sodium and plasma cortisol 
measurements. A central blue line of best fit is surrounded by grey shading defining the 95% 
confidence interval. 
 
A further analysis of the association between baseline plasma sodium and baseline plasma cortisol 
showed that significant correlation between these parameters is retained in participants with HIV 
co-infection (n=80, correlation co-efficient -0.25, p=0.03), and in HIV uninfected participants 
(n=110, correlation co-efficient -0.22, p=0.02). No significant correlation between baseline plasma 
sodium and baseline plasma cortisol was seen stratified by MRC TBM severity grade (grade 1: 
n=56, correlation co-efficient -0.21, p=0.08; grade 2: n=66, correlation co-efficient -0.09, p=0.39; 
grade 3: n=20, correlation co-efficient -0.36, p=0.05). 
5.3.5.5 Non-plasma sodium baseline correlations 
Urinary sodium correlated negatively with serum osmolality at baseline (n=130, correlation co-
efficient -0.24, p=0.01), and with urinary osmolality at baseline (n=126, correlation co-efficient 
0.44, p<0.001), but not with 24-hour urine output at baseline (n=115, correlation co-efficient 0.05, 
p=0.61). 
5.3.6 Assigning causality of hyponatraemia at baseline 
5.3.6.1 This study’s criteria 
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Of 176 hyponatraemic participants, 8 participants had urinary sodium ≤ 30mmol/L and could 
therefore not meet criteria for either CSW or SIADH. No participants had urinary osmolality ≤ 
100mOsm/Kg. Data were available for clinical (n=54), laboratory (n=176), fluid balance (n=142), 
IVC (n=48) and urinary output (n=142), respectively. Complete data sets assessing clinical, 
laboratory, fluid balance, and IVC ultrasound hypovolaemia parameters, were available for 34/168 
(20.2%) hyponatraemic participants who had progressed through figure 5-1 to fluid status 
assessment for CSW or SIADH. In this restricted sub-group, following the criteria described above, 
baseline diagnoses of CSW or SIADH were allocated as follows; 7/34 (20.6%) CSW, and 27/34 
(79.4%) SIADH. 
Of these 34 participants, all those with mild hyponatraemia (n=9) fitted the definition for SIADH. 
In those with moderate hyponatraemia (n=10) there were 2 cases of CSW (20%) and 8 cases of 
SIADH (80%), and in those with profound hyponatraemia (n=15) there were 5 cases of CSW 
(33.3%) and 10 cases of SIADH (66.7%). Individual scores contributing to diagnosis allocation are 
shown in table 5-10. Median urinary sodium (which did not contribute towards diagnosis allocation) 
of each group was CSW; 85 (IQR 72-109) and SIADH; 80 (IQR 49-126). 
Table 5-10: Individual scores contributing towards allocation of this study’s criteria 
 Number of times assessment criteria met 
All participants (N=34) Clinical Laboratory Fluid balance IVC Polyuria 
Participants with total score 
favouring CSW (hypovolaemia) 
(N=7) 
5 1 3 6 7 
Participants with total score 
favouring SIADH (euvolaemia) 
(N=27) 
21 26 22 23 5 
CSW=cerebral salt wasting. IVC=inferior vena cava. SIADH=syndrome of inappropriate anti-
diuretic hormone secretion 
 
To investigate whether this sub-population of 34 participants with complete data sets assessing 
clinical, laboratory, fluid balance, IVC ultrasound, and urinary output parameters, was 
representative of the study’s baseline-hyponatraemic population (n=176), these populations were 
compared (table 5-11). The population assessed by this study’s hyponatraemia causality criteria 
(n=34) appeared representative of the study’s baseline-hyponatraemic population (n=176). 
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Table 5-11: Comparison of study participants assessed by this study’s hyponatraemia 
causality criteria (n=34) with baseline-hyponatraemic population (n=176) 
 Participants with complete 
dataset for fluid balance 
assessment (%) 
N=34 
All hyponatraemic 
participants in this study (%) 
 
N=176 
HIV co-infection  
- Co-infected 
- Uninfected 
 
11 (32.4%) 
23 (67.6%) 
 
73 (41.5%) 
103 (58.5%) 
MRC TBM severity grade 
- 1 
- 2 
- 3 
 
10 (29.4%) 
20 (58.8%) 
4 (11.8%) 
 
66 (37.5%) 
88 (50.0%) 
22 (12.5%) 
Baseline plasma sodium 
severity 
- Mild 
- Moderate 
- Severe 
 
 
9 (26.5%) 
10 (29.4%) 
15 (44.1%) 
 
 
42 (23.9%) 
55 (31.3%) 
79 (44.9%) 
Survival by 3 months 
- Alive 
- Dead 
 
25 (73.5%) 
9 (26.5%) 
 
133 (75.6%) 
43 (24.4%) 
HIV=human immunodeficiency virus. MRC=Medical Research Council. N=number of participants. 
TBM=tuberculous meningitis.  
 
5.3.6.2 Urinary volume 
As a second novel analysis of hyponatraemia causality, the presence or absence of polyuria was 
used to allocate CSW (polyuria) or SIADH (non-polyuria) diagnoses, consistent with the clinical 
phenotypes of these two conditions. Baseline data were available for analysis in 142/176 (80.7%) 
hyponatraemic participants. Polyuria was present in 129/142 (90.8%) participants, with non-
polyuria urinary output present in 13/142 (9.2%) participants. This result differs from the first 
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causality analysis above (table 5-10), where 7/34 (20.6%) baseline-hyponatraemic participants were 
assigned a diagnosis of CSW. Polyuria, by a weight based definition, was present in most 
participants who were hyponatraemic at baseline, suggesting most participants may indeed have 
some degree of CSW (given SIADH would result in low-normal urinary volume) but not enough to 
impact upon clinical or laboratory criteria. The weighting given to polyuria in the first 
hyponatraemia causality analysis (table 5-10), i.e. 1 of 5 criteria, may be insufficient for assigning 
CSW, given polyuria is likely an important parameter in identifying CSW.   
5.3.6.3 Intravascular volume 
As a third novel analysis of hyponatraemia causality, the presence or absence of hypovolaemia by 
IVC ultrasound was used to allocate CSW (hypovolaemia) and SIADH (no hypovolaemia) 
diagnoses, again consistent with the clinical phenotypes of these two conditions. Baseline data were 
available for analysis for 54/176 (30.7%) hyponatraemic participants. Reduced intravascular 
volume, as defined in study methods, was used to allocate a diagnosis of CSW in 15/54 (27.8%) 
participants, with IVC ultrasound not suggestive of reduced intravascular volume in 33/54 (61.1%) 
participants.  
5.3.6.4 Urinary sodium 
As a fourth novel analysis of hyponatraemia causality, the degree of urinary sodium (≥ 100mmol/L, 
or <100mmol/L) was used to allocate CSW (hypovolaemia) and SIADH (no hypovolaemia) 
diagnoses, respectively, again consistent with the clinical phenotypes of these two conditions. Data 
were available for analysis for 125/176 (71.0%) hyponatraemic participants. Higher urinary sodium, 
as defined in study methods, was used to allocate CSW in 72/125 (57.6%) participants, with IVC 
ultrasound not suggestive of reduced intervascular volume in 53/125 (42.4%) participants.  
5.3.7 Re-assigning causality of hyponatraemia during the first 30 days of anti-tuberculous 
chemotherapy 
Causality of hyponatraemia was reassigned at each of day 3, 7, 14, 21, and 28 based on parameters 
available at each of these time points. Assessments were performed using urinary volume, 
intravascular volume (ultrasound), and urinary sodium methods, given lack of laboratory data 
(required for this study’s criteria) at these time points. These diagnosis allocations are shown in 
table 5-12. 
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Table 5-12: Allocation of hyponatraemia diagnosis at time points after baseline 
Day of 
testing 
Participants with plasma sodium <135 
mmol/L and urinary output 
measurement at time point 
Urinary output criteria (polyuria is defined 
as urine output ≥ 30mls/Kg in 24 hours) 
  CSW SIADH 
Day 3 74 73 (98.6%) 1 (1.4%) 
Day 7 87 84 (96.6%) 2 (2.3%) 
Day 14 67 67 (100%) 0 (0%) 
Day 21 61 59 (96.7%) 2 (3.3%) 
Day 28 23 23 (100%) 0 (0%) 
 
Day of 
testing 
Participants with plasma sodium <135 
mmol/L and IVC ultrasound 
measurement at time point 
IVC Ultrasound criteria for hypo- and 
euvolaemia 
  CSW SIADH 
Day 3 20 7 (35.0%) 12 (60%) 
Day 7 26 9 (34.6%) 13 (50.0%) 
Day 14 17 7 (41.1%) 7 (41.1%) 
Day 21 16 7 (43.8%) 8 (50.0%) 
Day 28 3 2 (66.7%) 1 (33.3%) 
 
Day of 
testing 
Participants with plasma sodium <135 
mmol/L and IVC ultrasound 
measurement at time point 
Urinary sodium criteria for hypo- and 
euvolaemia (CSW urinary sodium is 
defined as ≥100mmol/L) 
  CSW SIADH 
Day 3 54 29 (53.7%) 25 (46.3%) 
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Day 7 56 31 (55.4%) 25 (44.6%) 
Day 14 42 26 (61.9%) 16 (38.1%) 
Day 21 32 20 (62.5%) 12 (37.5%) 
Day 28 13 7 (53.8%) 6 (46.2%) 
Where the sum of CSW and SIADH participants does not match the number of participants with 
plasma sodium and urinary output, or with plasma sodium and ultrasound (whichever is the 
corresponding total column), the remaining cases (making up the sum total) were labelled as 
‘Unknown’ by the criteria (see above methods). For IVC ultrasound, ‘day 28’ scans were performed 
at day 30 (+/- 1 day) and are here associated with plasma sodium values at day 28 +/- 1 day. 
CSW=cerebral salt wasting. IVC=inferior vena cava. SIADH=syndrome of inappropriate anti-
diuretic hormone secretion. 
 
CSW accounted for nearly all diagnoses of hyponatraemia when using urinary output criteria. Using 
IVC ultrasound criteria, participants were allocated to CSW and SIADH in nearly equal measure. 
Using urinary sodium criteria, participants were predominantly allocated to CSW and SIADH.  
Allocation of hyponatraemia diagnosis at time points after baseline, using urinary output, IVC 
ultrasound, and urinary sodium, was then performed stratified by severity of hyponatraemia at that 
time point (table 5-13). CSW did not appear a more frequent diagnosis with increased severity of 
hyponatraemia; however, CSW was more frequent at later time points independent of 
hyponatraemia severity (table 5-12). Interestingly cases of SIADH were proportionally more 
frequent at worsening hyponatraemia severity (consistent with positive correlation between plasma 
sodium and urinary sodium in profound hyponatraemia vs. negative correlation between these 
parameters with mild or moderate hyponatraemia; albeit without statistical significance). A 
reduction in urinary sodium when plasma sodium is reduced (i.e. positive correlation) may reflect 
depletion of urinary sodium in profound hyponatraemia.  
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Table 5-13: Allocation of hyponatraemia diagnosis at time points after baseline, by severity of hyponatraemia at that time point 
Day of 
testing 
Severity Participants with 
plasma sodium 
<135 mmol/L 
and urinary 
output 
measurement at 
time point 
Urine output 
criteria 
Participants with 
plasma sodium 
<135 mmol/L 
and IVC 
ultrasound 
measurement at 
time point 
IVC ultrasound 
criteria 
Participants with 
plasma sodium 
<135 mmol/L 
and urinary 
sodium  
measurement at 
time point 
Urinary sodium 
criteria 
  N CSW SIADH N CSW SIADH  CSW SIADH 
Day 3 Mild 11 11 
(100%) 
0  
(0%) 
2 2  
(100%) 
0  
(0%) 
22 13 
(59.1%) 
9 
(40.9%) 
Day 3 Moderate 31 31 
(100%) 
0  
(0%) 
5 3 
(60.0%) 
2 
(40.0%) 
17 12 
(70.6%) 
5 
(29.4%) 
Day 3 Profound 17 16 
(94.1%) 
1 
(5.9%) 
9 3 
(33.3%) 
5 
(66.6%) 
15 4 
(26.7%) 
11 
(73.3%) 
 
Day 7 Mild 40 37 
(92.5%) 
0  
(0%) 
3 3  
(100%) 
0  
(0%) 
24 13 
(54.2%) 
11 
(45.8%) 
Day 7 Moderate 26 26 
(100%) 
0  
(0%) 
14 5 
(35.7%) 
4 
(28.6%) 
16 13 
(81.3%) 
3 
(18.8%) 
Day 7 Profound 21 21 
(100%) 
0  
(0%) 
4 0  
(0%) 
1 
(25.0%) 
16 5 
(31.3%) 
11 
(68.8%) 
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Day 
14 
Mild 32 32 
(100%) 
0 
(0%) 
3 0  
(0%) 
0  
(0%) 
18 13 
(72.2%) 
5 
(27.8%) 
Day 
14 
Moderate 20 20 
(100%) 
0  
(0%) 
7 3 
(42.9%) 
0  
(0%) 
15 12 
(80.0%) 
3 
(20.0%) 
Day 
14 
Profound 15 15 
(100%) 
0  
(0%) 
3 1 
(33.3%) 
0  
(0%) 
9 1 
(11.1%) 
8 
(88.9%) 
 
Day 
21 
Mild 32 31 
(96.9%) 
1 
(3.1%) 
3 0  
(0%) 
1 
(33.3%) 
18 13 
(72.2%) 
5 
(27.8%) 
Day 
21 
Moderate 20 19 
(95.0%) 
1 
(5.0%) 
5 3 
(60.0%) 
1 
(20.0%) 
9 4 
(44.4%) 
5 
(55.6%) 
Day 
21 
Profound 9 9  
(100%) 
0  
(0%) 
4 2 
(50.0%) 
1 
(25.0%) 
5 3 
(60.0%) 
2 
(40.0%) 
 
Day 
28 
Mild 7 7  
(100%)  
0  
(0%) 
1 1  
(100%) 
0  
(0%) 
3 3  
(100%) 
0  
(0%) 
Day 
28 
Moderate 7 7  
(100%) 
0  
(0%) 
1 1  
(100%) 
0  
(0%) 
3 2 
(66.6%) 
1 
(33.3%) 
Day 
28 
Profound 9 9  
(100%) 
0  
(0%) 
2 1 
(50.0%) 
0  
(0%) 
7 2 
(28.6%) 
5 
(71.4%) 
‘Severity’ is defined as severity of hyponatraemia, as per study methods. Where the sum of CSW and SIADH participants does not match 
the number of participants with plasma sodium and urinary output, or match plasma sodium and ultrasound (whichever is the corresponding 
total column), the remaining cases (making up the sum total) were labelled as ‘Unknown’ by the criteria (see above methods). For IVC 
ultrasound, ‘day 28’ scans were performed at day 30 (+/- 1 day) and are here associated with plasma sodium values at day 28 +/- 1 day. 
CSW=cerebral salt wasting. IVC=inferior vena cava. N=number of participants. SIADH=syndrome of inappropriate anti-diuretic hormone 
secretion. 
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5.3.8 Sodium parameters during the first 30 days of anti-tuberculous chemotherapy 
The number of plasma and urinary sodium, serum and urinary osmolality, and fluid balance 
parameters, measured at each time point are shown in table 5-14. A higher number of tests were 
performed at earlier time points largely due to deaths of participants given the high mortality 
associated with TBM, or discharge from the study site.  
Table 5-14: The number of tests at each time point 
 Day 0 
tests 
Day 3 
tests 
Day 7 
tests 
Day 14 
tests 
Day 21 
tests 
Day 28 
tests 
Plasma sodium (mmol/L) 190 94 140 128 122 60 
Urinary sodium (mmol/L) 144 62 71 61 50 19 
Serum osmolality (mOsm/Kg) 158 127 140 140 125 53 
Urinary osmolality (mOsm/Kg) 152 126 138 133 126 53 
24-hour fluid balance (mls) 166 138 137 135 127 66 
24-hour fluid output (mls) 166 136 136 134 126 6 
Each number represents the number of tests performed. Values of tests are not displayed in this 
table. 
 
Median sodium parameters with IQR are shown in figure 5-9, for all participants, and stratified by 
HIV co-infection status, and by MRC TBM severity grade. These data illustrate a trend of lower 
plasma sodium, higher urinary sodium, higher urinary osmolality, and higher urinary output in HIV 
co-infected participants vs. HIV uninfected participants. This same trend was seen in more severe 
TBM disease (higher MRC TBM severity grade), in addition to lower serum osmolality. 
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Figure 5-9: Sodium parameters shown in total, and stratified by HIV co-infection and TBM severity grade 
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Data are shown for plasma sodium (panels A-C), urinary sodium (panels D-F), serum osmolality (panels G-I), urinary osmolality (panels J-
L), and urinary output (panels M-O). Median values are shown for each parameter at each time point. The size of each median value point 
represents the number of samples contributing to the median value at this point. Median values are connected by a central line. The 
difference between upper and lower error bars represents the interquartile range.  
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Individual participant plasma sodium data is shown by HIV status (figure 5-10) and by MRC TBM 
severity grade (figure 5-11).  
Figure 5-10: Individual participant plasma sodium over the first 30 days of anti-TB 
chemotherapy, by HIV co-infection status 
 
Individual points represent individual participants’ measurements of plasma sodium. A central blue 
line of best fit is surrounded by grey shading defining the 95% confidence interval. Light grey lines 
represent individual participant plasma sodium trends. 
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Figure 5-11: Individual participant plasma sodium over the first 30 days of anti-TB 
chemotherapy, by TBM severity grade 
 
 
Individual points represent individual participants’ measurements of plasma sodium. A central blue 
line of best fit is surrounded by grey shading defining the 95% confidence interval. Light grey lines 
represent individual participant plasma sodium trends. Grade represents Medical Research Council 
tuberculous meningitis severity grade. 
 
5.3.9 The use of hypertonic saline therapy 
Electronic data describing hypertonic saline 3%, saline 0.9%, and furosemide 40mg, including fluid 
volume, and time and date of administration, were available for 205/208 (98.6%) participants. 
Mannitol use at HTD is exceptionally unusual; therefore, data for this fluid was not collected.  
There were 19 doses of furosemide used in 6 participants (totaling 420mg). In total 17004 sodium 
containing therapies (3% or 0.9% sodium chloride) were used in 169/205 (82.4%) participants. In 
total 1,194 litres of hypertonic saline 3% were used in 142/205 (69.3%) participants (mean ~8.4 
litres per participant). 
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Of these 1,194 litres of hypertonic saline 3%, 777 litres (65.0%) were administered to 70 HIV co-
infected participants, and 418 litres (35.0%) were administered to 72 HIV uninfected participants. 
By MRC TBM severity grade, 150 litres (12.6%) were administered to 40 grade 1 participants, 761 
litres (63.7%) were administered to 80 grade 2 participants, and 283 litres (23.7%) were 
administered to 22 grade 3 participants. During the first 30 days of from study randomisation, 132 
participants received 673 litres of hypertonic saline 3% (mean ~5.1 litres per participant).  
Use of hypertonic saline 3% vials per day was greatest in the most severely ill participants. 
However total use was lower in the most severely ill participants due to earlier death. In a treatment 
subgroup of participants with hyponatraemia at baseline (n=176), hypertonic saline 3% 
administration was stratified by baseline hyponatraemia severity; mild hyponatraemia: 31 litres, 
17/42 (40.5%) participants; moderate hyponatraemia: 57 litres, 37/59 (62.7%) participants; 
profound hyponatraemia: 172 litres, 65/75 (86.7%) participants. The use of hypertonic saline 3% in 
the treatment plans of two individual participants is described in figures 5-12 and 5-13.  
5.3.10 Assessing individual participants 
Individual participant analysis was performed for two contrasting participants (figures 5-12 and 5-
13), with measured variables, outcome, and use of hypertonic saline 3%. Participants were selected 
to reflect severe disease (baseline grade 3, HIV co-infected), and non-severe disease (baseline grade 
1, HIV uninfected), respectively, with the two participants with the two most complete datasets then 
selected.  
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Figure 5-12: Sodium parameters in a grade 3 HIV co-infected participant with TBM 
 
Data are shown for a HIV co-infected participant with grade 3 TBM at baseline. Plasma sodium 
values were as follows: baseline: 123 mmol/L, day 7: 121 mmol/L, day 15: 118 mmol/L, day 21: 
121 mmol/L, day 28: 122 mmol/L. Sodium represents plasma sodium and urine sodium measured in 
mmol/L. Osmolality represents plasma and urine osmolality measured in mOsm/Kg. Blue arrows 
indicate the days of hypertonic saline 3% administration, with the black number above each arrow 
indicating the number of 100mls vials of hypertonic saline 3% received on that day. HIV=human 
immunodeficiency virus. Hr=hour. Kg=kilogram. TBM=tuberculous meningitis.  
 
  
 
213 
 
Figure 5-13: Sodium parameters in a grade 1 HIV uninfected participant with TBM 
 
Data are shown for a HIV uninfected participant with grade 1 TBM at baseline. Plasma sodium 
values were as follows: plasma sodium values were as follows: baseline (day 0): 127 mmol/L, day 
3: 126 mmol/L, day 7: 121 mmol/L, day 14: 127 mmol/L, day 21: 130 mmol/L. Sodium represents 
plasma sodium and urine sodium measured in mmol/L. Osmolality represents plasma and urine 
osmolality measured in mOsm/Kg. Blue arrows indicate the days of hypertonic saline 3% 
administration, with the black number above each arrow indicating the number of 100mls vials of 
hypertonic saline 3% received on that day. HIV=human immunodeficiency virus. Hr=hour. 
Kg=kilogram. TBM=tuberculous meningitis.  
 
In these two illustrations the following can be observed: firstly, more hypertonic saline 3% is 
received in the grade 3 participant (figure 5-13), who remains grade 3 throughout the illness, with 
death occurring on day 32. Plasma sodium remains low in this grade 3 participant (122 mmol/L on 
day 28) but shows partial recovery in the grade 1 participant (figure 5-14). Urinary outputs are at 
least two times greater in the grade 3 participant (reaching more than 5000mls). During a period of 
hypertonic saline 3% administration urinary sodium rises in both participants. 
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5.3.11 Clinical outcome 
5.3.11.1 Plasma sodium and clinical outcome 
The associations between baseline plasma sodium and clinical outcomes are shown by subgroup in 
table 5-15.   
Table 5-15: Baseline plasma sodium and clinical outcomes 
 No. participants Plasma sodium 
(mmol/L) 
P value 
 
All participants 
(Median[IQR]) 
190 126 (125-127)   
Survival by 3 months  
(Median[IQR]) 
- Alive 
- Dead 
 
 
142 
48 
 
 
126 (122-131) 
125 (118-130) 
 
 
0.14 
Neurological complications by 3 months 
(Median[IQR]) 
- No 
- Yes 
 
 
141 
49 
 
 
126 (122-131) 
124 (120-129) 
 
 
0.05 
Median plasma sodium value is shown with IQR. P value represents Wilcoxon rank sum test; given 
plasma sodium values were non-normally distributed. HIV=human immunodeficiency virus. 
IQR=interquartile range. MRC=Medical Research Council. TBM=tuberculous meningitis. 
 
A trend towards a significant association was seen between lower baseline plasma sodium and 
neurological complication by 3 months (p=0.05). In figure 5-14 sodium parameters are shown in 
total, and stratified by survival by 3 months, and by neurological complications by 3 months. Data 
show trends of reduced survival by 3 months, and more neurological complications by 3 months, in 
participants with lower plasma sodium, and participants with higher urinary output.  
 
 
215 
 
Figure 5-14: Sodium parameters shown in total, and stratified by survival by 3 months, and by neurological complications by 3 
months 
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Data are shown for plasma sodium (panels A-B), urinary sodium (panels C-D), serum osmolality (panels E-F), urinary osmolality (panels G-
H), and urinary output (panels I-J). ). Median values are shown for each parameter at each time point. The size of each median value point 
represents the number of samples contributing to the median value at this point. Median values are connected by a central line. The 
difference between upper and lower error bars represents the interquartile range.  
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Plasma sodium was significantly lower at all time points after baseline in participants who died 
by 3 months (figure 5-15) and in participants who experienced neurological complications by 3 
months (figure 5-16). 
Figure 5-15: Plasma sodium stratified by survival by 3 months 
 
For each individual boxplot, the central horizontal bar represents the median value. The box 
contains data between 3rd quartile (upper end of box) and 1st quartile (lower end of box). 
Vertical lines above and below each box extend to the most extreme data point that is within 
1.5x the vertical height of the box. Dots represent individual data points. ‘Alive’ represents 
participants alive by 3 months. ‘Dead’ represents participants who died by 3 months. P values 
represent statistical comparison of groups by the Wilcoxon rank sum test, given data across all 
time points included non-normally distributed data. 
 
 
 
 
 
 
 
  
 
221 
 
Figure 5-16: Plasma sodium stratified by neurological complications by 3 months 
 
For each individual boxplot, the central horizontal bar represents the median value. The box 
contains data between 3rd quartile (upper end of box) and 1st quartile (lower end of box). 
Vertical lines above and below each box extend to the most extreme data point that is within 
1.5x the vertical height of the box. Dots represent individual data points. ‘No’ represents 
participants who did not experience neurological complications by 3 months. ‘Yes’ represents 
participants who experienced neurological complications by 3 months.  
 
5.3.11.2 Urinary output and clinical outcome 
24-hour urinary output was significantly higher at all time points after baseline in participants 
who died by 3 months (figure 5-17), and in participants who experienced neurological 
complications by 3 months (figure 5-18). An increased urinary volume favours a diagnosis of 
CSW over SIADH, in those participants with poor outcomes. However, in data assessing 
hyponatraemia causality (table 5-13 and 5-14), intravascular assessment (by IVC ultrasound) 
did not support intravascular depletion in most participants (widespread intravascular depletion 
would have supported a conclusion of CSW as the common aetiology of hyponatraemia in 
TBM).   
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Figure 5-17: Urinary output stratified by survival by 3 months 
 
For each individual boxplot, the central horizontal bar represents the median value. The box 
contains data between 3rd quartile (upper end of box) and 1st quartile (lower end of box). 
Vertical lines above and below each box extend to the most extreme data point that is within 
1.5x the vertical height of the box. Dots represent individual data points. P values represent 
statistical comparison of groups by the Wilcoxon rank sum test.  
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Figure 5-18: Urinary output stratified by neurological complications by 3 months 
 
For each individual boxplot, the central horizontal bar represents the median value. The box 
contains data between 3rd quartile (upper end of box) and 1st quartile (lower end of box). 
Vertical lines above and below each box extend to the most extreme data point that is within 
1.5x the vertical height of the box. Dots represent individual data points. P values represent 
statistical comparison of groups by the Wilcoxon rank sum test.  
 
5.3.11.3 IVC ultrasound and clinical outcome 
In a restrictive analysis of participants undergoing IVC ultrasound, hypovolaemia assessed by 
IVC ultrasound is shown stratified by survival by 3 months, and by neurological complications 
by 3 months, in tables 5-16 and 5-17 respectively. Hypovolaemia assessed by IVC ultrasound 
was not predictive of death by 3 months, or of neurological complications by 3 months, in this 
population.  
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Table 5-16: Hypovolaemia by IVC ultrasound stratified by survival by 3 months 
Day of 
assessment 
Number of 
participants 
Hypovolaemia  
by IVC ultrasound 
Number of 
participants 
No hypovolaemia by 
IVC ultrasound 
 Dead (%) Alive (%)  Dead (%) Alive (%) 
0 18 5 (27.8%) 13 (72.2%) 38 9  
(23.7%) 
29 (76.3%) 
3 13 1  
(7.7%) 
12 (92.3%) 24 6  
(25.0%) 
18 (75.0%) 
7 13 2 (15.4%) 11 (84.6%) 17 5  
(29.4%) 
12 (70.6%) 
14 15 3 (20.0%) 12 (80.0%) 15 6  
(40.0%) 
9  
(60.0%) 
21 12 3 (25.0%) 9  
(75.0%) 
23 9  
(39.1%) 
14 (60.9%) 
30 * 5 2 (40.0%) 3  
(60.0%) 
3 2  
(66.6%) 
1  
(33.3%) 
* For IVC ultrasound, ‘day 28’ scans were performed at day 30 (+/- 1 day). For consistency 
throughout this results chapter they are again referred to as ‘day 28’ here. IVC=inferior vena 
cava. 
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Table 5-17: Hypovolaemia by IVC ultrasound stratified by neurological complications by 3 months 
Day of assessment Number of 
participants 
Hypovolaemia  
by IVC ultrasound 
Number of 
participants 
No hypovolaemia by IVC ultrasound 
 Neurological 
complications  
 
(%) 
No neurological 
complications  
(%) 
 Neurological 
complications  
 
(%) 
No neurological 
complications (%) 
0 18 3 (16.7%) 15 (83.3%) 38 8 (21.1%) 30 (78.9%) 
3 13 0 (0%) 13 (100%) 24 3 (12.5%) 21 (87.5%) 
7 13 2 (15.4%) 11 (84.6%) 17 5 (29.4%) 12 (70.6%) 
14 15 1 (6.7%) 14 (93.3%) 15 3 (20.0%) 12 (80.0%) 
21 12 3 (25.0%) 9 (75.0%) 23 7 (30.4%) 16 (69.6%) 
30 * 34 2 (5.9%) 32 (94.1%) 3 1 (33.3%) 2 (66.6%) 
* For IVC ultrasound, ‘day 28’ scans were performed at day 30 (+/- 1 day). For consistency throughout this results chapter they are again referred to as ‘day 28’ 
here. IVC=inferior vena cava.
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5.3.11.4 Urinary sodium and clinical outcome 
Clinical outcomes stratified by urinary sodium are shown in figures 5-19 and 5-20, respectively. 
Urinary sodium was significantly higher in participants who died by 3 months, at both baseline 
and day 3, but not thereafter. Urinary sodium was significantly higher in participants who 
experienced neurological complications by 3 months, at baseline, day 3, and day 14. 
Figure 5-19: Urinary sodium stratified by survival by 3 months 
 
For each individual boxplot, the central horizontal bar represents the median value. The box 
contains data between 3rd quartile (upper end of box) and 1st quartile (lower end of box). 
Vertical lines above and below each box extend to the most extreme data point that is within 
1.5x the vertical height of the box. Dots represent individual data points. P values represent 
statistical comparison of groups by the Wilcoxon rank sum test.  
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Figure 5-20: Urinary sodium stratified by neurological complications by 3 months 
 
For each individual boxplot, the central horizontal bar represents the median value. The box 
contains data between 3rd quartile (upper end of box) and 1st quartile (lower end of box). 
Vertical lines above and below each box extend to the most extreme data point that is within 
1.5x the vertical height of the box. Dots represent individual data points. P values represent 
statistical comparison of groups by the Wilcoxon rank sum test.  
 
5.4 Discussion 
Hyponatraemia is commonly associated with TBM, although its pathogenesis, how it impacts 
upon clinical disease, and best management strategies, are poorly understood. Hyponatraemia 
may increase cerebral oedema, whilst its causative disease process also results in hypovolaemia, 
reduced cerebral perfusion, and worsening brain injury. Here I present a large and 
comprehensive descriptive analysis of hyponatraemia in HIV co-infected and HIV uninfected 
Vietnamese adults with TBM. 
I begin by describing plasma sodium at baseline, stratified by HIV co-infection and by TBM 
severity grade. I then separate baseline hyponatraemic participants into mild, moderate and 
severe severity categories, describing baseline plasma sodium and its associated parameters by 
these severity groups. Next, I correlate lower baseline plasma sodium with markers of increased 
disease severity; higher CSF opening pressure, more neutrophilic CSF, and lower CSF/blood 
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glucose ratio, in addition to higher plasma cortisol which likely indicates increased host stress. I 
explore causality of hyponatraemia, initially at baseline, and then at further time points, using 
adapted causality-assessment criteria, followed by more exploratory methods. I then 
significantly correlate lower plasma sodium with increased urinary output, and with increased 
death by 3 months, at time points after baseline. Finally, I join together a clinical picture of 
hyponatraemia in TBM; low plasma sodium, low serum osmolality, high urinary sodium, and 
high urinary osmolality. Initially, SIADH appears more common a cause of hyponatraemia; 
however, as treatment progresses increasing urinary output heralds an increased risk of death. In 
this discussion I will now address these points in more detail. 
I first demonstrate that hyponatraemia is a commonly associated abnormality of TBM, with 
hyponatraemia profound in almost 50% of cases in this study. Baseline plasma sodium was 
significantly lower with higher MRC TBM severity grade. Additionally, there were significant 
associations between lower plasma sodium, and higher lumbar CSF opening pressure, elevated 
baseline CSF neutrophil percentage, elevated absolute CSF neutrophils, and lower CSF/blood 
glucose ratio. These four parameters; MRC TBM severity grade, lumbar CSF opening pressure, 
CSF neutrophils, and CSF/blood glucose ratio, represent severity, ICP, and inflammation. The 
significant association between lower plasma sodium at baseline and each of these suggests 
hyponatraemia is a feature of more severe TBM disease and more severe intracerebral 
inflammation. Assessment of baseline plasma sodium by its severity, i.e. mild, moderate, or 
profound, demonstrated that profound hyponatraemia associated more frequently with HIV co-
infection (vs. HIV uninfected), and with higher MRC TBM severity grade. Both HIV co-
infection and high MRC TBM severity grade are association with excessive intracerebral 
inflammation,[18] indicating this inflammation as a possible mechanism of profound 
hyponatraemia. 
Secondly, lower baseline plasma sodium was significantly associated with increased death by 3 
months, and with neurological complications by 3 months, at all time points after baseline. Low 
plasma sodium after baseline appears to identify individuals with poor prognosis. A lack of 
significant association (of plasma sodium, with increased death or with increased neurological 
complications) at baseline may reflect the uncertain course and outcome of TBM disease when 
predicting at baseline; individuals with apparently stable disease at baseline may develop severe 
complications, and these individuals are often difficult to identify. This concept is further 
illustrated in the two illustrated individual participant datasets; plasma sodium is persistently 
low in the severe individual with poor outcome.  
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Thirdly, these baseline parameters identify a clinical pattern of hyponatraemia in TBM. Baseline 
plasma sodium significantly correlated with baseline serum osmolality, baseline urinary sodium, 
and baseline urinary osmolality. Interestingly urinary sodium levels appear to reduce when 
hyponatraemia becomes profound. It is possible that blood sodium-depletion eventually results 
in reducing urinary sodium, or alternatively that compensatory sodium-retention mechanisms 
are able to function when hyponatraemia becomes so severe. Interestingly a correlation was 
seen between baseline plasma sodium and baseline plasma cortisol. This may represent a stress 
response to TBM, with greater stress in more severe disease (where plasma sodium is lower). 
Whilst an Addisonian state may cause hyponatraemia (thereby associating low cortisol with low 
sodium), here it seems likely that plasma cortisol is responding to the hyponatraemia, rather 
than causing it. 
Data suggested SIADH may cause hyponatraemia initially; however, causality analyses were 
complex, and most hyponatraemic participants were in fact polyuric (with variable intravascular 
volume depletion). Critically, 24-hour urinary outputs were significantly higher at all time 
points after baseline in participants who died by 3 months, and in participants who experienced 
neurological complications by 3 months, illustrating the importance of urinary output in clinical 
outcome 
A tetrad of low plasma sodium, low serum osmolality, high urinary sodium and high urinary 
osmolality, followed by persistent hyponatraemia and very high urinary output in individuals 
with poor clinical outcome, describes a common set of events seen in clinical practice; rapid 
elevation in urine output heralds haemodynamic compromise, neurological deterioration, and 
poor outcome. This clinical picture moves away from the traditional method of focusing on 
assigning unique and single causality to hyponatraemia of TBM. This is often done to ascribe 
CSW or SIADH diagnoses; yet this is hugely challenging due to complicated criteria and 
subjective extracellular fluid assessments. The causality analyses performed in this manuscript 
illustrate the complexity of methodology and flaws in a causality-assignment approach.  
I argue that using distinct labels of CSW or SIADH is not hugely beneficial to clinicians. What 
is more important is that the common model of TBM-hyponatraemia (low plasma sodium, low 
serum osmolality, high urinary sodium, high urinary osmolality, followed by persistent 
hyponatraemia and an increasing urinary output) is monitored for and recognised. A systematic 
approach to hyponatraemia assessment should be followed, with causes such as vomiting, 
adrenal insufficiency and drugs screened for, and excluded or addressed. Crucially, ascribing a 
diagnosis of SIADH, followed by initiation of a fluid restriction strategy (as is common for 
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SIADH in non-TBM disease), has potential for harm in large urine volume hyponatraemic 
states. High urine volumes and haemodynamic insufficiency associate with death in TBM. 
Volume replacement appears critical to maintain blood pressure and cerebral perfusion in these 
scenarios (although optimal sodium containing therapy is less certain). 
This study has limitations. As discussed, any approach of allocating hyponatraemia causality (to 
CSW or SIADH) in TBM is likely too simplistic; both may occur in tandem, in sequence, or 
together with other causes such as vomiting. Hyponatraemia causality at baseline may not 
necessarily reflect ongoing causality. Analysis methods for assigning hyponatraemia causality 
are arbitrary and lack a strong evidence base. The use of ‘2 of 4’ or ‘2 of 5’ parameters to assign 
causality avoids a single erroneous result assigning erroneous hyponatraemia causality. Yet such 
an approach assumes equal weighting of contributing parameters (each scoring 1 point if 
present), and that when two parameters are present this is sufficient to assign hyponatraemia 
causality. In this study there were limitations in the data used to assign causality of 
hyponatraemia. IVC ultrasound data was not available for all participants, nor was a fluid 
balance clinical assessment. For this reason, hyponatraemia causality was assessed only in a 
smaller sub-population for whom all ‘hypovolaemia’ parameters; clinical, laboratory, fluid 
balance, IVC ultrasound, and urine output, were available. This may introduce bias; however, 
population comparison in this study suggested the population undergoing first causality 
assessment (n=34) was representative of the total study population. Even with a complete 
dataset, care must be taken in interpretation of parameters. Hypovolemia assessment is used as a 
proxy for extracellular fluid assessment and is not the same. Clinical signs used to assess 
hypovolaemia are subjective. Laboratory parameters such as haemoglobin and urea may only 
change at a late stage of hypovolaemia. Fluid balance may appear normal due to aggressive 
fluid resuscitation therapy (to match large urine outputs in a hypovolaemic individual). IVC 
ultrasound views may be challenging to obtain (when obscured by bowel gas and fat), and 
significant IVC variability may not necessarily reflect hypovolaemia. 
In this study, when assigning non-CSW non-SIADH causes of hyponatraemia, an additional 
limitation was the lack of data recording diarrhoea at baseline; however, it is unlikely that 
diarrhoea would be a frequent ailment in TBM, and less so a cause of hyponatraemia. Finally, 
causality of hyponatraemia is assigned independently of administration of confounding sodium-
containing therapies. Such therapies, including hypertonic 3% saline, may temporarily mask 
hyponatraemia, or cause rebound sodium-excretion effects after administration. For these 
reasons, a baseline assessment of hyponatraemia causality was exploratory only, and performed 
only where available data facilitated this. 
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An additional limitation of this study is that it is unable to link use of sodium-containing 
therapies to an effect on clinical outcome. Use of hypertonic saline 3% was more frequent in 
more severe TBM disease, given lower plasma sodium, for longer time periods, and worse 
neurological condition. Whether hypertonic saline 3% improves clinical outcomes in TBM 
cannot be answered by this data and requires a randomised controlled trial. Evidence supporting 
optimal sodium-containing therapies in TBM would be highly useful clinically and should be a 
future research priority. Reflecting the heterogeneity of individual participants is also a 
challenge for this study, where data is combined into, and compared between, groups. For this 
reason, two individual participants were shown in detail, to illustrate the complexities of 
analysing multiple sodium parameters and making patient decisions. 
Strengths of this study are that it is large and contains baseline and longitudinal data describing 
plasma sodium and associated parameters, for adults with TBM across a variety of TBM disease 
phenotypes. As part of two clinical trials, demographic, baseline, and outcome data were 
collected, strictly following trial protocols and standard operating procedures.  
In conclusion, this study describes plasma sodium and associated parameters during the first 30 
days of anti-TB chemotherapy. Baseline plasma sodium was significantly lower with more 
severe TBM, higher lumbar CSF opening pressure, and more inflammatory CSF. After baseline, 
lower plasma sodium and higher 24-hour urinary outputs strongly predicted poor outcomes. The 
mechanism of hyponatraemia in TBM appears to be through renal loss of sodium (with 
polyuria), with data suggesting this process is driven by intracerebral inflammation and ICP. 
Hyponatraemia causality assessment criteria such as those used in this study may place 
insufficient importance on urinary volume, and lack an evidence base to separate ‘high’ urinary 
sodium of SIADH from ‘higher’ urinary sodium of CSW. Persistent hyponatraemia and rising 
urinary output should be closely monitored for, and fluid restriction avoided in most cases. 
Further data is urgently required to guide best management approaches for TBM-associated 
hyponatraemia.   
5.5 Publications related to this chapter 
The methods described within this study are published in the research protocols below: 
1. Adjunctive dexamethasone for the treatment of HIV-uninfected adults with tuberculous 
meningitis stratified by Leukotriene A4 hydrolase genotype (LAST ACT): Study protocol for a 
randomised double blind placebo controlled non-inferiority trial 
Joseph Donovan, Nguyen Hoan Phu, Le Thi Phuong Thao, Nguyen Huu Lan, Nguyen Thi 
Hoang Mai, Nguyen Thi Mai Trang, Nguyen Thi Thu Hiep, Tran Bao Nhu, Bui Thi Bich Hanh, 
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Vu Thi Phuong Mai, Nguyen Duc Bang, Do Chau Giang, Dang Thi Minh Ha, Jeremy Day, 
Nguyen TT Thuong, Nguyen Nang Vien,  Ronald B. Geskus, Tran Tinh Hien, Evelyne 
Kestelyn, Marcel Wolbers, Nguyen Van Vinh Chau, Guy E. Thwaites 
Wellcome Open Research 2018 Mar 20;3:32 
2. Adjunctive dexamethasone for the treatment of HIV-infected adults with tuberculous 
meningitis (ACT HIV): Study protocol for a randomised controlled trial 
Joseph Donovan, Nguyen Hoan Phu, Nguyen Thi Hoang Mai, Le Tien Dung, Darma Imran, 
Erlina Burhan, Lam Hong Bao Ngoc, Nguyen Duc Bang, Do Chau Giang, Dang Thi Minh Ha, 
Jeremy Day, Le Thi Phuong Thao, Nguyen TT Thuong, Nguyen Nang Vien, Ronald B. Geskus, 
Marcel Wolbers, Raph L. Hamers, Reinout van Crevel, Mugi Nursaya, Kartika Maharani, Tran 
Tinh Hien, Kevin Baird, Nguyen Huu Lan, Evelyne Kestelyn, Nguyen Van Vinh Chau, Guy E. 
Thwaites 
Wellcome Open Research 2018 018 Jun 20;3:31 
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Chapter 6 
Discussion 
6.1 What were the goals of this thesis? 
This thesis set the ambitious goal of improving diagnosis and understanding of the 
pathophysiology of TBM. TBM is a devastating neurological disease with high morbidity and 
mortality. Poor clinical outcomes from TBM are likely multifactorial. Clinically TBM is hard to 
recognise, with clinical presentation overlapping with that of other diseases. Diagnostic tools are 
insufficiently sensitive, contributing to delayed diagnosis. Multiple disease complications are 
hard to predict, and their best management is frequently uncertain with a limited evidence base 
to guide patient management in TBM. Improving diagnosis and further understanding 
pathogenesis may allow earlier recognition of both TBM and its complications, and pave the 
way for novel treatment approaches. This could lead to further clinical trials to ascertain best 
management practice in TBM.   
As such, the goals of this thesis were divided into six chapters. Firstly, I have provided a general 
overview of TBM, discussing epidemiology, pathogenesis, diagnosis, monitoring and treatment. 
Whilst TBM data are not frequently published, several research groups are performing TBM 
research, therefore an up to date review of this field is necessary. In chapter two I have 
presented a prospective randomised diagnostic comparison study of Ultra and Xpert in TBM. 
The goal of this chapter was to assess for diagnostic superiority of the new Ultra cartridge over 
Xpert in TBM, i.e. provide an evidence base supporting use of Ultra in TBM in place of Xpert, 
consistent with current WHO advice.[167] In chapter three I have described the 
immunomodulatory influence of S. stercoralis co-infection on pathogenesis and intracerebral 
inflammation. Here my goal was to assess whether co-infection with the common helminth S. 
stercoralis was associated with less severe presenting phenotype, reduced neuroinflammation 
and improved clinical outcomes in TBM. Biological plausibility for this study derived from the 
known immunomodulation associated with helminth co-infection, and the detrimental effect of 
severe neuroinflammation in TBM. In chapter four I have evaluated whether ultrasound 
assessment of ONSD identifies severe disease, brain imaging abnormalities, and poor clinical 
outcomes in TBM. Given most neuro-complications of TBM have a final common pathway of 
elevated ICP, detection of this elevated ICP (by measurement of ONSD which becomes 
distended under elevated ICP) may have a role in TBM monitoring. In chapter five, I have 
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described the complexity of hyponatraemia in TBM, by longitudinal measurement of plasma 
sodium and its associated parameters. Very little is known of the role of plasma sodium in TBM 
(other than its association with both the disease, and poor outcome[35]). An increased 
understanding of plasma sodium in TBM, through detailed description, may provide data to 
support future clinical trials and treatment approaches. I conclude my thesis with this discussion 
(chapter six). 
6.2 What did I find? 
The road to improved diagnosis and understanding of pathophysiology is long, however, I 
believe the research contained within this thesis contributes towards advancement in this field. 
My key research findings, as described in the data chapters (chapters 2-5) of this thesis, were as 
follows. I was unable to show Ultra to have a 25% or more increased diagnostic sensitivity (vs. 
Xpert) for the detection of M. tuberculosis in CSF. Active S. stercoralis co-infection in TBM 
was significantly associated with reduced intracerebral inflammation and reduced neurological 
complications by 3 months. Using ultrasound, higher ONSD in TBM was significantly 
associated with abnormal brain imaging and with mortality by 3 months. Baseline plasma 
sodium was significantly lower in more severe TBM. Longitudinal sodium data during the first 
30 days of anti-TB chemotherapy showed correlation between lower plasma sodium, lower 
serum osmolality and higher urinary osmolality, with persistent hyponatraemia and an 
increasing urinary output associated with individuals with poor clinical outcome. 
6.2.1 GeneXpert MTB/RIF Ultra 
Given the impact of Xpert on the TB diagnostic field in the past 10 years, and the promising 
early data describing Ultra for TBM diagnosis,[67] there were high hopes that Ultra would 
provide the next much-needed step forward for TBM diagnostics. However, in Vietnamese 
adults with suspected TBM, Ultra was not superior to Xpert for the identification of M. 
tuberculosis in CSF. This finding was disappointing, given Ultra cartridge improvements 
facilitate detection of lower bacillary numbers, and superior performance in detecting M. 
tuberculosis from sputum.[173] In a study of Ultra for TBM diagnosis in an HIV co-infected 
cohort in Uganda,[66] published on the same day as the data described in this thesis,[68] Ultra 
showed diagnostic superiority to Xpert for TBM diagnosis. At first glance, results from these 
two studies appear inconsistent. Taken together, how should they be interpreted by the 
clinician?  
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Firstly, our Ultra study in Vietnam, alongside the Ultra study from Uganda, serves to illustrate 
the importance of not relying on a sole study from a single site to infer global policy. CSF 
sampling volume and processing steps, host (genetics, HIV) and bacillary (lineage, variable 
genome IS6110 copies) factors may all go some way to explaining why Ultra does not 
outperform Xpert in TBM in all settings.  
Ultra may indeed be superior to Xpert; but not in all settings. Ultra’s lower limit of detection of 
M. tuberculosis may have value in some cases, for example those with lower bacillary load who 
may be tipped from a negative result to a positive result by Ultra’s superiority over Xpert. In our 
Ultra study, Ultra was superior to Xpert for TBM diagnosis in HIV uninfected cases (who are 
considered to have lower M. tuberculosis bacillary load than HIV co-infected cases), albeit this 
difference was not significant. In optimally processed CSF samples with high bacillary load, 
Ultra may be unable to improve diagnosis over Xpert.  
Where does this leave the field of diagnostics in TBM? Certainly, this field is one of the most 
active in TBM research, perhaps the most active. Conventional molecular tests may be 
developed further, however whether further modifications can be applied to the Ultra cartridge 
to overcome the paucibacillary nature of CSF in TBM is far from certain. Additionally, Xpert 
and Ultra perform to a high level for the diagnosis of pulmonary TB, which makes up ~85% of 
global disease.[1] Once molecular tests have been optimised for pulmonary TB, further 
development may not proceed. CSF LAMP may be cheaper, quicker, and more suitable for local 
healthcare centres than Xpert and Ultra, however LAMP does not detect rifampicin resistance 
and data in TBM is limited. The new molecular assays Truenat MTB and Truenat MTB Plus 
(Truenat) (Molbio Diagnostics, Goa, India) have WHO approval for pulmonary TB[172], and 
will introduce competition into the field of molecular assays for TB diagnosis.  
Non-confirmatory tests utilizing proteomics and metabolomics, which are becoming more 
accessible as technological advances continue, have potential for the identification of highly 
sensitive and specific signatures typical of TBM. Likewise, metagenomic next generation 
sequencing (mNGS) may provide a diagnostic breakthrough, if ways can be found to overcome 
the low M. tuberculosis bacillary load in CSF, which will invariably result in M. tuberculosis 
DNA copies in an amplified sample becoming overwhelmed by huge copy numbers of host 
DNA.  
Until a ‘magic bullet’ test becomes available, the best diagnostic approach for TBM appears to 
be through utilization of multiple testing methods; reliance on a single diagnostic test is 
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dangerous in TBM, given none can rule out TBM when negative. All available information 
(clinical, CSF, imaging) should be combined with optimal sampling, processing, and technical 
expertise, a multiple-testing approach, plus clinical experience in diagnosis of this challenging 
disease.   
6.2.2 Strongyloides stercoralis co-infection 
Severe TBM is usually underpinned by excessive host inflammation, which through blockage of 
CSF flow and mass effect, elevates ICP and causes irreversible neurological injury. S. 
stercoralis, a helminth with global distribution, may be carried asymptomatically or lead to 
fulminant disease complications. The immunomodulatory effect of helminth co-infection, 
including by S. stercoralis, is well recognised, however the impact upon TBM where excessive 
host inflammation is so detrimental had not previously been studied.  
In chapter three I describe the effect of S. stercoralis co-infection on presenting severity, CSF 
parameters and cytokines, and neurological complications by 3 months, in TBM. S. stercoralis 
co-infection was indeed associated with less severe disease, reduced intracerebral inflammation, 
and improved outcome, as hypothesized. Association of S. stercoralis with reduced 
inflammation does not necessarily mean causation, however it seems more plausible that S. 
stercoralis is responsible for producing an improved phenotype and outcome, rather than less 
severe TBM providing an increased risk of acquiring S. stercoralis. Alternatively, an additional 
confounding factor may increase risk of both acquiring S. stercoralis co infection and 
developing less severe TBM.  
S. stercoralis co-infection appears able to beneficially influence host inflammatory response to 
TBM. But how does it do this? Given adjunctive host directed therapies aim to control or at 
least minimise excessive inflammation of TBM with varied success, unpicking the mechanisms 
by which S. stercoralis mediates such beneficial effects may identify pathways that can be 
targeted with novel therapies. Progressing to such a host directed therapy may need detailed 
‘omics data, with transcriptomic, proteomic, and metabolomic data potentially identifying 
differences in gene expression, translation, and molecules further downstream in the 
inflammatory process, between individuals with and without S. stercoralis co-infection. 
Theoretically an alternative approach could be to ‘hijack’ helminth-associated 
immunomodulation; for example, use of non-pathogenic helminth antigen. Whether this would 
provide the same immunomodulatory response as S. stercoralis is of course unknown, as is 
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whether this would translate to clinical benefit to some or all individuals. This would require 
initial in-vitro studies measuring host immunomodulation upon stimulation with helminth 
antigen, to identify best antigen, and best dose, that correlate with an appropriate shift towards a 
Th2 host response to M. tuberculosis infection. Moving successful in-vitro data to human trials 
of TBM needs in-depth consideration of safety, given immunomodulation towards a Th2 
response may be detrimental, not beneficial, in pulmonary TB, and may hasten progression from 
M. tuberculosis infection to TB. Numerous expensive therapeutic agents that are inaccessible to 
most individuals with TBM already exist, therefore benefit of the addition of a new agent to this 
list is uncertain. Additionally, reduction of host inflammation may indeed be detrimental for 
some individuals (who do not have an excessive neuroinflammatory response) with TBM. 
However, this point holds true for many current therapies (for example corticosteroids) where 
therapy is given to all or most individuals with benefit only expected in some.  
Current therapies for TBM have not yet been optimised; both for killing of mycobacteria, and 
control of host inflammation. Further progress towards understanding the complex 
pathophysiology of TBM and its influencing factors (for example helminth co-infection), should 
aid development and refining of these therapies.   
6.2.3 Optic nerve sheath diameter 
Once a diagnosis of TBM has been made and treatments initiated, the clinical course is highly 
variable and often hard to predict. Therefore, monitoring to identify individuals who experience 
life threatening neuro-complications is important; yet gold standard invasive monitoring is 
infrequently performed in brain infection and is not accessible to most individuals with TBM 
who reside in resource-poor settings. Given most neuro-complications result in elevated ICP, 
detecting this raised ICP may be valuable. Further data are needed to support ICP-targeted 
therapies in TBM, yet prevention of further brain injury by instituting drainage of CSF (e.g. 
ventriculoperitoneal shunting) or mass reduction therapies (e.g. corticosteroids) upon the 
detection of hydrocephalus or tuberculomas, respectively, makes early detection of raised ICP 
enticing in TBM. 
ONSD ultrasound may offer this early detection of raised ICP; a point-of-care tool, early to 
learn, and quick to perform. In this thesis I demonstrated that ONSD was significantly higher in 
TBM-affected individuals with abnormal brain imaging or who die by 3 months (vs. normal 
brain imaging, or survival by 3 months, respectively). This association between TBM severity 
and ONSD offers promise for ONSD ultrasound in TBM. However, important next steps must 
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be taken to show that ONSD ultrasound can be a useful clinical tool in TBM. Further research 
must demonstrate that the management steps taken upon detection of high ONSD result in 
improved clinical outcomes. This in turn requires ONSD thresholds to be set. i.e. what ONSD 
value should trigger a set of actions, and what should these actions be? In this thesis a receiver 
operating characteristic (ROC) curve analysis demonstrated ‘best’ ONSD cut-off values for 
predicting death by 3 months, with associated sensitivity and specificity. However, these 
sensitivity and specificity values (73% and 54%, respectively) are unlikely to be accurate 
enough to move forward with ONSD as a useful predictive tool at this point.  
Additionally, upon recording an extremely high ONSD value, which strongly predicts death, 
what steps should be taken? Performing 3D brain imaging would likely be a useful next step, to 
characterise the disease processes involved. Hydrocephalus and tuberculomas represent disease 
processes that raise ICP and have recognised management approaches that may be tried. 
Surgical intervention for hydrocephalus would need neurosurgical support, in addition to a 
procedure, which may not be indicated in early stage TBM (ventriculoperitoneal shunts can 
block), or in those with poor prognosis unlikely to benefit from the procedure. Little evidence 
guides medical therapies for hydrocephalus in TBM. Inflammatory tuberculomas may benefit 
from corticosteroids, however no trial has shown corticosteroids to confer benefit for 
tuberculomas.  
Despite uncertainty surrounding how to proceed after identification of a high ONSD value, this 
thesis has shown ONSD ultrasound to have promise as a monitoring tool in TBM. Consistency 
in scanning technique, with standardisation of measurement and interpretation, and development 
of teaching materials and guidelines, will help refinement of this technique, which may become 
a key part of TBM monitoring in the future. It now may be feasible to conduct a clinical trial 
where participants are randomised to standard care, or to daily ONSD ultrasound plus standard 
care. ONSD greater than a specific threshold (such as that threshold predicting death with 73% 
sensitivity) would result in 3D brain imaging being performed, followed by initiation of 
standard management strategies based upon 3D brain imaging findings. Clinical outcomes, 
survival, and neurological events would be measured. 
6.2.4 Hyponatraemia 
Hyponatraemia is common in TBM, yet why it occurs and what to do about it remain a mystery. 
The common clinical picture of hyponatraemia in TBM – as illustrated in this thesis; low 
plasma sodium, low serum osmolality and high urinary sodium, followed by persistent 
 
239 
 
hyponatraemia and an increasing urinary output, likely contributes to raised ICP. 
Hyponatraemia reduces oncotic pressure allowing free water to enter brain tissue, and it is 
possible this raised ICP effect may only serve to drive hyponatraemic pathology further. 
Knowledge of how to break this cycle, if indeed such a pathological cycle operates, would be 
valuable clinically. Low plasma sodium associates with severe TBM disease with poor outcome. 
Yet this does not automatically mean that the low sodium is the cause of poor outcome (rather it 
may be part of normal compensation), and no evidence exists to support correction of 
hyponatraemia for improved clinical outcomes. Administering large volumes of hypertonic 
saline may only serve to increase urinary sodium concentration with little benefit otherwise.  
An improved understanding of hyponatraemia, as is offered by this thesis, may provide clues to 
best therapeutic approaches to hyponatraemia of TBM. The biggest question regarding plasma 
sodium in TBM seems to be ‘should we try to correct it’? Certainly, hyponatraemia is associated 
with increased mortality in TBM, but this does not mean correcting hyponatraemia improves 
survival, if indeed it is possible to correct it. What does seem clear in clinical practice is that the 
hypovolaemic state accompanying hyponatraemia does need correcting; the alternative would 
be haemodynamic instability. In this case should fluid resuscitation contain sodium? 
Conventional wisdom would say ‘yes’, to avoid diluting plasma sodium further. However 
conclusive data are needed.  
A clinical trial comparing hypertonic saline therapies against conventional treatments would be 
valuable. Given the variety of management approaches, a multi-arm trial design may be most 
suitable. A trial arm could both dictate therapy (for example solely 3% hypertonic saline, or the 
local clinician’s choice given resources are likely to vary globally), in addition to targets (either 
a volume target [a defined correction of hypotension] or a volume plus sodium target [defined 
correction of hypotension, plus defined normalisation of plasma sodium]). All fluid therapies, 
plus inotrope use and complications would be recorded. Clinical outcomes would be measured.  
6.3 Limitations of research 
The research I have described within this thesis has limitations. Whilst limitations have been 
described in detail within each individual chapter, the limitation of blinded study drug 
(dexamethasone or placebo) at the time of writing requires re-discussion here. Three of my data 
chapters (chapters 3-5, inclusive) analyse data from the ACT HIV and LAST ACT clinical 
trials. These are randomised double blinded placebo controlled clinical trials of adjunctive 
dexamethasone for TBM. When devising my thesis questions, I tried to mitigate this effect of 
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blinded study drug, by either researching areas unlikely to be affected by the co-administration 
of dexamethasone or placebo, or by analysing clinical and sample data from before study drug 
was administered.  
For example, CSF cytokines (chapter 3, S. stercoralis) were measured in CSF taken at baseline 
(i.e. before study drug was administered). In chapter 4, ONSD was measured longitudinally 
(during the first 30 days of anti-TB chemotherapy, i.e. after study drug was administered). 
However, a conclusion of association between ONSD and brain imaging remains true whether 
the participants had received dexamethasone or placebo. The biggest consideration for these 
data was clinical outcome by 3 months. As explained in individual thesis chapters, I believe it 
highly unlikely that administration of dexamethasone or placebo would affect the conclusions I 
have drawn. For example, if baseline S. stercoralis co-infection in TBM reduced neurological 
complications by 3 months, there is a theoretical chance that this was because more participants 
in this S. stercoralis group received corticosteroids (and corticosteroids were beneficial). 
However, more corticosteroids administration in the S. stercoralis group is less likely, due to the 
1:1 randomisation nature of the trials. If those participants who received corticosteroids were 
then more likely to acquire S. stercoralis, then bias could be introduced, but this is implausible 
given study drug is first received after S. stercoralis sampling is performed. That these data 
chapters come from clinical trials (chapters 3-5) and a prospective brain infection study (chapter 
2) is a strength of these data; well defined research protocols with standard operating procedures 
allowed precise research to be performed. 
6.4 Next steps for the tuberculous meningitis research field 
6.4.1 Status of the field 
The TBM research community, and its scientific output, are growing. Clinical trial registry data 
show numerous ongoing and imminently starting clinical trials investigating anti-TB 
chemotherapy and/or adjunctive agents.[90] This will hopefully lead to evidence based 
management strategies in the near future. The Tuberculous Meningitis International Research 
Consortium, first convened in 2009,[10] now meets regularly, allowing sharing of ideas and 
dissemination of research. Elevating the research profile of TBM is important. TBM must be 
separated from ‘extrapulmonary TB’, a heterogenous group which do not all possess the 
challenges associated with TBM. TBM guidelines should be updated, and updated WHO 
treatment guidelines for TB should specifically consider TBM.   
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6.4.2 Direction of the field 
There are many directions in which research in the field of TBM could go, given the huge 
number of unanswered research questions. Focusing only on one research sub-area; patient 
management; TBM research gaps are quickly laid bare. Why is plasma sodium frequently low? 
Should we treat it, and if so how? Should we give corticosteroids, do they work for all patients, 
and what is the optimal corticosteroid dose, formulation and duration? How is supportive care 
best managed? What is the optimal temperature target, head-of-bed elevation angle, blood 
glucose target, blood transfusion threshold, and nutrition? Which drug best controls seizures 
with the fewest side effects and drug interactions? With hydrocephalus, when should an 
operation be done, on whom, by which method, and what is the best medical option if no 
surgery is available? Who gets paradoxical reactions and IRIS, how can they be predicted, and 
how should they be treated? Should we give aspirin for cerebral infarction, how much, and for 
how long? Many other sub-areas of TBM research have the same such research gaps. 
Regarding my own future research, firstly I am keen to ensure high quality research translates 
into improved health outcomes globally. I would like to survey TBM treatment approaches 
before and after publication of ACT HIV and LAST ACT, to assess for changes in clinical 
practice associated with the published optimal treatment approach (corticosteroids or not). 
Secondly, I believe a ‘low-cost tool’ approach to brain infection can be beneficial; combining a 
published TBM ‘priorities’ checklist[322] with a clinical management bundle of easy-to-
implement tools for improving patient outcome, including optimising head-of-bed angle and 
ventilation, temperature monitoring and normothermia maintenance, low-cost intracranial 
pressure monitoring (e.g. ultrasound), and hypotension/urine output monitoring; potentially 
developed and trialed through a global critical care network. I would like to explore translation 
of such tools to widely available smartphones, utilising their inbuilt technology, e.g. spirit level 
for head-of-bed elevation at home, and potentially colour intensity tools for rifampicin-urine or 
drug induced liver injury jaundice. Thirdly, more high-quality clinical trial data are needed for 
TBM, such as those proposed above (ONSD for raised ICP detection, and comparison of 
hyponatraemia management strategies), and those that address the TBM research gaps listed 
above. 
The reality that there are many research gaps illustrates not only that data are limited in TBM, 
but also the exciting direction that the TBM research field can move in. The thought that some 
(or all) of these research questions can be answered, and that outcomes of a disease that kills up 
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to 50% of 100,000 cases each year can be improved, is inspiration to continue scientific 
research into TBM.    
6.5 Conclusion 
I believe that the research contained within this thesis contributes to the global efforts to 
improve diagnosis and understand pathogenesis of TBM, and ultimately improve upon the dire 
clinical outcomes currently seen with this disease. Yet, I recognise the limitations of my 
research, and the huge number of research gaps that must be addressed to allow myself and 
others to continue to make progress in this field. Fortunately, senior leading researchers are 
driving this field forward, supported by researchers who are developing their research skills, and 
increasing their knowledge and experience of TBM. I have learned an enormous amount during 
my PhD, and I am extremely grateful to those individuals who have supported me, inspired me, 
nurtured my writing, taught me how to answer questions, and more importantly, ask questions. I 
intend to stay active in the TBM research field and build on the research I have performed to 
date.  
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Appendix A 
Diagnostic criteria for TBM [69] 
  
Diagnostic 
score 
Clinical 
criteria (Maximum category score=6) 
 
Symptom duration of >5 days 4 
 
Systemic symptoms suggestive of tuberculosis (one or 
more of the following): weight loss (or poor weight gain 
in children), night sweats, or persistent cough for >2 
weeks 2 
 
History of recent (within past year) close contact with an 
individual with pulmonary tuberculosis or a positive TST 
or IGRA (only in children <10 years of age) 2 
 
Focal neurological deficit (excluding cranial nerve 
palsies) 1 
 
Cranial nerve palsy 1 
 
Altered consciousness 1 
CSF 
criteria (Maximum category score=4) 
 
Clear appearance 1 
 
Cells: 10-500 per μl 1 
 
Lymphocytic predominance (>50%) 1 
 
Protein concentration >1 g/L 1 
 
CSF to plasma glucose ratio of less than 50% or an 
absolute CSF glucose concentration less than 2.2mmol/L 1 
Cerebral 
imaging 
criteria (Maximum category score=6) 
 
Hydrocephalus 1 
 
Basal meningeal enhancement 2 
 
Tuberculoma 2 
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Infarct 1 
 
Pre-contrast basal hyperdensity 2 
Evidence of 
tuberculosis 
elsewhere (Maximum category score=4) 
 
Chest radiograph suggestive of active tuberculosis: signs 
of tuberculosis=2; miliary tuberculosis=4 2 or 4 
 
CT/ MRI/ ultrasound evidence for tuberculosis outside 
the CNS 2 
 
AFB identified or Mycobacterium tuberculosis cultured 
from another source-i.e., sputum, lymph node, gastric 
washing, urine, blood culture 4 
 
Positive commercial M. tuberculosis NAAT from extra-
neural specimen 4 
Diagnostic criteria based on total score: 
Possible TBM: score 6-9 (if no brain imaging) or 6-11 (if brain imaging) 
Probable TBM: score >9 (if no brain imaging) or >11 (if brain imaging) 
Definite TBM: acid-fast bacilli seen in CSF or M. tuberculosis cultured or detected by 
commercial NAAT in CSF 
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Appendix B 
Stool concentration method 
The currently recommended stool concentration method uses 1g of faeces, with 10% formalin in 
water added to emulsify, plus a surfactant (0.1% Triton X100) when using ethyl acetate as a 
solvent.[203] The stool sample is sieved using a pore (size ≤ 0.5mm), vortexed for at least 15 
seconds, and then centrifuged at 3000rpm for 3 minutes.[203] Allen et al[323] described further 
modifications to the simplified version[324] of Richie’s original method.[325] The 
concentration method used by Allen et al[323] differed from that used by Ridley[324] in its use 
of formalin in water, in place of formol saline, and centrifugation at 3,000rpm instead of 
2,000rpm. These modifications led to increased S. stercoralis parasite detection.[324] The 
method by Allen et al [323] is largely similar to that recommended today.[203] A study of 200 
returned questionnaires from parasitology laboratories looked at variation in the stool 
concentration method, specifically, formalin diluted in water vs. formalin diluted in saline; sieve 
pore size during filtration, the use of ethyl acetate and Triton X, or ether alone, and 
centrifugation speed.[203] The study authors found formalin in water was significantly more 
effective than formalin in saline (p ≤0.005 for recovery of parasites), a sieve pore size of 
425μm, (as per the Ridley-Allen Method) gave the best recovery of parasites, ethyl acetate and 
Triton X were superior to ether alone, and the recovery of parasites was greatest if the samples 
were centrifuged for 3,500rpm for 10 minutes.[203] 
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Appendix C 
Additional stool S. stercoralis larval detection methods 
In the agar plate culture method, linear bacterial colonies originating from a stool sample placed 
in the centre of an agar plate reveal the presence of migrating S. stercoralis larvae, which can 
then be extracted and confirmed.[326] Additionally, stool culture methods have been developed 
which exploit the ability of S. stercoralis to enter a free living development cycle.[240] The 
Harada-Mori and Baermann methods use filter paper and mesh, respectively, to capture S. 
stercoralis larvae after they move from a stool sample to warm water.[240]  
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Appendix D 
Treatment of uncomplicated strongyloidiasis 
1. Thiabendazole and ivermectin 
Introduced in 1963, thiabendazole was the first line treatment for strongyloidiasis for many 
years; however ivermectin has now taken its place as the drug of choice.[192] Ivermectin binds 
to glutamate gated chloride ion channels of parasite neuronal cells, leading to hyperpolarisation 
and death.[190] Ivermectin is taken orally, and is generally well tolerated, with mild adverse 
reactions (for example pruritus, fever, rash, myalgia, and headache) usually occurring during the 
first 3 days after treatment.[327]  
Clinical trials have been unable to show a benefit in parasitological cure of single dose 
200µg/kg ivermectin over thiabendazole 50mg/kg daily, however ivermectin was associated 
with a better side effect profile making it a more appealing choice of therapy.[180,211–213] 
Bisoffi et al found significantly more mild-moderate side effects with thiabendazole than with 
single dose ivermectin (73.1 vs. 20.9%, respectively).[212] In two studies, a third intervention 
arm; two consecutive days of ivermectin at 200µg/kg per day, was also assessed.[180,211] A 
systematic review of 244 strongyloidiasis case reports found no significant difference in patient 
outcome between those treated with ivermectin and thiabendazole.[328] One of these studies 
found two days of ivermectin to result in improved parasitological cure vs. single dose 
ivermectin (n=35, cure=100% vs. n=22, cure=77%, respectively).[180] A further study 
comparing albendazole with both single dose ivermectin and with two doses of oral ivermectin 
200µg/kg given 2 weeks apart, did not find superiority of the two-dose ivermectin regimen over 
a single ivermectin dose.[209] Whilst the benefit of ivermectin over thiabendazole appears to be 
through its superior side effect prolife alone, the addition of a second dose of ivermectin has no 
clear benefit. However, recently a multicentre open-label randomised controlled trial compared 
single dose ivermectin 200µg/kg with four ivermectin 200µg/kg does given on days 1,2, 15 and 
16.[215] Clearance of S. stercoralis at 12 months was the primary endpoint. The multiple 
dosing regimen was less well tolerated and did not improve clearance of S. stercoralis, when 
compared with the single dose regimen. A single ivermectin 200µg/kg dose appears sufficient 
for uncomplicated strongyloidiasis.  
2. Albendazole and ivermectin 
The benefit of ivermectin over albendazole for the parasitological cure of strongyloidiasis has 
been demonstrated in multiple clinical trials, with parasitological care rates of single dose 
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ivermectin and 3-7 day albendazole regimens reported as 83 vs. 38%,[206] 83 vs. 43%,[207] 
98.7 vs. 78.7%,[208], and 96.8 vs. 63.3%.[209] In a Japanese study a fixed 6mg ivermectin dose 
led to higher parasitological cure than 3 days of 400mg/day albendazole.[329] Ivermectin has 
also shown superiority for strongyloidiasis treatment over higher dose albendazole therapy; 
800mg for 7 days.[210]  
A 2016 Cochrane review of strongyloidiasis treatment (7 trials, 1147 participants, 1994-2011) 
concluded superior parasitological cure with ivermectin compared to albendazole, no difference 
in cure with ivermectin compared to thiabendazole, (however more adverse events with 
thiabendazole), and no increase in cure when a second dose of ivermectin was added to a first 
dose of ivermectin.[214] This recommendation is supported by the recent trial[215] comparing 
single dose, and four dose, ivermectin.   
The role of combination therapy (ivermectin plus albendazole) is not clear, and has only been 
described in case report form.[330]  
3. Confirmation of S. stercoralis cure 
A hallmark of most trials to date is the confirmation of cure by stool microscopy, a test with low 
sensitivity. Confirmation of cure is challenging, however new stool PCR tests potentially offer a 
new way to assess the effectiveness of drug therapy for strongyloidiasis. In a recent prospective 
study, 48 patients were diagnosed and treated (200µg/kg orally daily for two days, repeated 
after 2 weeks) for S. stercoralis infection in Argentina.[331] Participants were resident in areas 
considered to be non-endemic to avoid future positive tests being attributed to re-infection, and 
parasite re-exposure through travel was excluded at follow up appointments. Of the 21/48 (44%) 
participants who returned for follow up (followed up for a median of 730 days), 14/21 (67%) 
had parasitological reactivation (agar plate culture or fresh stool larvae), 9/21 (43%) had clinical 
reactivation (6/21 had both parasitological and clinical reactivation), and interestingly 21/21 had 
a positive stool PCR test. Corticosteroid use was reported in 6/21 cases. Ivermectin appeared 
poor at eradicating S. stercoralis, which may persist despite drug therapy.  
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Appendix E 
Prophylaxis against S. stercoralis infection 
Prophylaxis for S. stercoralis-negative individuals undergoing corticosteroid therapy has been 
trialled without success.[332] Patients with haematological malignancies or benign conditions 
requiring corticosteroids were randomised to 25mg/kg thiabendazole orally twice daily for two 
days repeated monthly, or to placebo, after three negative stool samples for S. stercoralis. 
Thiabendazole was not superior to placebo in reducing the development of strongyloidiasis, and 
significantly more abdominal pain events occurred in the thiabendazole group.[332] Whether 
ivermectin would represent an effective prophylactic agent is unknown, and has not been 
trialled.  
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Appendix F 
Guidelines for treatment of tuberculous meningitis [41,85] 
1. First line treatment 
Rifampicin (10mg/kg/24hrs; maximum 600mg), isoniazid (5mg/kg/24hrs; maximum 300mg), 
pyrazinamide (25mg/kg/24hrs; maximum 2g) and ethambutol (20mg/kg/24hrs; maximum 1.2g) 
are given for for at least the first 2 months of treatment.  
Pyrazinamde will then be stopped and rifampicin, isoniazid and ethambutol (at the same doses) 
will then be given until at least 12 months anti-tuberculosis treatment in total has been given. If 
pyrazinamide cannot be given for at least 2 months (for example, because of drug-induced 
toxicity), then total treatment should be at least 12 months.  
2. Isoniazid-resistant tuberculosis 
Option 1: Follow the standard regimen above, but replace isoniazid with levofloxacin 
(20mg/kg/24 hrs; maximum 1000 mg/day). Pyrazinamide can be used throughout treatment in 
those with more severe disease who are responding slowly. 
Option 2: Stop isoniazid and treat with rifampicin, ethambutol and pyrazinamide for the entire 
9-12 months of treatment. This option is not suitable for those with confirmed ethambutol 
resistant bacteria; these participants should be treated with option 1. 
3. Multi-drug resistant tuberculosis 
Second line treatment for MDR TBM should be given as soon as possible, following National 
guidelines and local policies. 
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Appendix G 
Individual studies comparing ONSD with invasively measured ICP 
Geeraerts et al measured ONSD in 31 patients with severe TBI and found ONSD was 
significantly higher in patients who developed raised ICP in the 48 hours after trauma 
(6.3 ± 0.6mm) vs. patients with normal ICP (5.1 ± 0.7 mm).[333] A further study in neurocritical 
care patients assessed simultaneous measurement of ONSD by ultrasound and invasively 
monitoring ICP.[252] ONSD measurements were performed 78 times in 37 patients, with the 
causes of raised ICP as follows; severe TBI (n=22), subarachnoid haemorrhage (n=6), 
intracranial hematoma (n=8) and stroke (n=1). A ROC curve for ICP> 20 mmHg demonstrated 
that ONSD predicted raised ICP with a best cut-off value of 5.86 mm (sensitivity 95%, 
specificity 79%). Kimberley et al performed 38 ocular ultrasounds in 15 patients with TBI 
(n=4), and intracranial haemorrhage (n=11).[334] A ROC curve for ICP> 20 mmHg 
demonstrated that ONSD predicted raised ICP with a best cut-off value of 5.0mm (sensitivity 
88%, specificity 93%).[334] A cut-off value of 4.5mm gave a sensitivity of 100%, but a 
specificity of only 63%. Moretti et al performed 53 ONSD measurements prior to invasive ICP 
monitor placement in patients with intracranial haemorrhage and found that ONSD predicted 
ICP> 20 mmHg with a best cut-off value of 5.2mm (sensitivity 94%, specificity 76%).[335] A 
second study by Moretti et al measured ONSD 94 times in 63 patients with primary 
intracerebral haemorrhage (n=29) or subarachnoid haemorrhage (n=34).[336] ONSD predicted 
ICP> 20 mmHg with a best cut-off value of 5.2mm (sensitivity 93%, specificity 74%).[336] 
Soldatos et al measured ONSD in 89 critical care patients with brain trauma (n=62) and in 
control patients with no neurological injury (n=27).[266] ONSD predicted ICP>20 mmHg with 
a best cut-off value of 5.7mm (sensitivity 74%, specificity 93%).[266] Rajajee et al performed 
576 ONSD measurements in 65 patients with the following pathologies; subarachnoid 
haemorrhage (n=30), intracerebral haemorrhage (n=11), TBI (n=11), brain tumour (n=5), 
ventriculoperitoneal shunt malfunction (n=5), ischemic stroke (n=1), cerebral venous sinus 
thrombosis (n=1), and acute liver failure (n=1).[250] ONSD predicted ICP> 20 mmHg with an 
optimal cut-off value of 4.8mm (sensitivity 96%, specificity 94%).[250] 
In 110 Chinese patients with varying neurological diagnoses (diagnoses not stated) ONSD was 
compared with lumbar opening pressure.[337] An ONSD > 5.6mm predicted ICP > 20cmH2O 
with 86% sensitivity and 73% specificity. In a large prospective observational study in the 
United Kingdom, 445 ONSD measurements were performed in 64 patients with TBI, 
intracerebral haemorrhage or stroke, and compared against invasively measured ICP 
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measurements.[338] Mean ONSD in those who survived was 5.11 mm compared with 5.71 in 
those who died. In a prospective study of Malaysian neurosurgical patients an ONSD of 5.2mm 
detecting an ICP > 20mmHg with 96% sensitivity and 80% specificity.[339] In a Korean study 
an optimal cutoff for ICP detection was shown to be 5.6mm.[340]  
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Appendix H 
Validation of ONSD using brain imaging consistent with raised ICP 
Subsequent to correlation of ONSD with invasively measured ICP, research groups have set out 
to establish ONSD thresholds that define raised ICP in specific populations, using alternative 
comparator tests to gold standard invasive measurements for defining raised ICP. 3D brain 
imaging, such as CT or MRI, has emerged as such a comparator test. Whilst 3D brain imaging is 
unable to measure ICP, imaging features consistent with raised ICP can be noted. A study by 
Lee et al noted that most studies evaluating ONSD measured by ultrasound for ICP detection 
had been performed in European Caucasian populations, therefore the authors set out to 
demonstrate the role of ONSD ultrasound in a South Korean population.[341] A significant 
difference was seen between average ONSD values of patients with raised ICP and those of a 
healthy control group (median ONSD: 5.9mm, IQR 5.8-6.2mm, vs. 4.9mm, IQR 4.6-5.2mm, 
respectively, p<0.001).[341] ONSD predicted ICP> 20 mmHg with an optimal cut-off value of 
5.5mm (sensitivity 99%, specificity 85%).[341] The authors defined raised ICP based on brain 
MRI appearances rather than invasive intracranial measurements, with MRI brain imaging and 
ONSD ultrasound performed within 1 hour of each other. MRI findings consistent with one of 
the following criteria were used to define raised ICP: significant brain oedema, midline shift, 
compression of ventricle or basal cistern, effacement of sulci, insufficient grey/white 
differentiation or transfalcine herniation,[341] using criteria developed by Miller et al.[259]  
Miller et al originally developed a scoring system based on five CT brain imaging 
characteristics, with these characteristics chosen by the authors based on literature review and 
consultation with study investigators.[259] In their study, patients scored 1, 2 or 3 points for 
significant brain oedema, midline shift, compression of ventricle or basal cistern, effacement of 
sulci, insufficient grey/white differentiation or transfalcine herniation. Whilst this analysis 
indicated that initial ICP could not be predicted by the presence of these CT characteristics, a 
univariate linear regression analysis demonstrated a significant correlation between average 
initial ICP and the average radiologic score of four of five of these CT brain characteristics, 
with the fifth characteristic, basilar cistern size, trending toward linear association with average 
initial ICP.[259] More evidence is clearly required to directly link these CT scan characteristics 
to raised ICP, however these CT brain criteria, or adapted versions of them, have subsequently 
been used as surrogates for raised ICP. Goel et al measured ONSD in 100 patients with head 
injury, and correlated ONSD with CT brain imaging (CT brain and ONSD ultrasound were 
performed within 20 minutes of each other).[342] CT imaging was considered positive for 
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raised ICP if the following were present; significant oedema, midline shift of 3mm or more, 
mass effect, effacement of sulci, collapse of ventricles or compression of cisterns.[342] Blaivas 
et al performed ONSD ultrasound in 35 patients with suspected raised ICP caused by 
intracranial haemorrhage.[343] Patients were grouped by the presence of CT brain findings 
consistent with raised ICP; mass effect with a midline shift 3 mm or more, a collapsed third 
ventricle, hydrocephalus, effacement of sulci with significant edema, and abnormal 
mesencephalic cisterns. An average (across left and right eyes) ONSD of > 5mm was taken to 
be consistent with raised ICP. The mean ONSD of patients with CT brain imaging consistent 
with raised ICP (n=14) was 6.27mm (95% CI 5.6-6.9), compared with a mean ONSD for 
patients without these CT findings of 4.42mm (95% CI 4.2-4.7), with comparison between these 
groups statistically significant (p=0.001).[343] All 14 patients with average ONSD > 5mm had 
CT brain imaging consistent with raised ICP.[343] A study of 753 patients with severe non 
penetrating head injury found that CT findings indicating cerebral herniation (particularly 
abnormal mesencephalic cisterns and midline shift) were strongly associated with a risk of 
elevated ICP.[344] 
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Appendix I 
Methods for recording and averaging ONSD 
In a study of 115 adult patients at risk of raised ICP there was no significant difference between 
lateral and transverse measurements taken from each eye, and no significant difference between 
measurements taken from left vs. right eye, with a conclusion drawn that ONSD measurements 
can be taken in either eye, in either orientation.[345] However, in their study of 100 patients 
with non-TBI, Komut et al found that in those with unilateral pathology (n=45), ONSD was 
significantly higher when measured in the eye on the side of the affected brain hemisphere, 
compared with measurement on the side of the unaffected hemisphere.[273] In published 
literature, methods of measuring, repeating and averaging differ widely. Published methods 
include performing a sagittal and transverse measurement for each eye and averaging for that 
eye,[252,336] repeating sagittal and transverse measurements for each eye and then averaging 
for each eye,[78,268,334] and repeating measurements for each eye and using the highest value 
recorded for each eye.[273] 
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Appendix J 
Evidence supporting IVC ultrasound in fluid assessment 
The use of IVC ultrasound in mechanically ventilated patients is largely based on two 
studies[346,347] published in 2004.[348] Barbier et al used IVC distensibility (dIVC), 
calculated as end-inspiratory IVC diameter minus end-expiratory IVC diameter, divided by end-
expiratory IVC diameter, multiplied by100 to express the value as a percentage.[346] A dIVC of 
18% or above indicated a volume status responsive to intravenous fluid with 90% sensitivity 
and specificity.  
Feissel et al defined IVC diameter variation (∆DIVC) as [(Dmax−Dmin)/[(Dmax+Dmin)/2] and 
found a ∆DIVC value of 12% discriminated between responders and non-responders to 
intravenous fluid, with a positive predictive value of 93% and a negative predictive value of 
92%.[347] Despite the use of different calculation methods between the studies, changes in 
measured IVC were shown to correlate with fluid responsiveness, in patients perfectly 
synchronised with a mechanical ventilator in whom ventilation was predictable.[346,347]  
A study of 40 spontaneously breathing patients with circulatory failure due to sepsis (n=24), 
haemorrhage (n=11) or dehydration (n=5) investigated whether IVC diameter variation 
predicted fluid responsiveness in these non-mechanically ventilated patients.[349] The authors 
measured IVC using M-mode ultrasound, and used a calculation similar to Barbier et al after 
accounting for maximal IVC occurring in expiration in spontaneously breathing patients 
[(Dmax - Dmin/Dmax) × 100] to calculate the IVC variation. In this study 20 (50%) patients 
were fluid responsive, with IVC variation >40% during respiration usually associated with fluid 
responsiveness (70% sensitivity, 80% specificity).[349]  
Further studies have supported the use of IVC collapsibility for fluid resuscitation in critically ill 
patients who are spontaneously ventilated. Corl et al enrolled 124 spontaneously breathing 
patients with acute circulatory failure, and compared IVC ultrasound measurements to cardiac 
output fluid responsiveness (defined by a 10% increase in cardiac index after a 500mls 
intravenous fluid bolus, measured by a Non-Invasive Cardiac Output Measurement [NICOM] 
device.[350] An optimal caval index (cIVC) of 25% was identified (where cIVC = [IVC 
expiratory diameter – IVC inspiratory diameter]/IVC expiratory diameter,  x 100), with 87% 
sensitivity and 81% specificity.[350] Preau et al compared IVC collapsibility to stroke volume 
index increase after volume expansion with 500mls 4% gelatin, in 90 spontaneously ventilated 
patients.[351] A relevant increase (defined as ≥ 10% increase in stroke volume index) was 
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recorded in 56% patients, and when IVC collapsibility index was superior or equal to 48%, this 
relevant fluid responsiveness was predicted with 84% sensitivity and 90% specificity.[351] 
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Appendix K 
Serum osmolality storage 
 
Serum osmolality testing is not available at HTD where patient samples are taken; serum must 
be frozen and stored for future testing. Recent studies have provided an evidence base for 
storage of serum osmolality samples.[311,352,353] Assuming immediate sample centrifugation 
occurs, both serum and plasma have been shown to be stable for 7 days at room temperature, 
and for at least 4 weeks at standard refrigeration temperatures (2-80C), where a change >2.6% (2 
standard deviations from the mean) was considered significant.[352] In this study an osmometer 
(3320 Osmometer, Norwood, MA) was used for osmolality measurements.  
A study by Zhang et al found that time to separation from the clot in spun samples was 
important for the stability of glucose, a critical component of osmolality, with the authors 
recommending separation of serum from clot within 3 hours.[354] Deep freezing of samples 
may be more beneficial than standard freezing. In a study assessing freezing temperatures 25 
patients, blood was withdrawn and stored as serum, as plasma in EDTA, and in lithium heparin 
tubes.[353] Storage temperatures were 220C, 70C, -210C and -780C, with analysis at 1, 3, 14, 21, 
and 56 days of storage. Sample testing was by Mikro-Osmometer Automatic, type 13–Autocal 
(Roebling, Berlin, Germany). Whilst storage at 220C and 70C were associated with progressive 
rises in osmolality, samples stored at -210C were associated with a decrease in osmolality. 
Samples stored at -780C demonstrated stable osmolality testing at up to and including 56 days, 
both as serum and plasma.[353] The authors recommended that samples stored at -780C should 
be thawed quickly (5 mins at 370C) in a water bath, as a slow thawing process (12 hour defrost 
at 70C) led to an increased in measured osmolality.[353] 
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Appendix L 
Publications from this thesis 
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